

Supplementary Material

Table of Contents

Supplementary files.....	2
S1 File. PRISMA checklist	2
S2 File. Search strategy	4
S3 File. Tool for assessing study risk of bias	8
S4 File. Additional data analysis details.....	11
S5 File. Methods for selecting and gathering data on cumulative incidence and population size	14
References for supplementary files	15
Supplementary tables.....	16
S1 Table. Characteristics and primary results of studies reporting population-wide seroprevalence estimates	16
S2 Table. Characteristics and primary results of studies reporting population-specific seroprevalence estimates.....	156
S3 Table. Risk of bias results for each included study	222
S4 Table. Summary of unadjusted meta-analysis results.....	274
S5 Table. Summary of serological tests used in included seroprevalence studies	275
S6 Table. Summary of meta-regression results.....	277
Supplementary figures.....	278
S1 Figure. Map of serosurvey distribution by global burden of disease region	278
S2 Figure. Seroprevalence to cumulative case incidence ratios using cumulative incidence nine days prior to the serosurvey end date.....	279
References for all included studies.....	280

Supplementary files

S1 File. PRISMA checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5-6
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7-8
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7, S2 file, S4 file
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	S2 Appendix file
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7-8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8-9, S4 file
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9-11, S4 file
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8, S3 file
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	10-11
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	9-11, S4 file
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8, S3 file
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	11, S4 file
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	12, Fig 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	12, Table 1, Fig 2, Fig 3, S1 table, S2 table, S3 table
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	12, Fig 3, S4 table
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	S1 table, S2 table

Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	20, 21, Table 5, S4 table, S6 table
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Fig 3
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	21, 22 Table 6
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	23
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	27, 28
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	29, 30
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	11

S2 File. Search strategy

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Dates: January 1, 2020 to December 31, 2020

Notes: Covid-19 search terms were adapted from Ovid Expert Searches

#	Search terms
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	(coronavirus* or corona virus* or OC43 or NL63 or 229E or HKU1 or HCoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*).tw,kf.[EB2]
4	or/1-3
5	4 not ((MERS or MERS-CoV or Middle East respiratory syndrome or camel* or dromedar* or equine or coronary or coronal or cvidence* or covidien or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV).mp. or (animals/ not humans/))
6	((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars* or virus).tw,kf. or exp pneumonia/) and Wuhan.tw,kf.
7	(2019-ncov* or 2019nCov* or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2* or sars-cov-2* or sarscov2* or sarscov-2* or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or coronavirus 2 or coronavirus2* or corona or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or ((covid or covid19* or covid-19) and pandemic*2) or (coronavirus* and pneumonia).tw,kf.
8	COVID-19.rx,px,ox. or severe acute respiratory syndrome coronavirus 2.os.
9	or/6-8
10	5 or 9
11	immunoglobulins/ or antibodies/ or antibodies, blocking/ or exp antibodies, neutralizing/ or antibodies, viral/ or antigen-antibody complex/ or immune sera/ or exp immunoglobulin isotypes/ or immunoglobulin a/ or immunoglobulin d/ or immunoglobulin e/ or immunoglobulin g/ or immunoglobulin m/
12	serologic tests/ or complement fixation tests/ or hemagglutination inhibition tests/ or neutralization tests/
13	immunoassay/ or fluoroimmunoassay/ or exp immunoblotting/ or immunoenzyme techniques/ or exp enzyme-linked immunosorbent assay/ or exp enzyme-linked immunospot assay/ or immunosorbent techniques/ or serologic tests/ or complement fixation tests/ or hemagglutination inhibition tests/ or neutralization tests/ or Serology/di
14	(enzyme linked immunosorbent or enzyme-linked immunosorbent or ELISA or immunofluorescence or complement fixation or hemagglutination inhibition or immunoblot or western blot or neutrali*).tw,kf.
15	(antibod* or immunoglobulin* or immune globulin* or titer* or isotype* or IgG or IgM or IgA or neutrali* or sera or serum or serolog* or saliva).tw,kf.
16	or/11-14
17	seroepidemiologic studies/
18	incidence/ or prevalence/
19	(seroconver* or seroprevalence or sero-prevalence or seroincidence or sero-incidence or seroepidemiolog* or sero-epidemiolog*).mp.
20	(inciden* or prevalen* or count* or rate*).mp.
21	(serosurvey or sero-survey or screen* or diagnostic).mp.
22	(seroconver* or seroprevalence or sero-prevalence or seroincidence or sero-incidence or seroepidemiolog* or sero-epidemiolog* or inciden* or prevalen* or silent or asymptomatic or serosurvey or sero-survey).tw,kf.
23	or/17-21
24	10 and (16 and 23)
25	10 and 15
26	10 and 22
27	or/24-26
28	limit 27 to yr="2020-Current"
29	remove duplicates from 28

Database: Embase

Dates: January 1, 2020 to December 31, 2020

Notes: Covid-19 search terms were adapted from Ovid Expert Searches

#	Searches
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	(coronavirus* or corona virus* or OC43 or NL63 or 229E or HKU1 or HCoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*).tw,kw.
4	or/1-3
5	4 not ((MERS or MERS-CoV or Middle East respiratory syndrome or camel* or dromedar* or equine or coronary or coronal or coidence* or covdien or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV).mp. or (animals/ not humans/))
6	((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars*).tw,kw. or exp pneumonia/) and Wuhan.tw,kw.
7	(2019-ncov or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2 or sars-cov-2 or sarscov2 or sarscov-2 or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or ((covid or covid19 or covid-19) and pandemic*2) or (coronavirus* and pneumonia)).tw,kw.
8	(coronavirus disease 2019 or severe acute respiratory syndrome coronavirus 2).sh,dj.
9	6 or 7 or 8
10	5 or 9
11	virus antibody/ec [Endogenous Compound]
12	neutralizing antibody/ec [Endogenous Compound]
13	exp immunoglobulin/ or exp immunoglobulin A antibody/ or exp immunoglobulin class/ or exp immunoglobulin M antibody/ or exp immunoglobulin G antibody/ or exp immunoglobulin antibody/
14	11 or 12 or 13
15	serology/
16	serodiagnosis/ or complement fixation test/ or hemagglutination inhibition test/ or hemolytic plaque assay/
17	fluorescent antibody technique/
18	immunofluorescence test/ or viral disease immunofluorescence assay/
19	enzyme linked immunosorbent assay/
20	western blotting/
21	(enzyme linked immunosorbent or enzyme-linked immunosorbent or ELISA or immunoassay or immunofluorescence or fluorescent antibody or complement fixation or hemagglutination inhibition or hemolytic plaque assay or immunoblot or western blot or neutrali*).tw,kw.
22	(antibod* or immunoglobulin* or immune globulin* or titer* or isotype* or IgG or IgM or IgA or neutrali* or sera or serolog* or serum or saliva).tw,kw.
23	15 or 16 or 17 or 18 or 19 or 20 or 21
24	14 or 23
25	exp seroepidemiology/
26	*prevalence/
27	*incidence/
28	(seroconver* or seroprevalence or sero-prevalence or sero-incidence or seroepidemiolog* or sero-epidemiolog* or inciden* or prevalen* or count* or rate* or serosurvey or sero-survey or screen* or diagnostic).mp.
29	(seroconver* or seroprevalence or sero-prevalence or sero-incidence or seroepidemiolog* or sero-epidemiolog* or inciden* or prevalen* or silent or asymptomatic or serosurvey or sero-survey).tw,kw.
30	25 or 26 or 27 or 28
31	10 and (24 and 30)
32	10 and 22
33	10 and 29
34	31 or 32 or 33
35	limit 34 to yr="2020-Current"
36	remove duplicates from 35

Database: Web of Science Core Collection
 Date: January 1, 2020 to December 31, 2020

#	Searches
1	TS=(coronavirus* or corona virus* or OC43 or NL63 or 229E or HKU1 or HCoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*)
2	TS=(MERS or MERS-CoV or Middle East respiratory syndrome or camel* or dromedar* or equine or coronary or coronal or covidence* or covidien or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV)
3	#1 NOT #2
4	TS=((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars* or virus) AND Wuhan)
5	TS=(2019-ncov* or 2019nCov* or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2* or sars-cov-2* or sarscov2* or sarscov-2* or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or corona or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus*)) or (coronavirus* and pneumonia)).
6	TS=(COVID-19 or "severe acute respiratory syndrome coronavirus")
7	#6 OR #5 OR #4 OR #3
8	TS=(antibod* or immunoglobulin* or immune globulin* or titer* or isotype* or IgG or IgM or IgA or neutralization or sera or serolog* or saliva or serum).
9	TS=("enzyme linked immunosorbent assay" or "enzyme-linked immunosorbent assay" or "immunoenzyme" or ELISA or "lateral flow immunoassay" or LFIA or "immunofluorescence assay" or immunochromatography or "complement fixation test" or "hemagglutination inhibition" or immunoblot or "western blot" or "neutralization assay")
10	#9 OR #8
11	TI=(seroconversion or seroprevalence or seroincidence or seroepidemiolog* or incidence or prevalence or asymptomatic or sero-survey*) or AK=(seroconversion or seroprevalence or seroincidence or seroepidemiolog* or incidence or prevalence or asymptomatic or sero-survey*)
12	ALL=(prevalence or incidence or seroconversion or seroconvert or seroprevalence or seroincidence or seroepidemiolog* or serosurvey or sero-survey or survey or screen* or diagnostic test)
13	#12 AND #10 AND #7
14	#11 AND #7
15	TI=(antibod* or immunoglobulin* or immune globulin* or titer* or isotype* or IgG or IgM or IgA or neutralization or sera or serolog* or saliva or serum).
16	#15 AND #7
17	#16 OR #14 OR #13

Database: Europe PMC [Secondary search for pre-prints]
 Dates: January 1, 2020 to December 31, 2020

#	Searches
	("2019-nCoV" OR "2019nCoV" OR "COVID-19" OR "SARS-CoV-2" OR "COVID19" OR "COVID" OR "SARS-nCoV" OR ("wuhan" AND "coronavirus") OR "Coronavirus" OR "Corona virus" OR "corona-virus" OR "corona viruses" OR "coronaviruses" OR "SARS-CoV" OR "Severe Acute Respiratory Syndrome Coronavirus" OR ("SARS" AND "coronavirus")) AND ABSTRACT:(sera* OR sero* OR immun* OR Ig* OR "enzyme-linked immunosorbent assay" OR ELISA OR "neutralization assay" OR seroprevalence) AND (SRC:"PPR")

Sources: Health organizations

Dates: January 1, 2020 to December 31, 2020

Source	Search strategy	
WHO Situation Reports	1	“antibod”, “sero”, “immun”, “ELISA”
National Institutes of Health	1	("COVID" OR "SARS-CoV-2")
	2	("sero*" OR "antibod*" OR "immun*" OR "RDT" OR "ELISA" OR "LFIA")
	3	allintext:(1 AND 2) site:.nih.gov -site:ncbi.nlm.nih.gov
	3	2 AND 3
United States Centres for Disease Control and Prevention	1	("COVID" OR "SARS-CoV-2")
	2	("sero*" OR "antibod*" OR "immun*" OR "RDT" OR "ELISA" OR "LFIA")
	3	allintext:(1 AND 2) site:cdc.gov
	5	2 AND 3
European Centres for Disease Control and Prevention	1	("COVID" OR "SARS-CoV-2")
	2	("sero*" OR "antibod*" OR "immun*" OR "RDT" OR "ELISA" OR "LFIA")
	3	allintext:(1 AND 2) site:ecdc.europa.eu
	5	2 AND 3

Sources: Google News

Dates: January 1, 2020 to December 31, 2020

Source	Search strategy	
Google news	1	(antibody OR antibodies OR surveillance OR screen OR serology OR serological OR serosurvey OR ELISA OR LFIA OR assay OR blood OR serum OR immune OR immunity OR herd immunity OR random test)

S3 File. Tool for assessing study risk of bias

Item 1: Was the sample frame appropriate to address the target population?	
Yes	Sample frame described and it approximated the target population
No	Sample frame did not approximate the target population (e.g., blood donors do not represent general population, doctors do not represent all health care providers)
Exclude	Sample frame not described
*Notes	The term “target population” should not be taken to infer every individual from everywhere or with similar disease or exposure characteristics. Instead, give consideration to specific population characteristics in the study, including age range, gender, morbidities, medications, and other potentially influential factors. For example, a sample frame may not be appropriate to address the target population if a certain group has been used (such as those working for one organisation, or one profession) and the results then inferred to the target population (i.e. working adults). A sample frame may be appropriate when it includes almost all the members of the target population (i.e. a census, or a complete list of participants or complete registry data).

Item 2: Were study participants recruited in an appropriate way?	
Yes	Probability sampling method (simple or stratified random) or entire sample (e.g., an entire town) was used
No	Non-probability sampling
Exclude	Sampling method not reported

Item 3: Was the sample size adequate?	
Yes	≥599
No	<599
Exclude	Sample size not reported
*Notes	<p>To calculate the required sample size we used an assumed prevalence of 2.5%, which was the global average estimated by the WHO in April, 2020.¹ Based on guidance by the Joanna Briggs Institute and published medical statistical recommendations we selected a precision value that was half the assumed prevalence (1.25%)^{2,3} We calculated a minimum sample size of 599 using these inputs:</p> <p>Sample size calculation: $n = \frac{Z^2 P(1-P)}{d^2}$</p> <p>Where n = sample size; Z = Z statistic for level of confidence (95%); P = expected prevalence (2.5% WHO global estimate); d = precision (1.25%)</p> <p>In cases where the sample size calculation was provided and the required sample for 80% power was below our threshold (n<599), this item was marked as yes.</p>

Item 4: Were the study subjects and setting described in detail?	
Yes	Average age and distribution of gender/sex provided
No	Neither age or gender/sex is provided, or only one of age and gender/sex is provided

Item 5: Was data analysis conducted with sufficient coverage of the identified sample?	
Yes	The demographic characteristics (gender/sex, age, and ethnicity) of the sample is at least somewhat representative of the population
No	The demographic characteristics (gender/sex, age, and ethnicity) of the sample is not representative of the population
Unclear	Information is not provided about demographic characteristics of the sample (gender/sex, age, and ethnicity)

Item 6: Were valid methods used for the identification of the condition?	
Yes	The test used met the FDA standards for Emergency Use Authorizations for COVID-19 serological tests: sensitivity minimum 90%, specificity minimum 95%, as reported in the study. ⁴
No	The test used did not meet the FDA standards for Emergency Use Authorizations for COVID-19 serological tests: sensitivity minimum 90%, specificity minimum 95%.
Exclude	Test sensitivity and specificity not reported

Item 7: Was the condition measured in a standard, reliable way for all participants?	
Yes	The same serology test was used for all participants
No	Different serology tests were used for participants
Unclear	No details were provided about which participants received which serology tests

Item 8: Was there appropriate statistical analysis?	
Yes	Does all of the following: corrects for population characteristics or the sample is somewhat representative of the population (probability sampling), corrects for test characteristics), and provides the information necessary to determine the numerator, denominator, prevalence estimate, and confidence interval.
No	Does not correct for population characteristics and the sample is not likely representative of the population (non-probability sampling), does not correct for test or provide the information necessary to correct for test characteristics, or does not provide the information necessary to determine the numerator, denominator, prevalence estimate, and confidence interval.

Item 9: Was the response rate adequate, and if not, was the low response rate managed appropriately?	
Yes	Response rate > 60% or the demographics of the sample were a reasonable match to those of the target population ⁵
No	Response rate < 60% and the demographics of the sample were not a reasonable match to those of the target population
Unclear	Response rate not provided and it was unclear if the demographics of the sample differed from the target population

Item 10: Overall risk of bias	
Low	The estimates are very likely correct for the target population. To obtain a low risk of bias classification, all criteria must be met or departures from the criteria must be minimal and unlikely to impact on the validity and reliability of the prevalence estimate. These include sample sizes that are just below the threshold when all other criteria are met, reporting only some of characteristics of the sample, test characteristics below the threshold but corrections for the test performance, and response rates that are just below the threshold in the context of probability based sampling of an appropriate sampling frame with population weighted seroprevalence estimates.
Moderate	The estimates are likely correct for the target population. To obtain a moderate risk of bias classification, most criteria must be met and departures from the criteria are likely to have only a small impact on the validity and reliability of the prevalence estimates.
High	The estimates are not likely correct for the target population. To obtain a high risk of bias, many criteria must not be met or departures from criteria are likely to have a major impact on the validity and reliability of the prevalence estimates.
Unclear	There was insufficient information to assess the risk of bias.

S4 File. Additional data analysis details

Data Processing and Descriptive Statistics

Data processing and descriptive statistics were conducted in Python. The packages used were as follows: data manipulation: numpy, pandas, geopandas; Bayesian analysis: PyStan, arviz; regression modelling: statsmodels; data visualization: matplotlib, seaborn.

Grouping variables for analysis

Each study was grouped according to Global Burden of Disease (GBD) region^{6,7}

Age

Estimates were classified into four groups based on the reported ages of the included study participants: children and youth (0-17), adults (18-64), and seniors (65+). The following rules were used to categorize estimates when studies included participants of different ages:

- Participant age mean/median: select the category that it falls within
 - Participant age mean +/- SD: selected all categories within one standard deviation on either side of the mean
 - Participant age median and interquartile range: selected all categories that were included in the interquartile range
- Total age ranges: The age range needed to cover 30% or more of an age category to be classified in that category. As such, thresholds defining 30% for each category were defined.
 - Children and youth: Include "Children and youth" tag if age minimum was 12 or lower.
 - Adults: Include "Adults" tag if age minimum was 57 or lower
 - Adults: Include "Adults" tag if age maximum was 25 or higher.
 - Adults: Include "Adults" tag if age not reported but sample frame was health care workers
 - Seniors: Include "Seniors" tag if age maximum was 70 or higher.
 - For the seniors category, an upper limit of 72 was used (WHO reported world-wide life expectancy) in order to determine a 30% overlap⁸

Dates

When explicit dates were not provided, we inferred dates based on the reporting sampling where possible using the following rules:

- Description of a single month: selected first and last date of month
 - Example: "Samples were gathered in April" = April 1 - 30
- Description of a full month as part of a range: selected mid-month
 - Example: "Samples were gathered from April to June" = April 15 to June 15
- Description of early month: selected first two weeks as start and end end (14 days)
 - Example: "Samples were gathered in early April" = April 1 to April 13
- Description of mid-month: selected middle two weeks (14 days)
 - Example: "Samples were gathered in mid April" = April 6 to April 19
- Description of late month: selected the last two weeks as start and end date (14 days)
 - Example: "Samples were gathered in late April" = April 17 to April 30

Test correction

The sensitivity and specificity values for correction were derived, in order of preference, from: (i) the FINDDx-McGill database of independent evaluations of serological tests⁹; (ii) independent test evaluations conducted by serosurvey investigators and reported alongside serosurvey findings; (iii) manufacturer-reported sensitivity and specificity; (iv) published pooled sensitivity and specificity by immunoassay type.¹⁰ If uncorrected estimates were unavailable, we used author-reported corrected seroprevalence estimates in lieu of performing our own correction. When none of the above corrections were possible, we excluded estimates from further analysis. Details of this order of priority follow:

1. The FINDDx-McGill database of independent evaluations of serological tests.⁹ We only considered evaluations reporting both sensitivity and specificity for test performance across all sickness days (as opposed to day 1, day 5, etc). Where multiple evaluations were available, we prioritized in the following order:
 - a. The evaluation needed to match the test name, manufacturer, and target isotype used in the study

- b. The evaluation needed to match the sample specimen type used in the study
 - i. For sample types that were not reported in either the test evaluation or the serosurvey study we assumed whole blood was used for LFIA tests and serum/plasma was used for non-LFIA tests
 - ii. Plasma/Serum were used interchangeable when no direct match for index sample type was available
 - c. Prioritized reference specimen type which yield the most virus according to a systematic review and meta-analysis published in July 2020 that compared RT-PCR positivity of different specimens¹¹
 - i. It was assumed that “respiratory specimen” was referring to upper respiratory specimen as a conservative assumption as these viral loads are lower than bronchoalveolar lavage or sputum. We ranked it along side throat swab.
 - ii. “Lower respiratory specimen” was ranked with with bronchoalveolar lavage fluid
 - iii. “Upper respiratory specimen” was ranked with throat swab
 - iv. If a mixed reference sample was used in the independent evaluation then an even distribution of sample types was assumed; the average % yield of the viral load was calculated and the sample type was ranked accordingly
 - d. Largest sample size
2. Serological test evaluations conducted by study authors, where those authors were at arms-length from the design of the study in questions
 3. Manufacturer-reported sensitivity and specificity, which includes evaluations of in-house serological tests published by the research group that developed the same test
 4. Published pooled sensitivity and specificity results for ELISAs, LFIAs, and CLIAs, based on the test type known to have been used, and using the definitions for these test types provided in the cited article.¹⁰

Where evaluation sample sizes were not reported (primarily for manufacturer-conducted evaluations), we used the minimum required sample sizes for US Food and Drug Administration Emergency Use Authorization approval (30 true positive samples, 80 true negative samples).

Using the best available sensitivity and specificity values and the corresponding denominators, we corrected seroprevalence estimates for test sensitivity and specificity using Bayesian measurement error models, with binomial test evaluation data for test sensitivity and specificity, as described in Section 2 of Gelman and Carpenter (2020).¹² We built the Bayesian model described therein using the statistical package PyStan.

For each seroprevalence estimate, we used the matching seroprevalence, sensitivity, and specificity, and the corresponding denominators, to fit the specified model. The model was fit with four chains and 2000 iterations per chain (1000 warmup, 1000 sampling iterations). A model fit was considered “good” if said fit met all five of PyStan’s Hamiltonian Monte Carlo diagnostic criteria (no iterations ending with a divergence, no iterations saturating the max tree depth of 10, effective Bayesian fraction of missing information over 0.2 for all chains, a R-hat value between 0.9 and 1.1 for all parameters, the effective sample size n_{eff} being at least $0.001 \times$ the number of iterations).¹³ Model fits not meeting these criteria were discarded, and the model was rerun until five good fits were obtained for each seroprevalence estimate.

Corrected seroprevalence values were obtained for each model fit by taking the expectation of the true prevalence parameter across all sampling iterations. For each seroprevalence estimate, the corrected seroprevalence was taken to be the median corrected seroprevalence across the five good model fits. The credible interval was defined as the highest posterior density interval (equivalent to the shortest credible interval for these unimodal distributions), and was calculated using the `hpd` function from the `arviz` package.

Selecting summary seroprevalence estimates

Some studies did not report a single overall seroprevalence estimate. In most cases, this was because the study reported different sets of results for different non-overlapping subsets of the data: e.g., for multiple non-overlapping time points (e.g., May and June 2020), multiple distinct populations (e.g., teachers and schoolchildren), or multiple non-overlapping regions (e.g., two regions of the same city). Articles that provided information on two or more distinct cohorts (different sample frames or different samples at different time points) without a pooled estimate were considered to be multiple studies.

In some cases, studies did not report a single overall seroprevalence estimate because they reported different sets of results for different assays. When studies reported estimates derived from multiple assays used in combination, we prioritized a sub-group estimate based on a single test using the following prioritization (i) independent evaluation available; (ii) pan-Ig: IgG +/- IgM/IgA; IgM +/- IgA; IgA; (iii); highest combined sensitivity and specificity value. These prioritization criteria were designed to minimize bias: using data from independent evaluations is the most reliable way to correct seroprevalence estimates for test sensitivity and specificity; non-IgG antibodies appear to decline over time, especially among individuals without repeated exposure, while IgG antibodies against the spike protein appear to persist for at least three to five months after infection; and estimates that use tests with the highest sensitivity and specificity likely exhibit the least bias to begin with.¹⁴⁻¹⁷

Population differences in seroprevalence

Male and female estimates were included in the sex/gender analysis, with Female as the reference group. Estimates from Caucasian, Black, Asian, Indigenous, and Multi-racial/other racial groups were included for the race/ethnicity analysis, with Caucasian as the reference group. Children and youth (0-17), adult (18-64), and older adult (65+) estimates were included for the age analysis, with adults as the reference group. Health care workers and caregivers and the general population were included in the occupation analysis. Known and no known contact with a positive COVID-19 case were included in the exposure level analysis.

S5 File. Methods for selecting and gathering data on cumulative incidence and population size

Evidence-based timeline for COVID-19 clinical course and cumulative case data collection

- Day 0: Symptom onset
 - FYI: Exposure occurs a mean of -5 days from symptom onset¹⁵
- Day 5: Confirmation on pneumonia
 - Median of 5 days from symptom onset to confirmation of pneumonia^{18,19}
 - This is the assumed date of diagnosis
- Day 7: Presentation to hospital
 - Median of 7 days from symptom onset to presentation to hospital²⁰
 - Alternative assumption for day of diagnosis
- Day 14: Seroconversion
 - Median of 14 days from symptom onset to seroconversion (IgG)²¹

Data collection decisions

The cumulative case date of -9 days before serosurvey sampling end date was selected for analyses based on the evidence above. This assumes that the day of radiological confirmation of pneumonia is similar to the reporting date for laboratory confirmed cases of COVID-19, accounting for reporting delays. This corresponds to a median of 5 days after symptom onset and assumes a median of 14 days from symptom onset to seroconversion

Sources of data on cumulative incidence and population size

For studies reporting population-wide seroprevalence estimates, we gathered the number of total confirmed SARS-CoV-2 infections at nine days before the study end-date. We extracted case and population data at the country level for national studies. Our sources were the Johns Hopkins University (JHU) COVID-19²² tracker with population denominators from the UN Population Division estimates.²³ Using these data we calculated cases per 100,000 population for each country.

References for supplementary files

1. Boseley S. WHO warns that few have developed antibodies to Covid-19. The Guardian [Internet]. 2020 Apr 20; Available from: <https://www.theguardian.com/society/2020/apr/20/studies-suggest-very-few-have-had-covid-19-without-symptoms>
2. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc*. 2015 Sep;13(3):147–53.
3. Naing L, Winn T, Ruslil B. Practical issues in calculating the sample size for prevalence studies. *Arch Orofac Sci*. 2006;1:9–14.
4. U.S. Food & Drug Administration. Emergency Use Authorization for SARS-CoV-2 Antibody Tests [Internet]. 2020 [cited 2020 May 5]. Available from: <https://www.fda.gov/media/137470/download>.
5. Morton MBS, Bandara DK, Robinson EM, Carr PEA. In the 21st century, what is an acceptable response rate? *Aust N Z J Public Health*. 2012 April; 36 (2): 106-8.
6. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD 2019) Data Resources [Internet]. [cited 2020 Nov 11]. Available from: <http://ghdx.healthdata.org/gbd-2019>;
7. Institute for Health Metrics and Evaluation. Institute for Health Metrics and Evaluation Frequently Asked Questions [Internet]. [cited 2020 Nov 11]. Available from: <http://www.healthdata.org/gbd/faq>
8. World Health Organization. Mortality and global health estimates [Internet]. World Health Data Platform. 2020. Available from: <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates>
9. FIND. SARS-CoV-2 diagnostics: performance data [Internet]. 2020. Available from: <https://www.finddx.org/covid-19/dx-data/>
10. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ*. 2020 Jul 1;370:m2516.
11. Bwire GM, Majigo MV, Njiro BJ, Mawazo A. Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis. *J Med Virol* [Internet]. 2020 Jul 24 [cited 2020 Nov 12];n/a(n/a). Available from: <https://doi.org/10.1002/jmv.26349>
12. Gelman A, Carpenter B. Bayesian analysis of tests with unknown specificity and sensitivity. *J R Stat Soc Ser C Appl Stat*. 2020 Nov 1;69(5):1269–83.
13. Betancourt M. A Conceptual Introduction to Hamiltonian Monte Carlo. *ArXiv170102434 Stat* [Internet]. 2018 Jul 15 [cited 2020 Nov 12]; Available from: <http://arxiv.org/abs/1701.02434>
14. Bolotin S, Tran V, Osman S, Brown KA, Buchan SA, Joh E, et al. SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline. *medRxiv*. 2020 Jan 1;2020.09.28.20200915.
15. Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. *medRxiv*. 2020 Jan 1;2020.10.26.20219725.
16. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020 Oct 28;eabd7728.
17. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol*. 2020 Oct 8;5(52):eabe5511.
18. Wilson N, Kvalsvig A, Barnard LT, Baker M. Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality. *Emerg Infect Dis J*. 2020;26(6):1339.
19. Vanella P, Wiessner C, Holz A, Krause G, Moehl A, Wiegel S, et al. The role of age distribution, time lag between reporting and death and healthcare system capacity on case fatality estimates of COVID-19. *medRxiv*. 2020 Jan 1;2020.05.16.20104117.
20. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020 Aug 25;324(8):782–93.
21. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis*. 2020 Jul 28;71(15):778–85.
22. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*. 2020 May;20(5):533–4.
23. United Nations, Department of Economics and Social Affairs, Population Division. 2019 Revision of World Population Prospects [Internet]. [cited 2020 Nov 11]. Available from: <https://population.un.org/wpp/>

Supplementary tables

S1 Table. Characteristics and primary results of studies reporting population-wide seroprevalence estimates

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Central Europe, Eastern Europe, and Central Asia													
Bulgaria													
Tsaneva-Damyanova (Medical Diagnostic Laboratory "STATUS") ²	2020-03-26 to 2020-04-20	Varna Varna	Local	High	586	NR	56.1	Non-probability	Residual sera	4.8% (3.2-6.8%)	"Zhejiang Orient Gene Biotech Co.; LTD" COVID-19 IgG / IgM Rapid Test Cassette IgG, IgM	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Czechia													
Bloomfield (Charles University and Thomayer's Hospital) ⁷	2020-07-03 to 2020-08-19	Prague Prague	Sublocal	High	200	0-12 months (n=13); 1-5 years (n=52); 6-11 years (n=65); 12-18 years (n=70)	45.5	Non-probability	Residual sera	0.0% (0.0-0.5%)	Roche Diagnostics Elecsys Anti-SARS-CoV-2 assay NR	99.5%, 99.8% (Used author-adjusted estimate)	0.0% (0.0-1.2%)
Estonia													
Jogi (University of Tartu) ⁹	2020-05-08 to 2020-07-31	Saaremaa	Local	Moderate	954	0-9 (n=101); 10-19 (N=110); 20-29 (n=104); 30-39 (n=121); 40-49 (n=114); 50-59 (n=113); 60-69 (n=112); 70-79 (n=112); 80-100 (n=67)	61.7	Probability	Household and community samples	6.3% (5.0-7.9%)	Abbott; DiaSorin; SD Biosensor Abbott Architect SARS-CoV-2 IgG, Liaison DiaSorin IgG, Biosensor IgM/IgG test, Neutralization assays IgG, IgM	No data	-
Jogi (University of Tartu) ⁹	2020-05-08 to 2020-07-31	Tallinn	Local	Moderate	1006	0-9 (n=106); 10-19 (n=107); 20-29 (n=111); 30-39 (n=117); 40-49 (n=120); 50-59 (n=117);	55.9	Probability	Household and community samples	1.5% (0.9-2.5%)	Abbott; DiaSorin; SD Biosensor Abbott Architect SARS-CoV-2	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						60-69 (n=116); 70-79 (n=114); 80-100 (n=98)					IgG, Liaison DiaSorin IgG, Biosensor IgM/IgG test, Neutralization assays IgG, IgM		
Georgia													
Tsertsvadze (Infectious Diseases, AIDS and Clinical Immunology Research Center) ¹¹	2020-05-18 to 2020-05-27	Tbilisi Tbilisi	Local	Moderate	1086	18-64 (n=964); 65+ (n=104)	62.8	Non-probability	Household and community samples	1.0% (0.4-2.2%)	Zhejiang Orient Gene Biotech Co Ltd COVID 19 IgG/IgM Rapid Test Cassette IgG	93.1%, 99.2% (Used author-adjusted estimate)	1.0% (0.5-1.7%)
Hungary													
Merkely (Semmelweis University) ¹²	2020-05-01 to 2020-05-16		National	Moderate	10474	Mean 48.7 (SD 18)	53.6	Probability	Household and community samples	0.7% (0.5-0.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Russian Federation													
Popova (Saint-Petersburg Pasteur Research Institute) ¹⁷	2020-06-28 to 2020-07-19	Irkutsk Region	Regional	Moderate	2674	1-6 (n=102), 7-13 (n=191), 14-17 (n=94), 18-29 (n=385), 30-39 (n=373), 40-49 (n=374), 50-59 (n=386), 60-69 (n=390), Above 70 (n=379)	67.5	Probability	Household and community samples	5.8% (5.3-6.2%)	State Scientific Center Applied Microbiology and Biotechnology IFa anti-SARS-CoV-2 IgG IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	4.5% (2.8-6.3%)
Popova (Moscow Research Institute of Epidemiology and Microbiology named after V.I.G.N Gabrichevsky) ¹⁸	2020-06-22 to 2020-07-11	Central Russia Moscow Region	Regional	Unclear	2688	1-6 (n=111); 7-13 (n=185); 14-17 (n=88); 18-29 (n=384); 30-39 (n=384); 40-49 (n=384); 50-59 (n=384); 60-69 (n=384); 70+ (n=384)	71.0	Probability	Household and community samples	21.0%	FBSI "State scientific center for applied microbiology and biotechnology" ELISA anti-SARS-CoV-2 IgG IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	25.4% (23.0-27.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Popova (Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology) ¹⁹	2020-06-23 to 2020-06-26	Northwestern Federal District	Regional	High	3130	1-17 (n=401), 18-29 (n=464), 30-39 (n=474), 40-49 (n=510), 50-59 (n=480), 60-69 (n=422), 70+ (n=379)	NR	Probability	Household and community samples	20.7%	State Scientific Center of Applied Microbiology and Biotechnology (Obolensk) NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	24.9% (22.5-27.3%)
Barchuk (European University At St Petersburg) ²⁰	2020-05-27 to 2020-06-26	Saint Petersburg	Local	Low	988	18-34 (n=396); 35-49 (n=357); 50-64 (n=218); 65+ (n=67)	66.0	Probability	Household and community samples	9.1% (7.2-10.9%)	Genetico CoronaPass total antibodies test NR	98.7%, 100.0% (Used author-adjusted estimate)	9.1% (7.3-10.9%)
Popova (Saint-Petersburg Pasteur Research Institute of Epidemiology and Microbiology) ²¹	2020-06-15 to 2020-06-20	Saint-Petersburg	Local	High	2713	1-17 (n=377); 18-29 (n=390); 30-39 (n=416); 40-49 (n=395); 50-59 (n=413); 60-69 (n=442); >=70 (n=280)	NR	Probability	Household and community samples	26.0% (24.3-27.7%)	State Scientific Center for Applied Microbiology and Biotechnologies (Obolensk) NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	32.2% (29.5-34.9%)
Popova (Saint Petersburg Pasteur Institute) ²²	2020-06-07 to 2020-06-20	Tyumen region	Regional	High	2758	1-17 (n=356), 18-29 (n=485), 30-39 (n=452), 40-49 (n=447), 50-59 (n=482), 60-69 (n=387), >70 (n=149)	NR	Probability	Household and community samples	24.5% (22.9-26.1%)	State Research Center for Applied Microbiology and Biotechnology of Rospotrebnadzor NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	30.1% (27.6-32.9%)
Tickle (City of Moscow) ²³	2020-06-05 to 2020-06-18	Central Russia Moscow	Local	High	90000	NR	NR	Probability	Household and community samples	19.9%	NR NR NR	No data	-
Kiselyov (Russian National Council for Combating Coronavirus) ²⁵	Until 2020-06-10		National	Moderate	650000	NR	NR	Non-probability	Household and community samples	14.0%	Invitro NR NR	95.0%, 98.0% (Test developer / manufacturer evaluation)	12.2% (6.9-16.0%)
High-income													
Andorra													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Royo-Cebrecos (ISGlobal) ²⁶	2020-05-04 to 2020-05-28		National	Moderate	70494	Mean 40.4 (SD 20)	44.6	Non-probability	Household and community samples	11.0%	nCOV 2019 IgG/IgM-Zhuhai Livzon Diagnostics; Inc. Livzon® rapid test IgG, IgM	0.7%, 0.6% (FINDDx / MUHC independent evaluation)	-
Argentina													
Muñoz (Ministerio de Salud de la Provincia de Buenos Aires) ²⁷	2020-07-15 to 2020-07-16	Buenos Aires Quilmes	Sublocal	Moderate	284	Mean 40 (NR)	60.9	Non-probability	Household and community samples	14.8% (11.1-19.5%)	COVIDAR SEROKIT-ELISA COVIDAR IgG IgG	95.0%, 100.0% (Test developer / manufacturer evaluation)	15.5% (10.1-21.0%)
Austria													
Ladage (Danube Private University) ³³	2020-06-01 to 2020-06-15	Wösendorf, Weißenkirchen, Joching, St. Michael	Local	High	835	NR	51.5	Probability	Household and community samples	8.5%	N/A - Author Designed N/A - Author Designed IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	8.1% (5.4-10.9%)
Knabl (Medical University of Innsbruck) ³⁶	2020-04-21 to 2020-04-27	Tyrol Ischgl	Local	Moderate	1473	Mean 40.3 (Male); 40.9 (Female); 10.2 (Children); 45.8 (Adults) (SD 19.5 (Male); 20.1 (Female); 4.9 (Children); 16.5 (Adults))	51.5	Probability	Household and community samples	42.4% (39.8-44.7%)	EUROIMMUN ; Abbott Abbott SARS-CoV-2 IgG immunoassay, Euroimmun Anti-SARS-CoV-2 IgG IgA ELISA IgG	No data	-
Wagner (Medical University of Vienna) ³⁷	2020-04-02 to 2020-04-17	Vienna	Sublocal	High	1655	15-25 (n = 226) ; 25-50 (n = 1031) ; over 50 (n=395) ; ns (n=3)	53.5	Non-probability	Household and community samples	10.2%	Euroimmun Medizinische Labordiagnostika Euroimmune® IgG, IgA	0.9%, 0.8% (FINDDx / MUHC independent evaluation)	-
Belgium													
Herzog (University of Antwerp) ⁴¹	2020-06-29 to 2020-07-04	Wallonia, Brussels, Flanders	National	Moderate	3023	0-10 (n=110); 10-20 (n=413); 20-30 (n=394);	51.3	Non-probability	Household and	4.5% (3.7-5.4%)	EUROIMMUN Euroimmun Anti-SARS-	0.8%, 1.0% (FINDDx / MUHC	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						30-40 (n=396); 40-50 (n=403); 50-60 (n=400); 60-70 (n=403); 70-80 (n=204); 80-90 (n=160); >90 (n=140)			community samples		CoV-2 ELISA IgG IgG	independent evaluation)	
Herzog (University of Antwerp) ⁴¹	2020-06-08 to 2020-06-13	Wallonia, Brussels, Flanders	National	Moderate	2960	0-10 (n=124); 10-20 (n=375); 20-30 (n=383); 30-40 (n=395); 40-50 (n=394); 50-60 (n=393); 60-70 (n=399); 70-80 (n=201); 80-90 (n=166); >90 (n=130)	51.9	Non-probability	Household and community samples	5.5% (4.7-6.5%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Herzog (University of Antwerp) ⁴¹	2020-05-18 to 2020-05-25	Wallonia, Brussels, Flanders	National	Moderate	3242	0-10 (n=174); 10-20 (n=431); 20-30 (n=414); 30-40 (n=424); 40-50 (n=411); 50-60 (n=419); 60-70 (n=417); 70-80 (n=236); 80-90 (n=163); >90 (n=153)	51.0	Non-probability	Household and community samples	6.9% (5.9-8.0%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Herzog (University of Antwerp) ⁴¹	2020-04-20 to 2020-04-26	Wallonia, Brussels, Flanders	National	Moderate	3397	0-10 (n=85); 10-20 (n=442); 20-30 (n=375); 30-40 (n=407); 40-50 (n=406); 50-60 (n=430); 60-70 (n=426); 70-80 (n=316); 80-90 (n=315); >90 (n=195)	52.9	Non-probability	Household and community samples	6.0% (5.1-7.1%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Herzog (University of Antwerp) ⁴¹	2020-03-30 to 2020-04-05	Wallonia, Brussels, Flanders	National	Moderate	3910	0-10 (n=36); 10-20 (n=294); 20-30 (n=436); 30-40 (n=461); 40-50 (n=468); 50-60 (n=498); 60-70 (n=507); 70-80 (n=506); 80-90 (n=493); >90 (n=211)	54.0	Non-probability	Household and community samples	2.9% (2.3-3.4%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Canada													
Canadian Blood Services (Canadian Blood Services) ⁴⁷	2020-11-07 to 2020-11-25		National	Moderate	17049	17-24 (n=1,631); 25-39 (n=4644); 40-59 (n=6382); 60+ (n=4392)	43.7	Non-probability	Blood donors	1.5% (1.3-1.7%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	92.7%, 99.9% (Used author-adjusted estimate)	1.5% (1.3-1.7%)
Canadian Blood Services (Canadian Blood Services) ⁴⁸	2020-10-12 to 2020-10-31		National	Moderate	16811	17-24 (n=1,491); 25-39 (n=4,535); 40-59 (n=6,446); 60+ (n=4,339)	43.2	Non-probability	Blood donors	0.9% (0.7-1.0%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	92.7%, 99.9% (Used author-adjusted estimate)	0.9% (0.7-1.0%)
Manny (University of Alberta) ⁴⁹	2020-08-14 to 2020-10-23	Alberta Edmonton	Local	High	565	Mean 10.5 (SD 1.6)	49.2	Non-probability	Household and community samples	1.6%	Abbott Laboratories ARCHITECT i2000SR IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Bolotin (Public Health Ontario) ⁵¹	2020-08-01 to 2020-08-21	Ontario	Regional	High	5764	NR	NR	Non-probability	Residual sera	1.6%	Abbott Laboratories Abbott Architect Anti-SARS-CoV-2 IgG test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Bolotin (Public Health Ontario) ⁵¹	2020-07-04 to 2020-07-31	Ontario	Regional	High	7001	NR	NR	Non-probability	Residual sera	1.4%	Abbott Laboratories Abbott Architect Anti-SARS-CoV-2 IgG test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Héma-Québec (Héma-Québec) ⁵³	2020-05-25 to 2020-07-09	Quebec	Regional	Unclear	7691	NR	NR	Probability	Blood donors	2.2%	NR NR NR	No data	-
Bolotin (Public Health Ontario) ⁵¹	2020-06-05 to 2020-06-30	Ontario	Regional	High	7023	NR	NR	Non-probability	Residual sera	1.5%	USA: Abbott Laboratories Abbott architect SARSCoV-2 IgG test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Canadian Blood Services (Canadian Blood Services) ⁵⁵	2020-05-09 to 2020-06-18		National	Moderate	37737	17-25 (n=3581); 25-39 (n=10781); 40-59 (14147); 60+(n=9228)	46.9	Non-probability	Blood donors	0.7% (0.6-0.8%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Bolotin (Public health Ontario) ⁵¹	2020-05-05 to 2020-05-30	Ontario	Regional	High	1061	NR	NR	Non-probability	Residual sera	1.9%	USA; Abbott Laboratories Abbott architect SARS-CoV-2 IgG test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Skowronski (British Columbia Centre for Disease Control) ⁵⁶	2020-05-15 to 2020-05-27	British Columbia	Regional	Moderate	885	Median 45 (Range <10-80+)	50.5	Probability	Residual sera	0.6% (0.1-1.4%)	Ortho-Clinical Diagnostics; Abbott; Siemens Healthineers VITROS anti-SARS-CoV-2 total antibody, Abbott Architect SARS-CoV-2 IgG assay IgG, IgA, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.4%)
Bolotin (Public health Ontario) ⁵¹	2020-03-27 to 2020-04-30	Ontario	Regional	High	827	NR	NR	Non-probability	Residual sera	0.6%	USA; Abbott Laboratories Abbott architect SARS-CoV-2 IgG test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Skowronski (British Columbia Centre for Disease Control) ⁵⁶	2020-03-05 to 2020-03-13	British Columbia	Regional	Moderate	869	Median 45 (Range <10-80+)	51.1	Probability	Residual sera	0.3% (0.0-0.9%)	Ortho-Clinical Diagnostics; Abbott VITROS anti-SARS-CoV-2 total antibody, Abbott Architect SARS-CoV-2 IgG assay IgG, IgA, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.4%)
Denmark													
Jespersen (Aarhus)	2020-06-17 to 2020-06-30	Eastern Central	Regional	High	180	NR	NR	Non-probability	Blood donors	0.6% (0.0-3.5%)	Wantai Biological	96.7%, 99.5% (Used author-)	0.6% (0.1-2.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
University Hospital) ⁶¹		Denmark Region									Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG, IgA, IgM	adjusted estimate)	
Jespersen (Aarhus University Hospital) ⁶¹	2020-06-17 to 2020-06-30	Western Central Denmark Region	Regional	High	180	NR	NR	Non-probability	Blood donors	1.2% (0.0-4.4%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG, IgA, IgM	96.7%, 99.5% (Used author-adjusted estimate)	1.2% (0.2-3.5%)
Pedersen (Copenhagen University Hospital Rigshospitalet) ⁶²	2020-06-01 to 2020-06-26		National	Moderate	1110	NR	NR	Non-probability	Blood donors	2.5% (1.3-3.8%)	Beijing Wantai Biological Pharmacy Enterprise WANTAI SARS-CoV-2 Ab ELISA NR	96.7%, 99.5% (Used author-adjusted estimate)	2.5% (1.6-3.5%)
Pedersen (Copenhagen University Hospital Rigshospitalet) ⁶²	2020-06-02 to 2020-06-19		National	Moderate	1200	Median 73 (IQR 71-76)	43.0	Probability	Blood donors	1.4% (0.3-2.5%)	Beijing Wantai Biological Pharmacy Enterprise WANTAI SARS-CoV-2 Ab ELISA NR	96.7%, 99.5% (Used author-adjusted estimate)	1.4% (0.8-2.1%)
Erikstrup (Copenhagen University Hospital) ⁶⁵	2020-04-06 to 2020-05-03		National	Moderate	20640	17-69 (n=20640)	50.5	Probability	Blood donors	1.9% (0.8-2.3%)	Livzon Diagnostics 2019-nCoV IgG/IgM Antibody Detection Kit IgG, IgM	82.6%, 99.5% (Used author-adjusted estimate)	1.9% (1.7-2.1%)
Iversen (University of Copenhagen) ⁶⁶	2020-04-15 to 2020-04-22	Capital Region of Denmark	Regional	High	4672	NR	NR	Non-probability	Blood donors	3.0% (2.6-3.6%)	Livzon Diagnostics NR IgG, IgM	73.4%, 99.9% (Used author-adjusted estimate)	3.0% (2.6-3.6%)
Faroe Islands													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Petersen (University of the Faroe Islands) ⁶⁷	2020-04-27 to 2020-05-01	Faroe Islands	Regional	Low	1075	Mean 42.1 (SD 23.1)	50.0	Probability	Household and community samples	0.7%	Beijing Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG, IgM	94.4%, 100.0% (Used author-adjusted estimate)	0.7% (0.3-1.3%)
France													
Carrat (Paris University) ⁷⁵	2020-05-04 to 2020-06-23		National	Moderate	14628	<40 (n=2262), 40-50 (n=2897), 50-60 (n=3019), 60-70 (3272), 70+ (n=3175)	60.3	Probability	Household and community samples	6.7%	Euroimmun ELISA-S Anti-Sars-CoV-2 IgG IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Capai (Université de Corse) ⁷⁸	2020-04-16 to 2020-06-15	Corsica Ajaccio Corte	Regional	Moderate	1973	Median 52 (IQR 34-70)	60.2	Non-probability	Residual sera	5.5% (4.5-6.6%)	Bussy-Saint Martin; EUROIMMUN ; France EUROIMMUN ELISA IgG enzyme immunoassay kit IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Vu (Santé publique France) ⁸¹	2020-05-11 to 2020-05-17	Auvergne-Rhône-Alpes, Occitanie, Martinique, Bourgogne-Franche Comté, Île-de-France, Corse, Hauts-de-France, Guadeloupe, French Guiana, Bretagne, Pays de la Loire, Centre-Val-de-Loire,	National	Moderate	3592	0-9 (n=255); 10-19 (n=336); 20-29 (n=318); 30-39 (n=409); 40-49 (n=390); 50-59 (n=469); 60-69 (n=496); 70-79 (n=480); =>80 (n=439)	57.0	Non-probability	Residual sera	13.0%	N/A - Author Designed Luciferase-Linked ImmunoSorbent Assay N, Luciferase-Linked ImmunoSorbent Assay S, Pseudo-neutralisation assay IgG	100.0%, 100.0% (Test developer / manufacturer evaluation)	12.9% (11.5-14.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
		Grand-Est, Nouvelle-Aquitaine, La Reunion, Provence-Alpes-Côte d'Azur, Normandie											
Cohen (Centre Hospitalier Intercommunal de Créteil) ⁸²	2020-04-14 to 2020-05-12	Île-de-France Paris	Local	High	605	Mean 4.9 (SD 3.9)	46.8	Non-probability	Residual sera	10.7% (8.4-13.5%)	Biosynex Biosynex COVID-19 BSS test IgG, IgM	91.8%, 99.2% (Test developer / manufacturer evaluation)	9.9% (4.6-14.2%)
Fontanet (Institut Pasteur) ⁸⁴	2020-04-28 to 2020-04-30	Hauts-de-France Crepy-en-Valois	Local	Moderate	1340	Median NR (Pupils); 40 (parents); 47.5 (teachers); 47.5 (non-teaching staff) (IQR TR: 6-11 Pupils; 37-44 (Parents); 40-51 (Teachers); 32-54 (non-teaching staff))	57.4	Non-probability	Household and community samples	10.4%	Institut Pasteur S-Flow assay NR	99.4%, 100.0% (Test developer / manufacturer evaluation)	10.0% (7.9-12.1%)
Vu (Santé publique France) ⁸¹	2020-04-06 to 2020-04-12	Auvergne-Rhône-Alpes, Occitanie, Martinique, Bourgogne-Franche Comté, Île-de-France, Corse, Hauts-de-France, Pays de la Loire, Nouvelle-Aquitaine, Bretagne, French Guiana,	National	Moderate	3595	0-9 (n=167); 10-19 (n=298); 20-29 (n=355); 30-39 (n=461); 40-49 (n=455); 50-59 (n=489); 60-69 (n=487); 70-79 (n=455); =>80 (n=428)	56.7	Non-probability	Residual sera	10.7%	N/A - Author Designed Luciferase-Linked ImmunoSorbent Assay N, Luciferase-Linked ImmunoSorbent Assay S, Pseudo-neutralisation assay IgG	100.0%, 100.0% (Test developer / manufacturer evaluation)	10.5% (9.1-11.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
		Centre-Val-de-Loire, Grand-Est, Guadeloupe, La Reunion, Provence-Alpes-Côte d'Azur, Normandie											
Gallian (Unite des Virus Emergents) ⁸⁶	2020-03-25 to 2020-04-07	Hauts-de-France, Provence-Alpes-Côte d'Azur, Île-de-France, Grand-Est	National	High	998	Median 41 (NR)	49.0	Non-probability	Blood donors	2.7%	Author-designed N/A - Author-designed NR	No data	-
Grzelak (Institut Pasteur) ⁸⁷	2020-03-20 to 2020-03-24	Hauts-de-France Clermont, Lille, Noyon	Local	High	200	NR	NR	Non-probability	Blood donors	0.0%	Author-designed N/A - Author-designed IgG, IgA, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.5% (0.0-2.0%)
Vu (Santé publique France) ⁸¹	2020-03-09 to 2020-03-15	Auvergne-Rhône-Alpes, Occitanie, Martinique, Bourgogne-Franche Comté, Corse, Île-de-France, Hauts-de-France, Pays de la Loire, Nouvelle-Aquitaine, Bretagne, French Guiana,	National	Moderate	3834	0-9 (n=359); 10-19 (n=420); 20-29 (n=420); 30-39 (n=500); 40-49 (n=487); 50-59 (n=461); 60-69 (n=455); 70-79 (n=382); =>80 (n=347)	55.9	Non-probability	Residual sera	3.8%	N/A - Author Designed Luciferase-Linked ImmunoSorbent Assay N, Luciferase-Linked ImmunoSorbent Assay S, Pseudo-neutralisation assay IgG	100.0%, 100.0% (Test developer / manufacturer evaluation)	3.5% (2.3-4.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
		Grand-Est, Centre-Val-de-Loire, Guadeloupe, La Reunion, Provence-Alpes-Côte d'Azur, Normandie											
Germany													
Fuest (ifo Institute) ⁸⁹	2020-10-26 to 2020-11-18		National	Unclear	9929	18+	NR	Non-probability	Household and community samples	1.1% (0.9-1.3%)	Roche Elecsys NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Robert Koch Institute (Robert Koch Institute) ⁹⁰	2020-04-15 to 2020-11-05		National	Moderate	48976	NR	NR	Probability	Blood donors	1.8%	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.2% (0.0-0.5%)
Schwarz (University of Witten) ⁹³	2020-06-15 to 2020-09-01		National	High	731	NR	NR	Non-probability	Residual sera	11.2%	Cleartest IgM; Euroimmun IgA; Diasorin IgG; Euroimmun IgG; Nadal IgM; Microgen IgG; Roche IgM Multiple IgG, IgA, IgM	No data	-
Laub (University of Regensburg) ⁹⁷	2020-05-22 to 2020-07-22	Bavaria	Regional	Moderate	2832	NR	42.7	Non-probability	Household and community samples	4.9%	Roche Diagnostics Elecsys Anti-SARS-CoV-2 IgG, IgA, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Aziz (University of Bonn) ¹⁰¹	2020-04-24 to 2020-06-30	North Rhine-	Local	High	4771	30-100	56.9	Non-probability	Household and	1.0% (0.7-1.3%)	EUROIMMUN Euroimmun Anti-SARS-	0.6%, 0.9% (FINDDx / MUHC)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
		Westphalia Bonn							community samples		CoV-2 ELISA IgG IgG	independent evaluation)	
Aziz (University of Bonn) ¹⁰¹	2020-04-24 to 2020-06-30	North Rhine-Westphalia Bonn	Local	High	360	30-100	60.6	Non-probability	Household and community samples	1.9% (0.8-4.4%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Runkel (University Medical Center of The Johannes Gutenberg-University Mainz) ¹⁰⁴	2020-03-15 to 2020-06-15	Southwest	Regional	High	3880	18-29 (n=1292); 30-39 (n=772); 40-49 (n=537); 50-59 (n=797); 60-71 (n=282)	45.3	Non-probability	Blood donors	0.9%	Abbott Laboratories ARCHITECT Anti-SARS-CoV-2 IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Santos-Hovener (Robert Koch Institute) ¹⁰⁵	2020-05-20 to 2020-06-09	Baden-Württemberg Kupferzell	Local	Low	2203	18-34 (n= 713); 35-49 (n=533); 50-64 (n=572); =>65 (n= 385)	51.9	Probability	Household and community samples	12.0% (10.4-14.0%)	Euroimmun SARS-CoV-2-S1 ELISA IgG	88.3%, 99.2% (Used author-adjusted estimate)	12.0% (10.7-13.4%)
Herrmann (Internal medicine and laboratory medicine specialist practice and laboratory) ¹⁰⁷	2020-03-26 to 2020-06-04	North Rhine-Westphalia	Regional	High	415	Mean 42 (SD 27)	NR	Non-probability	Residual sera	1.2%	Euroimmun anti-SARS-CoV-2-ELISA-IgG IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Fischer (Heart and Diabetes Center NRW) ¹⁰⁸	2020-03-09 to 2020-06-03	Lower Saxony, North Rhine-Westphalia, Hesse	Regional	High	3186	NR	70.8	Non-probability	Residual sera	0.9% (0.6-1.2%)	DiaSorin; EUROIMMUN ; Abbott Abbott Architect SARS-CoV-2 IgG assay, Euroimmun Anti-SARS-CoV-2 ELISA IgG, LIAISON SARS-CoV-2 S1/S2 IgG IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.3%)
Weis (Jena University Hospital) ¹¹¹	2020-05-12 to 2020-05-22	Thuringia	Local	Moderate	620	Mean 58.1 (adults); 9.6 (children) (SD 16.5 (adults);	51.3	Probability	Household and community samples	8.4%	Snibe Diagnostic; EUROIMMUN ; Roche;	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						4.38 (children)					DiaSorin; Epitope Diagnostics; Abbott EDI Novel Coronavirus SARS-CoV-2 IgG ELISA kit, SARS-CoV-2 IgG ELISA kit, SARS-CoV-2 S1/S2 IgG CLIA kit, 2019-nCoV IgG kit, SARS-CoV-2 IgG CMIA kit, Elecsys Anti-SARS-CoV-2 kit IgG		
Weis (Friedrich Schiller University) ¹¹³	2020-05-13 to 2020-05-16	Thuringia	Sublocal	Moderate	620	Mean 58.1 (adults); 9.62 (children and adolescents) (SD 16.5 (adults); 4.38 (children and adolescents))	51.3	Non-probability	Household and community samples	8.4%	USA Euroimmun; Lübeck; USA Roche; Italy Snibe Co.; Ltd.; Basel Switzerland; China Abbott; Shenzhen; Saluggia; Germany DiaSorin; Epitope Diagnostics Inc.; San Diego; Chicago EDI Novel Coronavirus SARS-CoV-2 IgG ELISA kit, SARS-CoV-2 IgG ELISA kit, SARS-CoV-2 S1/S2 IgG CLIA kit, 2019-nCoV IgG kit, SARS-CoV-2 IgG CMIA kit and Elecsys Anti-SARS-CoV-2 kit. IgG	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Reisinger (Universitätsmedizin Rostock) ¹¹⁸	2020-04-20 to 2020-04-22	Mecklenburg-Westpomerania Rostock	Sublocal	High	401	Mean 36.9 (NR)	100.0	Non-probability	Household and community samples	3.0%	EUROIMMUN Euroimmun Anti-SARS-CoV-2 IgG IgA ELISA IgG, IgA	0.9%, 0.8% (FINDDx / MUHC independent evaluation)	-
Streeck (University of Bonn) ¹²⁵	2021-03-31 to 2020-04-06	Heinsberg Gangelt	Local	Low	919	Median 53 (Range 1-90)	50.8	Probability	Household and community samples	14.1% (11.2-17.3%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	90.9%, 99.1% (Used author-adjusted estimate)	14.1% (11.9-16.4%)
Greece													
Bogogiannidou (University of Thessaly) ¹²⁹	2020-03-01 to 2020-04-30	Epirus, Western Macedonia, Thessaly, Central Macedonia, Attica, Peloponnese, Western Greece, Central Greece	National	Moderate	6586	0-29 (n=1464); 30-49 (n=2066); 50-69 (n=1762); >=70 (n=1294)	55.0	Non-probability	Residual sera	0.4%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Iceland													
Gudbjartsson (deCODE Genetics) ¹³⁰	2020-04-27 to 2020-06-12		National	Moderate	23452	Mean 56 (SD 20)	NR	Non-probability	Household and community samples	0.3%	Wantai/Nordic BioSite; Roche International Roche Elecsys chemiluminescence assay, Wantai SARS CoV-2 Total Antibody ELISA IgG, IgA, IgM	91.1%, 99.8% (Test developer / manufacturer evaluation)	0.1% (0.0-0.3%)
Ireland													
Igoe (HSE Health Protection Surveillance)	2020-06-22 to 2020-07-16	Leinster, Connaught Dublin, Sligo	National	Moderate	1733	12-19 (n=3); 20-29 (n=7); 30-39 (n=5); 40-49 (n=7);	NR	Probability	Household and community samples	1.7% (1.1-2.4%)	FORTRESS; Abbott Abbott Architect SARS-CoV-2 IgG assay,	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author)	0.2% (0.0-0.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Centre (HPSC)) ¹³¹						50-59 (n=5); 60-69 (n=6)					FORTRESS (Wantai)-2 Assay IgG	adjustment available	
Israel													
Rabinowitz (The Central Bureau of Statistics) ¹³²	2020-06-15 to 2020-08-15	Bnei Brak	Local	Moderate	3500	NR	NR	Probability	Household and community samples	14.6%	NR NR NR	No data	-
Efrati (Israeli Pandemic Task Force) ¹³³	Until 2020-06-02	Israel	National	Moderate	1700	NR	NR	Probability	Household and community samples	2.5%	NR NR IgG	No data	-
Italy													
Italian Ministry of Health (Italian Ministry of Health) ¹³⁷	2020-05-25 to 2020-07-15	Molise, Campania, Friuli-Venezia Giulia, Abruzzo, Lazio, Liguria, Basilicata, Lombardy, Piemonte, Umbria, Sicily, Calabria, Sardegna, Valle D'Aosta, Veneto, Emilia Romagna, Puglia, Trentino-Alto Adige, Marche, Tuscany	National	Unclear	64660	NR	NR	Non-probability	Household and community samples	2.5%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Cento (Universita degli Studi di Milano) ¹³⁹	2020-05-11 to 2020-07-05	Lombardy Milan	Sublocal	Moderate	2753	=<10 (n=8); 11-24 (n=132); 25-49 years (n=786); 50-64 (n=545); 65-84	49.5	Non-probability	Residual sera	3.3%	Abbott Park; Abbott; Saluggia; Italy; Illinois; US; DiaSorin	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author	1.2% (0.2-2.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						(n=984); =>85 (n=316)					S.p.A. Abbott ARCHITECT SARS-CoV-2 IgG assay; LIAISON1 SARS-CoV-2 S1/S2 IgG assay IgG	adjustment available)	
Berte (University of Cagliari) ¹⁴¹	2020-04-15 to 2020-06-15	Lombardy Milan	Local	High	129	Median 45 (IQR 35-60)	34.9	Non-probability	Household and community samples	7.0% (4.4-9.6%)	University of Cagliari N/A - Author Designed IgG, IgA	97.6%, 95.2% (Test developer / manufacturer evaluation)	3.3% (0.0-8.5%)
Pagani (University of Milan) ¹⁴³	2020-05-18 to 2020-06-07	Lombardy Castiglione D'Adda	Local	Moderate	509	Median 46 (IgG negative); 55.4 (IgG positive) (SD 20.6 (IgG negative); 19.5 (IgG positive))	48.9	Probability	Household and community samples	22.6% (17.2-29.1%)	Abbott IgG Anti-SARS-CoV-2 CLIA IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Amante (Bergamo Health Agency) ¹⁴⁵	2020-04-23 to 2020-06-03	Lombardy	Regional	Moderate	9965	NR	NR	Probability	Household and community samples	57.0%	NR NR NR	No data	-
Fiore (University of Foggia) ¹⁴⁹	2020-05-01 to 2020-05-31	Apulia Foggia	Local	High	904	18 to 25 (n=112, 12.4%), 26 to 35 (n=195, 21.6%), 36 to 45 (n=202, 22.3%), 46 to 55 (n=149, 27.2%), 56 to 65 (n=149, 16.5%)	26.4	Non-probability	Blood donors	1.0%	"New Industries Biomedical Engineering Co.; Ltd" NR IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.5%)
Alessi (ASL Vercelli) ¹⁵⁴	2020-05-23 to 2020-05-24	Piedmont Borgosesia	Local	High	4987	Mean 55 years (Range 18-97)	54.2	Non-probability	Household and community samples	4.9% (4.3-5.5%)	Prima Lab SA COVID-19 IgG/IgM Rapid Test Cassette IgG, IgM	0.8%, 0.9% (FINDDx / MUHC independent evaluation)	-
Stefanelli (Azienda Provinciale per i Servizi Sanitari) ¹⁶¹	2020-05-05 to 2020-05-15	Trento	Regional	Low	6075	Median 50 (Range 10-98)	51.3	Probability	Household and community samples	25.7%	Abbott Laboratories Abbott SARS-CoV-2 IgG assay IgG	90.0%, 100.0% (Used author-adjusted estimate)	25.7% (24.6-26.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Guerrero (Istituto di Ricovero e Cura A Carattere) ¹⁶³	2020-04-25 to 2020-05-08	Veneto Verona	Local	Moderate	1515	Mean 52.1 (SD 20)	53.9	Probability	Household and community samples	2.7%	Abbott Laboratories Abbott test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Baracco (A.S.S.T.Lodi) ¹⁶⁴	2020-04-23 to 2020-05-05	Lombardy region Lodi	Local	Moderate	1792	Mean 44 (SD 16.0)	64.7	Probability	Household and community samples	29.8%	DiaSorin The Liaison® DiaSorin® SARS-CoV-2 S1/S2 IgG test IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Vena (University of Genoa) ¹⁶⁷	2020-03-01 to 2020-04-30	Lombardy , Liguria	Regional	High	3609	Median 51 (IQR 41-63)	55.6	Non-probability	Residual sera	11.0% (10.0-12.1%)	Biosynex; Realy-Tech; Maglumi MAGLUMI80 0TM 2019-nCoV IgG (Cat. Ref. 130219015M) and IgM (130219016M), Realy-Tech 2019 nCoV/COVID-19 IgG/IgM Rapid Test, Biosynex COVID-19 BSS test IgG, IgM	No data	-
Landro (ATS Bergamo) ¹⁷⁰	2020-04-23 to 2020-04-28	Lombardy Nembro, Alzano	Local	Unclear	750	NR	NR	Non-probability	Household and community samples	61.0%	NR NR NR	No data	-
Loconsole (Policlinico Hospital) ¹⁷³	2020-03-23 to 2020-04-21	Apulia Bari	Local	High	819	Median 66 (IQR 52-80)	44.6	Non-probability	Residual sera	8.6%	VivaChek Biotech VivaDiag COVID-19 IgM/IgG Rapid Test IgG, IgM	0.8%, 0.7% (FINDDx / MUHC independent evaluation)	-
Cito (Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise G. Caporale) ¹⁷⁴	2020-04-18 to 2020-04-19	Abruzzo Villa Caldari	Local	Moderate	667	Mean 58.6 (seropositive); 47.3 (seronegative) (IQR 28.5 (seropositive);	50.2	Probability	Household and community samples	10.9% (8.8-13.5%)	China; Beijing; Beijing Wantai Biological Pharmacy Enterprise Co. WANTAI SARS-CoV-2	1.0%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						28.1 (seronegative))					Total Ab ELISA NR		
Valenti (Fondazione IRCCS Ca' Granda Ospedale Maggiore) ¹⁷⁹	2020-02-24 to 2020-04-08	Lombardy Milan	Local	High	789	Mean 42.6 (SARS-CoV-2 antibodies present); 40.7 (SARS-CoV-2 antibodies absent); (SD 13.4 (SARS-CoV-2 antibodies present); 13.2 (SARS-CoV-2 antibodies absent);)	35.0	Non-probability	Blood donors	5.1%	Prima Lab PRIMA COVID-19 IgG/IgM Rapid Test IgG, IgM	0.8%, 0.9% (FINDDx / MUHC independent evaluation)	-
Percivalle (IRCCS Policlinico San Matteo) ¹⁸⁰	2020-03-18 to 2020-04-06	Lombardy Lodi	Local	High	390	Median 46 (Range 19-70)	30.3	Non-probability	Blood donors	23.3%	Author-designed N/A - Author-designed NR	95.0%, 100.0% (Test developer / manufacturer evaluation)	22.7% (15.0-30.6%)
Milani (University of Milan) ¹⁸²	2020-03-30 to 2020-03-31	Lombardy Milan	Local	High	197	NR	NR	Non-probability	Household and community samples	10.2%	EUROIMMUN ; Beijing Wantai Biological Pharmacy Enterprise Wantai SARS-CoV-2 Ab ELISA, Euroimmun Anti-SARS-CoV-2 ELISA IgG, Wantai Anti-SARS-CoV-2 IgM ELISA IgG, IgA, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	10.1% (4.8-16.0%)
Pancrazzi (Ospedale San Donato) ¹⁸³	2020-03-17 to 2020-03-21	Tuscany Arezzo	Local	High	516	Mean 53.7 years (NR)	54.5	Non-probability	Residual sera	13.0%	Acro Biotech Inc. Acro Biotech COVID-19 Rapid Test IgG, IgM	0.4%, 0.9% (FINDDx / MUHC independent evaluation)	-
Japan													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Nawa (Tokyo Medical and Dental University) ¹⁹⁰	2020-06-14 to 2020-07-05	Kantō Utsunomiya City	Local	Moderate	742	<10 (n=56); 10-17 (n=42); 18-65 (n=463); >65 (n=181)	52.6	Probability	Household and community samples	1.2% (0.2-1.2%)	Shenzhen YHLO Biotech Co NR IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Okuda (Health and Welfare Department) ¹⁹¹	2020-06-15 to 2020-06-28	prefecture 3	Regional	Unclear	3000	NR	NR	Non-probability	Residual sera	0.0%	NR NR IgG	No data	-
Takita (Navitas Clinic Tachikawa) ¹⁹⁷	2020-04-20 to 2020-05-20	Kantō, Chūbu Yamanashi, Chiba, Kangawa, Saitama, Tokyo	Local	High	1071	<=17 (n=13); 18-34 (n=134); 35-54 (n=653); >=55 (n=271)	46.2	Non-probability	Household and community samples	3.8% (2.8-5.2%)	Kurabo Industries SARS-CoV-2 Antibody Testing Kit IgG (RC - NC002) IgG	76.4%, 100.0% (Test developer / manufacturer evaluation)	4.3% (0.2-6.9%)
Doi (Kobe City Medical Center General Hospital) ²⁰⁰	2020-03-31 to 2020-04-07	Hyogo Prefecture Kobe	Local	High	1000	0-10 (n=81); 0-19 (n=27); 20-29 (n=36); 30-39 (n=90); 40-49 (n=155); 50-59 (n=164); 60-69 (n=171); 70-79 (n=166); 80-89 (n=164); >=90 (n=19)	51.1	Probability	Residual sera	2.7% (1.8-3.9%)	Kurabo Industries SARS-CoV-2 Antibody Testing Kit IgG (RC - NC002) IgG	76.4%, 100.0% (Test developer / manufacturer evaluation)	2.8% (0.0-4.8%)
Luxembourg													
Snoeck (Luxembourg Institute of Health) ²⁰³	2020-04-15 to 2020-05-05		National	Moderate	1820	Mean 47 (SD 15)	52.1	Probability	Household and community samples	2.1% (1.4-2.8%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Monaco													
Binacchi (Principality of Monaco) ²⁰⁴	2020-05-26 to 2020-06-16		National	Unclear	35000	NR	NR	Non-probability	Household and community samples	2.8%	NR NR NR	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.5%)
Netherlands													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Vos (Centre for Infectious Disease Control) ²⁰⁵	2020-03-31 to 2020-05-11		National	Low	570	2-17 (n = 93) ; 18-39 (n =196) ; 40-64 (n=198) ; 65-90 (n = 83)	40.9	Probability	Household and community samples	2.9% (1.4-6.3%)	NR fluorescent bead-based multiplex-immunoassay IgG	84.4%, 99.0% (Used author-adjusted estimate)	2.9% (1.7-4.4%)
Vos (Centre for Infectious Disease Control) ²⁰⁵	2020-03-31 to 2020-05-11		National	Low	2637	2-17 (n = 507) ; 18-39 (n = 735) ; 40-64 (n=919) ; 65-90 (n = 476)	55.1	Probability	Household and community samples	2.8% (2.1-3.7%)	NR fluorescent bead-based multiplex-immunoassay IgG	84.4%, 99.0% (Used author-adjusted estimate)	2.8% (2.2-3.4%)
Slot (Amsterdam UMC) ²⁰⁶	2020-04-01 to 2020-04-15		National	Moderate	7361	18-30 (n=1251); 31-40 (n=882); 41-50 (n=1354); 51-60 (n=2132); 60-72 (n=1742)	47.8	Non-probability	Blood donors	3.4%	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG, IgA, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Westerhuis (Erasmus Medical Centre) ²⁰⁷	2020-04-03 to 2020-04-07	Rotterdam	Sublocal	High	729	6-12 months (n=17); 1-2 (n=14); 2-5 (n=24); 5-10 (n=34); 10-20 (n=139); 20-40 (n=140); 40-60 (n=140); 60-80 (n=139); 80+ (n=82)	NR	Non-probability	Residual sera	2.3%	Author-designed N/A - Author-designed IgG	No data	-
Westerhuis (Erasmus Medical Centre) ²⁰⁷	2020-03-02 to 2020-03-06	Rotterdam	Sublocal	High	879	6-12 months (n=41); 1-2 (n=75); 2-5 (n=42); 5-10 (n=96); 10-20 (n=131); 20-40 (n=131); 40-60 (n=134); 60-80 (n=124); 80+ (n=105)	NR	Non-probability	Residual sera	0.1%	Author-designed N/A - Author-designed IgG	No data	-
Norway													
Tunheim (Norwegian Institute of	2020-04-20 to 2020-05-17		National	Moderate	900	0-4 (n=41); 5-14 (n=115);15-24 (n=166); 25-	56.6	Non-probability	Residual sera	1.1% (0.5-2.0%)	Oslo University Hospital"; " Department of	86.0%, 100.0% (Test developer	0.8% (0.0-1.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Public Health) ²⁰⁹						59 (n=372); ≥60 (n=206)					Immunology N/A - Author- designed IgG	/ manufacturer evaluation)	
Portugal													
Kislaya (Instituto Nacional de Saúde Doutor Ricardo Jorge) ²¹⁵	2020-05-21 to 2020-07-08	Alentejo Region, Centro Region, Algarve Region, Madeira, Lisboa Region, Norte Region, Azores	National	Moderate	2301	1-9 (n = 404) 10-19 (n = 377) 20-39 (n = 377) 40-59 (n = 479) >= 60 (n = 664)	54.1	Non-probability	Residual sera	2.9% (2.0-4.2%)	1) Wantai 2) EUROIMMUN 1) Wantai SARS-CoV-2 enzyme- linked immunosorbent assay (ELISA), 2) EUROIMMUN anti-SARS-CoV-2 assay IgG, IgM	96.0%, 98.7% (Test developer / manufacturer evaluation)	1.1% (0.0-2.6%)
Republic of Korea													
KBS World (Korea Disease Control and Prevention Agency) ²¹⁷	2020-08-15 to 2020-10-15		National	Unclear	1379	NR	NR	Non-probability	Household and community samples	0.2%	NR NR NR	No data	-
Ji-Ho (Korea Centers for Disease Control and Prevention) ²¹⁸	Until 2020-07-09	Korea	National	Unclear	3055	NR	NR	Non-probability	Household and community samples	0.0%	NR NR NR	No data	-
Noh (Korea University) ²²⁰	2020-05-25 to 2020-05-29	Seoul	Local	Moderate	1500	0-19 (n=226); 20-29 (n=258); 30-39 (n=261); 40-49 (n=254); 50-59 (n=255); >60 (n=246)	51.3	Non-probability	Residual sera	0.1%	Roche elecsys Elecsys Anti-SARS-CoV-2 kit NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Singapore													
Kurohi (Singapore National Centre for Infectious Diseases) ²²²	2020-02-15 to 2020-04-15	Singapore	Local	Unclear	774	NR	NR	Non-probability	Household and community samples	0.0%	NR NR NR	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Spain													
Flores (Municipality of Torrejon de Ardoz) ²³⁰	2020-05-29 to 2020-06-03	Torrejon de Ardoz	Local	Moderate	104299	>=1	NR	Probability	Household and community samples	23.1%	NR NR IgG, IgM	No data	-
Pollán (Institute of Health Carlos III) ²³⁶	2020-04-27 to 2020-05-11		National	Low	51958	0–19 (n=11422); 20–34 (n=8469); 35–49 (n=14532); 50–64 (n=15094); >=65 (n=11558)	61.1	Probability	Household and community samples	4.6% (4.3–5.0%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Montenegro (Sardenya Primary Health Care Center) ²⁴³	2020-04-21 to 2020-04-24	Catalonia Barcelona	Local	High	311	Mean 43.7 (SD 21.79)	55.0	Probability	Household and community samples	5.5% (3.4–8.6%)	Lysine and Sure Screen; Livzlon Livzlon, Lysine, Sure Screen IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	3.6% (0.0–7.5%)
Sweden													
The Local (Werlabs) ²⁵⁰	2020-07-01 to 2020-07-22	Uppland, Skåne, Västra Götaland Gothenburg, Stockholm, Malmo	Local	High	83000	NR	NR	Non-probability	Household and community samples	14.4%	Werlabs NR NR	No data	-
Region (Sweden Public Health Authority) ²⁵¹	2020-06-15 to 2020-07-15	Uppland Stockholm	Local	High	149616	NR	NR	Non-probability	Household and community samples	17.6%	NR NR NR	No data	-
Lundkvist (Uppsala University) ²⁵³	2020-06-17 to 2020-06-18	Uppland, Södermanland Stockholm	Sublocal	High	123	Mean 37 (NR)	57.7	Probability	Household and community samples	4.1% (0.6–7.6%)	Zhejiang Orient Gene Biotech Co Ltd COVID-19 IgG / IgM Rapid Test Cassette IgG, IgM	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Lundkvist (Uppsala University) ²⁵³	2020-06-17 to 2020-06-18	Uppland, Södermanland Stockholm	Sublocal	High	90	Mean 50 (NR)	28.9	Probability	Household and community samples	30.0% (20.3-39.7%)	Zhejiang Orient Gene Biotech Co Ltd COVID-19 IgG / IgM Rapid Test Cassette IgG, IgM	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Swedish Public Health Agency (Sweden Public Health Authority) ²⁵⁵	2020-06-08 to 2020-06-14	Örebro, Västerbotten Västra Götaland, Skåne, Jönköping, Kalmar, Uppsala, Stockholm, Jämtland-Härjedalen	National	High	1200	NR	NR	Non-probability	Residual sera	5.2% (3.7-7.1%)	Sci LifeLab / KTH NR NR	99.4%, 0.0% (Used author-adjusted estimate)	5.2% (4.0-6.5%)
Swedish Public Health Agency (Sweden Public Health Authority) ²⁵⁵	2020-06-01 to 2020-06-07	Örebro, Västerbotten Västra Götaland, Skåne, Jönköping, Kalmar, Uppsala, Stockholm, Jämtland-Härjedalen	National	High	1200	NR	NR	Non-probability	Residual sera	6.8% (5.1-8.8%)	Sci LifeLab / KTH NR NR	99.4%, 0.0% (Used author-adjusted estimate)	6.8% (5.4-8.3%)
Swedish Public Health Agency (Sweden Public Health Authority) ²⁵⁵	2020-05-25 to 2020-05-31	Örebro, Västerbotten Västra Götaland, Skåne, Jönköping, Kalmar, Uppsala, Stockholm, Jämtland-Härjedalen	National	High	1200	NR	NR	Non-probability	Residual sera	5.7% (4.0-7.7%)	Sci LifeLab / KTH NR NR	99.4%, 0.0% (Used author-adjusted estimate)	5.7% (4.5-7.1%)
Swedish Public Health	2020-05-18 to 2020-05-24	Örebro, Skåne,	National	High	1200	NR	NR	Non-probability	Residual sera	5.2% (3.7-7.0%)	Sci LifeLab / KTH NR NR	99.4%, 0.0% (Used author-	5.2% (4.0-6.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Agency (Sweden Public Health Authority) ²⁵⁵		Stockholm, Jönköping, Kalmar, Uppsala, Västerbotten, Västra Götaland, Jämtland-Härjedalen										adjusted estimate)	
Roxhed (KTH Royal Institute of Technology) ²⁵⁶	2020-04-01 to 2020-05-21	Uppland Stockholm	Local	Moderate	878	20-29 (n=135); 30-39 (n=174); 40-49 (n=165); 50-59 (n=151); 60-69 (n=130); 70-74 (n=79); Missing (n=44)	55.0	Probability	Household and community samples	5.4%	Author-designed N/A - Author-designed IgG, IgM	100.0%, 100.0% (Test developer / manufacturer evaluation)	5.4% (3.9-7.1%)
Swedish Public Health Agency (Sweden Public Health Authority) ²⁵⁵	2020-05-11 to 2020-05-17	Örebro, Västerbotten, Västra Götaland, Skåne, Jönköping, Kalmar, Uppsala, Stockholm, Jämtland-Härjedalen	National	High	1200	NR	NR	Non-probability	Residual sera	4.5% (3.1-6.2%)	Sci LifeLab / KTH NR NR	99.4%, 0.0% (Used author-adjusted estimate)	4.5% (3.4-5.8%)
Swedish Public Health Agency (Sweden Public Health Authority) ²⁵⁵	2020-05-04 to 2020-05-10	Örebro, Västerbotten, Västra Götaland, Skåne, Jönköping, Kalmar, Uppsala, Stockholm, Jämtland-Härjedalen	National	High	1200	NR	NR	Non-probability	Residual sera	3.9% (2.6-5.4%)	Sci LifeLab / KTH NR NR	99.4%, 0.0% (Used author-adjusted estimate)	3.9% (2.9-5.0%)
Swedish Public Health Agency (Sweden)	2020-04-27 to 2020-05-03	Örebro, Västerbotten, Västra Götaland,	National	High	1200	NR	NR	Non-probability	Residual sera	4.0% (2.7-5.7%)	Sci LifeLab / KTH NR NR	99.4%, 0.0% (Used author-adjusted estimate)	4.0% (3.0-5.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Public Health Authority) ²⁵⁵		Skåne, Jönköping, Kalmar, Uppsala, Stockholm, Jämtland-Härjedalen											
Swedish Public Health Agency (Sweden Public Health Authority) ²⁵⁵	2020-04-20 to 2020-04-26	Örebro, Västerbotten, Västra Götaland, Skåne, Jönköping, Kalmar, Uppsala, Stockholm, Jämtland-Härjedalen	National	High	1200	NR	NR	Non-probability	Residual sera	5.3% (3.8-7.1%)	Sci LifeLab / KTH NR NR	99.4%, 0.0% (Used author-adjusted estimate)	5.3% (4.1-6.6%)
Switzerland													
Ulyte (University of Zurich) ²⁵⁹	2020-06-16 to 2020-11-19	Zurich Zurich	Regional	Low	2507	Median 8 (lower school); 11 (middle school); 14 (upper school) (Range 6-10 (lower school); 8-13 (middle school); 11-16 (upper school))	NR	Probability	Household and community samples	8.2%	Institute of Medical Virology (IMV) of the University of Zurich ABCORA 2.0 binding assay IgG, IgA, IgM	94.3%, 99.0% (Test developer / manufacturer evaluation)	6.8% (2.5-9.8%)
Anker (Université de Fribourg) ²⁶⁰	2020-07-08 to 2020-10-14	Canton of Fribourg	Regional	Moderate	418	Mean 58 (SD 17)	54.1	Probability	Household and community samples	8.0% (4.0-12.0%)	N/A - institutionally designed (Centre Hospitalier Universitaire Vaudois (CHUV); l'École Polytechnique Fédérale de Lausanne (EPFL) et l'Institut Suisse	96.6%, 99.7% (Used author-adjusted estimate)	8.0% (5.6-10.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											de Recherche sur les Vaccins) SenASTrIS (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological) IgG, IgA		
Universita della Svizzera Italiana (The Institute of Public Health on the Università della Svizzera italiana) ²⁶²	2020-07-01 to 2020-07-31		Local	Unclear	647	20-64	NR	Probability	Household and community samples	11.0%	Centre Hospitalier Universitaire Vaudois (CHUV) in collaboration with the Swiss Federal Institute of Technology in Lausanne (EPFL) and the Swiss Centre for Vaccine Research. NR NR	No data	-
Emmenegger (University of Zurich) ²⁶³	2020-07-01 to 2020-07-15	Zurich Zurich	Local	Moderate	1067	NR	NR	Non-probability	Blood donors	0.7% (0.3-1.2%)	Author-designed Tripartite Automated Blood Immunoassay IgG	100.0%, 100.0% (Test developer / manufacturer evaluation)	0.4% (0.0-1.0%)
Emmenegger (University of Zurich) ²⁶³	2020-05-15 to 2020-07-15	Zurich Zurich	Local	Moderate	12831	NR	NR	Non-probability	Residual sera	0.9%	Author-designed Tripartite Automated Blood Immunoassay IgG	100.0%, 100.0% (Test developer / manufacturer evaluation)	0.5% (0.0-0.9%)
Ulyte (University of Zurich) ²⁶⁴	2020-06-16 to 2020-07-09	Zurich Zurich	Local	Moderate	577	NR	NR	Probability	Household and community samples	3.3% (1.4-5.5%)	Swiss Federal Institute of Technology in Lausanne; Swiss Vaccine Center; Centre Hospitalier Universitaire	98.3%, 98.4% (Used author-adjusted estimate)	3.3% (2.1-5.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											Vaudois SenASTrIS (Sensitive Anti-SARS-COV-2 Spike Trimer Immunoglobulin Serological) IgG, IgA		
Bi (Johns Hopkins Bloomberg School of Public Health) ²⁶⁵	2020-04-03 to 2020-06-30	Geneva	Regional	Moderate	4534	Median 53 (IQR 34-65)	53.6	Non-probability	Household and community samples	6.6% (6.0-7.0%)	Euroimmun NR IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Richard (Geneva University Hospital) ²⁶⁶	2020-04-06 to 2020-06-30	Canton of Geneva	Regional	Low	8344	Mean 46.9 (Range 5-94)	53.5	Probability	Household and community samples	7.8% (6.8-8.9%)	Euroimmun SARS-CoV-2 IgG ELISA IgG	93.0%, 100.0% (Used author-adjusted estimate)	7.8% (7.2-8.4%)
Fenwick (Lausanne University Hospital and University of Lausanne) ²⁶⁷	2020-05-04 to 2020-06-27	Vaud	Regional	High	311	NR	NR	Probability	Household and community samples	3.9%	Roche Elecsys anti-SARS-CoV-2 assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Posfay-Barbe (Geneva University Hospital) ²⁶⁹	2020-04-01 to 2020-04-30	Geneva	Sublocal	High	208	Median 9 (IQR 3.6-13.3)	44.7	Non-probability	Residual sera	9.1%	Euroimmun Euroimmun IgG assay IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Emmenegger (University of Zurich) ²⁶³	2020-04-01 to 2020-04-30	Zurich Zurich	Local	Moderate	1469	NR	NR	Non-probability	Blood donors	1.2%	Author-designed Tripartite Automated Blood Immunoassay IgG	100.0%, 100.0% (Test developer / manufacturer evaluation)	0.8% (0.0-1.5%)
Emmenegger (University of Zurich) ²⁶³	2020-04-01 to 2020-04-30	Zurich Zurich	Local	Moderate	4275	NR	NR	Non-probability	Residual sera	1.4% (1.0-1.7%)	Author-designed Tripartite Automated Blood Immunoassay IgG	100.0%, 100.0% (Test developer / manufacturer evaluation)	0.9% (0.0-1.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Emmenegger (University of Zurich) ²⁶³	2020-03-01 to 2020-03-31	Zurich Zurich	Local	Moderate	3806	NR	NR	Non-probability	Residual sera	0.3% (0.1-0.5%)	Author-designed Tripartite Automated Blood Immunoassay IgG	100.0%, 100.0% (Test developer / manufacturer evaluation)	0.2% (0.0-0.4%)
The United Kingdom													
Office for National Statistics (Office of National Statistics) ²⁷¹	2020-12-18 to 2021-01-14	England	Regional	Moderate	24150	older	NR	Probability	Household and community samples	15.3% (14.7-15.9%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	14.6% (13.9-15.4%)
Office for National Statistics (Office of National Statistics) ²⁷¹	2020-12-18 to 2021-01-14	Northern Ireland	Regional	High	313	older	NR	Probability	Household and community samples	12.0% (7.8-17.4%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	11.2% (7.8-15.1%)
Office for National Statistics (Office of National Statistics) ²⁷¹	2020-12-18 to 2021-01-14	Scotland	Regional	Moderate	1832	older	NR	Probability	Household and community samples	10.7% (9.1-12.4%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	9.9% (8.4-11.5%)
Office for National Statistics (Office of National Statistics) ²⁷¹	2020-12-18 to 2021-01-14	Wales	Regional	Moderate	732	older	NR	Probability	Household and community samples	11.5% (8.6-14.9%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	10.8% (8.4-13.3%)
Office for National Statistics (Office of National Statistics) ²⁷²	2020-11-20 to 2020-12-17	England	Regional	Moderate	21684	older	NR	Probability	Household and community samples	10.1% (9.6-10.6%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	9.3% (8.5-10.0%)
Office for National Statistics (Office of National Statistics) ²⁷²	2020-11-20 to 2020-12-17	Northern Ireland	Regional	High	248	older	NR	Probability	Household and community samples	3.7% (1.7-7.1%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	3.0% (0.7-5.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Office for National Statistics (Office of National Statistics) ²⁷²	2020-11-20 to 2020-12-17	Scotland	Regional	Moderate	1034	older	NR	Probability	Household and community samples	5.9% (4.4-7.6%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	5.1% (3.5-6.7%)
Office for National Statistics (Office of National Statistics) ²⁷²	2020-11-20 to 2020-12-17	Wales	Regional	Moderate	631	older	NR	Probability	Household and community samples	7.2% (5.1-9.9%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	6.3% (4.3-8.6%)
Office for National Statistics (Office of National Statistics) ²⁷⁵	2020-10-23 to 2020-11-19	Scotland	Regional	High	397	older	NR	Probability	Household and community samples	7.8% (5.0-11.7%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	6.8% (4.2-9.8%)
Office for National Statistics (Office of National Statistics) ²⁷⁵	2020-10-23 to 2020-11-19	Northern Ireland	Regional	High	333	older	NR	Probability	Household and community samples	3.5% (1.6-6.4%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	2.5% (0.7-4.9%)
Office for National Statistics (Office of National Statistics) ²⁷⁵	2020-10-23 to 2020-11-19	Wales	Regional	High	497	older	NR	Probability	Household and community samples	6.1% (4.0-9.0%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	5.3% (3.2-7.6%)
Office for National Statistics (Office of National Statistics) ²⁷⁵	2020-10-23 to 2020-11-19	England	Regional	Moderate	15834	older	NR	Probability	Household and community samples	8.7% (8.1-9.4%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	7.9% (7.1-8.6%)
Office for National Statistics (Office of National Statistics) ²⁷⁶	2020-09-25 to 2020-10-22	England	Regional	Moderate	15687	older	NR	Probability	Household and community samples	6.9% (6.4-7.5%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	6.0% (5.3-6.7%)
Office for National	2020-09-25 to 2020-10-22	Northern Ireland	Regional	High	249	older	NR	Probability	Household and	2.8% (1.2-5.5%)	University of Oxford	99.0%, 99.1% (Author-	1.7% (0.0-3.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Statistics (Office of National Statistics) ²⁷⁶									community samples		Oxford immunoassay IgG	reported independent evaluation)	
Office for National Statistics (Office of National Statistics) ²⁷⁶	2020-09-25 to 2020-10-22	Scotland	Regional	High	383	older	NR	Probability	Household and community samples	6.8% (4.3-10.2%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	6.0% (3.6-8.8%)
Office for National Statistics (Office of National Statistics) ²⁷⁶	2020-09-25 to 2020-10-22	Wales	Regional	High	473	older	NR	Probability	Household and community samples	4.7% (2.9-7.3%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	3.9% (1.9-6.1%)
Ward (Imperial College London) ²⁷⁷	2020-09-15 to 2020-09-28		National	Moderate	159367	18-24 (n=8763); 25-34 (n=20212); 35-44 (n=26687); 45-54 (n=32403); 55-64 (n=32870); 65-74 (n=26542); 75+ (n=11890)	56.4	Probability	Household and community samples	4.4% (4.3-4.5%)	Fortress Diagnostics; Northern Ireland LFIA IgG Fortress Diagnostics IgG	84.4%, 98.6% (Test developer / manufacturer evaluation)	2.3% (0.0-4.5%)
Office for National Statistics (Office of National Statistics) ²⁷⁸	2020-08-28 to 2020-09-24	Wales	Regional	High	236	older	NR	Probability	Household and community samples	4.7% (2.0-9.2%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	4.0% (1.3-7.2%)
Office for National Statistics (Office of National Statistics) ²⁷⁸	2020-08-28 to 2020-09-24	England	Regional	Moderate	8742	older	NR	Probability	Household and community samples	5.8% (5.1-6.5%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	4.9% (4.1-5.7%)
Public Health England (Public Health England) ²⁷⁹	2020-08-24 to 2020-09-18	England	National	Moderate	8230	>16	NR	Probability	Blood donors	6.1% (5.4-6.8%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	83.0%, 99.3% (Used author-adjusted estimate)	6.1% (5.6-6.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Abo-Leyah (Ninewells Hospital and Medical School) ²⁸⁰	2020-05-28 to 2020-09-02	Scotland	Regional	High	231	NR	NR	Probability	Residual sera	4.8%	Siemens Siemens SARS-CoV-2 antibody assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Public Health England (Public Health England) ²⁸¹	2020-07-27 to 2020-08-30	England	National	Moderate	8764	>16	NR	Probability	Blood donors	5.3% (4.8-5.8%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	83.0%, 99.3% (Used author-adjusted estimate)	5.3% (4.8-5.8%)
Office for National Statistics (Office of National Statistics) ²⁸²	2020-07-31 to 2020-08-27	England	Regional	Moderate	6189	older	NR	Probability	Household and community samples	5.6% (4.7-6.5%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	4.7% (3.8-5.5%)
Public Health England (Public Health England) ²⁷⁹	2020-06-15 to 2020-08-16	England	National	Moderate	4315	None	NR	Probability	Residual sera	6.5% (5.5-7.6%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Public Health England (Public Health England) ²⁷⁹	2020-06-15 to 2020-08-16	England	National	Low	1212	<30	NR	Probability	Residual sera	5.2% (3.9-7.0%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Ward (Imperial College London) ²⁷⁷	2020-07-31 to 2020-08-13		National	Moderate	105829	18-24 (n=6493); 25-34 (n=13573); 35-44 (n=17130); 45-54 (n=21487); 55-64 (n=21840); 65-74 (n=17617); 75+ (n=7689)	56.3	Probability	Household and community samples	4.7% (4.6-4.8%)	Fortress Diagnostics; Northern Ireland LFIA IgG Fortress Diagnostics IgG	84.4%, 98.6% (Test developer / manufacturer evaluation)	2.6% (0.0-4.9%)
Public Health Scotland (Public Health Scotland) ²⁸⁵	2020-06-29 to 2020-08-09	Scotland	National	Moderate	3220	NR	NR	Non-probability	Blood donors	3.1% (2.5-3.8%)	NR NR NR	87.5%, 98.6% (Used author-adjusted estimate)	3.1% (2.5-3.7%)
Public Health Scotland (Public Health Scotland) ²⁸⁵	2020-04-20 to 2020-08-09	Scotland	National	Moderate	9802	0-19 (n=2341); 20-39 (n=2407); 40-	50.5	Non-probability	Residual sera	4.9%	NR NR NR	87.5%, 98.6% (Test developer / manufacturer evaluation)	2.6% (0.1-5.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						59 (n=2171); 60+ (n=2883)							
Public Health England (Public Health England) ²⁸¹	2020-05-01 to 2020-08-05	England	National	Moderate	568	<20	NR	Probability	Household and community samples	5.2% (3.2-7.8%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Office for National Statistics (Office of National Statistics) ²⁸²	2020-07-03 to 2020-07-30	England	Regional	Moderate	3236	older	NR	Probability	Household and community samples	6.5% (5.2-8.1%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	5.6% (4.5-6.6%)
Public Health England (Public Health England) ²⁸⁸	2020-06-29 to 2020-07-28	England	National	Moderate	9388	>16	NR	Probability	Blood donors	5.9% (5.3-6.5%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	83.0%, 99.3% (Used author-adjusted estimate)	5.9% (5.4-6.4%)
Ward (Imperial College London) ²⁹⁰	2020-06-20 to 2020-07-13	England	National	Low	99908	18-24 (n=6499); 25-34 (n=13366); 35-44 (n=17052); 45-54 (n=20634); 55-64 (n=20404); 65-74 (n=15543); 75+ (n=6410)	56.1	Probability	Household and community samples	5.6% (5.4-5.7%)	Fortress Diagnostics; Northern Ireland Fortress Diagnostics LFIA IgG	84.4%, 98.6% (Test developer / manufacturer evaluation)	3.5% (0.2-6.1%)
Office for National Statistics (Office of National Statistics) ²⁹⁵	2020-06-05 to 2020-07-02	England	Regional	Moderate	2392	older	NR	Probability	Household and community samples	4.2%	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	3.2% (2.2-4.3%)
Public Health England (Public Health England) ²⁸⁸	2020-03-16 to 2020-06-30	England	National	Moderate	6000	>64	NR	Probability	Residual sera	3.9%	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.9% (3.4-4.4%)
Public Health England (Public Health England) ²⁹⁹	2020-06-01 to 2020-06-28	England	National	Moderate	10318	17-69	NR	Probability	Blood donors	7.2% (6.6-7.8%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5%, 99.1% (Used author-adjusted estimate)	7.2% (6.7-7.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Arif (Watford General Hospital) ³⁰⁶	2020-03-27 to 2020-06-08	Watford	Sublocal	High	443	Mean 50.51 (NR)	50.6	Non-probability	Residual sera	1.6%	NR NR NR	No data	-
Office for National Statistics (Office of National Statistics) ³¹²	2020-05-08 to 2020-06-04	England	Regional	Moderate	1575	older	NR	Probability	Household and community samples	6.3% (4.5-8.7%)	University of Oxford Oxford immunoassay IgG	99.0%, 99.1% (Author-reported independent evaluation)	5.4% (4.1-6.9%)
Wells (King's College London) ³¹³	2020-04-27 to 2020-06-02	South East England	Regional	High	431	Mean 48.38 (SD 28)	85.2	Non-probability	Household and community samples	12.0% (9.1-15.2%)	Imperial College London NR IgG, IgM	90.0%, 100.0% (Author-reported independent evaluation)	12.6% (4.3-21.6%)
Public Health England (Public Health England) ²⁹⁹	2020-05-04 to 2020-05-31	England	National	Moderate	7686	17-69	NR	Probability	Blood donors	8.3% (7.5-9.2%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5%, 99.1% (Used author-adjusted estimate)	8.3% (7.7-8.9%)
Public Health England (Public Health England) ²⁸¹	2020-05-01 to 2020-05-31	England	National	Moderate	1061	<30	NR	Probability	Residual sera	7.3% (5.6-9.2%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	95.7%, 99.1% (Used author-adjusted estimate)	7.3% (5.8-8.9%)
Hughes (The Francis Crick Institute) ³¹⁶	2020-03-16 to 2020-05-24	Scotland Glasgow	Local	Moderate	6635	18-44 (n=1,662); 45-64 (n=2202); 65-74 (n=1244); >75 (n=1527)	53.4	Non-probability	Residual sera	7.8% (7.2-8.5%)	Francis Crick Institute In house ELISA IgG	95.3%, 97.2% (Test developer / manufacturer evaluation)	5.3% (2.9-7.0%)
Thompson (University of Oxford) ³¹⁷	2020-03-17 to 2020-05-18	Scotland	Regional	Moderate	3500	Median 47 (IQR 34-56)	53.4	Probability	Blood donors	3.2%	N/A - Author designed N/A - Author designed NR	94.0%, 100.0% (Test developer / manufacturer evaluation)	2.9% (0.5-4.7%)
Public Health England (Public Health England) ³¹⁹	2020-04-01 to 2020-04-30	England	National	Moderate	647	<30	NR	Probability	Residual sera	6.1% (4.1-8.4%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	95.7%, 99.1% (Used author-adjusted estimate)	6.1% (4.4-8.1%)
Public Health England (Public Health England) ³¹⁹	2020-04-01 to 2020-04-30	England	National	Moderate	201	<20	NR	Probability	Household and community samples	3.8% (1.2-7.5%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	95.7%, 99.1% (Used author-adjusted estimate)	3.8% (1.6-6.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Public Health England (Public Health England) ³²⁰	2020-04-24 to 2020-04-26	England	Regional	Moderate	865	>16	NR	Probability	Blood donors	5.0% (3.2-7.0%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5%, 99.1% (Used author-adjusted estimate)	5.0% (3.7-6.6%)
Public Health England (Public Health England) ³²⁰	2020-04-23 to 2020-04-24	England	Regional	Moderate	1043	>16	NR	Probability	Blood donors	7.3% (5.4-9.4%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5%, 99.1% (Used author-adjusted estimate)	7.3% (5.8-9.0%)
Public Health England (Public Health England) ³²⁰	2020-04-15 to 2020-04-20	England	Regional	Moderate	936	>16	NR	Probability	Blood donors	6.2% (4.4-8.4%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	79.0%, 99.0% (Used author-adjusted estimate)	6.2% (4.8-7.9%)
Public Health England (Public Health England) ³²⁰	2020-04-14 to 2020-04-16	England	Regional	Moderate	1017	>16	NR	Probability	Blood donors	4.6% (3.0-6.4%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	79.0%, 99.0% (Used author-adjusted estimate)	4.6% (3.4-5.9%)
Public Health England (Public Health England) ³²⁰	2020-04-09 to 2020-04-13	England London	Regional	Moderate	1085	>16	NR	Probability	Blood donors	11.1% (8.9-13.6%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5%, 99.1% (Used author-adjusted estimate)	11.1% (9.3-13.0%)
Public Health England (Public Health England) ³²⁰	2020-04-02 to 2020-04-03	England	Regional	Moderate	916	>16	NR	Probability	Blood donors	2.4% (1.0-4.0%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5%, 99.1% (Used author-adjusted estimate)	2.4% (1.5-3.4%)
Public Health England (Public Health England) ³¹⁹	2020-02-01 to 2020-03-31	England	National	Moderate	443	<30	NR	Probability	Residual sera	0.8% (0.0-2.5%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	95.7%, 99.1% (Used author-adjusted estimate)	0.8% (0.2-1.8%)
Public Health England (Public Health England) ³¹⁹	2020-02-01 to 2020-03-31	England	National	Moderate	106	<20	NR	Probability	Household and community samples	0.5% (0.0-3.6%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	95.7%, 99.1% (Used author-adjusted estimate)	0.5% (0.0-2.3%)
Public Health England (Public Health England) ³²⁰	2020-03-26 to 2020-03-27	England London	Regional	Moderate	757	>16	NR	Probability	Blood donors	2.6% (1.1-4.4%)	EUROIMMUN Euroimmun Anti-SARS-	82.5%, 99.1% (Used author-adjusted estimate)	2.6% (1.6-3.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											CoV-2 ELISA IgG IgG		
United States of America													
Maleck (University of Wisconsin) ³²⁵	2020-10-18 to 2020-12-14	Wisconsin	Regional	Moderate	994	NR	NR	Probability	Household and community samples	6.8% (4.3-9.4%)	Abbott Abbott Architect SARS-CoV- 2 IgG antibody test IgG	0.0%, 99.6% (Used author-adjusted estimate)	6.8% (5.3-8.4%)
Craver (Wake Forest Baptist Medical Center) ³²⁶	2020-04-15 to 2020-12-09	North Carolina	Regional	Unclear	8006	16-95	NR	Probability	Household and community samples	9.3%	NR NR NR	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	9.4% (8.0-10.8%)
Stout (Clinical Reference Laboratory Inc.) ³²⁷	2020-05-12 to 2020-12-06		National	High	126587	Median 44 (SARS-CoV-2 Negative); 41 (SARS-CoV-2 Positive) (IQR 34-54 (SARS-CoV-2 Negative); 32-50 (SARS-CoV-2 Positive))	44.8	Non-probability	Residual sera	5.9%	Roche Roche Elecsys Anti-SARS-CoV-2 Kit NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Jolley (Florida Department of Health) ³²⁸	2020-05-01 to 2020-11-30	Florida	Regional	Unclear	630838	NR	NR	Non-probability	Household and community samples	11.0%	NR NR IgG	No data	-
Coffman (University of Louisville) ³²⁹	2020-11-09 to 2020-11-16	Kentucky	Local	Unclear	1091	NR	NR	Probability	Household and community samples	2.0%	NR NR NR	No data	-
Coffman (University of Louisville) ³²⁹	2020-11-09 to 2020-11-16	Kentucky	Local	Unclear	1709	NR	NR	Non-probability	Household and community samples	3.3%	NR NR NR	No data	-
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-24	Delaware	Regional	Moderate	980	0-17 (n=6612); 18-49 (n=15157); 50-	NR	Non-probability	Residual sera	7.5% (4.9-10.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	7.5% (5.9-9.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=13207); ≥65 (n=12933)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-24	Iowa	Regional	Moderate	977	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	7.6% (5.6-10.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.6% (6.0-9.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-24	Maine	Regional	Moderate	987	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	0.5% (0.1-0.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.5% (0.1-1.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-24	Missouri	Regional	Moderate	1031	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.5% (2.1-5.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.5% (2.5-4.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-24	New Mexico	Regional	Moderate	1014	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	2.4% (1.2-3.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.4% (1.6-3.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-11 to 2020-09-24	New York	Regional	Moderate	1168	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	17.0% (14.7-19.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	17.0% (14.9-19.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-24	North Dakota	Regional	High	113	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	1.2% (0.0-3.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.2% (0.1-4.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-24	Rhode Island	Regional	Moderate	795	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	2.7% (1.1-4.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.7% (1.7-3.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-24	Texas	Regional	Moderate	988	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	8.2% (6.2-10.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.2% (6.6-10.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-24	Vermont	Regional	High	497	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	1.7% (0.3-4.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.7% (0.8-3.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-24	Washington D.C	Regional	Moderate	976	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	6.5% (4.5-8.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.5% (5.0-8.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-24	Wisconsin	Regional	Moderate	976	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.8% (2.2-5.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	3.8% (2.7-5.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-24	Wyoming	Regional	High	111	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	1.5% (0.0-4.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.5% (0.1-4.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-23	Arizona	Regional	Moderate	1208	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	5.4% (3.1-8.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.4% (4.2-6.8%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-23	Indiana	Regional	Moderate	1155	0-17 (n=6612); 18-49 (n=15157); 50-	NR	Non-probability	Residual sera	4.0% (1.4-8.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	4.0% (3.0-5.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=13207); ≥65 (n=12933)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-10 to 2020-09-23	Maryland	Regional	Moderate	1242	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	10.2% (7.9-12.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	10.2% (8.6-11.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-23	Minnesota	Regional	Moderate	1033	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	8.0% (4.7-11.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.0% (6.4-9.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-23	Montana	Regional	High	508	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	2.2% (0.7-4.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.2% (1.2-3.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-23	New Jersey	Regional	Moderate	1050	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	15.1% (12.7-17.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	15.1% (13.0-17.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-23	Pennsylvania	Regional	Moderate	1341	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	11.1% (8.8-13.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	11.1% (9.4-12.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-23	South Dakota	Regional	High	99	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	1.8% (0.0-4.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.8% (0.1-4.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-10 to 2020-09-23	Virginia	Regional	Moderate	1111	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.2% (1.8-5.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.2% (2.2-4.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-22	Hawaii	Regional	High	516	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	0.8% (0.0-2.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.8% (0.3-1.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-22	Michigan	Regional	Moderate	980	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.7% (2.5-4.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.7% (2.6-5.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-22	Mississippi	Regional	Moderate	980	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	7.9% (5.3-10.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.9% (6.3-9.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-10 to 2020-09-22	Ohio	Regional	Moderate	978	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	2.8% (1.7-4.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	2.8% (1.9-3.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-22	Oregon	Regional	Moderate	971	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	2.6% (1.5-4.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.6% (1.7-3.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-22	Washington	Regional	Moderate	968	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	2.5% (1.3-3.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.5% (1.6-3.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-22	West Virginia	Regional	Moderate	968	0-17 (n=6612); 18-49 (n=15157); 50-	NR	Non-probability	Residual sera	1.3% (0.5-2.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	1.3% (0.7-2.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=13207); ≥65 (n=12933)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Fountain Hills Times (Maricopa County Department of Public Health) ³³²	2020-09-11 to 2020-09-21	Arizona	Local	Unclear	260	NR	NR	Probability	Household and community samples	10.7%	NR NR NR	No data	-
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-19	Kansas	Regional	Moderate	1007	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.5% (2.3-4.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.5% (2.5-4.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-19	Louisiana	Regional	Moderate	952	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	12.5% (10.0-15.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2	0.0%, 0.0% (Used author-adjusted estimate)	12.5% (10.5-14.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Alabama	Regional	Moderate	905	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	8.7% (6.2-11.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.7% (6.9-10.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Alaska	Regional	Moderate	681	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	0.4% (0.1-0.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.4% (0.1-0.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Arkansas	Regional	Moderate	990	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	6.3% (4.6-8.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	6.3% (4.9-7.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											n immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Colorado	Regional	Moderate	1032	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.3% (1.9-4.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.3% (2.3-4.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Georgia	Regional	Moderate	1100	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	13.0% (10.5-15.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	13.0% (11.1-15.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-18	Idaho	Regional	Moderate	732	0-17 (n=6612); 18-49 (n=15157); 50-	NR	Non-probability	Residual sera	5.2% (2.7-8.5%)	Ortho-Clinical Diagnostics; Abbott; Roche	0.0%, 0.0% (Used author-	5.2% (3.8-7.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=13207); ≥65 (n=12933)					Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	adjusted estimate)	
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Kentucky	Regional	Moderate	980	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.6% (2.3-5.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.6% (2.5-4.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Nebraska	Regional	Moderate	976	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	6.7% (4.8-8.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.7% (5.2-8.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Oklahoma	Regional	Moderate	980	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	5.0% (3.4-6.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.0% (3.8-6.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	South Carolina	Regional	Moderate	975	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	7.8% (5.6-10.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.8% (6.2-9.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-18	Utah	Regional	Moderate	1022	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	5.1% (3.3-7.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.1% (3.9-6.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-17	Illinois	Regional	Moderate	992	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	4.5% (3.1-6.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.5% (3.3-5.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-17	New Hampshire	Regional	Moderate	1034	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	0.7% (0.3-1.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.7% (0.3-1.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-17	North Carolina	Regional	Moderate	925	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	6.8% (4.8-8.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.8% (5.2-8.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-10 to 2020-09-16	California	Regional	Moderate	979	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	4.9% (3.2-6.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.9% (3.6-6.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-16	Tennessee	Regional	Moderate	1028	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	6.7% (5.0-8.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.7% (5.2-8.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-15	Massachusetts	Regional	Moderate	988	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.7% (2.2-5.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	3.7% (2.6-5.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-08 to 2020-09-15	Puerto Rico	Regional	Moderate	970	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.0% (1.8-4.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.0% (2.1-4.2%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-14	Connecticut	Regional	Moderate	982	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	3.1% (2.1-4.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.1% (2.1-4.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-09-09 to 2020-09-12	Nevada	Regional	Moderate	979	0-17 (n=6612); 18-49 (n=15157); 50-	NR	Non-probability	Residual sera	7.8% (5.9-10.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	7.8% (6.2-9.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=13207); ≥65 (n=12933)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-09-11 to 2020-09-11	Florida	Regional	Moderate	979	0-17 (n=6612); 18-49 (n=15157); 50-64 (n=13207); ≥65 (n=12933)	NR	Non-probability	Residual sera	8.5% (6.6-10.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.5% (6.9-10.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	Delaware	Regional	Moderate	914	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	4.5% (2.4-7.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.5% (3.3-6.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-25 to 2020-09-10	Georgia	Regional	Moderate	1020	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	8.7% (6.7-11.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.7% (7.0-10.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	Idaho	Regional	Moderate	790	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	5.7% (2.9-9.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.7% (4.2-7.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-25 to 2020-09-10	Iowa	Regional	Moderate	1006	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	8.4% (6.2-10.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.4% (6.8-10.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	Maine	Regional	Moderate	759	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	1.5% (0.4-3.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.5% (0.8-2.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	Mississippi	Regional	Moderate	987	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	8.4% (4.9-12.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.4% (6.7-10.2%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-10	Missouri	Regional	Moderate	1024	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	2.9% (1.7-4.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.9% (1.9-4.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-10	Nebraska	Regional	Moderate	938	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	6.3% (4.5-8.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.3% (4.9-8.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	New York	Regional	Moderate	1043	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	19.5% (16.9-22.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	19.5% (17.1-21.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-27 to 2020-09-10	Ohio	Regional	Moderate	983	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	5.0% (3.2-7.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	5.0% (3.8-6.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	Oregon	Regional	Moderate	968	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	1.9% (0.9-2.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.9% (1.1-2.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-27 to 2020-09-10	Rhode Island	Regional	Moderate	786	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	3.1% (1.7-4.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.1% (2.0-4.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	South Carolina	Regional	Moderate	927	0-17 (n=6484); 18-49 (n=14079); 50-	NR	Non-probability	Residual sera	7.2% (5.1-9.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	7.2% (5.6-8.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=12426); ≥65 (n=12316)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	South Dakota	Regional	High	97	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	0.7% (0.0-2.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.7% (0.0-2.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	Vermont	Regional	High	485	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	0.4% (0.0-0.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.4% (0.0-1.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-25 to 2020-09-10	Washington	Regional	Moderate	820	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	4.5% (2.6-6.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.5% (3.1-6.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-27 to 2020-09-10	Washington D.C	Regional	Moderate	643	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	5.0% (2.8-7.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.0% (3.5-6.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-10	West Virginia	Regional	Moderate	1128	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	1.5% (0.8-2.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.5% (0.8-2.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-25 to 2020-09-10	Wisconsin	Regional	Moderate	976	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	2.6% (1.5-4.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.6% (1.7-3.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-09	Alaska	Regional	Moderate	610	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	1.0% (0.2-2.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.0% (0.4-2.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-09	Arizona	Regional	Moderate	1030	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	4.9% (3.0-7.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.9% (3.7-6.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-28 to 2020-09-09	California	Regional	Moderate	983	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	6.0% (4.2-7.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.0% (4.6-7.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-27 to 2020-09-09	Florida	Regional	Moderate	981	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	5.7% (3.9-7.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.7% (4.3-7.2%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-09	Indiana	Regional	Moderate	984	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	2.4% (1.4-3.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	2.4% (1.5-3.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-09	Montana	Regional	High	518	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	0.9% (0.2-1.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.9% (0.3-1.8%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-09	North Carolina	Regional	Moderate	982	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	3.8% (2.3-5.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.8% (2.7-5.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-09	North Dakota	Regional	High	109	0-17 (n=6484); 18-49 (n=14079); 50-	NR	Non-probability	Residual sera	0.2% (0.0-1.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	0.2% (0.0-2.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=12426); ≥65 (n=12316)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-09	Pennsylvania	Regional	Moderate	845	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	9.5% (6.6-13.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	9.5% (7.6-11.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-08	Alabama	Regional	Moderate	955	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	9.9% (7.2-12.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	9.9% (8.1-11.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-08	Arkansas	Regional	Moderate	992	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	4.9% (3.5-6.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.9% (3.6-6.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-08	Kentucky	Regional	Moderate	983	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	3.1% (1.9-4.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.1% (2.1-4.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-08	Louisiana	Regional	Moderate	1001	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	8.6% (6.7-11.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.6% (7.0-10.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-08	Maryland	Regional	Moderate	980	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	7.9% (5.7-10.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.9% (6.3-9.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-08	Minnesota	Regional	Moderate	974	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	9.2% (6.7-11.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	9.2% (7.4-11.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-25 to 2020-09-08	New Mexico	Regional	Moderate	985	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	3.7% (2.3-5.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.7% (2.6-5.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-25 to 2020-09-08	Tennessee	Regional	Moderate	950	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	5.4% (3.6-7.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.4% (4.1-6.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-08	Utah	Regional	Moderate	1104	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	4.9% (2.8-7.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.9% (3.7-6.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-08	Virginia	Regional	Moderate	1007	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	3.5% (2.0-5.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	3.5% (2.5-4.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-07	New Jersey	Regional	Moderate	944	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	12.8% (10.5-15.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	12.8% (10.7-15.0%)
Demonbreun (Northwestern University) ³³⁴	2020-06-24 to 2020-09-06	Illinois Chicago	Local	High	1545	Median 37 (IQR 18)	59.3	Non-probability	Household and community samples	19.8%	In-House NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	23.6% (20.6-26.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-27 to 2020-09-05	Massachusetts	Regional	Moderate	981	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	3.6% (2.4-5.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2	0.0%, 0.0% (Used author-adjusted estimate)	3.6% (2.5-4.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-04	Colorado	Regional	Moderate	1025	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	3.6% (2.3-5.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.6% (2.5-4.8%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-04	Connecticut	Regional	Moderate	983	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	4.3% (2.9-5.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.3% (3.1-5.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-03	Illinois	Regional	Moderate	979	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	5.6% (3.9-7.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2	0.0%, 0.0% (Used author-adjusted estimate)	5.6% (4.2-7.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-03	Kansas	Regional	Moderate	1025	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	2.9% (1.6-4.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.9% (1.9-4.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-03	Michigan	Regional	Moderate	976	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	3.4% (2.2-5.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.4% (2.4-4.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-26 to 2020-09-03	New Hampshire	Regional	Moderate	1147	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	1.6% (0.7-2.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	1.6% (1.0-2.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											n immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-03	Puerto Rico	Regional	Moderate	980	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	2.5% (1.4-3.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.5% (1.6-3.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-25 to 2020-09-02	Texas	Regional	Moderate	979	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	5.8% (4.0-7.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.8% (4.4-7.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-24 to 2020-09-01	Oklahoma	Regional	Moderate	979	0-17 (n=6484); 18-49 (n=14079); 50-	NR	Non-probability	Residual sera	5.4% (3.8-7.3%)	Ortho-Clinical Diagnostics; Abbott; Roche	0.0%, 0.0% (Used author-	5.4% (4.0-6.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=12426); ≥65 (n=12316)					Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	adjusted estimate)	
Maleck (University of Wisconsin) ³²⁵	2020-07-01 to 2020-08-31	Wisconsin	Regional	Moderate	996	NR	NR	Probability	Household and community samples	1.6% (0.6-2.5%)	Abbott Abbott Architect SARS-CoV-2 IgG antibody test IgG	0.0%, 99.6% (Used author-adjusted estimate)	1.6% (0.9-2.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-27 to 2020-08-29	Nevada	Regional	Moderate	980	0-17 (n=6484); 18-49 (n=14079); 50-64 (n=12426); ≥65 (n=12316)	NR	Non-probability	Residual sera	6.5% (4.6-8.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.5% (5.0-8.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Delaware	Regional	Moderate	1004	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	8.5% (5.8-11.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.5% (6.9-10.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Illinois	Regional	Moderate	985	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	4.9% (3.4-6.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.9% (3.7-6.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Iowa	Regional	Moderate	980	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	9.4% (7.1-11.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	9.4% (7.7-11.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Maine	Regional	Moderate	609	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	0.6% (0.0-1.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	0.6% (0.1-1.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Massachusetts	Regional	Moderate	980	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.7% (2.3-5.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.7% (2.6-5.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-11 to 2020-08-27	Minnesota	Regional	Moderate	978	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	4.5% (3.0-5.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.5% (3.3-5.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Mississippi	Regional	Moderate	968	0-17 (n=6920); 18-49 (n=14571); 50-	NR	Non-probability	Residual sera	10.0% (6.7-14.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	10.0% (8.2-11.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=12514); ≥65 (n=11856)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-27	New Mexico	Regional	Moderate	976	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	2.5% (1.5-3.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.5% (1.6-3.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-11 to 2020-08-27	North Carolina	Regional	Moderate	982	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.8% (2.3-5.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.8% (2.7-5.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Ohio	Regional	Moderate	985	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	2.1% (1.1-3.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.1% (1.3-3.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-27	Oregon	Regional	Moderate	1086	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	2.4% (1.4-3.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.4% (1.6-3.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Rhode Island	Regional	High	570	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.6% (1.7-5.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.6% (2.2-5.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	South Carolina	Regional	Moderate	1063	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	6.0% (4.4-8.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.0% (4.6-7.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-13 to 2020-08-27	Vermont	Regional	High	382	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	0.3% (0.0-0.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.3% (0.0-1.2%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Washington	Regional	Moderate	1238	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.0% (1.8-4.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.0% (2.1-4.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-13 to 2020-08-27	Washington D.C	Regional	Moderate	781	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	6.8% (4.6-9.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.8% (5.2-8.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-13 to 2020-08-27	West Virginia	Regional	Moderate	637	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	2.2% (0.5-4.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.2% (1.3-3.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-27	Wisconsin	Regional	Moderate	838	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.3% (2.0-4.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	3.3% (2.2-4.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	Alabama	Regional	Moderate	974	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	7.6% (5.3-9.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.6% (6.1-9.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	Alaska	Regional	Moderate	704	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	1.3% (0.5-2.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.3% (0.6-2.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	Arizona	Regional	Moderate	1304	0-17 (n=6920); 18-49 (n=14571); 50-	NR	Non-probability	Residual sera	4.7% (2.7-7.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	4.7% (3.6-5.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=12514); ≥65 (n=11856)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-13 to 2020-08-26	Georgia	Regional	Moderate	1031	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	7.4% (5.5-9.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.4% (5.9-9.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	Idaho	Regional	Moderate	651	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	4.6% (1.7-9.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.6% (3.1-6.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	Indiana	Regional	Moderate	906	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.1% (1.5-4.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.1% (2.1-4.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	Kentucky	Regional	Moderate	1126	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.1% (2.0-4.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.1% (2.1-4.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-26	Maryland	Regional	Moderate	1174	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	7.0% (4.9-9.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.0% (5.6-8.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	Nevada	Regional	Moderate	972	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	7.9% (6.1-9.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.9% (6.3-9.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-26	New Jersey	Regional	Moderate	1127	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	12.2% (10.2-14.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	12.2% (10.3-14.2%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-26	New York	Regional	Moderate	1122	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	20.6% (18.0-23.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	20.6% (18.3-23.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	North Dakota	Regional	High	135	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	0.6% (0.0-1.4%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.6% (0.0-1.8%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-26	Pennsylvania	Regional	Moderate	887	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	10.1% (7.5-13.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	10.1% (8.2-12.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	South Dakota	Regional	High	83	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	0.0% (0.0-4.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	0.0% (0.0-3.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-26	Tennessee	Regional	Moderate	1029	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	6.7% (5.1-8.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.7% (5.2-8.2%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-26	Virginia	Regional	Moderate	1243	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	4.7% (2.5-7.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.7% (3.6-5.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-11 to 2020-08-25	Arkansas	Regional	Moderate	998	0-17 (n=6920); 18-49 (n=14571); 50-	NR	Non-probability	Residual sera	3.0% (1.8-4.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	3.0% (2.0-4.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=12514); ≥65 (n=11856)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-25	Colorado	Regional	Moderate	1019	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.3% (1.8-4.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.3% (2.3-4.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-11 to 2020-08-25	Kansas	Regional	Moderate	1016	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.7% (2.0-5.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.7% (2.6-4.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-25	Louisiana	Regional	Moderate	989	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	11.8% (9.3-14.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	11.8% (9.8-13.8%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-25	Michigan	Regional	Moderate	983	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	4.2% (2.9-5.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.2% (3.1-5.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-11 to 2020-08-25	Nebraska	Regional	Moderate	990	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	7.9% (5.5-10.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.9% (6.3-9.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-13 to 2020-08-25	New Hampshire	Regional	Moderate	1125	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	0.8% (0.3-1.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.8% (0.4-1.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-15 to 2020-08-25	Utah	Regional	Moderate	871	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	5.5% (2.9-8.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.5% (4.0-7.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-11 to 2020-08-24	Connecticut	Regional	Moderate	983	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	2.4% (1.4-3.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.4% (1.5-3.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-24	Montana	Regional	High	383	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	1.3% (0.4-2.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.3% (0.4-2.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-24	Texas	Regional	Moderate	1001	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	6.5% (4.7-8.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.5% (5.1-8.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-13 to 2020-08-24	Wyoming	Regional	High	86	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	0.8% (0.0-3.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	0.8% (0.0-2.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-12 to 2020-08-21	Missouri	Regional	Moderate	1021	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	3.5% (2.2-5.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.5% (2.4-4.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-13 to 2020-08-19	California	Regional	Moderate	980	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	4.3% (2.9-6.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.3% (3.1-5.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-18	Oklahoma	Regional	Moderate	979	0-17 (n=6920); 18-49 (n=14571); 50-	NR	Non-probability	Residual sera	4.0% (2.7-5.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	4.0% (2.9-5.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=12514); ≥65 (n=11856)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-08-10 to 2020-08-17	Puerto Rico	Regional	Moderate	986	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	2.2% (1.2-3.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.2% (1.4-3.2%)
Bruckner (University of California Irvine) ³³⁶	2020-07-10 to 2020-08-16	California	Local	Low	2979	18-34 (n=673), 35-54 (n=1362), 55+ (n=944)	56.4	Probability	Household and community samples	11.5% (10.5-12.4%)	NR coronavirus antigen microarray (CoVAM) IgG, IgM	94.0%, 100.0% (Author-reported independent evaluation)	11.5% (8.8-13.6%)
Heim (UW-Madison) ³³⁹	2020-07-15 to 2020-08-15	Wisconsin	Regional	Unclear	1056	NR	NR	Probability	Household and community samples	1.6%	NR NR NR	No data	-
Bajema (CDC COVID-19 Response) ³³¹	2020-08-14 to 2020-08-14	Florida	Regional	Moderate	978	0-17 (n=6920); 18-49 (n=14571); 50-64 (n=12514); ≥65 (n=11856)	NR	Non-probability	Residual sera	4.5% (3.1-6.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-	0.0%, 0.0% (Used author-adjusted estimate)	4.5% (3.3-5.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-13	Alabama	Regional	Moderate	938	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	5.8% (4.2-7.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.8% (4.4-7.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-13	Arkansas	Regional	Moderate	937	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	4.1% (2.7-5.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.1% (2.9-5.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-13	Delaware	Regional	Moderate	804	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	5.7% (3.5-8.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.7% (4.2-7.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-13	Iowa	Regional	Moderate	811	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	8.6% (6.0-11.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.6% (6.7-10.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-13	Kentucky	Regional	Moderate	975	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	2.4% (1.3-3.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.4% (1.5-3.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-28 to 2020-08-13	Louisiana	Regional	Moderate	1002	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	9.6% (6.9-12.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	9.6% (7.9-11.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-13	Minnesota	Regional	Moderate	879	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	3.5% (2.1-5.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.5% (2.4-4.8%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-13	Mississippi	Regional	Moderate	769	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	7.1% (3.8-11.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.1% (5.4-9.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-28 to 2020-08-13	Nebraska	Regional	Moderate	954	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	7.4% (5.2-9.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.4% (5.8-9.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-13	New Mexico	Regional	Moderate	964	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	2.0% (1.1-3.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.0% (1.2-3.0%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-13	South Carolina	Regional	Moderate	840	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	8.1% (5.8-10.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	8.1% (6.4-10.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-13	Washington D.C.	Regional	Moderate	717	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	3.9% (2.2-5.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.9% (2.6-5.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-13	West Virginia	Regional	High	317	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	1.2% (0.2-2.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.2% (0.3-2.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-13	Wisconsin	Regional	Moderate	814	0-17 (n=6700); 18-49 (n=11237); 50-	NR	Non-probability	Residual sera	1.8% (0.8-3.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	1.8% (1.0-2.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=10367); ≥65 (n=10408)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-12	North Dakota	Regional	High	121	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	7.3% (1.3-14.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	7.3% (3.2-12.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-06 to 2020-08-11	Alaska	Regional	High	242	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	0.3% (0.0-1.1%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.3% (0.0-1.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-31 to 2020-08-11	Arizona	Regional	High	591	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	8.2% (4.1-13.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	8.2% (6.1-10.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-02 to 2020-08-11	Georgia	Regional	Moderate	985	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	6.8% (4.8-8.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.8% (5.3-8.4%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-04 to 2020-08-11	Idaho	Regional	High	246	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	4.5% (1.8-8.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.5% (2.4-7.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-31 to 2020-08-11	Indiana	Regional	High	579	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	2.2% (1.1-3.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.2% (1.1-3.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-11	Maine	Regional	High	598	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	0.5% (0.0-1.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.5% (0.1-1.1%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-31 to 2020-08-11	Maryland	Regional	Moderate	783	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	9.7% (7.3-12.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	9.7% (7.7-11.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-11	Michigan	Regional	Moderate	982	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	3.4% (2.2-4.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.4% (2.4-4.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-11	New Hampshire	Regional	Moderate	809	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	0.8% (0.2-1.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.8% (0.3-1.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-31 to 2020-08-11	New Jersey	Regional	Moderate	871	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	14.8% (12.2-17.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	14.8% (12.5-17.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-31 to 2020-08-11	New York	Regional	Moderate	846	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	23.3% (20.1-26.3%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	23.3% (20.5-26.2%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-11	Ohio	Regional	Moderate	786	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	2.3% (1.1-3.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.3% (1.4-3.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-08-05 to 2020-08-11	Oregon	Regional	Moderate	658	0-17 (n=6700); 18-49 (n=11237); 50-	NR	Non-probability	Residual sera	2.3% (1.0-3.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	2.3% (1.3-3.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=10367); ≥65 (n=10408)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-31 to 2020-08-11	Pennsylvania	Regional	High	575	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	10.2% (5.7-17.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	10.2% (7.8-12.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-11	Rhode Island	Regional	Moderate	684	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	3.0% (1.2-5.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.0% (1.9-4.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-11	Tennessee	Regional	Moderate	1003	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	6.3% (4.4-8.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	6.3% (4.9-7.9%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-11	Utah	Regional	Moderate	880	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	3.2% (1.7-5.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.2% (2.2-4.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-11	Vermont	Regional	High	346	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	0.5% (0.0-1.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	0.5% (0.0-1.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-31 to 2020-08-11	Virginia	Regional	Moderate	730	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	4.1% (1.8-6.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.1% (2.7-5.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-11	Washington	Regional	Moderate	684	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	2.1% (0.8-3.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.1% (1.2-3.3%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-10	Illinois	Regional	Moderate	1004	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	3.9% (2.5-5.2%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.9% (2.8-5.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-10	Massachusetts	Regional	Moderate	978	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	4.2% (2.9-5.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.2% (3.1-5.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-28 to 2020-08-10	Missouri	Regional	Moderate	979	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	2.5% (1.4-3.6%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.5% (1.6-3.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-10	Montana	Regional	High	199	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	0.5% (0.0-1.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin	0.0%, 0.0% (Used author-adjusted estimate)	0.5% (0.0-1.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-10	North Carolina	Regional	Moderate	928	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	2.5% (1.3-3.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	2.5% (1.6-3.6%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-08	Kansas	Regional	Moderate	962	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	1.6% (0.7-2.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.6% (0.9-2.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-07	Colorado	Regional	Moderate	1001	0-17 (n=6700); 18-49 (n=11237); 50-	NR	Non-probability	Residual sera	2.4% (0.9-4.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-	0.0%, 0.0% (Used author-adjusted estimate)	2.4% (1.6-3.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						64 (n=10367); ≥65 (n=10408)					SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-27 to 2020-08-07	Puerto Rico	Regional	Moderate	984	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	1.1% (0.4-1.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.1% (0.5-1.8%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-05	California	Regional	Moderate	980	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	5.7% (4.0-7.8%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT- ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.7% (4.3-7.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-29 to 2020-08-05	Texas	Regional	Moderate	986	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	5.9% (4.0-8.0%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.9% (4.5-7.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-28 to 2020-08-04	Oklahoma	Regional	Moderate	979	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	1.6% (0.9-2.5%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	1.6% (0.9-2.5%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-03	Connecticut	Regional	Moderate	994	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	3.4% (2.0-4.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG	0.0%, 0.0% (Used author-adjusted estimate)	3.4% (2.3-4.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											immunoassay IgG		
Bajema (CDC COVID-19 Response) ³³¹	2020-07-31 to 2020-08-03	Florida	Regional	Moderate	980	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	4.3% (2.8-5.9%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	4.3% (3.1-5.7%)
Bajema (CDC COVID-19 Response) ³³¹	2020-07-30 to 2020-08-02	Nevada	Regional	Moderate	979	0-17 (n=6700); 18-49 (n=11237); 50-64 (n=10367); ≥65 (n=10408)	NR	Non-probability	Residual sera	5.1% (3.6-6.7%)	Ortho-Clinical Diagnostics; Abbott; Roche Elecsys Anti-SARS-CoV-2 pan-immunoglobulin immunoassay, ARCHITECT SARS-CoV-2 IgG immunoassay, VIT-ROS SARS-CoV-2 IgG immunoassay IgG	0.0%, 0.0% (Used author-adjusted estimate)	5.1% (3.8-6.5%)
Feehan (Louisiana State University) ³⁴¹	2020-07-15 to 2020-07-31	Louisiana Baton Rouge	Local	Moderate	2138	Mean 48.7 (Range 18-91)	63.6	Probability	Household and community samples	3.6% (2.8-4.4%)	Abbott Abbott ARCHITECT i2000SR IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Vassallo (Vitalant) ³⁴²	2020-06-01 to 2020-07-31	Colorado, Mississippi, North Dakota, Nevada,	National	Moderate	252882	16-17 (n=1812); 18-29 (n=22048); 30-39 (n=30956); 40-	39.4	Non-probability	Blood donors	1.8%	Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 Total Reagent	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
		Louisiana, Tennessee, Washington, Wyoming, California, Montana, South Dakota, New Mexico, Texas, Arizona Reno, Las Vegas, Cheyenne, Phoenix, Lubbock, Billings, Albuquerque, Rapid City, Tupelo, San Francisco, Spokane, McAllen, El Paso, Fargo, Newark, ventura, Memphis, Lafayette, Sacramento, Denver				49 (n=34151); 50-64 (n=66030); 65-74 (n=28453); 75-84 (n=5848); >85 (n=357)					Pack IgG, IgA, IgM		
Spencer (American Red Cross) ³⁴⁵	2020-06-15 to 2020-07-27		National	High	573586	=>18	NR	Non-probability	Blood donors	1.5%	Ortho Ortho Anti-SARS-CoV2 Total Ig Test IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Yamaki (St. Jude Medical Center) ³⁴⁶	2020-07-15 to 2020-07-27	California Fullerton	Local	High	865	10-19 (N=9), 20-29 (n=55), 30-39 (n=81), 40-49 (n=83), 50-59 (n=133), 60-69 (n=159), 70-79 (n=164), 80-89 (n=144), 90-99 (n=35), 100-109 (n=2)	55.3	Non-probability	Residual sera	9.4% (8.0-12.0%)	Abbott Laboratories Abbott Architect IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Mahajan (Yale School of Medicine) ³⁴⁹	2020-06-23 to 2020-07-22	Connecticut	Regional	High	148	Mean 46.4 (SD 13.0)	64.2	Probability	Household and community samples	6.4% (0.9-11.9%)	Ortho-Clinical Diagnostics Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Mahajan (Yale School of Medicine) ³⁴⁹	2020-06-23 to 2020-07-22	Connecticut	Regional	High	171	Mean 39.9 (SD 15.5)	60.2	Probability	Household and community samples	19.9% (13.2-26.6%)	Ortho-Clinical Diagnostics Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
McMillan (Riverside University Health System) ³⁵⁰	2020-07-06 to 2020-07-20	California	Local	Unclear	1726	NR	NR	Probability	Household and community samples	5.9%	NR NR NR	No data	-
Zauzmer (Washington DC Public Health) ³⁵²	2020-06-15 to 2020-07-15	Washington D.C Washington DC	Local	High	13706	NR	NR	Non-probability	Household and community samples	5.9%	DiaSorin LIAISON; Abbot Alinity i NR NR	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	3.8% (3.2-4.6%)
Jin (New York Blood Centre) ³⁵³	2020-06-15 to 2020-07-15	New York New York City	Local	High	1000	Median 48 (95% CI 46-49)	38.5	Non-probability	Blood donors	12.8%	Ortho Clinical Diagnostics; Abbott Labs VITROS™ SARS-CoV-2 Total Ig assay, Abbott Labs Architect SARS-CoV-2 IgG IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	11.2% (8.9-13.5%)
Kaufman (Quest Diagnostics) ³⁵⁵	2020-04-21 to 2020-07-10		National	High	2402282	NR	NR	Non-probability	Household and community samples	11.8%	Ortho-Clinical Diagnostics; EUROIMMUN; Abbott Laboratories Architect, VITROS, EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG) IgG	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Kamath (Serimmune) ³⁵⁹	2020-03-01 to 2020-07-07	New York New York City	Local	High	1559	17-25 (n=395, 25%); 26-35 (n=200, 13%); 36-45 (n=164, 11%); 46-55 (n=206, 13%); 56-65 (n=370, 24%); 66-80 (n=224, 14%).	48.4	Non-probability	Blood donors	4.4%	Serimmune Serum Epitope Repertoire Analysis (SERA) IgG	91.0%, 99.3% (Test developer / manufacturer evaluation)	4.0% (2.7-5.2%)
Childs (Oxnard Fire Department) ³⁶⁰	2020-06-22 to 2020-07-06	California	Local	High	6794	13+	60.7	Non-probability	Household and community samples	1.3%	1) Abbott 2) Bio-Rad NR NR	No data	-
Stadlbauer (Icahn School of Medicine at Mount Sinai) ³⁶¹	2020-02-02 to 2020-07-05	New York New York City	Local	High	6590	0-20 (n=358); 21-40 (n=2808); 41-60 (n=1381); >=61 (n=2043)	67.6	Non-probability	Residual sera	11.1%	Mount Sinai Hospital New York N/A - Author-designed IgG	95.0%, 100.0% (Test developer / manufacturer evaluation)	11.0% (7.9-13.2%)
Stadlbauer (Icahn School of Medicine at Mount Sinai) ³⁶¹	2020-02-02 to 2020-07-05	New York New York City	Local	High	4101	0-20 (n=115); 21-40 (n=616); 41-60 (n=1185); >=61 (n=2185)	45.5	Non-probability	Residual sera	26.0%	Mount Sinai Hospital New York N/A - Author-designed IgG	95.0%, 100.0% (Test developer / manufacturer evaluation)	27.0% (23.1-30.7%)
Walker (DaVita Clinical Research) ³⁶³	2020-05-27 to 2020-07-01		National	Moderate	4297	<50 (n=2398), 50-59 (n=2669), 60-69 (n=3568), 70-79 (n=2873), 80+ (n=1424)	125.5	Probability	Residual sera	4.8% (4.1-5.4%)	Diazyme Laboratories; Inc Indirect chemiluminescence immunoassays for anti-SARS-CoV2 IgG antibodies IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	2.7% (2.2-3.2%)
Viglienzoni (University of Vermont) ³⁶⁷	Until 2020-06-30	Vermont	Local	High	455	NR	NR	Non-probability	Household and community samples	2.2%	University of Vermont NR NR	No data	-
Samore (University of Utah) ³⁶⁸	2020-05-04 to 2020-06-30	Utah	Regional	Moderate	8108	Median 44 (IQR 30-62)	53.5	Probability	Household and community samples	0.8% (0.1-1.6%)	Abbott Abbott SARS-CoV-2 IgG IgG	86.4%, 99.6% (Used author-adjusted estimate)	0.8% (0.6-1.0%)
Mahajan (Yale School of Medicine) ³⁴⁹	2020-06-04 to 2020-06-23	Connecticut	Regional	Moderate	567	Mean 50.1 (SD 17.2)	57.0	Probability	Household and community samples	4.0% (2.0-6.0%)	Ortho-Clinical Diagnostics Ortho-Diagnostics	0.8%, 1.0% (FINDDx / MUHC)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											VITROS anti-SARS-CoV-2 IgG assay IgG	independent evaluation)	
Barzin (University of North Carolina Chapel Hill) ³⁷⁴	2020-04-28 to 2020-06-19	North Carolina	Regional	Moderate	2973	20-29 (n=342), 30-39 (n=599), 40-49 (n=518), 50-59 (n=602), 60-69 (n=489), 70-79 (n=310) 80+ (n=77)	65.8	Non-probability	Residual sera	0.0% (0.0-0.9%)	Abbott Laboratories Abbott SARS-CoV-2 IgG assay IgG	100.0%, 98.9% (Used author-adjusted estimate)	0.0% (0.0-0.1%)
Spectrum News Staff (University of Louisville) ³⁷⁵	2020-06-10 to 2020-06-19	Kentucky	Local	High	2237	18-34 (n=470); 35-59 (n=895); >=60 (n= 895)	NR	Non-probability	Household and community samples	4.0%	NR NR NR	No data	-
Dodd (American Red Cross Scientific Affairs) ³⁷⁷	2020-06-15 to 2020-06-15		National	Moderate	953926	16-17 (n=8375); 18-24 (n=51763); 25-39 (n=204407); 40-54 (n=262912); 55+ (n=426469)	55.0	Non-probability	Blood donors	1.8%	Ortho-Clinical Diagnostics Ortho VITROS anti-SARS-CoV-2 S1 Total Ig assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Reifer (Sherman Abrams Laboratory) ³⁷⁸	2020-05-15 to 2020-06-15	New York New York	Local	High	28523	>=0	NR	Non-probability	Residual sera	44.0%	DiaSorin LIAISON Liaison® SARS- CoV-2 S1/S2 IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Sutton (Oregon Health Authority) ³⁷⁹	2020-05-11 to 2020-06-15	Oregon	Regional	High	897	0-4 (n=5); 5-17 (n=24); 18-49 (n=274); 50-64 (n=211); 65-74 (n=178); 75-84 (n=144); >=85 (n=61)	NR	Probability	Residual sera	1.0% (0.2-1.8%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Anand (Stanford University) ³⁸¹	2020-06-15 to 2020-06-15		National	Moderate	28503	18-44 (n=3303); 45-64 (n=11541); 65-79 (n=10220); 80+ (n=3439)	42.6	Probability	Residual sera	9.3% (8.8-9.9%)	Siemens Healthineers SARS-CoV-2 spike protein receptor binding domain (S1RBD) total antibody	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											chemiluminescence assay NR		
Hynes (Washoe County Health District) ³⁸⁴	2020-06-09 to 2020-06-10	Nevada	Local	High	234	NR	NR	Probability	Household and community samples	2.3%	Abbott NR NR	No data	-
Harden (Routt County Board of Health) ³⁸⁵	Until 2020-06-10	Colorado Steamboat Springs	Local	High	649	NR	NR	Non-probability	Household and community samples	2.6%	NR NR NR	No data	-
Rudavsky (Indiana University Fairbanks School of Public Health) ³⁸⁸	2020-06-03 to 2020-06-08	Indiana	Regional	Moderate	3600	NR	NR	Probability	Household and community samples	1.5%	NR NR NR	No data	-
Barzin (University of North Carolina Chapel Hill) ³⁷⁴	2020-03-03 to 2020-06-04	North Carolina	Regional	Moderate	1449	=>18	NR	Non-probability	Residual sera	0.7%	Abbott Laboratories Abbott SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Ohnesorge (Psalms/Solid Rock Medicine Group) ³⁹³	2020-05-29 to 2020-05-29	North Carolina	Local	Unclear	329	NR	NR	Non-probability	Household and community samples	1.5%	NR NR NR	No data	-
Hayden (Desert Healthcare District) ³⁹⁵	Until 2020-05-28	California	Local	Unclear	896	NR	50.0	Non-probability	Household and community samples	6.0%	Phamatech NR IgG, IgM	0.9%, 0.9% (FINDDx / MUHC independent evaluation)	-
Liu (Yale School of Medicine) ³⁹⁶	2020-02-19 to 2020-05-26	Connecticut New Haven	Sublocal	High	3048	NR	NR	Non-probability	Residual sera	5.9%	In-house In-house ELISA test IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	4.6% (2.9-6.3%)
Osher (BioSolutions)	2020-04-22 to 2020-05-26	Illinois Chicago	Sublocal	High	113	3 to 84	NR	Non-probability	Residual sera	15.9%	CLUNGENE CLUNGENE SARS-COV-2	66.0%, 96.6% (Used Bastos SR/MA data;	19.3% (8.9-29.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Services LLC) ³⁹⁷											VIRUS (COVID-19) IgG/IgM Rapid Test Cassette lateral flow immunoassay (LFI). IgG, IgM	no sens, spec, or author adjustment available)	
Mukherjee (Humboldt County Department of Health and Human Services) ³⁹⁸	Until 2020-05-26	California	Local	High	1000	NR	NR	Non-probability	Household and community samples	1.0%	NR NR NR	No data	-
Alfini (UW Health) ⁴⁰⁷	2020-05-13 to 2020-05-20	Wisconsin Madison	Local	Unclear	433	NR	NR	Non-probability	Household and community samples	0.3%	NR NR NR	No data	-
Alfini (UW Health) ⁴⁰⁷	2020-05-13 to 2020-05-20	Wisconsin Madison	Local	Unclear	5303	NR	NR	Non-probability	Household and community samples	1.5%	NR NR NR	No data	-
Montgomery (Iowa Department of Public Health) ⁴⁰⁸	2021-04-01 to 2020-05-20	Iowa	Regional	High	18160	NR	NR	Non-probability	Household and community samples	10.0%	NR NR IgG	No data	-
McLaughlin (University of Washington) ⁴¹²	2020-05-04 to 2020-05-19	Idaho	Local	Moderate	917	18-29 (n=96); 30-39 (n=151); 40-49 (n=186); 50-59 (n=225); 60-69 (n=172); >=70 (n=87);	52.2	Non-probability	Household and community samples	23.1% (19.8-26.5%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	92.9%, 99.6% (Used author-adjusted estimate)	23.1% (20.4-25.8%)
Feehan (Oschner Clinic Foundation) ⁴¹⁴	2020-05-09 to 2020-05-15	Louisiana	Local	Moderate	2640	Mean 50.6 (NR)	63.5	Probability	Household and community samples	6.9% (6.8-6.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Meyer (Winona Health) ⁴¹⁵	2020-05-10 to 2020-05-15	Minnesota Winona	Local	High	1000	NR	NR	Non-probability	Household and community samples	7.0%	NR NR IgG	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Dietrich (Tulane University) ⁴¹⁶	2020-03-18 to 2020-05-15	Louisiana Orleans	Local	High	812	Median 11.0 (IQR 4-15)	50.4	Non-probability	Residual sera	7.6%	Author-designed N/A - Author-designed IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	6.9% (4.1-9.6%)
City of Boston (Boston Public Health Commission) ⁴¹⁷	Until 2020-05-15	Massachusetts Boston	Local	Moderate	750	Median 42.4 (NR)	61.6	Probability	Household and community samples	9.9%	NR NR NR	No data	-
CBS Los Angeles (University of Southern California) ⁴²⁰	2020-05-08 to 2020-05-12	California	Local	Unclear	1014	NR	NR	Non-probability	Household and community samples	2.1%	NR NR NR	No data	-
Nesbitt (New York Blood Center) ⁴²¹	2020-04-27 to 2020-05-11	Rhode Island	Regional	Moderate	1996	Median 56 (NR)	47.3	Non-probability	Blood donors	0.7%	Ortho-Clinical Diagnostics Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Ripperger (University of Arizona) ⁴²⁴	2020-04-30 to 2020-05-07	Arizona	Local	High	5882	Median NR40 (Range 18-85)	52.4	Non-probability	Household and community samples	1.2%	NR NR IgG, IgM	97.6%, 100.0% (Test developer / manufacturer evaluation)	1.0% (0.2-1.5%)
Bajema (Centers for Disease Control and Prevention) ⁴²⁸	2020-04-28 to 2020-05-03	Georgia Atlanta	Local	Low	669	Median 46 (IQR 36-73)	54.9	Probability	Household and community samples	3.6%	Centers for Disease Control and Prevention (CDC) CDC SARS-CoV-2 ELISA NR	96.0%, 99.3% (Test developer / manufacturer evaluation)	2.1% (0.0-4.2%)
Biggs (CDC COVID-19 Response Team) ⁴²⁹	2020-04-28 to 2020-05-03	Georgia	Local	Moderate	696	NR	54.2	Probability	Household and community samples	2.7%	Ortho-Clinical Diagnostics VITROS anti-SARS-CoV-2 total antibody IgG, IgA, IgM	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Menachemi (Indiana University)	2020-05-02 to 2020-05-03	Indiana Indianapolis	Local	High	898	<20 (n=77); 20-39 (n=277); 40-59 (n=369);	58.2	Non-probability	Household and	5.8%	Author derived NR IgG	100.0%, 99.6% (Test developer)	4.1% (0.4-6.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Fairbanks School of Public Health) ⁴³⁰						60-79 (n=169); ≥80 (n=6)			community samples			/ manufacturer evaluation)	
Bajema (Centers for Disease Control and Prevention) ⁴²⁸	2020-04-27 to 2020-05-01	Georgia Atlanta	Local	Moderate	1343	Median 57 (IQR 36-73)	55.2	Non-probability	Residual sera	4.2%	Centers for Disease Control and Prevention (CDC) CDC SARS-CoV-2 ELISA NR	96.0%, 99.3% (Test developer / manufacturer evaluation)	2.7% (0.1-4.8%)
Menachemi (Indiana University Fairbanks School of Public Health) ⁴³⁰	2020-04-25 to 2020-04-29	Indiana	Regional	Moderate	3518	<40 (n=1017); 40 to 59 (n=1328); ≥60 (n=1313)	56.7	Probability	Household and community samples	1.1% (0.8-1.5%)	Author derived NR IgG	100.0%, 99.6% (Test developer / manufacturer evaluation)	0.4% (0.0-1.0%)
Chamie (University of California, San Francisco) ⁴³⁶	2020-04-25 to 2020-04-28	California San Francisco	Local	Moderate	3861	4-10 (n=109); 11-17 (n=135); 18-50 (n=2466); 51-70 (n=916); >70 (n=190)	42.6	Non-probability	Household and community samples	3.4% (2.9-4.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Rosenberg (New York State Department of Health) ⁴³⁷	2020-04-19 to 2020-04-28	New York	Regional	Moderate	15101	18-34 (n=3151); 35-44 (n=2628); 45-54 (n=3345); ≥55 (n=5977)	56.1	Non-probability	Household and community samples	14.0% (13.3-14.7%)	NYSDOH Wadsworth Center SARS-CoV IgG Microsphere Immunoassay IgG	87.9%, 99.8% (Used author-adjusted estimate)	14.0% (13.5-14.6%)
Zou (Georgia State University) ⁴³⁸	2020-04-17 to 2020-04-27	Georgia Atlanta	Local	High	127	NR	NR	Non-probability	Household and community samples	2.4%	Author-designed Krammer and colleagues ELISA S1 IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	1.2% (0.0-4.7%)
Bryan (University of Washington School of Medicine) ⁴³⁹	2020-04-20 to 2020-04-26	Idaho Boise	Local	High	4856	0-19 (n=240); 20-29 (n=301); 30-39 (n=831); 40-49 (n=1102); 50-59 (n=1142); 60-69 (n=888);	54.2	Non-probability	Household and community samples	1.8%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						70-79 (n=327); ≥80 (n=25)							
Appa (University of California San Francisco) ⁴⁴¹	2020-04-20 to 2020-04-24	California Bolinas	Local	Moderate	1880	NR	NR	Non-probability	Household and community samples	0.2%	University of California In-House ELISA IgG	96.2%, 99.9% (Test developer / manufacturer evaluation)	0.1% (0.0-0.3%)
Sassoon (OMNI Healthcare) ⁴⁴³	2020-04-17 to 2020-04-24	Florida	Local	High	1000	NR	NR	Non-probability	Household and community samples	1.0%	NR NR IgG, IgM	100.0%, 100.0% (Test developer / manufacturer evaluation)	0.7% (0.0-1.4%)
Dingens (Fred Hutchinson Cancer Research Center) ⁴⁴⁴	2020-03-03 to 2020-04-24	Washington Seattle	Sublocal	High	1076	0-4 (n=192); 5-9 (n=214); 10-14 (n=301); >15 (n=369)	49.7	Non-probability	Residual sera	0.9%	Abbott; N/A In-house ELISA assays, Abbott Architect SARS-CoV-2 IgG assay IgG	No data	-
Morrison (Crush The Curve Idaho) ⁴⁴⁶	Until 2020-04-22	Idaho	Regional	High	1946	NR	NR	Non-probability	Residual sera	1.8%	University of Washington NR IgG	100.0%, 99.6% (Test developer / manufacturer evaluation)	0.8% (0.0-1.7%)
Paterson (Baton Rouge General Hospital) ⁴⁴⁹	Until 2020-04-21	Louisiana Baton Rouge	Local	Unclear	432	NR	NR	Non-probability	Household and community samples	4.4%	Mayo Clinic NR NR	No data	-
Naranbhai (Massachusetts General Hospital) ⁴⁵³	2020-04-14 to 2020-04-15	Massachusetts Chelsea	Local	Moderate	200	Median 46 (IQR 27-55)	40.0	Non-probability	Household and community samples	32.8% (27.2-38.8%)	BioMedomics BioMedomics SARS-CoV-2 combined IgM/IgG LFA IgG, IgM	90.0%, 99.0% (Used author-adjusted estimate)	32.8% (26.3-39.2%)
Sood (Stanford University School of Medicine) ⁴⁵⁴	2020-04-10 to 2020-04-14	California	Local	Moderate	863	18-34 (n=191); 35-54 (n=475); ≥55 years (n=197)	59.6	Probability	Household and community samples	4.7% (2.5-7.1%)	Premier Biotech NR IgG, IgM	82.7%, 99.5% (Used author-adjusted estimate)	4.7% (3.4-6.2%)
Ng (University of California, San Francisco) ⁴⁵⁵	2020-03-17 to 2020-04-13	California San Francisco	Local	High	387	≤19 (n=15); 20-29 (n=28); 30-39 (n=41); 40-49 (n=54); 50-59 (n=68);	48.1	Non-probability	Residual sera	0.3% (0.0-0.8%)	Abbott Abbott Architect SARS-CoV-2 IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						60-69 (n=71); 70-79 (n=56); 80-89 (n=20); 90-99 (n=5); unknown (n=29)							
Bendavid (Stanford University School of Medicine) ⁴⁵⁷	2020-04-03 to 2020-04-04	California	Local	High	3328	0-19 (n=637); 20-39 (n=907); 40-69 (n=1706); ≥70 (n=78)	63.1	Non-probability	Household and community samples	2.8% (1.3-4.2%)	Premier Biotech NR IgG, IgM	85.6%, 99.5% (Used author-adjusted estimate)	2.8% (2.2-3.3%)
Ng (University of California, San Francisco) ⁴⁵⁵	2020-03-01 to 2020-03-31	California San Francisco	Local	Moderate	1000	≤19 (n=18); 20-29 (n=152); 30-39 (n=205); 40-49 (n=172); 50-59 (n=185); 60-69 (n=197); 70-79 (n=63); 80-89 (n=7)	49.1	Non-probability	Blood donors	0.1% (0.0-0.6%)	Ortho-Clinical Diagnostics; Abbott Abbott Architect SARS-CoV-2 IgG, VITROS anti-SARS-CoV-2 total antibody, SARS-CoV-2 neutralization assay. IgG	No data	-
Schuchat (University of Washington) ⁴⁵⁹	2020-03-01 to 2020-03-31	Washington Seattle	Local	High	221	NR	NR	Non-probability	Residual sera	0.4%	NR NR NR	No data	-
Basavaraju (American Red Cross) ⁴⁶²	2019-12-13 to 2020-01-17	Wisconsin, Oregon, Massachusetts, Michigan, Connecticut, Washington, California, Iowa, Rhode Island	National	Moderate	7389	16-29 (n = 895); 30-39 (n = 885); 40-49 (n = 1070); 50-59 (n = 1844); 60-69 (n = 1893); 70+ (n = 802)	46.0	Non-probability	Blood donors	1.4%	CDC pan-IgG ELISA NR	96.0%, 99.3% (Test developer / manufacturer evaluation)	0.6% (0.0-1.1%)
Latin America and Caribbean													
Brazil													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-10-12 to 2020-10-24	Sao Paulo State Sao Paulo	Local	Moderate	877	NR	NR	Non-probability	Blood donors	18.2% (15.0-21.7%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	18.2% (15.7-20.8%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-10-10 to 2020-10-17	Amazonas Manaus	Local	Moderate	882	NR	NR	Non-probability	Blood donors	43.1% (38.3-47.9%)	Abbott Laboratories Abbott N IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	56.3% (52.5-59.6%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-09-07 to 2020-09-29	Sao Paulo State Sao Paulo	Local	Moderate	933	NR	NR	Non-probability	Blood donors	15.1% (12.3-18.2%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	15.1% (12.8-17.4%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-09-05 to 2020-09-14	Amazonas Manaus	Local	Moderate	868	NR	NR	Non-probability	Blood donors	45.4% (40.8-50.1%)	Abbott Laboratories Abbott N IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	54.0% (50.4-57.5%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-08-10 to 2020-08-29	Sao Paulo State Sao Paulo	Local	Moderate	906	NR	NR	Non-probability	Blood donors	15.5% (12.3-18.2%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	15.5% (13.2-17.9%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-08-08 to 2020-08-19	Amazonas Manaus	Local	Moderate	881	NR	NR	Non-probability	Blood donors	44.0% (40.0-48.0%)	Abbott Laboratories Abbott N IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	55.4% (51.8-58.8%)
daSilva (Federal University of Maranhao) ⁴⁶⁵	2020-07-27 to 2020-08-08	Maranhao	Regional	Moderate	3156	1-9 (n=124); 10-19 (n=10-19); 20-29 (n=427); 30-39 (n=475); 40-49 (n=502); 50-59 (n=501); 60-69 (n=409); >70 (n=386).	62.0	Probability	Household and community samples	40.4% (35.6-45.3%)	Roche Diagnostics Elecsys Anti-SARS-CoV-2 assay IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	59.6% (57.8-61.5%)
Oliveira (Universidade de São Paulo) ⁴⁶⁶	2020-06-30 to 2020-08-04	State of Sao Paulo Sao Paulo	Sublocal	High	439	18-39 years old (n=121); 40-59 years (n=185); ≥ 60 years old (n=133)	64.5	Non-probability	Residual sera	13.9%	Roche Diagnostics; DiaSorin S.p.A. LIAISON® SARS-CoV-2 S1/S2 IgG, Elecsys Anti-	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	12.4% (9.0-15.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											SARSCoV-2 Cobas® assay IgG		
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-07-01 to 2020-07-31	Sao Paulo State Sao Paulo	Local	Unclear	1000	NR	NR	Non-probability	Blood donors	13.3%	Abbott Laboratories; Roche Diagnostics Abbott N IgG Assay; Roche Elecsys SARS-CoV-2 IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	11.7% (9.6-14.1%)
Paula (Universidade Federal de Mato Grosso (UFMT)) ⁴⁶⁸	2020-04-01 to 2020-07-31	Mato Grosso Cuiabá	Sublocal	High	6392	0-9 (n=168); 10-19 (n= 220); 20-29 (n= 782); 30-39 (n= 1562); 40-49 (1472); 50-59 (n=1076); 60-69 (n=748); 70-79 (n=272); 80-89 (n= 74); 90-100 (n=14); 101-120 (n=4).	59.7	Probability	Residual sera	22.1%	Carlos Chagas Laboratory SOROVID-19? IgG, IgM	No data	-
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-07-13 to 2020-07-25	Sao Paulo State Sao Paulo	Local	Moderate	879	NR	NR	Non-probability	Blood donors	10.6% (8.1-13.5%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	10.6% (8.7-12.7%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-07-06 to 2020-07-15	Amazonas Manaus	Local	Moderate	1147	NR	NR	Non-probability	Blood donors	46.9% (42.7-51.1%)	Abbott Laboratories Abbott N IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	52.5% (49.3-55.7%)
Horta (Universidade Federal de Pelotas) ⁴⁷⁰	2020-05-14 to 2020-06-24		National	Moderate	89362	≤ 9 (n= 4 263) 10 – 19 (n = 8 024) 20 – 39 (n = 27 485) 40 – 59 (n = 28 402) 60+ (n = 21 188)	58.2	Probability	Household and community samples	2.3%	China; Guangzhou; Wondfo Biotech; Co. WONFDO SARS-CoV-2 Antibody Test IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-06-08 to 2020-06-20	Sao Paulo State Sao Paulo	Local	Moderate	880	NR	NR	Non-probability	Blood donors	13.1% (10.3-16.3%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	13.1% (11.0-15.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Picon (Universidade do Vale do Taquari) ⁴⁷¹	2020-06-13 to 2020-06-17	Rio Grande do Sul Lajeado	Local	Moderate	1127	Median 49.9 (positive); 49.9 (negative) (IQR 31.1 (positive); 26.9 (negative))	84.5	Probability	Household and community samples	2.6% (1.8-3.7%)	Guangzhou Wondfo Biotech Wondfo Lateral Flow Immunoassay IgG, IgM	76.2%, 99.6% (Used author-adjusted estimate)	2.6% (1.8-3.6%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-06-05 to 2020-06-15	Amazonas Manaus	Local	Moderate	911	NR	NR	Non-probability	Blood donors	52.7% (48.5-56.9%)	Abbott Laboratories Abbott N IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	46.5% (42.7-50.0%)
Picon (Universidade do Vale do Taquari) ⁴⁷¹	2020-05-30 to 2020-06-04	Rio Grande do Sul Lajeado	Local	Moderate	1450	Median 45.4 (positive); 49.6 (negative) (IQR 24.8 (positive); 27.8 (negative))	49.9	Probability	Household and community samples	4.0% (3.1-5.2%)	Guangzhou Wondfo Biotech Wondfo Lateral Flow Immunoassay IgG, IgM	76.2%, 99.6% (Used author-adjusted estimate)	4.0% (3.1-5.1%)
Vieira (Centro de Operações de Emergências em Saúde Pública) ⁴⁷²	2020-05-31 to 2020-05-31	Piauí Teresina	Local	Moderate	900	NR	NR	Probability	Household and community samples	8.3% (6.6-10.3%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Sales (Universidade Federal do Ceará) ⁴⁷³	2020-05-22 to 2020-05-31	State of Pernambuco Fernando de Noronha	Local	Moderate	904	<10 (n=31), 10-18 (n=46), 19-39 (n=366), 40-58 (n=375), 59-68 (n=69), =>69 (n=17)	52.1	Probability	Household and community samples	4.3% (3.2-5.9%)	Ltd.; Guangzhou Wondfo Biotech Co. SARS-CoV-2 Antibody Test Kit (IgG / IgM) IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Jr (Secretaria Municipal de Saude) ⁴⁷⁴	2020-05-30 to 2020-05-30	Biguacu	Local	Unclear	217	<20 (n=39); 20-30 (n=29); 30-40 (n=46); 40-50 (n=36); 50-60 (n=29); 70-80 (n=19); >80 (n=18)	58.1	Probability	Household and community samples	0.4%	NR NR NR	No data	-
Vieira (Centro de Operações de Emergências)	2020-05-24 to 2020-05-24	Piauí Teresina	Local	Moderate	900	NR	NR	Probability	Household and community samples	5.8% (4.3-7.3%)	Wondfo Biotech Co. WONDFO SARS-CoV-2	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
em Saúde Pública) ⁴⁷²											Antibody Test IgG, IgM		
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-05-08 to 2020-05-21	Sao Paulo State Sao Paulo	Local	Moderate	826	NR	NR	Non-probability	Blood donors	4.7% (2.6-7.3%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	4.7% (3.3-6.2%)
Vieira (Centro de Operações de Emergências em Saúde Pública) ⁴⁷²	2020-05-17 to 2020-05-17	Piaui Teresina	Local	Moderate	900	NR	NR	Probability	Household and community samples	3.8% (2.6-5.2%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Chioro (Baixada Santista Metropolitan Region) ⁴⁷⁶	2020-05-13 to 2020-05-15	São Paulo state Baixada Santista	Local	High	2415	Mean 37.55 (NR)	NR	Probability	Household and community samples	2.2%	Wondfo Wondfo SARS-CoV-2 test NR	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Gomes (Secretaria de Estado da Saúde do Espírito Santo) ⁴⁷⁷	2020-05-13 to 2020-05-15	Espírito Santo	Regional	Moderate	4612	<=20 years (n=434); 21-40 (n=1367); 41-60 (n=1583); 61-80 (n=1081); >= 81 (n=143)	60.9	Probability	Household and community samples	2.1% (1.7-2.5%)	Celer Technologies Inc. NR IgG, IgM	86.4%, 97.6% (Test developer / manufacturer evaluation)	0.8% (0.0-2.0%)
Gomes (Secretaria de Estado da Saúde do Espírito Santo) ⁴⁷⁷	2020-05-13 to 2020-05-15	Espírito Santo	Regional	Moderate	1163	NR	NR	Probability	Household and community samples	0.3% (0.1-0.8%)	Celer Technologies Inc. NR IgG, IgM	86.4%, 97.6% (Test developer / manufacturer evaluation)	0.1% (0.0-0.5%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-05-05 to 2020-05-14	Amazonas Manaus	Local	Moderate	901	NR	NR	Non-probability	Blood donors	42.1% (37.5-46.7%)	Abbott Laboratories Abbott N IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	57.3% (53.6-60.6%)
Tess (Universidade de São Paulo) ⁴⁷⁸	2020-05-04 to 2020-05-12	São Paulo São Paulo	Local	Moderate	517	18-44 (n=269); >= 45 (n=248)	54.9	Probability	Household and community samples	4.7% (3.0-6.6%)	SNIBE – Shenzhen New Industries Biomedical Engineering Co. MAGLUMI 2019-nCoV	100.0%, 99.5% (Test developer / manufacturer evaluation)	3.0% (0.0-5.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											IgG (CLIA) IgG, IgM		
Watanabe (Grupo Fleury) ⁴⁷⁹	2020-05-04 to 2020-05-12	São Paulo São Paulo	Sublocal	Unclear	520	NR	NR	Probability	Household and community samples	5.2%	NR NR NR	No data	-
Silveira (Universidade Federal de Pelotas) ⁴⁸⁰	2020-05-09 to 2020-05-11	Rio Grande do Sul Pelotas, Santa Maria, Canoas, Ijuí, Uruguaiãna, Porto Alegre, Passo Fundo, Santa Cruz do Sul, Caxias	Regional	Low	4500	0-9 (n=113); 10-19 (n=266); 20-29 (n=581); 30-39 (n=684); 40-49 (n=689); 50-59 (n=769); 60-69 (n=734); 70-79 (n=464); >=80 (n=202);	58.9	Probability	Household and community samples	0.2% (0.1-0.4%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Vieira (Centro de Operações de Emergências em Saúde Pública) ⁴⁷²	2020-05-10 to 2020-05-10	Piauí Teresina	Local	Moderate	900	NR	NR	Probability	Household and community samples	2.0% (1.2-3.1%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Borges (Federal University of Sergipe) ⁴⁸¹	2020-05-02 to 2020-05-09	Sergipe Nossa Senhora do, São Cristóvão, Lagarto, Estância, Tobias Barreto, Itabaiana, Nossa Senhora da Glória, Itabaianinha, Simão Dias, Aracaju	Regional	High	2635	Mean 39.76 (SD 16.83)	59.8	Non-probability	Household and community samples	8.3% (7.2-9.4%)	Boditech Med Inc. Ichroma2™ COVID-19 Ab IgG	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	7.8% (5.8-9.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Vieira (Centro de Operações de Emergências em Saúde Pública) ⁴⁷²	2020-05-03 to 2020-05-03	Piauí Teresina	Local	Moderate	900	NR	NR	Probability	Household and community samples	1.4% (0.8-2.5%)	Wondfo Biotech Co. WONFDO SARS-CoV-2 Antibody Test IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Buss (Universidade de São Paulo) ⁴⁶³	2020-04-08 to 2020-04-30	São Paulo State São Paulo	Local	Moderate	900	NR	NR	Non-probability	Blood donors	4.0% (1.8-6.6%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	4.0% (2.9-5.4%)
Silveira (Universidade Federal de Pelotas) ⁴⁸⁰	2020-04-25 to 2020-04-27	Rio Grande do Sul Pelotas, Canoas, Santa Maria, Ijuí, Uruguaiãna, Porto Alegre, Passo Fundo, Santa Cruz do Sul, Caxias	Regional	Low	4501	0-9 (n=116); 10-19 (n=227); 20-29 (n=508); 30-39 (n=753); 40-49 (n=647); 50-59 (n=798); 60-69 (n=798); 70-79 (n=459); >=80 (n=156)	58.9	Probability	Household and community samples	0.1% (0.0-0.3%)	Wondfo Biotech Co. WONFDO SARS-CoV-2 Antibody Test IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Filho (Universidade do Estado do Rio de Janeiro) ⁴⁸³	2020-04-14 to 2020-04-27	Rio de Janeiro Rio de Janeiro	Local	Moderate	2857	18-29 (n=870); 30-49 (n=1443); 50-69 (n=544)	49.2	Non-probability	Blood donors	4.0% (3.3-4.7%)	MedLevensohn MedTest Coronavirus 2019-nCoV IgG/IgM IgG, IgM	85.0%, 99.0% (Test developer / manufacturer evaluation)	2.8% (0.0-4.9%)
Vieira (Centro de Operações de Emergências em Saúde Pública) ⁴⁷²	2020-04-26 to 2020-04-26	Piauí Teresina	Local	Moderate	900	NR	NR	Probability	Household and community samples	0.9% (0.4-1.8%)	Wondfo Biotech Co. WONFDO SARS-CoV-2 Antibody Test IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Vieira (Centro de Operações de Emergências em Saúde Pública) ⁴⁷²	2020-04-19 to 2020-04-19	Piauí Teresina	Local	Moderate	900	NR	NR	Probability	Household and community samples	0.6% (0.2-1.3%)	Wondfo Biotech Co. WONFDO SARS-CoV-2 Antibody Test IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-04-06 to 2020-04-17	Amazonas Manaus	Local	Moderate	829	NR	NR	Non-probability	Blood donors	5.0% (2.9-7.4%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	5.0% (3.6-6.6%)
Gurgel (Federal University of Sergipe) ⁴⁸⁴	2020-01-15 to 2020-04-15	Sergipe Aracaju	Local	Moderate	987	Mean 38.9 (SD 22.2)	69.2	Non-probability	Residual sera	1.6%	Nantong Egens Biotechnology CO; Ltd.; China and Bodytech Med Inc. Nantong Egens Biotechnology CO, Ltd; iChroma2™ IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.2% (0.0-0.9%)
Silveira (Universidade Federal de Pelotas) ⁴⁸⁰	2020-04-11 to 2020-04-13	Rio Grande do Sul Pelotas, Santa Maria, Canoas, Ijuí, Uruguaiãna, Porto Alegre, Passo Fundo, Santa Cruz do Sul, Caxias	Regional	Low	4151	0-9 (n=149); 10-19 (n=224); 20-29 (n=506); 30-39 (n=635); 40-49 (n=643); 50-59 (n=734); 60-69 (n=685); 70-79 (n=3985); >=80 (n=183)	58.3	Probability	Household and community samples	0.0% (0.0-0.2%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-03-09 to 2020-03-21	Sao Paulo State Sao Paulo	Local	Moderate	2454	NR	NR	Non-probability	Blood donors	2.8% (1.8-3.9%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	2.8% (2.2-3.5%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-03-06 to 2020-03-12	Amazonas Manaus	Local	Moderate	832	NR	NR	Non-probability	Blood donors	0.0% (0.0-0.8%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	0.0% (0.0-0.3%)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-02-08 to 2020-02-29	Sao Paulo State Sao Paulo	Local	Moderate	799	NR	NR	Non-probability	Blood donors	1.0% (0.0-2.9%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	1.0% (0.4-1.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Buss (Universidade de Sao Paulo) ⁴⁶³	2020-02-07 to 2020-02-13	Amazonas Manaus	Local	Moderate	821	NR	NR	Non-probability	Blood donors	0.4% (0.0-3.3%)	Abbott Laboratories Abbott N IgG Assay IgG	92.2%, 96.1% (Used author-adjusted estimate)	0.4% (0.1-1.0%)
Columbia													
Mattar (Universidad de Córdoba) ⁴⁸⁵	2020-08-04 to 2020-09-01	Caribbean Region Monteria	Local	Moderate	1368	NR	57.8	Probability	Household and community samples	55.3% (52.5-57.8%)	Ingenasa INgezim COVID 19 DR test IgG, IgA, IgM	92.0%, 100.0% (Author-reported independent evaluation)	59.4% (50.4-68.7%)
Dominican Republic													
Paulino-Ramirez (Universidad Iberoamericana) ⁴⁸⁹	2020-04-15 to 2020-06-15		National	High	12897	Mean 42 (NR)	48.8	Probability	Household and community samples	5.5%	GenBody Inc. Confiscope G20 IgG	56.7%, 100.0% (Test developer / manufacturer evaluation)	8.3% (3.2-13.0%)
Ecuador													
Brutto (Universidad Peruana Cayetano Heredia) ⁴⁹⁰	2020-06-25 to 2020-06-30	Atahualpa	Local	High	362	Mean 59.9 (SD 13)	56.6	Probability	Household and community samples	7.7%	BIOHIT Health Care BIOHIT SARS-CoV-2 antibody test IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	6.7% (2.3-11.2%)
Brutto (Universidad Peruana Cayetano Heredia) ⁴⁹¹	2020-05-01 to 2020-05-25	El Oro	Local	Moderate	673	Mean 59.2 (SD 12.8)	56.6	Probability	Household and community samples	45.0%	Biohit Health Care Ltd BIOHIT SARS-CoV-2 antibody test kit (Colloidal gold method) IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	66.3% (60.1-72.3%)
French Guiana													
Flamand (Institut Pasteur) ⁴⁹²	2020-07-15 to 2020-07-23		National	Moderate	480	Mean 38.3 (Range 0.2 - 87)	68.1	Non-probability	Residual sera	15.4% (9.3-24.4%)	Euroimmun anti-SARS-CoV-2 IgG ELISA IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Honduras													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Núñez (Colegio Médico) ⁴⁹³	2020-06-16 to 2020-06-23		National	Moderate	792	Median 37 (IQR 27-50)	54.7	Probability	Household and community samples	6.2%	NR NR IgG, IgM	93.4%, 97.7% (Test developer / manufacturer evaluation)	3.7% (0.0-6.6%)
Mexico													
Martínez-Acuña (Autonomous University of Nuevo Leon) ⁴⁹⁵	2020-01-01 to 2020-08-30	Nuevo Leon	Regional	High	1968	Mean 34.8 (Range 18 to 65)	27.0	Non-probability	Blood donors	4.0%	Abbott Laboratories SARS-CoV-2 IgG ARCHITECT IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Remes-Troche (Universidad Veracruzana) ⁴⁹⁶	2020-06-01 to 2020-07-31	Veracruz City	Sublocal	High	2174	Mean 41.8 (Range 18-98)	53.6	Non-probability	Residual sera	29.5% (27.6-31.5%)	Ortho-Clinical Diagnostics; Abbott Abbott SARS- CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Panama													
Villarreal (Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT -AIP)) ⁴⁹⁸	2020-04-30 to 2020-07-07	Colon, Panama	National	High	255	Median 73.2 (SD 11.1)	29.0	Non-probability	Blood donors	11.7% (8.3-16.3%)	N/A - Author Designed Chinese Academy of Science Test (CAST) IgG, IgM	87.0%, 98.9% (Test developer / manufacturer evaluation)	11.4% (4.5-17.6%)
Paraguay													
Ultimahora (Ministerio de Salud Pública) ⁴⁹⁹	2020-11-29 to 2020-12-15	Ciudad del Este	Local	Unclear	1675	NR	NR	Non-probability	Household and community samples	30.0%	NR NR NR	No data	-
Peru													
Peruvian Government (National Center for Epidemiology, Prevention and Control of Diseases) ⁵⁰¹	2020-06-28 to 2020-07-09	Callao, Lima Callao, Lima	Local	High	3118	NR	NR	Probability	Household and community samples	21.6% (18.7-24.6%)	NR NR IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	29.1% (26.4-31.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Angulo-Bazán (National Institute of Health (INS)) ⁵⁰²	2020-04-23 to 2020-05-02	Lima Lima	Local	Moderate	236	Mean 36.2 (SD 20.1)	54.7	Non-probability	Household and community samples	53.0%	Core Technology Co. Ltd Coretests COVID-19 IgM/IgG Ab Test IgG, IgM	97.6%, 100.0% (Test developer / manufacturer evaluation)	55.8% (47.9-65.8%)
North Africa and Middle East													
Iran													
Poustchi (Tehran University of Medical Sciences) ⁵⁰⁵	2020-04-17 to 2020-06-02	Kerman, Shiraz, Esfahan, Urmia, Tehran, Ardabil, Ahvaz, Sari, Qom, Zahedan, Hamedan, Sanandaj, Kermanshah, Mashhad, Gorgan, Tabriz, Babol, Rasht	National	Low	3530	≤19 (n = 140); 20–29 (n = 470); 30–39 (n = 992); 40–49 (n = 937); 50–59 (n = 590); ≥60 (n = 401)	49.2	Probability	Household and community samples	12.9% (11.3-14.5%)	Pishtaz Teb PT-SARS-COV-2.IgM-96 and PT-SARS-COV-2.IgG-96 IgG, IgM	66.9%, 98.2% (Author-reported independent evaluation)	16.2% (10.7-20.6%)
Shakiba (Tehran University of Medical Sciences) ⁵⁰⁹	2020-04-11 to 2020-04-19	Guilan	Regional	Moderate	528	<5 (n = 26) ; 5-17 (n = 101) ; 18-59 (n = 329) ; 60+ (n=72)	51.3	Probability	Household and community samples	22.2% (16.4-28.5%)	VivaChek VivaDiag Rapid test kit IgG, IgM	83.3%, 99.0% (Used author-adjusted estimate)	22.2% (18.8-25.8%)
Libya													
Elfakhri (The Center of Infectious Diseases-Benghazi) ⁵¹³	2020-05-02 to 2020-05-07	Benghazi	Local	Moderate	600	Mean 38.2 (SD 17.5)	50.5	Probability	Household and community samples	0.0%	Biotest Right Sign (Lot No. COV20030003) IgG, IgM	81.7%, 96.7% (Test developer / manufacturer evaluation)	0.2% (0.0-0.7%)
Saudi Arabia													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Mahallawi (Taibah University) ⁵¹⁷	2020-05-15 to 2020-07-15	Al-Madinah	Local	High	1212	Mean 31.73 (SD 9.05)	0.0	Non-probability	Blood donors	19.3% (17.1-21.6%)	In-house; NR In-house ELISA, NR IgG	No data	-
Turkey													
Sozcu (Unclear (Turkey Ministry of Health)) ⁵²⁰	2020-06-15 to 2020-06-25		National	Unclear	132000	NR	NR	Non-probability	Household and community samples	0.8%	NR NR NR	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)
South Asia													
India													
Khan (Government Medical College Sringer) ⁵²²	2020-10-17 to 2020-11-04		Regional	Low	6230	18-29 (n=1513); 30-49 (n=2672); 50-69 (n=1643); >70 (n=402)	49.8	Probability	Household and community samples	36.7% (34.3-39.2%)	Abbott Abbott SARS-CoV-2 IgG assay IgG	100.0%, 99.6% (Used author-adjusted estimate)	36.7% (35.5-37.9%)
Kumar (Unclear) ⁵²³	2020-10-18 to 2020-10-24	Haryan	Regional	Unclear	16477	NR	NR	Probability	Household and community samples	14.8%	NR NR NR	No data	-
Sharma (Government of National Capital Territory of Delhi) ⁵²⁴	2020-10-15 to 2020-10-21	NCT Delhi	Regional	Low	15015	<18 (n=2430); 18-49 (n=9420); =>50 (n=3043)	52.9	Probability	Household and community samples	25.2% (24.5-25.9%)	NR ERBALISA COVID-19 IgG IgG	99.1%, 99.3% (Test developer / manufacturer evaluation)	25.0% (20.8-29.2%)
Ramanath (The Regional Medical Research Centre in Bhubaneswar) ⁵²⁵	2020-10-16 to 2020-10-18	Bhubaneswar	Local	Unclear	1403	NR	NR	Probability	Household and community samples	50.0%	NR NR NR	No data	-
Banerjee (Dr DY Patil Medical College) ⁵²⁶	2020-10-07 to 2020-10-17	Maharashtra Pune	Local	Moderate	5000	NR	NR	Probability	Household and community samples	34.0% (31.3-36.8%)	IL; Abbott Chicago; USA. Abbott IgG IgG	92.7%, 99.9% (Used author-adjusted estimate)	34.0% (32.7-35.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Babu (Indian Institute of Public Health) ⁵²⁷	2020-09-03 to 2020-09-16	Karnataka	Regional	Moderate	15939	18-29 (n=5184); 30-39 (n=3353); 40-49 (n=2447); 50-59 (n=1792); >=60 (n=2848)	51.2	Non-probability	Household and community samples	16.1%	India; Zydus Cadila Covid Kavach Anti SARS-CoV-2 IgG antibody detection ELISA IgG	92.1%, 99.8% (Test developer / manufacturer evaluation)	16.3% (11.4-20.0%)
Sharma (Government of National Capital Territory of Delhi) ⁵²⁴	2020-09-01 to 2020-09-07	NCT Delhi	Regional	Low	17409	<18 (n=3013); 18-49 (n=10544); >=50 (n=3392)	52.3	Probability	Household and community samples	24.6% (23.9-25.2%)	NR ERBALISA COVID-19 IgG IgG	99.1%, 99.3% (Test developer / manufacturer evaluation)	24.3% (20.3-28.1%)
Kshatri (Indian Council of Medical Research-Regional Medical Research Centre in Bhubaneswar (ICMR-RMRC) Serosurvey group) ⁵²⁹	2020-08-01 to 2020-08-31	Odisha Bhubaneswar, Berhampur, Rourkela	Local	High	4146	Mean 44.2 (NR)	37.5	Probability	Household and community samples	20.8% (19.6-22.1%)	NR Elecsys® Anti-SARS-CoV-2 NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Singh (The Times of India) ⁵³⁰	2020-08-27 to 2020-08-30	Madhya Pradesh	Regional	Unclear	3000	NR	NR	Non-probability	Household and community samples	11.9%	NR NR NR	No data	-
Mohanani (Mapmygenome) ⁵³¹	2020-06-15 to 2020-08-29	Karnataka	Regional	Moderate	1197	12 or 15-24 (n = 192) ; 25-39 (n=363) ; 40-59 (n = 742) ; >= 60 (n = 111)	NR	Probability	Household and community samples	39.6% (35.7-43.4%)	India; Translational Health Science and Technology Institute NR IgG	84.7%, 100.0% (Test developer / manufacturer evaluation)	48.1% (39.9-59.3%)
Dixit (Government Medical School, Aurangabad) ⁵³³	2020-08-10 to 2020-08-19	Maharashtra	Local	Moderate	6571	18-20 (n = 367); 21-30 (n = 1732); 31-40 (n = 1844); 41-50 (n = 1356); 51-60 (n = 761); 61-70 (n = 427); 71-80	NR	Probability	Household and community samples	5.8%	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	4.5% (2.9-5.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						(n = 99); >80 (n = 23)							
Ray (All India Institute of Medical Sciences) ⁵³⁵	2020-06-08 to 2020-08-08	Punjab New Delhi	Local	High	212	Mean 41.2 (SD 15.4)	44.8	Non-probability	Residual sera	19.8% (14.7-25.8%)	"Translational Health Science and Technology Institute (THSTI); Faridabad" THSTI ELISA IgG IgG	88.2%, 99.8% (Test developer / manufacturer evaluation)	21.0% (13.8-30.1%)
Satpati (Medical College Kolkata) ⁵³⁶	2020-07-26 to 2020-08-08	West Bengal	Regional	Moderate	458	0-5 (n=1); 11-19 (n=28); 20-45 (n=290); 46-59 (n=101); 60 and above (n=38)	37.3	Probability	Household and community samples	4.2% (2.5-6.4%)	Calbiotech Inc. ErbaLisa COVID-19 IgG ELISA Kit IgG	98.3%, 98.1% (Test developer / manufacturer evaluation)	2.0% (0.0-4.6%)
Bedi (National Centre for Disease Control) ⁵³⁷	2020-08-01 to 2020-08-07	NCT Delhi	Regional	Unclear	15289	NR	NR	Non-probability	Blood donors	28.3%	NR NR NR	No data	-
Sharma (Government of National Capital Territory of Delhi) ⁵²⁴	2020-08-01 to 2020-08-07	NCT Delhi	Regional	Low	15046	<18 (n=2446); 18-49 (n=9191); >=50 (n=3036)	49.5	Non-probability	Household and community samples	28.8% (28.1-29.6%)	NR ELISA COVID-Kavach IgG IgG	92.1%, 97.7% (Test developer / manufacturer evaluation)	30.1% (25.2-37.0%)
Dey (National Centre for Disease Control) ⁵³⁸	2020-08-01 to 2020-08-07	NCT Delhi New Delhi	Local	Unclear	15311	NR	NR	Non-probability	Household and community samples	29.1% (28.5-29.9%)	ICMR-National Institute of Virology KOVID KAVACH ELISA test IgG	92.4%, 97.9% (Test developer / manufacturer evaluation)	30.4% (24.1-36.7%)
Ghose (Indian Institute of Science Education and Research) ⁵³⁹	2020-07-20 to 2020-08-05	Maharashtra Pune	Local	Moderate	1659	18-30 (n=394); 31-50 (n=677); 51-65 (n=417); >65 (n=171)	48.3	Probability	Household and community samples	51.3% (39.9-62.4%)	In-house developed. THSTI RBD-IgG ELISA IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	66.8% (62.4-70.8%)
Malani (Tata Institute for	2020-06-29 to 2020-07-19	Mumbai	Local	Low	2702	12-24 (n=176), 25-39 (n=733), 40-60	29.7	Probability	Household and	17.1% (15.8-18.4%)	Abbott Laboratories Abbott	90.0%, 99.0% (Used author-	17.1% (15.7-18.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Fundamental Research) ⁵⁴¹						(n=1349), 61+ (n=444)			community samples		Diagnostics Architect IgG	adjusted estimate)	
Husain (King George's Medical University) ⁵⁴²	2020-07-05 to 2020-07-19	Uttar Pradesh Lucknow	Local	High	1235	NR	NR	Non-probability	Blood donors	3.7%	NR NR IgG	No data	-
India.com News Desk (Thyrocare) ⁵⁴³	2020-06-28 to 2020-07-19		National	High	53000	NR	NR	Probability	Household and community samples	15.0%	NR NR NR	No data	-
Khan (Government Medical College Srinagar) ⁵⁴⁴	2020-07-01 to 2020-07-15	Srinagar District Srinagar	Regional	Moderate	2906	<30 (n=836); 30-49 (n=1424); 50-69 (n=556); >70 (n=90)	49.7	Non-probability	Residual sera	3.6% (2.9-4.3%)	Abbott ARCHITECT i2000SR analyzer IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Mishra (Haryana Health Department) ⁵⁴⁵	2020-06-21 to 2020-07-15	Haryana Panchkula, Sonipat, Faridabad, Gurugram, Ambala	Regional	High	1544	NR	NR	Probability	Household and community samples	12.0%	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	13.0% (10.5-15.6%)
Saxena (Indian Center for Disease Control) ⁵⁴⁷	2020-06-27 to 2020-07-10	NCT Delhi	Regional	Moderate	21387	NR	NR	Probability	Household and community samples	23.5%	Zydus Cadila Healthcare COVID KAVACH IgG	98.7%, 100.0% (Test developer / manufacturer evaluation)	24.0% (20.9-27.9%)
Dey (National Centre for Disease Control) ⁵³⁸	2020-06-26 to 2020-07-10	NCT Delhi New Delhi	Local	Unclear	21387	NR	NR	Non-probability	Household and community samples	23.5% (23.0-24.0%)	ICMR-National Institute of Virology KOVID KAVACH ELISA test IgG	92.4%, 97.9% (Test developer / manufacturer evaluation)	23.8% (18.6-29.2%)
Prakash (Municipal Medical College) ⁵⁴⁸	2020-06-16 to 2020-07-07	Gujarat Ahmedabad	Local	High	29891	Mean 39.1 (SD 14.54)	46.3	Non-probability	Residual sera	17.6% (17.2-18.0%)	Zydus Diagnostics 'Covid Kavach IgG	92.4%, 97.9% (Test developer / manufacturer evaluation)	16.9% (12.0-21.6%)
Kumar (Thiruvananthapuram Health Department) ⁵⁵²	2020-06-09 to 2020-06-12	Kerala Thiruvananthapuram	Local	Unclear	450	NR	NR	Non-probability	Household and community samples	2.7%	NR NR IgG, IgM	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Murhekar (Indian Council of Medical Research) ⁵⁵⁴	2020-05-11 to 2020-06-04		National	Low	28000	Mean 45.3 (SD 15.2)	51.4	Probability	Household and community samples	0.6% (0.3-1.0%)	Cadila Healthcare Limited; EUROIMMUN COVID Kavach-Anti-SARS-CoV-2 IgG Antibody Detection ELISA, Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)
Kher (Indian Council of Medical Research) ⁵⁵⁵	2020-05-11 to 2020-05-25	Uttarakhand, Kashmir, Rajasthan, Jharkhand, Punjab, Gujarat, Haryana, Assam, Telangana, Maharashtra, Madhya Pradesh, Jammu, Chhattisgarh, West Bengal, Tamil Nadu, Bihar, Uttar Pradesh, Himachal Pradesh, Kerala, Karnataka, Andhra Pradesh, Odisha	National	Moderate	26400	NR	NR	Probability	Household and community samples	0.7%	ICMR-National Institute of Virology NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)
Pakistan													
Nisar (Aga Khan University) ⁵⁵⁶	2020-08-17 to 2020-08-22	Sindh Karachi	Sublocal	Moderate	500	Mean 27.1 (SD 17.7)	57.8	Probability	Household and community samples	21.5% (15.6-28.0%)	Roche Elecsys Anti-SARS-Cov2	100.0%, 99.8% (Used author-adjusted estimate)	21.5% (18.0-25.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											Immunoassay IgG, IgM		
Nisar (Aga Khan University) ⁵⁵⁶	2020-08-17 to 2020-08-22	Sindh Karachi	Sublocal	Moderate	501	Mean 26 (SD 16.7)	58.9	Probability	Household and community samples	12.8% (8.3-17.7%)	Roche Elecsys Anti-SARS-Cov2 Immunoassay IgG, IgM	100.0%, 99.8% (Used author-adjusted estimate)	12.8% (10.1-15.9%)
Younas (National Institute of Blood Diseases & Bone Marrow Transplantation) ⁵⁵⁸	2020-05-15 to 2020-07-15	Sindh Karachi	Local	High	370	Mean 30.6 (SD 6.3)	0.0	Non-probability	Blood donors	34.6%	Roche Diagnostics Elecsys Anti-SARS-Cov2 Immunoassay IgG, IgA, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Nisar (Aga Khan University) ⁵⁵⁶	2020-06-25 to 2020-07-11	Sindh Karachi	Sublocal	Moderate	504	Mean 24.3 (SD 16.7)	60.5	Probability	Household and community samples	8.7% (5.1-13.1%)	Roche Elecsys Anti-SARS-Cov2 Immunoassay IgG, IgM	100.0%, 99.8% (Used author-adjusted estimate)	8.7% (6.3-11.2%)
Nisar (Aga Khan University) ⁵⁵⁶	2020-06-25 to 2020-07-11	Sindh Karachi	Sublocal	Moderate	500	Mean 25.9 (SD 16.7)	55.0	Probability	Household and community samples	15.1% (9.4-21.7%)	Roche Elecsys Anti-SARS-Cov2 Immunoassay IgG, IgM	100.0%, 99.8% (Used author-adjusted estimate)	15.1% (12.1-18.3%)
Nisar (Aga Khan University) ⁵⁵⁶	2020-04-15 to 2020-04-25	Sindh Karachi	Sublocal	Moderate	500	Mean 28.5 (SD 17.9)	58.6	Probability	Household and community samples	0.2% (0.0-0.7%)	Roche Elecsys Anti-SARS-Cov2 Immunoassay IgG, IgM	100.0%, 99.8% (Used author-adjusted estimate)	0.2% (0.0-0.9%)
Nisar (Aga Khan University) ⁵⁵⁶	2020-04-15 to 2020-04-25	Sindh Karachi	Sublocal	Moderate	500	Mean 26.2 (SD 17.9)	48.8	Probability	Household and community samples	0.4% (0.0-1.3%)	Roche Elecsys Anti-SARS-Cov2 Immunoassay IgG, IgM	100.0%, 99.8% (Used author-adjusted estimate)	0.4% (0.1-1.3%)
Southeast Asia, East Asia, and Oceania													
China													
Wang (Capital Medical University) ⁵⁶³	2020-01-01 to 2020-08-31	Beijing	Sublocal	Moderate	19797	<1 (n = 2461) ; 1-<3 (n = 4383) ; 3-<6	54.4	Non-probability	Residual sera	0.1%	Beijing Innovita Biological Technology	0.5%, 1.0% (FINDDx / MUHC)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						(n=4334) ; >= 6 (n = 8619)					Innovita 2019-nCoV Ab Test (Colloidal Gold) IgG	independent evaluation)	
He (Renmin Hospital of Wuhan University) ⁵⁶⁵	2020-05-15 to 2020-05-29	Hubei Wuhan	Local	Unclear	4454	Median 36.89 (SD 10.811)	50.2	Non-probability	Household and community samples	2.9%	Livzon Diagnostics Inc. Diagnostic Kit for IgM/IgG Antibody IgG	0.5%, 0.6% (FINDDx / MUHC independent evaluation)	-
Liu (Huazhong University of Science and Technology) ⁵⁶⁶	2020-03-27 to 2020-05-26	Hubei Wuhan	Local	High	35040	Median 36 (IQR 30-45)	50.7	Non-probability	Household and community samples	3.9% (3.7-4.1%)	China; Bioscience; Tianjin MCLIA kits IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Pan (Wuhan University) ⁵⁶⁷	2020-05-15 to 2020-05-26	Hubei Wuhan	Local	Moderate	61437	Median 48 (IQR 32-64)	51.1	Probability	Household and community samples	2.4% (2.3-2.5%)	Ltd; Nanjing Vazyme Medical technology Co. a 2019-nCoV IgG/IgM detection kit (catalogue number: C6603C; Colloidal Gold-Based IgG, IgM	91.5%, 97.0% (Test developer / manufacturer evaluation)	0.6% (0.0-1.7%)
Chang (Beijing Hospital) ⁵⁷⁰	2020-01-15 to 2020-04-30	Hubei Wuhan	Local	High	17794	Median 33 (IQR 19-47)	37.7	Non-probability	Blood donors	2.3% (2.1-2.5%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG, IgA, IgM	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Liu (Zhongnan Hospital of Wuhan University) ⁵⁷¹	2020-02-29 to 2020-04-29	Hubei Wuhan	Local	Moderate	19555	Mean 41.6 (95% CI 41.4-41.8)	50.2	Non-probability	Household and community samples	4.6% (4.3-4.9%)	YHLO SARS-CoV-2 IgM/IgG CLIA kits IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Liu (Zhongnan Hospital of)	2020-02-29 to 2020-04-29	Hubei Wuhan	Local	Moderate	1616	Mean 53.3 (95% CI 52.4-54.2)	56.2	Non-probability	Residual sera	1.0% (0.5-1.5%)	YHLO SARS-CoV-2	0.7%, 1.0% (FINDDx / MUHC	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Wuhan University) ⁵⁷¹											IgM/IgG CLIA kits IgG	independent evaluation)	
Ling (Chinese Center for Disease Control and Prevention) ⁵⁷³	2020-03-25 to 2020-04-28	Hubei Wuhan	Local	Moderate	18712	Median 40 (Range 4-81)	39.1	Non-probability	Household and community samples	3.3% (3.0-3.5%)	Innovita 2019-nCoV Ab Test (Colloidal Gold) IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Wang (Peking University) ⁵⁷⁶	2020-04-15 to 2020-04-18	Hebei Beijing	Local	Moderate	2184	Mean 42.3 (SD 19.5)	54.3	Probability	Household and community samples	0.2%	Innovita Biological Technology Co Ltd; Wondfo Biotech Co. WONFDO SARS-CoV-2 Antibody Test, Tangshan Colloidal Gold Immunochromatography Assay IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.2%)
Wu (Wuhan University) ⁵⁷⁷	2020-04-03 to 2020-04-15	Hubei Wuhan	Sublocal	High	381	NR	NR	Non-probability	Residual sera	10.5%	Innovita Biological Technology Co. Ltd 2019-nCoV Ab Test IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Xu (Institute of Blood Transfusion) ⁵⁷⁹	2020-03-23 to 2020-04-02	Guangdong Guangzhou	Local	High	2199	Median 34 (Range 18 to 59)	32.3	Probability	Blood donors	0.3%	Lizhu Diagnostics; Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG, IgA	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.2%)
To (Queen Mary Hospital) ⁵⁸⁷	2020-03-04 to 2020-03-17	Hubei	Regional	Moderate	452	Median 41 (NR)	58.6	Non-probability	Household and community samples	2.9%	Author-designed NR IgG	73.3%, 100.0% (Test developer / manufacturer evaluation)	3.5% (0.6-6.5%)
Chang (Beijing Hospital) ⁵⁷⁰	2020-02-02 to 2020-03-15	Guangdong Shenzhen	Local	High	6810	Median 36 (IQR 19-53)	35.0	Non-probability	Blood donors	0.0% (0.0-0.1%)	Wantai Biological Pharmacy	0.9%, 1.0% (FINDDx / MUHC)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG, IgA, IgM	independent evaluation)	
Chang (Beijing Hospital) ⁵⁷⁰	2020-01-23 to 2020-03-15	Hebei Shijiazhuang	Local	High	13540	Median 40 (IQR 33-48)	29.5	Non-probability	Blood donors	0.0% (0.0-0.0%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG, IgA, IgM	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Zhang (Shengjing Hospital of China Medical University) ⁵⁹⁰	2020-01-21 to 2020-02-16	Liaoning Shenyang	Regional	High	225	Median 35 (Range 1-86)	71.1	Non-probability	Residual sera	0.4%	Shenzhen Yahuilong Biotechnology Co. Chemiluminescence Detection Kit IgG	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Zhang (Shengjing Hospital of China Medical University) ⁵⁹⁰	2020-01-21 to 2020-02-16	Liaoning Shenyang	Regional	High	222	Median 50 (Range 27-85)	72.1	Non-probability	Residual sera	0.9%	Shenzhen Yahuilong Biotechnology Co. Chemiluminescence Detection Kit IgG	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
To (Queen Mary Hospital) ⁵⁸⁷	2020-02-01 to 2020-02-13	Hong Kong	Regional	High	233	NR	NR	Non-probability	Residual sera	0.4% (0.0-2.4%)	Author-designed NR IgG	73.3%, 100.0% (Test developer / manufacturer evaluation)	0.8% (0.0-2.6%)
To (Queen Mary Hospital) ⁵⁸⁷	2020-01-01 to 2020-01-31	Hong Kong	Regional	High	580	NR	NR	Non-probability	Residual sera	2.6% (1.5-4.2%)	Author-designed NR IgG	73.3%, 100.0% (Test developer / manufacturer evaluation)	3.2% (0.8-5.7%)
Hallowell (US Centers for Disease Control and Prevention) ⁵⁹¹	2020-01-28 to 2020-01-28	Hubei Wuhan	Sublocal	High	186	Median 42.0 (NR)	47.8	Non-probability	Household and community samples	0.5%	SeraCare Life Sciences HRP-conjugated anti human IgM/IgA/IgG IgG, IgA, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.6% (0.0-2.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Malaysia													
Sam (University Malaya) ⁵⁹²	2020-01-29 to 2020-06-06	Selangor Kuala Lumpur	Regional	High	588	NR	62.6	Non-probability	Residual sera	0.4% (0.0-0.9%)	Author-designed N/A - Author-designed IgG	97.0%, 100.0% (Test developer / manufacturer evaluation)	0.4% (0.0-1.0%)
Sub-Saharan Africa													
Congo													
Batchi-Bouyou (Fondation Congolaise pour la Recherche Médicale) ⁵⁹⁶	2020-04-01 to 2020-07-31	Brazzaville	Local	High	754	Mean 36.7 (SD 13.07)	38.6	Non-probability	Household and community samples	19.7%	Wuhan UNniscience Biotechnology; Salofa Oy manufacturer; Finland UNsciences COVID-19 IgG/IgM rapid test, Sienna™ IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	26.0% (21.3-30.8%)
Ethiopia													
Kempen (Kuwait University) ⁵⁹⁷	2020-05-18 to 2020-05-21	Addis Ababa	Local	High	99	Mean 37.8 (SARS-CoV-2 IgG negative), 33.3 (SARS-CoV-2 IgG positive) (NR)	55.6	Non-probability	Residual sera	3.0% (0.6-8.6%)	Abbott Abbott IgG Architect IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Alemu (Ministry of Health, Ethiopia) ⁵⁹⁸	2020-04-23 to 2020-04-28	Addis Ababa	Local	Moderate	301	Median 30 (SD 10.9)	37.5	Probability	Household and community samples	8.8% (5.5-11.6%)	China; Zhejiang Orient Gene Biotech Co Ltd; Zhejiang; Huzhou Immunolateral flow immunoassay kit IgG, IgM	87.9%, 100.0% (Used author-adjusted estimate)	8.8% (5.9-12.2%)
Keyna													
Adetifa (KEMRI-Wellcome)	2020-04-30 to 2020-09-30		National	Low	9922	15-24 n = 2,763 25-34 n = 3,902 35-44	19.2	Non-probability	Blood donors	9.4% (8.8-9.9%)	N/A - in-house N/A - in-house IgG	92.7%, 99.0% (Author-reported)	9.0% (8.1-10.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Trust Research Programme) ⁵⁹⁹						n = 2,261 45-54 n = 794 55-64 n = 202						independent evaluation)	
Nigeria													
Majiya (Ibrahim Badamasi Babangida University) ⁶⁰¹	2020-06-26 to 2020-06-30	Niger State	Regional	Moderate	185	NR	44.3	Probability	Household and community samples	25.4%	Cambridge Network COVID-19 IgG and IgM Rapid Test IgG	100.0%, 100.0% (Author-reported independent evaluation)	19.5% (0.5-31.9%)
South Africa													
Hsiao (University of Cape Town) ⁶⁰⁴	2020-06-15 to 2020-08-07	Cape Town	Local	High	2791	< 20 (n = 151) ; 20-50 (n = 2349) ; >50 (n = 291)	80.3	Non-probability	Residual sera	40.2% (38.4-42.1%)	Roche Diagnostics Elecsys TM anti-SARS-CoV-2 assay IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	59.8% (57.9-61.8%)

S2 Table. Characteristics and primary results of studies reporting population-specific seroprevalence estimates

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Central Europe, Eastern Europe, and Central Asia													
Armenia													
Grigoryan (Ministry of Health of the Republic of Armenia) ¹	2020-06-29	Yerevan Yerevan	Local	High	380	NR	NR	Non-probability	Health care workers and caregivers	16.1%	NR NR NR	100.0%, 99.8% (Test developer / manufacturer evaluation)	14.4% (9.4-19.3%)
Croatia													
Vince (Croatian Football Federation) ³	2020-05-29 to 2020-07-31		Sublocal	Moderate	305	Mean 28.5 (SD 9.1)	0.0	Non-probability	Non-essential workers and unemployed persons	20.0%	Euroimmun Medizinische Labordiagnostika AG Anti-SARS-CoV-2 IgA, Anti-SARS-CoV-2 IgG S and Anti-SARS-CoV-2 IgG NCP IgG, IgA	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	24.1% (18.3-30.8%)
Lapić (Zagreb University) ⁴	2020-05-01 to 2020-05-31	Zagreb	Sublocal	Moderate	1678	Median 43 (NR)	78.2	Non-probability	Health care workers and caregivers	0.6%	Abbott Laboratories Abbott SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Vilibic-Cavlek (University of Zagreb) ⁵	2020-04-25 to 2020-05-24		National	High	592	20-65	74.3	Non-probability	Health care workers and caregivers	2.7%	Vircell Spain S.L.U NR IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Jerkovic (University of Split) ⁶	2020-04-23 to 2020-04-28		Local	High	1494	Median 46 (Range 19-79)	11.9	Non-probability	Essential non-healthcare workers	1.3% (0.8-2.0%)	AMP Diagnostics AMP Rapid Test SARS-CoV-2 IgG/IgM IgG, IgM	91.8%, 96.4% (Test developer / manufacturer evaluation)	0.3% (0.0-1.1%)
Czechia													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Malickova (Clinical and Research Center for Inflammatory Bowel Disease)*	Until 2020-04-15	Central Bohemian Prague	Sublocal	Unclear	92	Median 45 (IQR 38-57)	71.7	Non-probability	Health care workers and caregivers	2.2%	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Estonia													
Veerus (University of Tartu) ¹⁰	2020-05-04 to 2020-06-10		National	High	433	Mean 31 (SD 5.89)	100.0	Non-probability	Pregnant or parturient women	0.5%	Abbott SARS-CoV-2 IgG Architect IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Poland													
Ciechanowicz (Central Clinical Hospital MSWiA) ¹³	2020-04-01 to 2020-10-31	Warsaw	Sublocal	High	61	Mean 46 (SD 14)	34.4	Non-probability	Patients seeking care for non-COVID-19 reasons	16.4%	Vircell Microbiologist; Spain:: Granada Vircell anti-SARS-CoV-2 IgM, IgA and IgG ELISA; ref. MA1032 and G103 IgG, IgA, IgM	100.0%, 95.0% (Test developer / manufacturer evaluation)	10.6% (1.0-21.1%)
Kasztelewicz (The Children's Memorial Health Institute) ¹⁴	2020-07-01 to 2020-08-09	Masovia Warsaw	Sublocal	Moderate	1879	Median 48 (IQR 38-56)	85.8	Non-probability	Health care workers and caregivers	0.9%	Abbott Laboratories Abbott SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Gujski (Medical University of Warsaw) ¹⁵	2020-06-22 to 2020-07-08	Mazowieckie Province	Regional	Moderate	5082	Mean 39.6 (SD 9)	33.5	Probability	Essential non-healthcare workers	4.3% (3.7-4.9%)	Vircell S.L COVID-19 ELISA IgG Kit IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Romania													
MedLife (MedLife) ¹⁶	2020-03-24 to 2020-04-21	Nord-Vest, Bucuresti-Ilfov, Sud-Vest Oltenia, Vest, Sud-Mutenia,	National	Unclear	371	NR	NR	Non-probability	Health care workers and caregivers	3.0%	Maglumi; Abbott; YHLO Multiple tests used in combination IgG, IgM	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
		Sud-Est, Centru, Nord-Est Brasov, Sibiu, Timisoara, Pitesti, Targoviste, Arad, Galati, Braila, Ploiesti, Bucharest, Piatra Neamt											
Russian Federation													
Krechetova (Ministry of Health of Russia) ²⁴	2020-04-15 to 2020-06-15	Moscow	Sublocal	Unclear	1589	NR	NR	Non-probability	Health care workers and caregivers	8.9%	"NMITs Hematology" Ministry of Health of the Russian Federation SARS-CoV-2-IgG-ELISA IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	8.8% (6.4-11.1%)
High Income													
Argentina													
Silva (Instituto Nacional de Epidemiologia) ²⁸	2020-06-03 to 2020-07-06	Buenos Aires Buenos Aires	Sublocal	Moderate	738	NR	NR	Probability	Health care workers and caregivers	0.8% (0.0-8.1%)	CONICET COVIDAR IgG ELISA, COVIDAR IgM Test IgG, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.2% (0.0-0.8%)
Figar (Minister of Health, Buenos Aires City) ²⁹	2020-06-10 to 2020-07-01	Buenos Aires Buenos Aires	Sublocal	High	60	NR	NR	Non-probability	Persons living in slums	36.0%	Laboratio Lemos COVIDAR IgG ELISA IgG	95.0%, 100.0% (Test developer / manufacturer evaluation)	38.4% (24.2-51.8%)
Insúa (Hospital General de Niños Pedro de Elizalde) ³⁰	2020-06-08 to 2020-06-09	Province of Buenos Aires Autonomous City of Buenos Aires	Sublocal	High	116	Mean 45.6 (SD 13.3)	NR	Probability	Health care workers and caregivers	0.9% (0.1-5.5%)	Snibe (Shenzen New Industries) MAGLUMI 2019-nCoV IgM and 2019-nCoV IgG IgG, IgM	95.6%, 96.0% (Test developer / manufacturer evaluation)	0.8% (0.0-3.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Australia													
Hicks (Australian National University) ³¹	2020-05-15 to 2020-06-15		National	Unclear	2991	Mean 54 (Range 15-95)	51.2	Non-probability	Patients seeking care for non-COVID-19 reasons	1.4%	In House Dual-antigen IgG ELISA IgG, IgA, IgM	100.0%, 98.9% (Test developer / manufacturer evaluation)	0.4% (0.0-1.0%)
Macartney (University of Sydney) ³²	2020-01-25 to 2020-04-10	New South Wales	Regional	Moderate	173	NR	NR	Non-probability	Contacts of COVID patients	2.3%	Author-designed N/A - Author-designed IgG, IgA, IgM	91.3%, 98.9% (Test developer / manufacturer evaluation)	1.3% (0.0-3.9%)
Austria													
Fuereder (Medical University of Vienna) ³⁴	2020-04-01 to 2020-06-04	Vienna Vienna	Sublocal	High	62	Median 41 (Range 23-59)	71.0	Non-probability	Health care workers and caregivers	3.2% (0.4-11.2%)	Abbott; Roche Elecsys Anti-SARS-CoV-2 kit, Abbott Architect SARS-CoV-2 IgG assay IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	1.7% (0.0-6.4%)
Fuereder (Medical University of Vienna) ³⁴	2020-03-21 to 2020-06-04	Vienna Vienna	Sublocal	High	84	Median 61 (NR)	48.8	Non-probability	Patients seeking care for non-COVID-19 reasons	2.4% (0.3-8.3%)	Abbott; Roche Elecsys Anti-SARS-CoV-2 kit, Abbott Architect SARS-CoV-2 IgG assay IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	1.8% (0.0-5.9%)
Hackner (Karl Landsteiner University of Health Sciences) ³⁵	2020-04-01 to 2020-04-30		Sublocal	High	130	Median 41 (Range 19-64)	76.9	Non-probability	Health care workers and caregivers	2.3%	Epitope Diagnostics NR IgG, IgM	0.8%, 0.9% (FINDDx / MUHC independent evaluation)	-
Reiter (Medical University of Vienna) ³⁸	2020-03-15 to 2020-03-29	Vienna	Sublocal	High	235	Mean 44.2 (SD 11.4)	70.2	Non-probability	Health care workers and caregivers	25.5% (20.4-31.5%)	ImmunoDiagnostics ImmunoDiagnostics test system IgG IgM IgG, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	31.1% (23.9-39.0%)
Orth-Höller (Innsbruck Clinical)	2020-03-20 to 2020-03-27	Tyrol	Regional	High	377	Median 51 (NR)	46.7	Non-probability	Health care workers and caregivers	0.3% (0.0-1.5%)	EUROIMMUN Euroimmun Anti-SARS-	0.8%, 1.0% (FINDDx / MUHC)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Microbiology Laboratory ³⁹											CoV-2 ELISA IgG IgG	independent evaluation)	
Belgium													
Duysburgh (Sciensano) ⁴⁰	2020-04-22 to 2020-09-30		National	Unclear	850	NR	NR	Non-probability	Health care workers and caregivers	9.5%	Euroimmun Medizinische Labordiagnostika EUROIMMUN -Anti-SARS-CoV-2 ELISA (IgG) IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Blairon (Iris Hospitals South) ⁴²	2020-05-25 to 2020-06-19	Brussels City of Brussels	Local	High	1485	Median 47.45 (Males); 43.90 (Females) (Range 46.00–48.84 (Males); 42.80–45.10 (Females))	73.1	Non-probability	Health care workers and caregivers	14.6%	DiaSorin Liaison® SARS- CoV-2 S1/S2 IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Berardis (Cliniques universitaires Saint-Luc) ⁴³	2020-04-16 to 2020-05-19	City of Brussels	Local	High	149	Mean 24.9 (SD 15)	49.0	Non-probability	Patients seeking care for non-COVID-19 reasons	2.7%	"SNIBE – Shenzhen New Industries Biomedical Engineering Co.; Ltd" MAGLUMI 2019-nCov IgG/IgM CLIA IgG, IgM	95.6%, 96.0% (Test developer / manufacturer evaluation)	1.2% (0.0-4.1%)
Martin (Université Libre de Bruxelles) ⁴⁴	2020-04-15 to 2020-05-18	Brussels City of Brussels	Local	High	326	Mean 37 (Range 21-66)	73.3	Non-probability	Health care workers and caregivers	11.0%	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Steensels (ZiekenhuisOost-Limburg) ⁴⁵	2020-04-22 to 2020-04-30	Limburg Genk	Sublocal	High	3056	Mean 39.5 (staff with antibodies); 41.3 (staff without antibodies) (SD 13.1 (staff with antibodies);	NR	Non-probability	Health care workers and caregivers	6.4% (5.5-7.3%)	Multi-G COVID-19 IgG/IgM Rapid Test Cassette IgG	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						12.4 (staff without antibodies)							
Buntinx (University of Leuven) ⁴⁶	2020-04-14 to 2020-04-16	Limburg Lanaken	Sublocal	High	188	Mean 86 (NR)	100.0	Non-probability	Multiple populations	18.6%	SureScreen Diagnostics; UK; Derby SureScreen Diagnostics Covid-19 IgG/IgM Rapid test cassette IgG, IgM	74.7%, 95.1% (Author-reported independent evaluation)	17.4% (6.1-27.2%)
Canada													
Brousseau (Institut National de Sante Publique) ⁵⁰	2020-07-06 to 2020-09-24	Quebec	Regional	High	2056	18-29 (n = 427) ; 30-39 (n = 643) ; 40-49 (n = 547) ; 50-59 (n = 356) ; 60+ (n = 83)	76.1	Non-probability	Health care workers and caregivers	11.7%	DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Bardai (Shriners Hospital for Children) ⁵²	2020-06-10 to 2020-07-27	Quebec Montreal	Sublocal	High	199	Median Patients: 15.6, Accompanying persons: 47.1, Employees 42.5 (IQR Patients 13.4-16.8, accompanying persons 41.4- 50.8, employees 32.5-52.5)	69.8	Non-probability	Multiple populations	11.0%	Omega Diagnostics Mologic, Omega Diagnostics IgG	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Majdoubi (BC Children's Hospital) ⁵⁴	2020-05-17 to 2020-06-19	British Columbia Vancouver	Local	High	276	Mean 42.4 (SD 11.9)	67.4	Non-probability	Multiple populations	0.6% (0.0-2.7%)	Ortho-Clinical Diagnostics; Meso Scale Diagnostics VITROS 5600 analyser, 10-plex multiplex assay IgG, IgA, IgM	0.0%, 0.0% (Used author-adjusted estimate)	0.6% (0.0-1.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Vijh (University of British Columbia) ⁵⁷	2020-05-04 to 2020-05-14	British Columbia Vancouver	Sublocal	High	291	Median 86 (residents); 49 (staff) (IQR 15 (residents); 18 (staff))	72.2	Non-probability	Assisted living and long-term care facilities	39.0%	Abbott; DiaSorin; Ortho Vitros; Siemens DiaSorin Liaison IgG, Ortho Vitros Total Antibody, Ortho Vitros IgG, Abbott Architect IgG, Siemens Centaur Total Antibody IgG	No data	-
Chile													
Torres (Universidad de Chile) ⁵⁸	2020-05-04 to 2020-05-19	Santiago Vitacura	Sublocal	High	1009	Mean 10.8 (SD 4.1)	46.0	Probability	Students and Daycares	9.9% (8.6-11.5%)	Genrui Biotech Genrui Biotech IgG/IgM Test Kit (Colloidal Gold) IgG, IgM	91.0%, 95.4% (Test developer / manufacturer evaluation)	5.2% (1.3-9.0%)
Torres (Universidad de Chile) ⁵⁸	2020-05-04 to 2020-05-19	Santiago Vitacura	Sublocal	High	235	Mean 42.8 (SD 10.4)	73.2	Probability	Essential non-healthcare workers	16.6% (12.1-21.9%)	Genrui Biotech Genrui Biotech IgG/IgM Test Kit (Colloidal Gold) IgG, IgM	91.0%, 95.4% (Test developer / manufacturer evaluation)	13.3% (7.1-20.0%)
Denmark													
Laursen (Copenhagen University Hospital) ⁵⁹	2020-06-22 to 2020-08-10		National	High	2024	<40 (n=542); 40-60 (n=1045); 60+ (n=437)	24.5	Non-probability	Health care workers and caregivers	2.8%	Zuhai; China; Guangzhou Wondfo Biotech; Livson Diagnostics; Gunangdong Livzon lateral flow test, WONDFO lateral flow IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.3% (0.0-1.1%)
Egerup (Copenhagen University Hospital Hvidovre) ⁶⁰	2020-04-04 to 2020-07-03	Capital Region of Denmark Copenhagen	Sublocal	High	1206	Median 31.5 (IQR 28.6-34.7 (antibody positive);	47.5	Non-probability	Perinatal	1.4%	Shenzhen Yhlo Biotech iFlash 1800 and SARS-CoV-2	94.0%, 99.3% (Test developer / manufacturer evaluation)	0.6% (0.0-1.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						28.2-33.4 (antibody negative)					IgM and IgG kits IgG, IgM		
Egerup (Copenhagen University Hospital Hvidovre) ⁶⁰	2020-04-04 to 2020-07-03	Capital Region of Denmark Copenhagen	Sublocal	Moderate	1188	Median 33.4 - without antibodies 32.4 - with antibodies (IQR 30.2-37.2 - without antibodies 30.6-35.8 - with antibodies)	NR	Non-probability	Hospital visitors	2.7%	Shenzhen Yhlo Biotech iFlash 1800 and SARS-CoV-2 IgM and IgG kits IgG, IgM	94.0%, 99.3% (Test developer / manufacturer evaluation)	1.5% (0.0-3.0%)
Egerup (Copenhagen University Hospital Hvidovre) ⁶⁰	2020-04-04 to 2020-07-03	Capital Region of Denmark Copenhagen	Sublocal	Moderate	1313	Median 31.5 (IQR 28.2-33.4 - Women with antibodies 28.6 - 34.7 - Women without antibodies)	100.0	Non-probability	Pregnant or parturient women	2.1%	Shenzhen Yhlo Biotech iFlash 1800 and SARS-CoV-2 IgM and IgG kits IgG, IgM	94.0%, 99.3% (Test developer / manufacturer evaluation)	1.0% (0.0-2.3%)
Jespersen (Aarhus University Hospital) ⁶¹	2020-05-18 to 2020-06-19	Central Denmark Region	Regional	Moderate	17948	<=29 (n=2032); 30-39 (n=3938); 40-49 (n=4735); 50-59 (n=4666); >=60 (2577)	85.9	Non-probability	Health care workers and caregivers	3.4% (2.4-3.8%)	Wantai Biological Pharmacy Enterprise Co; Beijing; China; Ltd SARS-CoV-2 total antibody enzyme-linked immunosorbent assay IgG, IgA, IgM	96.7%, 99.5% (Used author-adjusted estimate)	3.4% (3.1-3.6%)
Storgaard (Aarhus Department of Public Health) ⁶³	2020-06-01 to 2020-06-04	Central Denmark Region Aarhus	Local	High	129	Median 53 (Range 42-61)	24.0	Non-probability	Persons experiencing homelessness	4.7% (2.1-9.8%)	NR NR IgG, IgM	98.9%, 97.6% (Test developer / manufacturer evaluation)	2.8% (0.0-7.3%)
Freiesleben (Copenhagen University Hospital) ⁶⁴	2020-04-14 to 2020-05-21	Copenhagen Copenhagen	Sublocal	High	36	Mean 32.96 (SD 5.22)	100.0	Non-probability	Pregnant or parturient women	0.0%	YHLO Biotechnology YHLO's SARS-CoV-2 IgM/IgG kits IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author)	1.9% (0.0-8.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
												adjustment available)	
Iversen (University of Copenhagen) ⁶⁶	2020-04-15 to 2020-04-22	Capital Region of Denmark	Regional	Low	28792	Mean 44.4 (SD 12.6)	78.9	Probability	Health care workers and caregivers	4.4% (4.1-4.7%)	Livzon Diagnostics NR IgG, IgM	73.4%, 99.9% (Used author-adjusted estimate)	4.4% (4.1-4.6%)
Freiesleben (Copenhagen University Hospital) ⁶⁴	2020-02-17 to 2020-04-17	Copenhagen Copenhagen	Sublocal	High	1019	Mean 31.71 (SD 4.52)	100.0	Non-probability	Pregnant or parturient women	1.8%	YHLO Biotechnology YHLO's iFlash 1800 and SARS-CoV-2 IgM/IgG kits IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.3% (0.0-0.9%)
Finland													
Kantele (University of Helsinki) ⁶⁸	2020-04-22 to 2020-05-15	Uusimaa Helsinki	Sublocal	High	1095	Median 38 (IQR 31-48)	81.7	Non-probability	Health care workers and caregivers	6.7%	Euroimmun EUROLabwork station SARS-CoV-2 IgG ELISA IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
France													
Anna (Institut Curie) ⁶⁹	2020-04-28 to 2020-07-31	Île-de-France Paris	Local	Moderate	1847	Mean 38 (Range 19-75)	77.4	Non-probability	Health care workers and caregivers	11.6% (10.2-13.2%)	Institut Curie - author designed N/A - author designed IgG	No data	-
Dimeglio (Centre Hospitalier Universitaire (CHU) de Toulouse) ⁷⁰	2020-06-10 to 2020-07-10	Toulouse	Sublocal	High	8758	Median 40 (IQR 32-50)	80.4	Non-probability	Health care workers and caregivers	3.2% (2.8-3.5%)	Beijing Wantai Biological Pharmacy Enterprise Co. Wantai ELISA kit NR	1.0%, 1.0% (FINDDx / MUHC independent evaluation)	-
Roederer (Médecins sans Frontières (Epicentre)) ⁷¹	2020-06-23 to 2020-07-02	Ile de France Paris	Local	High	818	Mean 39 (NR)	20.4	Non-probability	Persons experiencing homelessness	52.0%	N/A - Author Designed Luciferase-Linked Immunosorbent Assay N, Luciferase-Linked Immunosorbent Assay S, Pseudo	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											Neutralization Test IgG		
Pere (Hopital Europeen Georges Pompidou) ⁷²	2020-05-02 to 2020-06-26	Île-de-France Paris	Sublocal	High	3569	Median 39.6 (NR)	74.8	Non-probability	Health care workers and caregivers	11.9%	Abbott Abbott Architect SARS-CoV-2 IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Tsatsaris (Université Paris-Saclay) ⁷³	2020-04-29 to 2020-06-26	Île-de-France Paris	Sublocal	High	529	Mean 33.7 (SD 4.7)	100.0	Non-probability	Pregnant or parturient women	4.7% (3.0-6.7%)	Abbott SARS-CoV-2 IgG Architect assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Gallais (Strasbourg University Hospital) ⁷⁴	2020-05-07 to 2020-06-26	Grand-Est Strasbourg	Local	High	11	Mean 50.6 (SD 7.8)	45.5	Non-probability	Contacts of COVID patients	0.0%	Abbott Laboratories Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Mesnil (Rothschild Foundation Hospital) ⁷⁶	2020-06-08 to 2020-06-22	Paris Paris	Sublocal	High	646	Mean 39 (Range 28-50)	73.1	Non-probability	Health care workers and caregivers	12.0%	Roche Elecsys Anti-SARS-CoV-2 Roche COBAS 6000 IgG	99.5%, 99.8% (Test developer / manufacturer evaluation)	10.7% (6.2-14.6%)
Delmas (Cochin APHP) ⁷⁷	2020-05-14 to 2020-06-17	Île-de-France Paris	Sublocal	High	4607	Mean 41.8 (SD 12.6)	75.1	Non-probability	Health care workers and caregivers	11.5% (10.6-12.4%)	Abbott Laboratories Abbott-Architect test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Mattern (Paris Saclay University) ⁷⁹	2020-05-04 to 2020-05-31	Paris Paris	Sublocal	High	249	Median 33 (IQR 29-36)	100.0	Non-probability	Pregnant or parturient women	8.0%	Ortho-Clinical Diagnostics; Abbott Abbott SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Bal (Université Claude Bernard Lyon) ⁸⁰	2020-04-10 to 2020-05-28	Auvergne-Rhône-Alpes Lyon	Sublocal	High	190	Median 36 (NR)	NR	Non-probability	Health care workers and caregivers	3.7%	Beijing; China bioMérieux; France; Lyon; Wantai Wantai SARS-CoV-2 Ab ELISA kit VIDAS SARS-CoV-2 IgG test IgG	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Fumery (Picardie University) ⁸³	2020-03-25 to 2020-05-11	Somme Amiens	Sublocal	High	146	Median 38 (Range 17-81)	49.3	Non-probability	Patients seeking care for non-COVID-19 reasons	4.8%	DiaSorin Liaison® SARS- CoV-2 S1/S2 IgG IgG	97.4%, 98.5% (Test developer / manufacturer evaluation)	4.0% (0.3-8.3%)
Solodky (Centre Leon Berard) ⁸⁵	2020-03-01 to 2020-04-16	Auvergne-Rhône-Alpes Lyon	Sublocal	High	85	NR	NR	Non-probability	Health care workers and caregivers	5.9%	TODA Pharma TODA Coronadiag IgG, IgM	100.0%, 100.0% (Test developer / manufacturer evaluation)	4.6% (0.1-10.0%)
Solodky (Centre Leon Berard) ⁸⁵	2020-03-01 to 2020-04-16	Auvergne-Rhône-Alpes Lyon	Sublocal	High	244	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	5.3%	TODA Pharma TODA Coronadiag IgG, IgM	100.0%, 100.0% (Test developer / manufacturer evaluation)	4.8% (1.0-8.4%)
Germain (CHU Lille) ⁸⁸	2019-11-01 to 2020-03-16	Lille	Local	High	235	Median 68yo (IQR 57-79)	51.9	Non-probability	Tissue donor	0.9%	Wantai SARS-CoV-21 total Ab ELISA test NR	1.0%, 1.0% (FINDDx / MUHC independent evaluation)	-
Germany													
Armann (Technische Universität Dresden) ⁹¹	2020-09-15 to 2020-10-13	Saxony	Regional	Moderate	1779	Median 15 (students); 50 (teachers) (IQR 14-16 (students); 36-57 (teachers))	55.8	Non-probability	Multiple populations	0.7%	1) DiaSorin LIAISON; 2) Abbott; 3) EUROIMMUN 1) Liaison® SARS- CoV-2 S1/S2 IgG, 2) Abbott Architect SARS-CoV-2 IgG assay, 3) Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	No data	-
Thielecke (Berlin Institute of Health) ⁹²	2020-09-28 to 2020-10-02	City State of Berlin Berlin	Local	Moderate	672	Median Children (4.4), Educators (44), Household Members (36) (Range Children (1-	NR	Probability	Multiple populations	0.1%	Euroimmun AG; Germany EUROLabWorkstation anti-SARS-CoV-2 IgG IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						6.3), Educators (18-78), Household Members (0-90))							
Rauber (University Hospital Heidelberg) ⁹⁴	2020-05-05 to 2020-08-06	Baden-Württemberg Heidelberg	Sublocal	High	219	Median 56.9 (Range 18.1-78.2)	40.6	Non-probability	Patients seeking care for non-COVID-19 reasons	3.2%	EUROIMMUN TM Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Hoffmann (Brandenburg University of Technology Cottbus-Senftenberg) ⁹⁵	2020-07-01 to 2020-07-31	Brandenburg Oberspreewald-Lausitz	Sublocal	High	156	Mean 42.7 (very-high-risk group); 46.77 (high-risk group); 44.7 (medium risk group); 45.6 (low-risk group) (SD 11.6 (very-high-risk group); 11.91 (high-risk group); 10.9 (medium risk group); 8.5 (low-risk group))	86.5	Non-probability	Health care workers and caregivers	1.3%	Author-designed NR NR	99.5%, 99.8% (Test developer / manufacturer evaluation)	1.5% (0.0-3.8%)
Finkenzeller (Munich Clinic) ⁹⁶	2020-06-29 to 2020-07-29	Bavaria Tirschenreuth, Wieden	Sublocal	Moderate	1838	18-29 (n=322); 30-39 (n=321); 40-49 (n=396); 50-59 (N=536); 60-69 (n=176); >69 (n=2);	78.5	Non-probability	Health care workers and caregivers	15.1%	Roche Diagnostics Elecsys® Anti-SARS-CoV-2 immunassay IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Finkenzeller (Munich Clinic) ⁹⁶	2020-06-29 to 2020-07-29	Bavaria Tirschenreuth, Wieden	Sublocal	High	986	18-29 (n=329); 30-39 (n=227); 40-49 (n=151); 50-59 (N=163); 60-69	22.8	Non-probability	Essential non-healthcare workers	3.7%	Roche Diagnostics Elecsys® Anti-SARS-CoV-2 immunassay IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						(n=34); >69 (n=1);							
Brehm (University Medical Center Hamburg-Eppendorf) ⁹⁸	2020-06-22 to 2020-07-17	Hamburg Hamburg	Sublocal	Moderate	1253	Median 36 (IQR 29-48)	74.5	Non-probability	Health care workers and caregivers	1.8% (1.0-2.5%)	Euroimmun Euroimmun SARS-CoV-2 IgG ELISA IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Mack (Saarland University) ⁹⁹	2020-06-16 to 2020-06-30		National	High	1007	Median 31 (IQR 25-37)	2.5	Non-probability	Non-essential workers and unemployed persons	2.1% (1.4-3.2%)	Roche; EUROimmun; NR EUROimmun anti-SARS-CoV-2 ELISA (IgG), Cobas Elecsys Anti-SARS-CoV-2 chemiluminescent immunoassay (CLIA), Neutralizing assay IgG	No data	-
Epstude (Thuringia Clinic) ¹⁰⁰	2020-06-15 to 2020-06-30	Thuringia Saalfeld	Sublocal	High	45	Mean 47.8 (SD 10.4)	86.7	Non-probability	Health care workers and caregivers	0.0%	PerkinElmer Inc Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Epstude (Thuringia Clinic) ¹⁰⁰	2020-06-15 to 2020-06-30	Thuringia Saalfeld	Sublocal	High	20	Mean 39.4 (SD 10.2)	70.0	Non-probability	Health care workers and caregivers	5.0%	PerkinElmer Inc Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Bahrs (Jena University Hospital) ¹⁰²	2020-05-19 to 2020-06-19	Thuringia Jena	Sublocal	High	660	Median 40.5 (IQR 32-49)	73.6	Non-probability	Health care workers and caregivers	2.7%	Roche; Epitope Diagnostics EDI Novel Coronavirus SARS-CoV-2 IgG ELISA kit, Elecsys Anti-SARS-CoV-2 kit IgG	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Herzberg (University Hospitals of the Ruhr-University of Bochum) ¹⁰³	2020-04-14 to 2020-06-16	Schleswig-Holstein Hamburg	Sublocal	High	871	Mean 40 (SD 14.2)	75.1	Non-probability	Health care workers and caregivers	2.6%	Mikrogen Diagnostik; Euroimmun recomWell SARS-CoV2 IgG immunoassay test, anti-SARS-CoV-2 ELISA (IgG) test IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.7% (0.0-2.1%)
Malfertheiner (University of Regensburg) ¹⁰⁶	2020-03-15 to 2020-06-07	Bavaria Regensburg	Sublocal	High	139	18-35 (n = 27); 36-50 (n = 43); 51-65 (n = 32)	NR	Non-probability	Health care workers and caregivers	0.0%	EUROIMMUN AG; Roche Diagnostics Anti-SARS-CoV-2 IgG and IgA ELISA, Elecsys Anti-SARS-CoV-2 IgG, IgA	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.7% (0.0-2.9%)
Thieme (Ruhr-University Bochum) ¹⁰⁹	2020-04-01 to 2020-05-31	Bochum	Local	High	99	Median 51 (IQR 41-62)	43.4	Non-probability	Patients seeking care for non-COVID-19 reasons	3.0%	Euroimmun NR IgG, IgA	0.9%, 0.8% (FINDDx / MUHC independent evaluation)	-
Erber (Technical University of Munich) ¹¹⁰	2020-04-14 to 2020-05-29	Bavaria Munich	Sublocal	High	4554	Mean 38.5 (NR)	70.4	Non-probability	Health care workers and caregivers	2.4% (1.9-2.9%)	Unclear Unclear which chemiluminescent immunoassay was used. "In all samples with incongruent results, IgG antibodies against SARS-CoV-2 S1 protein were determined using an enzyme linked immunosorbent assay (ELISA) (Euroimmun, Luebeck, Germany), and immunoblot was used to differentiate antibodies against N, S1	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.3% (0.0-0.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											and the receptor binding domain of SARS-CoV-2 from those against seasonal coronaviruses 165 (Mikrogen, Neuried, Germany)" IgG		
Choi (Charité University) ¹¹²	2020-03-19 to 2020-05-19	Berlin Berlin	Sublocal	High	223	Median 54 (IQR 42.64)	38.1	Non-probability	Patients seeking care for non-COVID-19 reasons	7.1%	Euroimmun Medizinische Labordiagnostika AG Euroimmun Analyzer I IgG, IgA	0.9%, 0.8% (FINDDx / MUHC independent evaluation)	-
Neumann (University of Bremen) ¹¹⁴	2020-03-31 to 2020-05-16	Bremen	Local	High	281	NR	NR	Non-probability	Multiple populations	2.1%	Euroimmun Euroimmun AG ELISA IgG, IgA	0.7%, 0.7% (FINDDx / MUHC independent evaluation)	-
Tonshoff (Heidelberg University) ¹¹⁵	2020-04-22 to 2020-05-15	Baden-Württemberg Tübingen, Ulm, Freiburg, Heidelberg	Regional	Moderate	4964	Median 40 (IQR 36-43)	61.1	Non-probability	Multiple populations	1.7% (1.3-2.0%)	Euroimmun; Roche Elecsys' Mikrogen in-house Euroimmun SARS-CoV-2 IgG; Roche Elecsys Anti-SARS-CoV-2; Mikrogen recomWell EILSA; in-house Luminex-based assay IgG	75.6%, 97.6% (None)	0.3% (0.1-0.4%)
Zöllkau (Universitätsklinikum Jena) ¹¹⁶	2020-04-06 to 2020-05-13	Thuringia Jena	Local	High	180	NR	100.0	Non-probability	Pregnant or parturient women	0.6% (0.0-1.7%)	Epitope Diagnostics NR IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Schmidt (University of Hannover) ¹¹⁷	2020-04-20 to 2020-04-30	Lower Saxony Hannover	Sublocal	High	385	18-29 (n=55); 30-49 (n=154); 50-64	80.0	Non-probability	Health care workers and caregivers	2.9%	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						(n=170); ≥65 (n=6)							
Korth (University Hospital Essen) ¹¹⁹	2020-03-25 to 2020-04-21	North Rhine-Westphalia Essen	Sublocal	High	316	Mean 36.7 (Average age of high-risk group); 42.3 (Average age of low-risk group) (SD 10.7 (SD of high-risk group); 13.2 (SD of low-risk group))	64.6	Non-probability	Health care workers and caregivers	1.6%	EUROIMMUN Euroimmun Anti-SARS-CoV-2-IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Harsch (Thuringia Clinic) ¹²⁰	2020-04-16 to 2020-04-21	Thuringia Saalfeld	Sublocal	High	18	Mean 44.9 (Range 21-60)	NR	Non-probability	Health care workers and caregivers	0.0%	EUROIMMUN EUROIMMUN™ IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Behrens (Hannover Medical School) ¹²¹	2020-03-23 to 2020-04-17	Lower Saxony Hannover	Local	High	217	Mean 36.5 (Range 18-63)	65.0	Non-probability	Health care workers and caregivers	1.4%	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Kern (Universitätsmedizin Marburg) ¹²²	2020-04-09 to 2020-04-16	Fulda	Sublocal	High	1780	10-19 (n=52, 2.9%), 20-29 (n=422, 23.7%), 30-39 (n=378, 21.2%), 40-49 (n=347, 19.5%), 50-59 (n=431, 24.2%), 60-69 (n=150, 8.4%)	79.8	Non-probability	Multiple populations	1.0% (0.6-1.5%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 IgG IgA ELISA IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Kraehling (Goethe-University Frankfurt) ¹²³	2020-04-06 to 2020-04-14	Hesse Frankfurt	Local	High	998	<30 (n=115); 30-40 (n=172); 41-50 (n=213); 51-60 (n=399); >60 (n=101)	21.5	Non-probability	Essential non-healthcare workers	0.4% (0.2-1.0%)	Author-designed N/A - Author-designed IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Lackermair (University Hospital Munich) ¹²⁴	2020-04-02 to 2020-04-06	Bavaria Dachau	Regional	High	151	Mean 38 (Range 26-47)	83.4	Non-probability	Health care workers and caregivers	2.6% (0.8-7.1%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Greece													
Tsitsilonis (National and Kapodistrian University of Athens) ¹²⁵	2020-06-15 to 2020-07-15	Athens	Sublocal	Moderate	2500	18-34 (n=1268); 35-54 (n=916); 55-74 (n=309); Unknown (n=7)	64.0	Non-probability	Non-essential workers and unemployed persons	0.9% (0.3-2.1%)	Roche Diagnostics CE-IVD Roche Cobas Elecsys® Anti-SARS-CoV-2 NR	100.0%, 99.8% (Used author-adjusted estimate)	0.9% (0.6-1.4%)
Psichogiou (University of Athens) ¹²⁷	2020-04-13 to 2020-05-15	Attica Athens	Sublocal	Moderate	1495	Mean 46.4 (SD 10.3)	69.7	Non-probability	Health care workers and caregivers	1.0%	Genebody Inc GeneBody COVID-19 IgM/IgG detection IgG, IgM	74.1%, 100.0% (Test developer / manufacturer evaluation)	0.8% (0.0-1.7%)
Vlachoyiannopoulos (National and Kapodistrian University of Athens/Laiko University Hospital) ¹²⁸	2020-04-25 to 2020-05-10	Attica Athens	Sublocal	High	321	Mean 42.71 (NR)	67.9	Non-probability	Health care workers and caregivers	2.2%	EUROIMMUN ; Germany EUROIMMUN IgG ELISA IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Italy													
Caponigro (ASST della Valtellina Alto Lario-Oncologia Medica Sondrio) ¹³⁴	2020-03-01 to 2020-10-19	Lombardy Sondrio	Sublocal	Unclear	220	NR	NR	Non-probability	Health care workers and caregivers	11.4%	Nal Von Minden GmbH (Germany) NADAL® COVID-19 IgG/IgM Rapid Test (test cassette) REF 243001N-10; IgG, IgM	94.1%, 99.2% (Test developer / manufacturer evaluation)	10.0% (4.1-16.1%)
Russo (University of Campania) ¹³⁵	2020-03-27 to 2020-08-30	Campania Naples	Sublocal	High	65	Median 32 (IQR 28-43)	61.5	Non-probability	Health care workers and caregivers	0.0%	Xiamen WANTAI SARS-CoV-2 Ab ELISA NR	1.0%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Ralli (Eleemosynaria Apostolica) ¹³⁶	2020-04-14 to 2020-07-31	Lazio Rome	Local	High	173	Mean 45.6 (Range 10-80)	29.5	Non-probability	Multiple populations	1.8%	Inzek B.V Biozek Medical COVID-19 Rapid Test, IgG, IgM	96.0%, 96.0% (Test developer / manufacturer evaluation)	0.8% (0.0-3.1%)
Norsa (Papa Giovanni XXII) ¹³⁸	2020-03-04 to 2020-07-10	Lombardy Bergamo	Sublocal	High	90	<28 (n=32); 38-47 (n=27); >47 (n=31)	46.7	Non-probability	Patients seeking care for non-COVID-19 reasons	21.1%	VivaChek VivaDiag COVID-19 IgM/IgG Rapid Test IgG, IgM	0.7%, 0.9% (FINDDx / MUHC independent evaluation)	-
Medas (University of Cagliari) ¹⁴⁰	2020-03-31 to 2020-06-30	Sardinia Cagliari	Sublocal	High	86	Mean 57.6 (NR)	62.8	Non-probability	Patients seeking care for non-COVID-19 reasons	5.8%	Snibe Maglumi platform IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	3.4% (0.0-8.3%)
Berte (University of Cagliari) ¹⁴¹	2020-04-15 to 2020-06-15	Milan, Cagliari, Erlangen	Local	High	354	Median 43 (IQR 31-57)	37.9	Non-probability	Patients seeking care for non-COVID-19 reasons	2.3% (0.8-3.8%)	University of Cagliari N/A - Author Designed IgG, IgA	97.6%, 95.2% (Test developer / manufacturer evaluation)	0.7% (0.0-2.4%)
Capasso (University of Naples) ¹⁴²	2020-05-11 to 2020-06-15	Campania Naples	Sublocal	High	235	Mean 39.4 (SD 10.9)	54.5	Non-probability	Health care workers and caregivers	10.6%	Ltd.; Shanghai Kehua Bio-engineering Co.; China; Shanghai NR IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Capasso (University of Naples) ¹⁴²	2020-05-11 to 2020-06-15	Campania Naples	Sublocal	Moderate	862	Mean 42.9 (SD 13.3)	47.8	Non-probability	Health care workers and caregivers	1.3%	Ltd.; Shanghai Kehua Bio-engineering Co.; China; Shanghai NR IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Capasso (University of Naples) ¹⁴²	2020-05-11 to 2020-06-15	Campania Naples	Sublocal	Moderate	310	Mean 42.3 (SD 12.4)	67.1	Non-probability	Patients seeking care for non-COVID-19 reasons	2.9%	Ltd.; Shanghai Kehua Bio-engineering Co.; China; Shanghai NR IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Cosma (University of Turin) ¹⁴⁴	2020-04-16 to 2020-06-04	Piedmont Turin	Local	High	138	NR	100.0	Non-probability	Pregnant or parturient women	5.8%	Boditech AFLIASTM COVID-19 IgG	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec,	3.7% (0.0-9.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
												or author adjustment available)	
Lorenzo (Santagostino Medical Center) ¹⁴⁶	2020-05-02 to 2020-05-31	Lombardy Milan	Local	High	119	Mean 47 (healthcare workers); 79 (family member old); 42 (family member middle age); 11 (family member youth) (SD 18 (health care workers); 6 (family member old); 12 (family member middle age); 7 (family member young);)	54.6	Non-probability	Family of essential workers	23.5%	Prima Lab IgM/IgG serological rapid tests IgG, IgM	0.8%, 0.9% (FINDDx / MUHC independent evaluation)	-
Lastrucci (University of Florence) ¹⁴⁷	2020-05-01 to 2020-05-31	Prato	Regional	Moderate	4656	Median 49 (IQR 38-57)	67.1	Non-probability	Multiple populations	3.0% (2.5-3.5%)	Hangzhou Laihe Biotech Co.; Ltd; Hangzhou China LYHER Novel Coronavirus (2019-nCoV) IgM/IgG Antibody Combo Test Kit(Colloidal Gold) IgG, IgM	100.0%, 98.8% (Test developer / manufacturer evaluation)	1.5% (0.0-2.8%)
Papalini (University of Perugia) ¹⁴⁸	2020-05-04 to 2020-05-31	Umbria Perugia	Local	Unclear	2843	NR	NR	Non-probability	Multiple populations	5.4%	Screen Italia SCREEN test COVID-19 IgG	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	3.2% (1.4-4.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Papalini (University of Perugia) ¹⁴⁸	2020-05-04 to 2020-05-31	Umbria Perugia	Sublocal	High	270	Median 52 (Range 10-83)	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	3.7%	Screen Italia SCREEN test COVID-19 IgG	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	1.4% (0.0-4.5%)
Sperotto (The University of Udine) ¹⁵⁰	2020-04-01 to 2020-05-30	Udine Udine	Sublocal	High	70	Median 56 (Range 23-73)	51.4	Non-probability	Patients seeking care for non-COVID-19 reasons	1.4%	Cellex Cellex qSARS-CoV-2 immunoglobulin G (IgG)/immunoglobulin M (IgM) point-of-care antibodies diagnostic rapid test IgG, IgM	0.8%, 0.9% (FINDDx / MUHC independent evaluation)	-
Stellato (Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon) ¹⁵¹	2020-04-03 to 2020-05-29	Campania Naples	Sublocal	High	249	NR	NR	Non-probability	Health care workers and caregivers	2.0%	VivaDiag; N/A NR IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.8% (0.0-3.2%)
Stellato (Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon) ¹⁵¹	2020-04-03 to 2020-05-29	Campania Naples	Sublocal	High	1397	NR	NR	Non-probability	Multiple populations	0.4%	VivaDiag; N/A NR IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.4%)
Plebani (University Hospital Of Padova) ¹⁵²	2020-02-22 to 2020-05-29	Veneto	Regional	High	8285	Mean 43.2 (SD 11.6)	71.6	Non-probability	Health care workers and caregivers	4.6% (4.1-5.0%)	SNIBE – Shenzhen New Industries Biomedical Engineering Co. MAGLUMI 2019-nCov IgG/IgM CLIA IgG, IgM	73.0%, 98.0% (Author-reported independent evaluation)	3.7% (2.6-4.6%)
Poletti (Bruno Kessler Foundation) ¹⁵³	2020-04-16 to 2020-05-25	Lombardy	Regional	Moderate	4120	Median 50 (IQR 30-61)	75.0	Non-probability	Contacts of COVID patients	53.1%	LIAISON® LIAISON® SARS-CoV-2 test IgG	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	46.8% (44.6-48.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Calcagno (University of Torino) ¹⁵⁵	2020-04-17 to 2020-05-20	Piemonte Torino (Turin)	Local	Moderate	5444	Mean 49.4 (SD 10.6)	74.7	Non-probability	Health care workers and caregivers	6.9%	DiaSorin LIAISON® SARS-CoV-2 S1/S2 IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Carlo (Azienda Ospedaliera-Universitaria Policlinico Riuniti di Foggia) ¹⁵⁶	2020-03-17 to 2020-05-18	Province of Foggia, Apulia Foggia	Sublocal	Moderate	3242	Mean 46.5 (SD 11.7)	NR	Non-probability	Health care workers and caregivers	1.9% (1.4-2.3%)	Shenzhen YHLO Biotech iFlash1800 SARS-COV-2 IgG & IgM IgG, IgM	97.0%, 98.8% (Test developer / manufacturer evaluation)	0.9% (0.0-1.9%)
Martella (Azienda Usl Toscana Centro Oncology) ¹⁵⁷	2020-05-11 to 2020-05-17	Tuscany Florence	Sublocal	Unclear	1145	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	2.3%	NR Quantitative serologic IgM and IgG test (Qt-ST) IgG, IgM	No data	-
Cavaliere (Santo Stefano Hospital) ¹⁵⁸	2020-04-04 to 2020-05-16	Tuscany Prato	Local	High	134	NR	100.0	Non-probability	Pregnant or parturient women	4.5%	Acro Biotech Inc. COVID-19 IgG/IgM Rapid Test Cassette IgG, IgM	0.4%, 0.9% (FINDDx / MUHC independent evaluation)	-
Sandri (IRCCS) ¹⁵⁹	2020-04-28 to 2020-05-16	Lombardy Milan, Castellanza, Varese	Regional	Moderate	3985	Median 42 (Range 21-86)	66.8	Non-probability	Health care workers and caregivers	13.4%	DiaSorin Liaison® SARS- CoV-2 S1/S2 IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Bianchi (Università degli Studi di Milano) ¹⁶⁰	2020-04-15 to 2020-05-15	Lombardy Milan	Sublocal	Unclear	42	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	9.5%	Diasorin; Abbott Laboratories NR IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	6.6% (0.0-15.1%)
Bianchi (Università degli Studi di Milano) ¹⁶⁰	2020-04-15 to 2020-05-15	Lombardy Milan	Sublocal	Unclear	34	NR	NR	Non-probability	Health care workers and caregivers	5.9%	Diasorin; Abbott Laboratories NR IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	3.6% (0.0-11.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Marra (Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)) ¹⁶²	2020-03-30 to 2020-05-11	Lombardy	Regional	High	166	Median 46 (IQR 21)	71.1	Non-probability	Multiple populations	41.6%	PRIMA Lab SA 2019-nCoV IgG/IgM Rapid Test Cassette IgG	0.7%, 0.9% (FINDDx / MUHC independent evaluation)	59.7% (50.6-69.2%)
Baracco (A.S.S.T. Lodi) ¹⁶⁴	2020-04-23 to 2020-05-05	Lombardy Region	Sublocal	High	2415	Mean 48 (SD 10.0)	72.6	Non-probability	Health care workers and caregivers	16.8%	DiaSorin The Liaison® DiaSorin® SARS-CoV-2 S1/S2 IgG test IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Denina (University of Turin) ¹⁶⁵	2020-03-08 to 2020-04-30	Piedmont	Regional	High	24	Mean 13 (Range 6-17)	66.7	Non-probability	Patients seeking care for non-COVID-19 reasons	12.5%	DiaSorin Liaison® SARS-CoV-2 S1/S2 IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Zambelli (Ospedale Papa Giovanni XXIII) ¹⁶⁶	2020-04-01 to 2020-04-30	Lombardy Bergamo	Sublocal	High	560	Median 65 (Range 19-89)	60.0	Non-probability	Patients seeking care for non-COVID-19 reasons	31.0%	Moers; Germany NADAL COVID-19 IgG/IgM Test IgG, IgM	92.1%, 99.2% (Author-reported independent evaluation)	32.6% (27.9-36.9%)
Carozzi (Arezzo Hospital) ¹⁶⁸	2020-04-01 to 2020-04-30	Tuscany	Regional	High	17098	NR	NR	Non-probability	Health care workers and caregivers	3.1%	"Zhejiang Orient Gene Biotech Co.; LTD"; Screen Italia S.R.L Screen Test COVID-19 2019-nCoV IgG/IgM, COVID-19 IgG /IgM Rapid Test Cassette IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.2% (0.0-0.8%)
Bontadi (National Association of Company and Competent Doctors) ¹⁶⁹	2020-04-11 to 2020-04-29	Veneto	Local	High	1267	Mean 44 (Range 19-69)	17.1	Non-probability	Essential non-healthcare workers	1.6%	NR; MAGLUMI; NR Rapid Test (NR), MAGLUMI CLIA, ELISA (NR) IgG, IgM	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Volta (University of Brescia) ¹⁷¹	2020-04-27 to 2020-04-27	Lombardy Brescia	Sublocal	High	76	Median 46 (IQR 23-69)	75.0	Non-probability	Health care workers and caregivers	11.8%	DiaSorin NR IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Lahner (University of Rome) ¹⁷²	2020-04-07 to 2020-04-27	Lazio Rome	Sublocal	High	1084	Median 46 (Range 19-69)	60.9	Non-probability	Health care workers and caregivers	0.7%	Medical Systems 2019-nCoV IgM/IgG CLIA IgG	50.0%, 99.1% (Author-reported independent evaluation)	0.3% (0.0-1.3%)
Landro (Hospital of Bergamo) ¹⁷⁰	Until 2020-04-24	Lombardy Bergamo	Sublocal	Unclear	3000	NR	NR	Non-probability	Health care workers and caregivers	13.0%	NR NR NR	No data	-
Paradiso (Istituto Tumori G. Paolo II) ¹⁷⁵	2020-03-26 to 2020-04-17	Puglia Bari	Sublocal	High	606	Median 47.5 (Range 20-73)	60.6	Non-probability	Health care workers and caregivers	0.3%	Snibe Diagnostic MAGLUMI800 TM IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Sotgiu (Università degli Studi di Milano) ¹⁷⁶	2020-04-02 to 2020-04-16	Lombardy Milan	Local	High	202	20-29 (n=27); 30-39 (n=44); 40-49 (n=57); 50-59 (n=51); 60-69 (n=23)	65.3	Non-probability	Health care workers and caregivers	7.4% (3.8-11.0%)	BioMedomics BioMedomics IgM-IgG Combined Antibody Rapid Test IgG	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Amendola (University of Milan) ¹⁷⁷	2020-04-15 to 2020-04-15	Lombardy Milan	Sublocal	High	663	Median 44 (NR)	83.7	Non-probability	Health care workers and caregivers	5.1%	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Canetti (San Raffaele Scientific Institute) ¹⁷⁸	2020-03-15 to 2020-04-15	Lombardy Milan	Sublocal	High	40	Median 51 (IQR 34-58)	77.5	Non-probability	Health care workers and caregivers	5.0%	Diasorin; Prima lab SA COVID-19 IgG/IgM Rapid Test , DiaSorin LIAISON® SARSCoV-2 S1/S2 IgG test IgG	No data	-
Fusco (D. Cotugno' Hospital) ¹⁸¹	2020-03-23 to 2020-04-02	Campania Naples	Sublocal	High	115	Median 43 (IQR 32-51.5)	48.7	Non-probability	Health care workers and caregivers	1.7%	Snibe Diagnostic MAGLUMI 2019-nCoV IgG (CLIA) IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Apolone (Istituto Nazionale Tumori) ¹⁸⁴	2019-09-01 to 2020-03-10		National	High	959	<55 (n=75); 55-65 (n=606); >=65 (n=278)	41.4	Non-probability	Patients seeking care for non-COVID-19 reasons	11.6%	Mazzini et al In house ELISA IgG, IgM	85.7%, 98.1% (Test developer / manufacturer evaluation)	10.7% (4.7-16.1%)
Japan													
Oka (Tokyo National Hospital) ¹⁸⁵	2020-06-01 to 2020-10-30	Tokyo	Sublocal	High	93	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	0.0%	Roche Diagnostics Elecsys Anti-SARS-CoV-2 IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Matthews (Okinawa Institute of Science and Technology) ¹⁸⁶	2020-08-01 to 2020-08-31	Okinawa Prefecture Okinawa	Sublocal	High	634	20-40 (n=124), 40-60 (n=74), 60+ (n=4)	NR	Non-probability	Multiple populations	0.0%	N/A - institution designed N/A - institution designed NR	92.5%, 100.0% (Test developer / manufacturer evaluation)	0.1% (0.0-0.6%)
Hibino (Medical Corporation Koshikai) ¹⁸⁷	2020-05-26 to 2020-08-25	Tokyo	Local	High	615	NR	NR	Non-probability	Non-essential workers and unemployed persons	34.3%	Aurora Biomed COVID-19 IgG / IgM Rapid Test Cassette IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Fukuda (Juntendo University) ¹⁸⁸	2020-07-06 to 2020-08-21	Kantō Tokyo	Sublocal	Moderate	4147	20-29 (n=1461); 30-39 (n=1245); 40-49 (n=776); 50-59 (n=424); 60-69 (N=193); 70+ (n=48) Mean = 36.8	63.9	Non-probability	Health care workers and caregivers	0.3% (0.2-0.6%)	Roche Diagnostics Elecsys Anti-SARS-CoV-2 electrochemiluminescence immunoassay IgG, IgA, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Hibino (Shonan Fujisawa Tokushukai Hospital) ¹⁸⁹	2020-06-01 to 2020-07-30	Kanagawa Fujisawa	Sublocal	Unclear	806	Median 33 (Range 21-83)	71.6	Non-probability	Health care workers and caregivers	0.7% (0.3-1.6%)	Abbott Abbott Architect SARS-CoV-2 IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Nishida (Toyonaka Municipal Hospital) ¹⁹²	2020-06-12 to 2020-06-19	Kansai Osaka	Sublocal	Moderate	925	Mean 40 (SD 11.8)	80.0	Non-probability	Health care workers and caregivers	0.4% (0.2-1.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Chong (Kanenokuma Hospital) ¹⁹³	2020-06-12 to 2020-06-15	Kyushu Fukuoka City	Sublocal	High	108	NR	NR	Non-probability	Assisted living and long-term care facilities	2.8%	Hangzhou Alltest Biotech Co. Ltd. All Test@2019-nCoV IgG/IgM RapidTest Cassette IgG	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Suda (Hokkaido University Graduate School of Medicine) ¹⁹⁴	2020-05-01 to 2020-05-31	Hokkaido Sapporo	Sublocal	High	300	Mean 66.5 (Range 20-84)	42.0	Non-probability	Patients seeking care for non-COVID-19 reasons	0.0% (0.0-0.0%)	Roche Diagnostics Elecsys Anti-SARS-Cov2 Immunoassay IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Nakamura (Iwate Prefectural Central Hospital) ¹⁹⁵	2020-05-18 to 2020-05-29	Honshu Morioka	Sublocal	High	1000	Mean 40 (SD 11)	73.6	Non-probability	Health care workers and caregivers	0.0%	Abbott Laboratories: Roche Abbott Architect® SARS- CoV- 2 IgG Assay; Roche IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.3%)
Kobashi (Hirata Central Hospital) ¹⁹⁶	2020-05-08 to 2020-05-28	Fukushima Prefecture Hirata	Sublocal	High	637	Median 44 (IQR 34, 56)	75.8	Non-probability	Health care workers and caregivers	0.9%	YHLO Biotech Shenzhen; China iFlash-SARS-CoV-2 IgM/IgG IgG	1.0%, 0.0% (FINDDx / MUHC independent evaluation)	-
Denyer (SoftBank) ¹⁹⁸	2020-05-12 to 2020-05-18		Sublocal	Unclear	44066	NR	NR	Non-probability	Multiple populations	0.4%	Innovita; "Zhejiang Orient Gene Biotech Co.; LTD" NR NR	No data	-
Fujita (National Hospital Organization Kyoto Medical Center) ¹⁹⁹	2020-04-10 to 2020-04-20	Kansai Kyoto	Sublocal	High	92	20-29 (n=30), 30-39 (n=29), 40-49 (n=21), 50+ (n=12)	64.1	Non-probability	Health care workers and caregivers	5.4%	Inc.; DRG international COVID-19 IgG ELISA kits IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Suzuki (National Center for Global Health and Medicine) ²⁰¹	2020-02-14 to 2020-04-03	Tokyo	Sublocal	High	49	20-29 (n = 5), 30-39 (n = 25), 40-49 (n = 11), 50-59 (n = 4), 60+ (n = 2)	69.4	Non-probability	Health care workers and caregivers	0.0%	N/A - in house N/A - in house IgG	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Suda (Hokkaido University Graduate School of Medicine) ¹⁹⁴	2020-03-01 to 2020-03-31	Hokkaido Sapporo	Sublocal	High	300	Mean 68 (Range 20-80)	49.0	Non-probability	Patients seeking care for non-COVID-19 reasons	0.3% (0.0-1.8%)	Roche Diagnostics Elecsys Anti-SARS-CoV2 Immunoassay IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Liechtenstein													
Schaffner (Kantonsspital Graubunden) ²⁰²	2020-06-02 to 2020-10-06		National	Unclear	1159	Median 45 (IQR 39-48)	53.6	Non-probability	Multiple populations	7.8% (6.4-9.5%)	Switzerland Diasorin Euroimmun; Switzerland Abbott Diagnostics Baar; Rotkreuz; Roche Diagnostics Elecsys®Anti-SARS-CoV-2 S antibody assay Abbott test Diasorin test Euroimmun test Sugentech, Daejeon, Republic of Korea; SGTi-flex COVID-19 IgM/IgG IgG, IgM	97.6%, 99.8% (Author-reported independent evaluation)	7.7% (6.2-9.5%)
New Zealand													
Craigie (Southern Community Laboratories) ²⁰⁸	2020-06-04 to 2020-08-04	Southern Region	Regional	High	1127	Median 46 (Range 4-90)	76.0	Non-probability	Contacts of COVID patients	1.0%	Abbott Abbott Architect SARS-CoV-2 IgG chemiluminescent microparticle immunoassay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Norway													
Trieu (University of Bergen) ²¹⁰	2020-03-06 to 2020-04-09	Midhordland Bergen	Local	High	607	Median 39 (SD 12.6)	77.1	Non-probability	Health care workers and caregivers	5.3%	Sigma-Aldrich In house ELISA test IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author)	3.7% (1.2-6.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
												adjustment available)	
Kuvelker (University of Bergen) ²¹¹	2020-02-28 to 2020-04-04	Hordaland Bergen	Local	High	179	Median 30 (IQR 17-50)	55.3	Non-probability	Contacts of COVID patients	45.3%	N/A - Author Designed N/A - Author Designed IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	58.6% (48.8-68.7%)
Cox (University of Bergen) ²¹²	2020-02-28 to 2020-04-04	Western Norway Bergen	Local	High	77	NR	NR	Probability	Contacts of COVID patients	31.2%	Amant et al. N/A - Author-designed IgG, IgA, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	39.7% (25.8-53.2%)
Portugal													
Figueiredo-Campos (Universidade de Lisboa) ²¹³	2020-05-13 to 2020-07-10	Lisbon	Sublocal	High	2715	NR	NR	Non-probability	Non-essential workers and unemployed persons	2.6%	N/A - author designed N/A - author designed IgG	99.0%, 100.0% (Author-reported independent evaluation)	2.2% (0.2-3.4%)
Figueiredo-Campos (University of Lisbon) ²¹⁴	2020-05-13 to 2020-07-10	Estremadura Lisbon	Sublocal	Moderate	2571	NR	NR	Non-probability	Non-essential workers and unemployed persons	1.5%	et al. [Independent third party]; Krammer SARS-CoV-2 ELISA IgG, IgA, IgM	94.7%, 98.0% (Author-reported independent evaluation)	0.5% (0.0-1.3%)
Gonçalves (NOVA University of Lisbon) ²¹⁶	2020-06-15 to 2020-06-30	Lisboa Region Lisbon	Sublocal	Moderate	1636	17-76	65.9	Non-probability	Non-essential workers and unemployed persons	3.0%	NOVA University of Lisbon In-House ELISA anti-SARS-CoV-2 assay IgG	94.7%, 99.5% (Test developer / manufacturer evaluation)	2.0% (0.2-3.5%)
Republic of Korea													
KBS World (Korea Disease Control and	2020-08-15 to 2020-10-15		National	Unclear	6900	NR	0.0	Non-probability	Essential non-healthcare workers	0.4%	NR NR NR	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Prevention Agency) ²¹⁷													
Song (Daegu Catholic University Hospital) ²¹⁹	2020-05-25 to 2020-06-05	North Gyeongsang Daegu	Local	High	198	Mean 51.7 (Range 18-82)	50.0	Non-probability	Multiple populations	7.6%	Shin Jin Medics Inc DIAKEY COVID-19 IgM/IgG Rapid Test Kit IgG	100.0%, 92.0% (Author-reported independent evaluation)	2.3% (0.0-6.6%)
Ko (Sungkyunkwan University School of Medicine) ²²¹	2020-04-26 to 2020-05-09		National	High	309	Mean 31.1 (SD 7.84)	84.5	Non-probability	Health care workers and caregivers	0.3%	PCL Inc PCL COVID-19 Total Ab EIA test NR	98.2%, 100.0% (Test developer / manufacturer evaluation)	0.2% (0.0-1.0%)
Ko (Sungkyunkwan University School of Medicine) ²²¹	2020-04-26 to 2020-05-09		National	High	123	Mean 34.9 (SD 10.9)	75.6	Non-probability	Health care workers and caregivers	0.0%	PCL Inc PCL COVID-19 Total Ab EIA test NR	98.2%, 100.0% (Test developer / manufacturer evaluation)	0.6% (0.0-2.5%)
Singapore													
Kurohi (Singapore National Centre for Infectious Diseases) ²²²	2020-02-15 to 2020-04-15	Singapore	Sublocal	Unclear	1096	NR	NR	Non-probability	Health care workers and caregivers	0.0%	NR NR NR	No data	-
Ng (National Centre for Infectious Diseases, Singapore) ²²³	2020-01-23 to 2020-04-03		National	Moderate	1150	Median 35 (IQR 26-51)	54.2	Probability	Contacts of COVID patients	3.8%	N/A - author designed N/A - author designed NR	98.9%, 100.0% (Test developer / manufacturer evaluation)	3.1% (0.5-4.9%)
Spain													
Savirón-Cornudella (University of Zaragoza) ²²⁴	2020-03-31 to 2020-08-31	Madrid	Sublocal	High	260	NR	100.0	Non-probability	Pregnant or parturient women	6.9%	Vircell; Abbott; Biozek Biozek COVID-19 IgG/IgM Rapid Test Cassette IgG Abbott reactive Vircell reactive IgG, IgM	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Garde-Noguera (Hospital Arnau de Vilanova de Valencia, Spain) ²²⁵	2020-05-02 to 2020-06-30	Valencia Valencia	Local	High	166	Median 63 (Range 33-86)	42.2	Non-probability	Patients seeking care for non-COVID-19 reasons	1.8%	DiaSorin LIASON SARS-CoV-2 S1/S2IgG test and LIASON SARS-CoV-2 IgM test IgG, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.9% (0.0-3.4%)
Prados (IVIRMA Global Headquarters) ²⁶	2020-04-27 to 2020-06-26		National	Unclear	6140	NR	72.8	Non-probability	Patients seeking care for non-COVID-19 reasons	0.7%	Epitope Diagnostics EDI Novel Coronavirus COVID-19 ELISA kit IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Cabezón-Gutiérrez (Hospital General Universitario Gregorio Marañón) ²²⁷	2020-06-01 to 2020-06-19	Community of Madrid Torrejón de Ardoz	Sublocal	High	229	<50 (n=35); 51-70 (n=122); >70 (n=72)	54.1	Non-probability	Patients seeking care for non-COVID-19 reasons	31.4%	Hangzhou Testsea Biotechnology Testsealabs IgG/IgM Rapid Test Cassette IgG, IgM	0.8%, 0.9% (FINDDx / MUHC independent evaluation)	-
Camba (Quirónsalud Tenerife Hospital) ²²⁸	2020-04-27 to 2020-06-15	Canary Islands Tenerife	Sublocal	High	211	Median 53.9 (NR)	55.9	Non-probability	Patients seeking care for non-COVID-19 reasons	1.9% (0.1-4.8%)	Roche Diagnostics; Unclear Elecsys Anti-SARS-CoV-2, solid phase immunochromatographic analysis NR	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.8% (0.0-2.7%)
Brotos (University Hospital Sant Joan de Deu) ²²⁹	2020-04-28 to 2020-06-03	Catalonia Barcelona	Local	Moderate	1084	Mean Children 5.9; Adults 40 (SD Children 3.7; adults 10.2)	45.4	Non-probability	Contacts of COVID patients	18.0%	Innovita Tangshan Biological Technology Co 2019-n-CoV Ab Test IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Perez-Garcia (Hospital Universitario Príncipe de Asturias) ²³¹	2020-05-01 to 2020-05-30	Madrid	Sublocal	High	2424	Median 42.6 (HCW without evidence of infection); 50.0 (HCW symptomatic with positive serology);	80.4	Non-probability	Health care workers and caregivers	22.4%	AllTest Biotech AllTest COVID-19 IgG/IgM kit IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						38.6 (HCW asymptomatic with positive serology) (IQR 29.9-54.8 (HCW without evidence of infection); 36.9-57.3 (HCW symptomatic with positive serology); 28.5-52.1 (HCW asymptomatic with positive serology))							
Fabre (Hospital Clínico Universitario Lozano Blesa) ²³²	2020-04-27 to 2020-05-29	Zaragoza Zaragoza	Sublocal	High	169	NR	100.0	Non-probability	Pregnant or parturient women	8.3%	Abbott; Guangzhou Wondfo Biotech Co.; Vircell Microbiologists Wondfo SARS-CoV-2 Antibody Test, IgG-CMIA; Abbott SARS-CoV-2 IgG Assay; Vircell COVID-19 VIRCLIA IgM/IgA, IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	7.3% (1.1-14.0%)
Barallat (Institut Català de la Salut) ²³³	2020-05-04 to 2020-05-22	Barcelona	Local	High	7563	Mean 43.8 (SD 12.43)	76.0	Non-probability	Health care workers and caregivers	9.4%	Italy; DiaSorin; Vercelli SARS-CoV-2 S1/S2 IgG LIAISON® IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Viñuela (University Hospital Gregorio Marañón) ²³⁴	2020-05-06 to 2020-05-21	Madrid	Local	High	100	Median 32 (Range 16-44)	100.0	Non-probability	Pregnant or parturient women	13.0%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Soriano (Universidad Autónoma de Madrid) ²³⁵	2020-04-26 to 2020-05-16	Community of Madrid Madrid	Local	High	674	Median 42 (Range 18-89)	70.2	Non-probability	Multiple populations	13.8%	PCL Inc. PCL COVID19 IgG/IgM Rapid Gold IgG, IgM	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Villalan (The Universidad Complutense de Madrid) ²³⁷	2020-02-28 to 2020-05-10	Madrid	Sublocal	Moderate	769	Median 32 (IQR 11)	100.0	Non-probability	Pregnant or parturient women	11.2%	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	12.0% (8.8-15.3%)
Gras-Valentí (COVID-19 Group of the Infections Commission) ²³⁸	2020-04-24 to 2020-05-08	Alacant Alicante	Sublocal	Unclear	4179	NR	73.3	Non-probability	Health care workers and caregivers	6.6% (5.8-7.3%)	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	5.6% (3.9-7.1%)
Crovetto (Universitat de Barcelona) ²³⁹	2020-04-14 to 2020-05-05	Barcelona	Sublocal	High	874	NR	100.0	Non-probability	Pregnant or parturient women	14.0%	Ortho Clinical Diagnostics; Vircell Microbiologist VIRCLIA, VITROS (Ortho) IgG, IgA, IgM	No data	-
Valdivia (Hospital Clínico Universitario) ²⁴⁰	2020-04-13 to 2020-04-30	Valencia Valencia	Local	High	1153	NR	NR	Non-probability	Health care workers and caregivers	3.5%	Snibe Diagnostic MAGLUMI 2019-nCov IgG/IgM CLIA IgG, IgM	95.6%, 96.0% (Test developer / manufacturer evaluation)	0.9% (0.0-2.6%)
Galán (Hospital Universitario Fundación Alcorcón) ²⁴¹	2020-04-14 to 2020-04-27	Madrid	Sublocal	High	2590	Mean 43.8 (SD 11.1)	73.9	Non-probability	Health care workers and caregivers	31.6%	Palex Diapro IgG	88.9%, 91.8% (Author-reported independent evaluation)	26.9% (16.9-35.2%)
Olalla (Hospital Costa del Sol) ²⁴²	2020-04-15 to 2020-04-25	Marbella	Sublocal	High	498	Mean 41.5 (95% CI 40.8-42.3)	71.1	Non-probability	Health care workers and caregivers	2.2%	"Zhejiang Orient Gene Biotech Co.; LTD" COVID-19 IgG/IgM Rapid Test IgG, IgM	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Borraz (Hospital San Juan de Dios) ²⁴⁴	2020-03-20 to 2020-04-21	Aragon Zaragoza	Sublocal	High	289	Median 41.9 (SD 12.7)	77.2	Non-probability	Health care workers and caregivers	5.9%	Madrid; Master Labor S.L. 2019-nCoV IgG/IgM Rapid Test IgG, IgM	100.0%, 98.0% (Test developer / manufacturer evaluation)	3.1% (0.0-6.2%)
Borraz (Hospital San Juan de Dios) ²⁴⁴	2020-03-20 to 2020-04-21	Aragon Zaragoza	Sublocal	High	229	Median 74.4 (SD 13.9)	43.2	Non-probability	Patients seeking care for non-COVID-19 reasons	7.0%	Madrid; Master Labor S.L. 2019-nCoV IgG/IgM Rapid Test IgG, IgM	100.0%, 98.0% (Test developer / manufacturer evaluation)	4.4% (0.4-8.7%)
Dacosta-Urbieta (Hospital Clinico Universitario de Santiago de Compostela) ²⁴⁵	2020-04-14 to 2020-04-16	Galicia Santiago de Compostela	Sublocal	High	175	NR	NR	Non-probability	Health care workers and caregivers	4.0% (1.1-6.9%)	Genobio Pharmaceutical (Shanghai; China) Virusee Immunochromatographic Rapid Method IgG, IgM	No data	-
Martin (Gerencia de Atención Primaria del Área de Salud de León, Spain) ²⁴⁶	2020-04-01 to 2020-04-15	León León	Local	High	676	Mean 48.5 (SD 12.8)	74.1	Non-probability	Health care workers and caregivers	7.4% (5.5-10.0%)	Hangzhou All Test Biotech Co Ltd All Test@2019-nCoV IgG/IgM RapidTest Cassette IgG, IgM	0.0%, 0.0% (Used author-adjusted estimate)	7.4% (5.6-9.6%)
Fernandez (Hospital Universitario de Fuenlabrada) ²⁴⁷	2020-05-13 to 2020-04-14	Fuenlabrada	Sublocal	High	2439	Mean 42.1 (Range 18-65)	78.4	Non-probability	Health care workers and caregivers	16.9%	Snibe diagnostic Maglumi 2000 IgG	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Sweden													
Dopico (Karolinska Institutet) ²⁴⁸	2020-03-14 to 2020-12-11	Uppland Stockholm	Local	High	4100	NR	NR	Probability	Multiple populations	14.8% (12.2-18.0%)	NR - In-house Anti-SARS-CoV-2 ELISA IgG	0.0%, 0.0% (Used author-adjusted estimate)	14.8% (13.7-15.9%)
Rashid-Abdi (The Hospital of Vastmanland) ²⁴⁹	2020-05-04 to 2020-08-19	Vasteras	Sublocal	High	131	Mean 39 (SD 12)	84.0	Non-probability	Health care workers and caregivers	19.1%	Abbott Abbott's SARS-CoV-2 IgG immunoassay, IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Laursen (Copenhagen University Hospital) ⁵⁹	2020-06-22 to 2020-08-10		National	High	1248	<40 (n=374); 40-60 (n=687); 60+ (n=187)	67.1	Non-probability	Health care workers and caregivers	8.3%	Zhuhai; China; Guangzhou Wondfo Biotech; Livzon Diagnostics; Gunangdong Livzon lateral flow test, WONDFO lateral flow IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	7.8% (5.2-10.5%)
Lidström (Uppsala University) ²⁵²	2020-05-27 to 2020-06-25	Uppsala	Regional	Moderate	8679	Mean 45 (IgG negative); 42 (IgG positive) (Range 18-85 (IgG negative); 18-78 (IgG positive))	76.7	Probability	Health care workers and caregivers	6.6%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Hassan (Karolinska University Hospital) ²⁵⁴	2020-05-11 to 2020-06-17	Stockholm	Sublocal	High	403	Median 43 (NR)	52.9	Non-probability	Assisted living and long-term care facilities	20.1%	(Luminex Corp) FlexMap3D IgG	99.2%, 99.8% (Author-reported independent evaluation)	20.1% (16.2-24.1%)
Rudberg (Danderyd Hospital) ²⁵⁷	2020-04-14 to 2020-05-08	Sodermanland Stockholm	Sublocal	Moderate	2149	Mean 44 (SD 12)	84.5	Non-probability	Health care workers and caregivers	19.1%	Author designed Author designed IgG	99.2%, 99.8% (Test developer / manufacturer evaluation)	19.0% (17.2-20.8%)
Lindh (Uppsala University) ²⁵⁸	2020-04-01 to 2020-04-20	Stockholm	Local	High	1005	36-50 (n=133/332); 51-65 (n=116/332)	24.3	Non-probability	Health care workers and caregivers	22.9% (20.4-25.7%)	Zhejiang Orient Gene Biotech Co Ltd COVID-19 IgG / IgM Rapid Test Cassette IgG, IgM	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Switzerland													
Kahlert (Cantonal Hospital St Gallen) ²⁶¹	2020-06-22 to 2020-08-15	Canton of St. Gallen	Regional	Moderate	4664	Median 38.3 (IQR 29.7-49.5)	78.3	Non-probability	Health care workers and caregivers	3.0%	Switzerland ELISA: Euroimmune; Rotkreuz; ECLIA: Roche Diagnostics;	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											Germany electrochemiluminescence immunoassay (ECLIA) and Enzyme-linked Immunosorbent Assay (ELISA) IgG, IgA		
Fenwick (Lausanne University Hospital and University of Lausanne) ²⁶⁷	2020-05-04 to 2020-06-27	Vaud	Regional	High	177	NR	NR	Non-probability	Contacts of COVID patients	32.2%	Roche Elecsys anti-SARS-CoV-2 assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Dupraz (University of Lausanne) ²⁶⁸	2020-05-04 to 2020-06-27	Vaud	Regional	Moderate	69	Mean 47.8 (SD 17)	56.5	Probability	Contacts of COVID patients	17.4%	Switzerland; Lausanne University Hospital in-house Luminex S protein trimer IgG Assay IgG	96.7%, 99.2% (Test developer / manufacturer evaluation)	17.2% (7.3-28.0%)
Dupraz (University of Lausanne) ²⁶⁸	2020-05-04 to 2020-06-27	Vaud	Regional	Moderate	302	Mean 37 (SD 21.3)	51.7	Probability	Contacts of COVID patients	53.0%	Switzerland; Lausanne University Hospital in-house Luminex S protein trimer IgG Assay IgG	96.7%, 99.2% (Test developer / manufacturer evaluation)	55.3% (47.2-64.0%)
Kohler (Cantonal Hospital St. Gallen) ²⁷⁰	2020-03-19 to 2020-04-03	St. Gallen St. Gallen	Regional	High	1012	Median 38.3 (Range 16.9-64.8)	75.2	Non-probability	Health care workers and caregivers	1.0%	Daejeon; Basel; Yuseong-gu; IL); a chemiluminescence microparticle immunoassay (CMIA; Roche Diagnostics; and an electrochemiluminescence immunoassay (ECLIA; Sugentech; Abbott Diagnostics; Lake Bluff;	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											lateral flow immunochromatographic assay (LFIA; Switzerland); Republic of Korea) NR IgG		
The United Kingdom													
Taubel (Richmond Pharmacology Ltd) ²⁷³	2020-03-19 to 2020-12-02	England London	Local	High	6061	3-89	11.3	Non-probability	Multiple populations	6.4%	NR NR IgG	No data	-
Lumley (Oxford University Hospitals) ²⁷⁴	2020-04-23 to 2020-11-30		Local	Moderate	12541	Median 38 (IQR 29 to 49)	73.9	Probability	Health care workers and caregivers	10.1%	University of Oxford N/A - Author Designed IgG	99.1%, 99.0% (Test developer / manufacturer evaluation)	8.7% (4.7-11.2%)
Abo-Leyah (Ninewells Hospital and Medical School) ²⁸⁰	2020-05-28 to 2020-09-02	Scotland	Regional	High	2062	Mean 44.8 (NR)	81.7	Non-probability	Health care workers and caregivers	14.5%	Siemens Siemens SARS-CoV-2 antibody assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Harris (Public Health England) ²⁸³	2020-03-23 to 2020-08-20		Sublocal	Moderate	2247	NR	NR	Non-probability	Health care workers and caregivers	12.1%	Euroimmun Euroimmun anti-SARS-CoV-2 ELISA (IgG) serology assay IgG	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Roarty (Queens University Belfast) ²⁸⁴	2020-06-26 to 2020-08-15	Belfast, London, Glasgow, Manchester, Cardiff	National	Moderate	849	2-15	NR	Non-probability	Family of essential workers	7.7% (6.0-9.6%)	Basel; Switzerland; DiaSorin; Roche; Saluggia; Italy Elecsys ANti-SARS-CoV-2 Total Antibody assay; LIAISON SARS-CoV-2 S1/S2 IgG assay IgG	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Cooper (Cambridge University Hospitals NHS Foundation Trust) ²⁸⁶	2020-06-10 to 2020-08-07	England Cambridge	Sublocal	Moderate	5698	Median 38 (Range 17-83)	77.3	Non-probability	Health care workers and caregivers	7.2%	Siemens Healthcare Limited Centaur XP SARS-Cov-2 Total Antibody assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Black (University Hospitals of Leicester NHS Trust) ²⁸⁷	2020-05-29 to 2020-08-03	England Leicester	Sublocal	High	200	Mean 45.3 (SD 12)	75.0	Non-probability	Health care workers and caregivers	12.0%	Abbott Laboratories Abbott SARS CoV-2 assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Claudiani (Imperial College London) ²⁸⁹	2020-06-01 to 2020-07-27	England London	Sublocal	High	161	Median 54 (Range 18-92)	41.6	Non-probability	Patients seeking care for non-COVID-19 reasons	11.2%	Imperial College London Imperial Hybrid DABA NR	No data	-
Martin (University of Leicester) ²⁹¹	2020-05-29 to 2020-07-13	East Midlands Leicester	Sublocal	Moderate	10662	Median 44 (IQR 33-53)	79.8	Non-probability	Health care workers and caregivers	10.8%	Abbott Abbott SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Hanrath (Newcastle-upon-Tyne Hospitals NHS Trust) ²⁹²	2020-05-29 to 2020-07-06	England Newcastle-Upon-Tyne	Sublocal	High	11103	Median 43 (IQR 32-53)	77.0	Non-probability	Health care workers and caregivers	8.4%	Roche Diagnostics Roche Anti-SARS-CoV-2 serology assay IgG	No data	-
Predecki (Imperial College London) ²⁹³	2020-06-01 to 2020-07-03	Greater London London	Sublocal	High	855	Median 57 (Range 45-77)	34.7	Non-probability	Patients seeking care for non-COVID-19 reasons	8.1% (6.4-10.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	68.4%, 100.0% (Author-reported independent evaluation)	10.0% (2.1-16.0%)
Waterfield (Royal Belfast Hospital for Sick Children) ²⁹⁴	2020-04-16 to 2020-07-03	Wales, England, Scotland, Ireland Belfast, London, Glasgow, Manchester, Cardiff	National	High	992	Median 10.1 (Range 2.03-15.99)	48.7	Non-probability	Family of essential workers	3.1%	DiaSorin - Spike protein assays (DiaSorin LIAISON SARS CoV-2 S1/ S2 IgG assay) IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Rowland (Public Health England) ²⁹⁶	2020-06-03 to 2020-06-30	Greater London London	Sublocal	High	327	0-39 (n=142); 40-49 (n=149); 60+ (n=36)	77.7	Non-probability	Health care workers and caregivers	47.1%	Abbott Abbott Architect nucleocapsid IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	52.2% (46.1-57.4%)
Graham (Imperial College London) ²⁹⁷	2020-06-01 to 2020-06-30	Greater London London	Sublocal	High	241	NR	NR	Non-probability	Assisted living and long-term care facilities	71.8% (66.0-77.0%)	Abbott Abbott Architect nucleocapsid IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Davis (King's College London) ²⁹⁸	2020-06-01 to 2020-06-30	England London	Sublocal	High	1882	Median 37 (NR)	71.1	Non-probability	Multiple populations	7.0%	Sure Screen Diagnostics SureScreen Diagnostics Rapid COVID-19 IgG/IgM Immunoassay Test Cassette IgG, IgM	94.0%, 96.3% (Author-reported independent evaluation)	3.6% (2.1-5.2%)
Gulraj (Gibraltar Government) ³⁰⁰	2020-06-03 to 2020-06-17	Gibraltar	Regional	Unclear	1247	NR	NR	Non-probability	Health care workers and caregivers	1.4%	NR NR IgG	No data	-
Lumley (University of Oxford) ³⁰¹	2020-04-14 to 2020-06-15	Oxford	Local	Moderate	1000	Median 32 (IQR 28-35)	100.0	Non-probability	Pregnant or parturient women	5.3% (4.0-6.9%)	University of Oxford IgG ELISA IgG	99.1%, 99.0% (Test developer / manufacturer evaluation)	3.7% (0.4-6.2%)
Jones (North Bristol NHS Trust) ³⁰²	2020-01-15 to 2020-06-15	England North Somerset, Bristol, South Gloucestershire	Sublocal	High	6858	<=20years (n=114); 21-30 (n=1757); 31-40 (n=1624); 41-50 (n=1536); 51-60 (n=1408); 61-70 (n=402)	77.8	Non-probability	Health care workers and caregivers	9.3%	Abbott laboratories; RocheDiagnostics Abbott SARS-CoV-2 IgG chemiluminescent microparticle assay; RocheTMElectrochemiluminescence immunoassay IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	7.4% (6.5-8.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Favara (Cambridge University Hospitals NHS Foundation Trust) ³⁰³	2020-06-15 to 2020-06-15	East of England	Regional	High	434	Median 41 (Range 19-66)	82.0	Non-probability	Health care workers and caregivers	18.4%	Cambridge University Hospitals Luminex IgG	84.0%, 100.0% (Test developer / manufacturer evaluation)	21.6% (15.1-28.4%)
Pallett (Chelsea and Westminster Hospital NHS Trust) ³⁰⁴	2020-04-08 to 2020-06-12	England London	Local	High	504	Mean 42.4 (Range 20.3-72.1)	59.1	Non-probability	Health care workers and caregivers	10.6% (7.6-13.6%)	CTK Biotech; Zhuhai Encode Medical Engineering Onsite CTK Biotech COVID-19 split IgG/IgM Rapid Test, Encode SARS-CoV-2 split IgM/IgG One Step Rapid Test Device IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	11.5% (7.4-16.2%)
Baxendale (Royal Papworth Hospital NHS Trust) ³⁰⁵	2020-04-20 to 2020-06-10	England Cambridge	Sublocal	High	500	Median 42 (IQR 33-51)	61.6	Non-probability	Health care workers and caregivers	14.0%	Addenbrookes Hospital NHS Trust Luminex based multiplexed particle flow cytometry assay IgG	97.0%, 100.0% (Author-reported independent evaluation)	14.2% (10.6-17.7%)
Razvi (Gateshead Health NHS Foundation Trust) ³⁰⁷	2020-05-28 to 2020-06-08	England Gateshead	Sublocal	High	2521	Mean 42.5 (SD 12.6)	91.9	Non-probability	Health care workers and caregivers	19.4%	Roche Elecsys Anti-SARS-CoV-2 kit IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Favara (The Queen Elizabeth Hospital) ³⁰⁸	2020-06-01 to 2020-06-07	England King's Lynn	Sublocal	High	70	NR	NR	Non-probability	Health care workers and caregivers	21.4%	Unclear Luminex SARS-CoV-2 IgG multiplex particle-based flow cytometry assay IgG	No data	-
Bampoe (University College London) ³⁰⁹	2020-05-11 to 2020-06-05	England London	Sublocal	High	200	Mean 37 (IQR 30-37)	83.5	Non-probability	Health care workers and caregivers	14.5% (9.9-20.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Grant (Whittington Health NHS Trust) ³¹⁰	2020-05-15 to 2020-06-05	England London	Sublocal	High	2004	Mean 40.21 (Range 18-73)	NR	Non-probability	Health care workers and caregivers	31.6%	Roche Diagnostics Elecsys Anti-SARS-CoV2 Immunoassay IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
McCafferty (Barts Health NHS Trust) ³¹¹	2020-05-01 to 2020-06-04	London	Sublocal	High	1253	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	18.0%	Roche Elecsys Anti-SARS-CoV-2 test IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Ladhani (Immunisation and Countermeasures Division) ³¹⁴	2020-05-01 to 2020-05-31	Belfast, London, Glasgow, Manchester, Cardiff	National	High	44	Median 6.3 (seronegative); 9.1 (seropositive) (IQR 3.3-8.6 (seronegative); 5.9-11.6 (seropositive))	54.5	Non-probability	Contacts of COVID patients	36.2% (9.0-63.4%)	Abbott Commerce Abbott SARS-CoV-2 IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Khalil (St George's University of London) ³¹⁵	2020-05-15 to 2020-05-28	England London	Sublocal	High	190	NR	NR	Non-probability	Health care workers and caregivers	22.0%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Poulikakos (Salford Royal NHS Foundation Trust) ³¹⁸	2020-05-04 to 2020-05-06	England	Sublocal	High	281	NR	73.0	Non-probability	Health care workers and caregivers	6.0%	Snibe Diagnostic MAGLUMI 2019-nCoV IgG (CLIA) IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Shields (University Hospitals Birmingham NHS Foundation Trust) ³²¹	2020-04-24 to 2020-04-25	England Birmingham	Sublocal	High	516	Median 42 (IQR 30-51)	75.2	Non-probability	Health care workers and caregivers	24.4%	University of Birmingham Clinical Immunology Service ELISA developed inhouse IgG, IgA, IgM	100.0%, 97.8% (Test developer / manufacturer evaluation)	22.5% (18.6-26.7%)
Sikora (Rutherford Health) ³²²	2020-04-14 to 2020-04-24	England Bedlington, Liverpool, Newport, Reading	Local	High	161	Mean 43 (NR)	50.3	Non-probability	Health care workers and caregivers	1.2%	Sugentech Sugentech SGTi-flex COVID-19 IgM/IgG IgG	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author)	0.8% (0.0-3.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
												adjustment available)	
Ladhani (Public Health England) ³²³	2020-04-10 to 2020-04-13	England London	Local	High	394	19-39 (n=66); 40-59 (n=113); 60-79 (n=71); 80+ (n=144)	75.9	Non-probability	Assisted living and long-term care facilities	77.9% (73.6-81.7%)	In House: PHE England SARS-CoV-2 infected virus lysate assay NR	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	98.4% (94.6-100.0%)
Houlihan (University College London Hospitals) ³²⁴	2020-03-26 to 2020-04-08	England London	Sublocal	High	181	Median 34 (IQR 29-44)	67.4	Non-probability	Health care workers and caregivers	45.3%	in-house flow cytometry and ELISA assays developed as part of the Crick-COVID-Consortium NR IgG, IgA, IgM	No data	-
United States of America													
Godbout (Virginia Commonwealth University) ³³⁰	2020-07-27 to 2020-10-02	Virginia Richmond	Sublocal	High	1962	Mean 37 (Range 19-75)	77.3	Non-probability	Health care workers and caregivers	1.4%	Abbott Laboratories Abbott Architect SARS-CoV-2 IgG antibody immunoassay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Jimenez-Kurlander (Memorial Sloan Kettering Cancer Center) ³³³	2020-05-05 to 2020-09-10	New York New York City	Sublocal	High	257	Median 6.9 (Range 1-18.6)	65.0	Non-probability	Patients seeking care for non-COVID-19 reasons	7.8%	Abbott Abbott architect IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Halbrook (University of California Los Angeles) ³³⁵	2020-05-19 to 2020-08-31	California	Local	Moderate	679	20-29 (n = 53) 30-39 (n = 237) 40-49 (n = 182) 50-59 (n = 182) 60+ (n = 15)	6.0	Non-probability	Essential non-healthcare workers	8.1%	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	7.5% (4.8-10.9%)
Halbrook (University of California Los Angeles) ³³⁵	2020-04-08 to 2020-08-31	California	Local	Moderate	1108	20-29 (n = 172) 30-39 (n = 418) 40-	64.1	Non-probability	Health care workers and caregivers	3.9%	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data;	2.0% (0.2-3.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
California Los Angeles) ³³⁵						49 (n = 235) 50-59 (n = 148) 60+ (n = 55)						no sens, spec, or author adjustment available)	
Brant-Zawadzki (Hoag Memorial Hospital Presbyterian) ³³⁷	2020-07-15 to 2020-08-15	California	Local	High	92	Mean 42.05 (SD 8.27)	13.0	Non-probability	Essential non-healthcare workers	4.3% (1.2-10.8%)	Ortho Diagnostics Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG assay IgG	93.6%, 100.0% (Used author-adjusted estimate)	4.3% (1.5-10.0%)
Brant-Zawadzki (Hoag Memorial Hospital Presbyterian) ³³⁷	2020-07-15 to 2020-08-15	California	Local	High	2754	Mean 43.06 (SD 12.05)	72.1	Non-probability	Health care workers and caregivers	2.8% (2.2-3.4%)	Ortho Diagnostics Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG assay IgG	93.6%, 100.0% (Used author-adjusted estimate)	2.8% (2.2-3.4%)
Sabourin (University of Colorado) ³³⁸	2020-07-15 to 2020-08-15	Colorado	Local	High	264	Median 38 (IQR 32-48)	54.2	Non-probability	Essential non-healthcare workers	4.0%	Exsera BioLabs NR IgG	85.0%, 98.6% (Test developer / manufacturer evaluation)	3.1% (0.4-6.1%)
Coffman (University of Louisville) ³⁴⁰	2020-07-01 to 2020-07-31	Kentucky Louisville	Local	Unclear	1100	NR	NR	Non-probability	Health care workers and caregivers	2.2%	NR NR NR	No data	-
Azzi (Albert Einstein College of Medicine) ³⁴³	2020-05-03 to 2020-07-29	New York New York City	Sublocal	Moderate	912	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	16.7%	Abbott Abbott SARS-CoV-2 IgG antibody test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Nicholson (Scripps Clinic) ³⁴⁴	2020-04-14 to 2020-07-28	California San Diego	Local	High	11993	NR	NR	Non-probability	Health care workers and caregivers	0.9%	Diazyme; Abbott Laboratories Diazyme DZ-Lite 2019-nCoV IgG (CLIA) Assay, Abbott Architect SARS-CoV-2 IgG assay IgG	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Haizler-Cohen (Donald and Barbara Zucker School of Medicine) ³⁴⁷	2020-05-27 to 2020-07-24	New York	Regional	High	1671	NR	100.0	Non-probability	Pregnant or parturient women	16.1%	Roche Roche Elecsys® Anti-SARS-CoV-2 RUO Assay IgG	No data	-
Klawiter (Massachusetts General Hospital) ³⁴⁸	2020-05-29 to 2020-07-23	Massachusetts Boston	Sublocal	High	143	NR	NR	Non-probability	Multiple populations	6.3%	Massachusetts General Hospital MGH SARS-CoV-2 IgG ELISA IgG	99.7%, 100.0% (Test developer / manufacturer evaluation)	6.1% (1.0-10.9%)
Klawiter (Massachusetts General Hospital) ³⁴⁸	2020-05-29 to 2020-07-23	Massachusetts Boston	Local	High	227	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	3.5%	Massachusetts General Hospital MGH SARS-CoV-2 IgG ELISA IgG	99.7%, 100.0% (Test developer / manufacturer evaluation)	2.7% (0.0-5.3%)
Lopez (Harvard Medical School) ³⁵¹	2020-07-15 to 2020-07-20	Indiana St. John Township	Sublocal	Moderate	753	18-35 (n=153); 36-50 (n=287); 51-65 (n=282); 66+ (n=30)	84.3	Non-probability	Essential non-healthcare workers	1.7% (0.3-3.3%)	Abbott Alinity Abbott Alinity SARS-CoV-2 IgG antibody test IgG	100.0%, 99.0% (Used author-adjusted estimate)	1.7% (0.9-2.7%)
Reuben (District of Columbia Department of Health (DC Health)) ³⁵⁴	2020-05-28 to 2020-07-15	Washington D.C Washington	Regional	High	310	Mean 42.55 (SD 9.07)	23.5	Non-probability	Essential non-healthcare workers	3.5%	DiaSorin Inc. DiaSorin LIAISON® XL assay IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Shah (Mayo Clinic) ³⁵⁶	2020-05-25 to 2020-07-09	Minnesota Rochester	Sublocal	High	320	Mean 36.3 (SD 10.8)	78.1	Non-probability	Health care workers and caregivers	0.6%	Ortho-Clinical Diagnostics; EUROIMMUN; Roche Diagnostics Euroimmun anti-SARS-CoV-2 IgG ELISA, Ortho-Clinical Diagnostics anti-SARS-CoV-2 IgG Antibody Immunoassay, Roche Diagnostics	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											anti-SARS-CoV-2 Total Antibody Immunoassay IgG		
Shah (Mayo Clinic) ³⁵⁶	2020-05-25 to 2020-07-09	Minnesota Rochester	Sublocal	High	248	Mean 47.1 (SD 11.7)	87.5	Non-probability	Health care workers and caregivers	0.0%	Ortho-Clinical Diagnostics; EUROIMMUN ; Roche Diagnostics Euroimmun anti-SARS-CoV-2 IgG ELISA, Ortho-Clinical Diagnostics anti-SARS-CoV-2 IgG Antibody Immunoassay, Roche Diagnostics anti-SARS-CoV-2 Total Antibody Immunoassay IgG	No data	-
Mohr (University of Iowa) ³⁵⁷	2020-05-13 to 2020-07-08		National	Moderate	1606	<30 (n = 376); 31-40 (n = 622); 41-50 (n = 319); 51-60 (n = 222); >61 (n = 67)	63.4	Non-probability	Health care workers and caregivers	1.7%	IL EUROIMMUN ; Abbott Laboratories; Chicago Architect i2000 ELISA EUROIMMUN IgG	No data	-
Dimcheff (Veterans Affairs Ann Arbor Healthcare System) ³⁵⁸	2020-06-08 to 2020-07-08	Michigan	Local	Moderate	1476	18-30 (n=111, 7.5%); 31-40 (n=372, 25.2%); 41-50 (n=392, 26.6%); 51-60 (n=406, 27.5%); >60 (n=149, 10.1%); No response (n=46, 3.1%)/	64.0	Non-probability	Health care workers and caregivers	4.9% (3.8-6.1%)	Abbott ARCHITECT i2000SR analyzer IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Freeman (University of Pittsburgh School of Medicine) ³⁶²	2020-03-15 to 2020-07-04	Pennsylvania Pittsburgh	Sublocal	High	485	Mean 10.96 (Range 0.79-18.96)	46.6	Non-probability	Patients seeking care for non-COVID-19 reasons	1.0% (0.3-2.4%)	Euroimmun; Siemens; Beckman Coulter Euroimmun Assay, Beckman Coulter SARS-CoV-2 IgG automated Emergency Use Authorization (EUA) assay, Siemens Centaur SARS-CoV-2 Total automated EUA assay IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.3% (0.0-1.2%)
Barrett (Rutgers Robert Wood Johnson Medical School) ³⁶⁴	2020-04-28 to 2020-06-30	New Jersey New Brunswick, Somerville	Sublocal	Moderate	3907	20-39 (N=1703); 40-59 (n=1690); 60+ (n=472)	73.6	Non-probability	Health care workers and caregivers	9.6%	Abbott Laboratories Abbott Architect SARS-CoV-2 assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Wilkins (Northwestern University) ³⁶⁵	2020-05-28 to 2020-06-30	Illinois Chicago	Local	Moderate	6510	Mean 40.6 (SD 12)	79.6	Non-probability	Health care workers and caregivers	5.3% (4.8-5.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Nailescu (Indiana University) ³⁶⁶	2020-05-01 to 2020-06-30	Indiana Indianapolis	Local	High	31	Median 12 (Range 2-21)	32.3	Non-probability	Patients seeking care for non-COVID-19 reasons	3.2%	Mount Sinai medical center; Abnova; Eli Lilly and Co & IUSM (1) Abnova (#KA5826) (2) Indiana University School of Medicine (IUSM) in collaboration with Eli Lilly and Co., Indianapolis, IN, (LSN3832334); (3) Mount Sinai Medical Center's (MSM	94.4%, 98.5% (Test developer / manufacturer evaluation)	2.4% (0.0-10.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											C) 2-Step ELISA IgG, IgM		
Rivas (Cedars-Sinai Medical Center) ³⁶⁹	2020-05-11 to 2020-06-28	California Los Angeles	Local	Moderate	6201	Mean 41.46 (SD 12.01)	67.9	Non-probability	Health care workers and caregivers	3.5%	Abbott Architect SARS-CoV-2 IgG chemiluminescent microparticle immunoassay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Patel (Vanderbilt University Medical Center) ³⁷⁰	2020-06-02 to 2020-06-27	Tennessee Nashville	Sublocal	High	230	NR	NR	Non-probability	Health care workers and caregivers	3.5%	CDC NR NR	96.0%, 99.0% (Test developer / manufacturer evaluation)	2.4% (0.0-5.5%)
Baker (Emory University Hospital) ³⁷¹	2020-04-19 to 2020-06-26	Atlanta	Local	Moderate	10275	<30 (n=1581); 30-39 (n=2953); 40-49 (n=2118); 50-59 (n=1805); >=60 (n=1153)	72.6	Non-probability	Health care workers and caregivers	5.7% (5.2-6.1%)	Emory University In house ELISA IgG	97.5%, 98.0% (Test developer / manufacturer evaluation)	3.0% (0.0-5.3%)
McBride (Memorial Sloan Kettering Cancer Center) ³⁷²	2020-05-07 to 2020-06-25	New York New York City	Sublocal	High	952	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	5.5%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Moscola (Northwell Health COVID-19 Research Consortium) ³⁷³	2020-04-20 to 2020-06-23	New York New York City	Local	High	40329	Median 42 (IQR 31.5-54.5)	73.7	Non-probability	Health care workers and caregivers	13.7%	AnshLabs; Roche; DiaSorin; Abbott Laboratories; Ortho Clinical Diagnostics; Euroimmun Euroimmun SARS-CoV-2 ELISA, AnshLabs SARS-CoV-2 IgG ELISA, Abbott	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											Architect SARS-CoV-2 IgG, Ortho Clinical Diagnostics VITROS Anti-SARSCoV-2 IgG, Ortho Clinical Diagnostics VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Calibrator, DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG, Roche Elecsys Anti-SARS-CoV-2 IgG		
Self (CDC COVID-19 Response Team) ³⁷⁶	2020-04-03 to 2020-06-19	Colorado, Minnesota, Oregon, Utah, Washington, Tennessee, New York, California, North Carolina, Massachusetts, Ohio, Maryland Winston-Salem, Murray, Portland, Baltimore, Bronx, Springfield, Los Angeles, Aurora, Nashville, Seattle, Columbus, Boston, Minneapolis	National	Moderate	3248	Median 36 (NR)	65.5	Non-probability	Health care workers and caregivers	6.0%	CDC NR NR	96.0%, 99.0% (Test developer / manufacturer evaluation)	4.5% (0.5-6.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Rebeiro (Vanderbilt University) ³⁸⁰	2020-05-15 to 2020-06-15	Tennessee	Regional	High	11787	Median 40.3 (IgG Negative); 32.4 (IgG Positive) (IQR 30.9-52.4 (IgG Negative); 26.5-43.4 (IgG Positive))	NR	Non-probability	Health care workers and caregivers	1.0%	Abbott Abbott ARCHITECT SARS-CoV-2 IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Akinbami (Region 2 South Healthcare Coalition) ³⁸²	2020-05-18 to 2020-06-13	Michigan Detroit	Local	Moderate	16397	Mean 42.1 (SD 12.2)	68.6	Non-probability	Health care workers and caregivers	6.9% (6.5-7.3%)	Ortho Clinical Diagnostics VITROS Immunodiagnostic Products Anti- SARS-CoV-2 IgG Test IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Dora (Veterans Affairs Healthcare System) ³⁸³	2020-06-05 to 2020-06-12	California Los Angeles	Sublocal	High	150	Median 75 (PCR positive); 74 (PCR negative) (NR)	NR	Non-probability	Assisted living and long-term care facilities	17.3%	DiaSorin DiaSorin Liaison IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Yogo (Sharp Healthcare) ³⁸⁶	2020-05-20 to 2020-06-08	California San Diego	Local	High	1770	18-35 (n=802); 36-45 (n=460); 45-55 (n=323); 56-65 (n=146); >65 (n=39)	75.5	Non-probability	Health care workers and caregivers	2.2%	Roche Diagnostics Elecsys Anti-SARS-CoV-2 NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Hogan (Stanford University) ³⁸⁷	2020-04-20 to 2020-06-08	California San Francisco	Local	High	12418	Median 39.5 (IQR 32.4-50.3)	70.7	Non-probability	Health care workers and caregivers	0.9% (0.7-1.1%)	Stanford Health Care SHC Laboratory - Developed ELISA IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.2%)
Flannery (University of Pennsylvania) ³⁸⁹	2020-04-04 to 2020-06-03	Pennsylvania Philadelphia	Local	Moderate	1293	Median 31 (IQR 27-35)	100.0	Non-probability	Pregnant or parturient women	6.2% (4.9-8.0%)	Author-designed N/A - Author-designed IgG, IgM	100.0%, 98.9% (Author-reported independent evaluation)	5.3% (3.6-7.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Coffman (University of Louisville) ³⁴⁰	2020-04-01 to 2020-05-31	Kentucky Louisville	Local	Unclear	1372	NR	NR	Non-probability	Health care workers and caregivers	1.0%	NR NR NR	No data	-
Addetia (University of Washington) ³⁹⁰	2020-05-01 to 2020-05-31	Washington Seattle	Sublocal	High	120	NR	7.5	Probability	Essential non-healthcare workers	5.0%	Abbott Abbott Architect SARS-CoV-2 IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Gray (Truckee Meadows Fire Protection District) ³⁹¹	2020-05-01 to 2020-05-31	Nevada	Sublocal	High	132	NR	NR	Non-probability	Essential non-healthcare workers	14.0%	NR NR NR	No data	-
Brunner (Bassett Medical Center) ³⁹²	2020-05-04 to 2020-05-29	New York Upstate New York	Local	High	764	Mean 41.8 (seropositive); 43.7 (seronegative) (SD 16.0 (seropositive); 13.7 (seronegative))	56.9	Non-probability	Health care workers and caregivers	2.0%	Abbott Laboratories SARS-CoV-2 IgG Abbott Architect assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Brunner (Bassett Medical Center) ³⁹²	2020-05-04 to 2020-05-29	New York Upstate New York	Local	High	762	Mean 41.8 (igg+); 43.7 (igg-) (SD 16 (igg+); 13.7(igg-))	NR	Non-probability	Health care workers and caregivers	4.5%	Linden; Ortho-Clinical Diagnostics; NJ VITROS Anti-SARS-CoV-2 IgG Test IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Sims (Oakland University) ³⁹⁴	2020-04-13 to 2020-05-28	Michigan Trenton, Wayne, Grosse Pointe, Farmington Hills, Dearborn, Taylor, Canton, Royal Oak, Troy	Sublocal	Moderate	20614	Mean 43.1 (SD 13)	76.3	Non-probability	Health care workers and caregivers	8.1% (6.8-8.9%)	EUROIMMUN Lübeck EUROIMMUN SARS-CoV-2 IgG assay IgG	98.1%, 99.4% (Used author-adjusted estimate)	8.1% (7.7-8.5%)
Stavert (Cambridge Health Alliance) ³⁹⁹	2020-04-13 to 2020-05-24	Massachusetts Cambridge	Sublocal	High	24	11-64	45.8	Non-probability	Patients seeking care for non-COVID-19 reasons	0.0%	DiaSorin DiaSorin Liaison IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Ahmad (The Lundquist Institute) ⁴⁰⁰	2020-04-21 to 2020-05-22	California	Local	High	244	Mean 51.1 (NR)	50.0	Non-probability	Multiple populations	20.9%	Hangzhou Testsea Biotechnology Co. One Step SARS-CoV2 (COVID-19) IgG/IgM Rapid Test IgG, IgM	0.8%, 0.9% (FINDDx / MUHC independent evaluation)	-
Jackson (Michigan Department of Corrections) ⁴⁰¹	2020-05-14 to 2020-05-22	Michigan	Sublocal	Unclear	1248	NR	NR	Non-probability	Persons who are incarcerated	92.0%	NR NR NR	No data	-
Jackson (Michigan Department of Corrections) ⁴⁰¹	2020-05-14 to 2020-05-22	Michigan Lenox Township	Sublocal	Unclear	1201	NR	NR	Non-probability	Persons who are incarcerated	65.6%	NR NR NR	No data	-
Jackson (Michigan Department of Corrections) ⁴⁰¹	2020-05-14 to 2020-05-22	Michigan Detroit	Sublocal	Unclear	57	NR	NR	Non-probability	Persons who are incarcerated	35.0%	NR NR NR	No data	-
Jackson (Michigan Department of Corrections) ⁴⁰¹	2020-05-14 to 2020-05-22	Michigan	Sublocal	Unclear	867	NR	NR	Non-probability	Persons who are incarcerated	12.2%	NR NR NR	No data	-
Staletovich (Coral Springs City Government) ⁴⁰²	2020-05-17 to 2020-05-22	Florida Coral Springs	Local	Unclear	700	NR	NR	Non-probability	Essential non-healthcare workers	0.0%	Cellex NR NR	No data	-
Leidner (Chiles Research Institute) ⁴⁰³	2020-04-08 to 2020-05-22	Oregon Seaside, Newberg, Portland, Oregon City, Hood River, Medford, Milwaukie	Regional	High	10019	Median 42 (Range 18-82)	75.7	Non-probability	Health care workers and caregivers	2.5%	Author-designed N/A - Author-designed IgG	80.0%, 100.0% (Test developer / manufacturer evaluation)	3.2% (2.5-4.3%)
Pritchett (University of Utah) ⁴⁰⁴	2020-04-18 to 2020-05-21	Utah	Sublocal	High	39	Median 45 (Range 23 to 76)	89.7	Non-probability	Patients seeking care for non-	2.6%	in house - ARUP NR IgG	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
									COVID-19 reasons				
Shukla (Vincere Cancer Center) ⁴⁰⁵	2020-04-24 to 2020-05-21	Arizona Tempe, Peoria, Phoenix, Glendale, Chandler, Surprise	Regional	Moderate	3326	Median 41.3 (IQR 9.6)	16.4	Non-probability	Essential non-healthcare workers	1.5%	Ray Biotech RayBiotech Coronavirus (COVID-19) IgG Rapid Test Kit IgG	0.1%, 0.8% (FINDDx / MUHC independent evaluation)	-
Rosser (Stanford Health Care) ⁴⁰⁶	2020-04-20 to 2020-05-20	California San Francisco Bay Area	Local	High	10449	Mean 40.9 (SD 11.6)	65.0	Non-probability	Health care workers and caregivers	1.3%	Stanford Clinical Laboratory anti-SARS-CoV-2 RBD enzyme-linked immunosorbent assay IgG	87.0%, 99.8% (Test developer / manufacturer evaluation)	0.6% (0.0-1.3%)
Geraci (MUSC Health-Lancaster) ⁴⁰⁹	2020-03-16 to 2020-05-20	South Carolina Lancaster	Sublocal	High	230	NR	NR	Non-probability	Health care workers and caregivers	2.2%	Abbott NR NR	No data	-
Tarabichi (Case Western Reserve University) ⁴¹⁰	2020-04-20 to 2020-05-19	Ohio Cleveland	Local	High	296	Mean 44.1 (NR)	14.2	Non-probability	Essential non-healthcare workers	5.4% (3.1-8.6%)	Epitope Diagnostics; Inc EDI™ Novel Coronavirus COVID-19 ELISA Kits IgG, IgM	0.8%, 0.9% (FINDDx / MUHC independent evaluation)	-
Mughal (Monmouth Medical Centre) ⁴¹¹	2020-05-14 to 2020-05-19	New Jersey Long Branch	Sublocal	High	121	Mean 39.2 (IQR 28-48.5)	82.6	Non-probability	Health care workers and caregivers	0.8%	SD Biosensor Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit IgG	96.2%, 96.6% (Test developer / manufacturer evaluation)	0.9% (0.0-3.3%)
Morris (Emory University) ⁴¹³	2020-04-16 to 2020-05-18	Georgia Atlanta	Sublocal	Unclear	300	Mean 41-50 (NR)	83.0	Non-probability	Health care workers and caregivers	4.7%	NR NR IgG	No data	-
Parker-Magyar (Summit Medical Center) ⁴¹⁸	2020-05-01 to 2020-05-14	New Jersey Long Hill Township	Sublocal	High	70	NR	NR	Non-probability	Essential non-healthcare workers	4.3%	NR NR NR	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Iwuiji (Texas Tech University) ⁴¹⁹	2020-05-12 to 2020-05-13	Texas Lubbock	Local	High	683	18-76	NR	Non-probability	Essential non-healthcare workers	0.7%	Abbott Abbott SARS-CoV-2 IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Tilley (University of Southern California) ⁴²²	2020-04-29 to 2020-05-08	California Los Angeles	Sublocal	Moderate	790	NR	48.2	Non-probability	Students and Daycares	4.0% (3.0-5.1%)	EUROIMMUN EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG) IgG	90.0%, 100.0% (Used author-adjusted estimate)	4.0% (2.7-5.5%)
Hunter (Indiana University) ⁴²³	2020-04-29 to 2020-05-08	Indiana Indianapolis	Regional	High	734	Mean 42.8 (NR)	70.0	Non-probability	Health care workers and caregivers	1.6%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Racine-Brzostek (Weill Cornell Medicine) ⁴²⁵	2020-04-17 to 2020-05-07	New York New York City	Local	Moderate	2274	Median 37 (IQR 31-48)	63.3	Non-probability	Health care workers and caregivers	35.4%	ET Healthcare SARS-CoV-2 cyclic enhanced fluorescence assay (CEFA) IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Regan (Fellowship Village) ⁴²⁶	2020-04-15 to 2020-05-06	New Jersey Basking Ridge	Sublocal	Unclear	371	NR	NR	Probability	Assisted living and long-term care facilities	34.8%	NR NR IgG, IgM	No data	-
Regan (Fellowship Village) ⁴²⁶	2020-04-15 to 2020-05-06	New Jersey Basking Ridge	Sublocal	Unclear	305	NR	NR	Probability	Assisted living and long-term care facilities	23.6%	NR NR IgG, IgM	No data	-
Sydney (Jacobi Medical Center) ⁴²⁷	2020-04-28 to 2020-05-04	New York New York City	Sublocal	High	1700	NR	NR	Non-probability	Health care workers and caregivers	19.2%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Reagan (Medical University South Carolina) ⁴³¹	2020-04-27 to 2020-05-02	South Carolina Charleston	Sublocal	High	920	NR	NR	Non-probability	Multiple populations	2.0%	Abbott Not possible to determine NR	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Venugopal (NYC Health + Hospitals/Lincoln) ⁴³²	2020-03-01 to 2020-05-01	New York New York City	Local	Moderate	500	20-39 (n=230), 40-59 (n=196), 60+ (n=52)	65.8	Non-probability	Health care workers and caregivers	27.0%	Abbott Laboratories Abbott Architect SARS-CoV-2 IgG Assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Jeremias (St Francis Hospital) ⁴³³	2020-03-01 to 2020-04-30	New York New York City	Sublocal	High	1699	Mean 42.8 (SD 13.8)	74.1	Non-probability	Health care workers and caregivers	9.8%	EUROIMMUN ; Abbott Euroimmun Anti-SARS-CoV-2 ELISA IgG, SARS-CoV-2 IgG IgG	No data	-
Cohen (DaVita Clinical Research) ⁴³⁴	2020-04-23 to 2020-04-30	Florida Miami	Local	High	677	Mean 65.7 (SD +/- 14.5 years)	41.1	Non-probability	Patients seeking care for non-COVID-19 reasons	5.6% (4.0-7.6%)	Diazyme Laboratories Inc DZ-Lite SARS-CoV-2 IgG IgM CLIA Kit IgG, IgM	57.1%, 85.0% (Author-reported independent evaluation)	2.8% (0.0-9.6%)
Jeong (Columbia University Medical Center) ⁴³⁵	2020-02-01 to 2020-04-30	New York New York City	Sublocal	High	50	Median 35 (IQR 31-49)	42.0	Non-probability	Health care workers and caregivers	46.0%	Abbott Laboratories SARS-CoV-2 immunoglobulin G antibody test IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	53.3% (39.9-66.9%)
Lewis (Centers for Disease Control) ⁴⁴⁰	2020-03-22 to 2020-04-25	Utah, Wisconsin Milwaukee, Salt Lake City	Local	High	178	Median 22 (Range <1-76)	53.9	Non-probability	Contacts of COVID patients	25.8%	CDC CDC-developed SARS-CoV-2 ELISA NR	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	31.5% (22.7-40.1%)
Payne (US Navy) ⁴⁴²	2020-04-20 to 2020-04-24	Guam	Sublocal	High	382	Median 30 (IQR 24-35)	24.3	Non-probability	Essential non-healthcare workers	59.7%	CDC CDC Pan-immunoglobulin ELISA IgG, IgA, IgM	96.0%, 99.3% (Test developer / manufacturer evaluation)	64.6% (56.4-75.8%)
Kiefer (Ohio State University College of Medicine) ⁴⁴⁵	2020-04-23 to 2020-04-23	Ohio Columbus	Sublocal	High	110	Median 34 (IQR 28.8-45.0)	100.0	Non-probability	Health care workers and caregivers	20.0%	Epitope Diagnostics Novel Coronavirus COVID-19 IgG ELISA Kit IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Morcuende (Columbia University Irving Medical Center) ⁴⁴⁷	2020-03-01 to 2020-04-21	New York New York City	Sublocal	High	91	NR	42.9	Non-probability	Health care workers and caregivers	12.1%	"Zhejiang Orient Gene Biotech Co.; LTD" COVID-19 IgG / IgM Rapid Test Cassette IgG, IgM	93.1%, 99.2% (Test developer / manufacturer evaluation)	12.1% (3.7-21.2%)
McCormack (Stanford University) ⁴⁴⁸	2020-04-08 to 2020-04-21		National	Unclear	5603	NR	NR	Non-probability	Non-essential workers and unemployed persons	0.7% (0.3-1.1%)	NR NR NR	No data	-
Stock (Albert Einstein College of Medicine) ⁴⁵⁰	2020-04-04 to 2020-04-20	New York New York City	Local	High	98	Mean 37.6 (SD 10.6)	50.0	Non-probability	Health care workers and caregivers	15.3%	Epitope Diagnostics anti-n IgG ELISA IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Madsen (University of Utah) ⁴⁵¹	2020-04-13 to 2020-04-19	Utah Salt Lake City	Sublocal	High	270	NR	NR	Non-probability	Health care workers and caregivers	5.9%	EUROIMMUN Euroimmun Anti-SARS-CoV-2-IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Caban-Martinez (University of Miami) ⁴⁵²	2020-04-16 to 2020-04-17	Florida	Sublocal	High	203	21-30 (n=33); 31-40 (n=51); 41-50 (n=67); 51+ (n=52)	6.4	Non-probability	Essential non-healthcare workers	8.9%	BioMedomics Rapid immunoglobulin (IgM)-IgG combined point-of-care (POC) lateral flow immunoassay IgG, IgM	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Goldberg (Harvard Medical School) ⁴⁵⁶	2020-04-01 to 2020-04-06	Massachusetts	Sublocal	High	140	Mean 83 (resident age); 45 (staff) (Range 54-102 (resident); NR (staff))	NR	Non-probability	Assisted living and long-term care facilities	10.7%	BioMedomics COVID-19 IgM-IgG Dual Antibody Rapid Test IgG, IgM	0.6%, 0.9% (FINDDx / MUHC independent evaluation)	-
Mansour (Icahn School of Medicine at	2020-03-24 to 2020-04-04	New York New York City	Local	High	285	Mean 38.36 (NR)	33.3	Non-probability	Health care workers and caregivers	32.6%	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec,	40.9% (33.2-48.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Mount Sinai) ⁴⁵⁸												or author adjustment available)	
McPherson (US Centers for Disease Control and Prevention) ⁴⁶⁰	2020-03-03 to 2020-03-06	Illinois	Sublocal	High	59	Median 39 (IQR 32-54)	79.7	Non-probability	Contacts of COVID patients	0.0%	CDC SARS-CoV-2 spike enzyme-linked immunosorbent assay IgG, IgA, IgM	96.0%, 99.0% (Test developer / manufacturer evaluation)	1.3% (0.0-5.5%)
Chu (US Centers for Disease Control and Prevention) ⁴⁶¹	2020-01-20 to 2020-02-03	Washington	Regional	High	32	Median 45 (Range 0-78)	NR	Non-probability	Contacts of COVID patients	0.0%	Author-designed CDC SARS-CoV-2 ELISA NR	96.0%, 99.0% (Test developer / manufacturer evaluation)	2.3% (0.0-9.6%)
Latin America and Caribbean													
Brazil													
Santana (Clínica de Reumatologia) ⁴⁶⁴	2020-03-15 to 2020-08-15	State of Sao Paulo São Paulo	Local	High	100	Mean 46.5 (SD 14.2)	85.0	Non-probability	Patients seeking care for non-COVID-19 reasons	21.0%	Snibe Diagnostics MAGLUMI anti-SARS-CoV-2 IgG/IgM IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	20.2% (12.2-28.4%)
Silva (Adolfo Lutz Central Institute) ⁴⁶⁷	2020-06-05 to 2020-07-31	State of Sao Paulo Sao Paulo	Sublocal	High	406	Median 50 (IQR 40-57)	72.9	Non-probability	Multiple populations	8.6%	Ltd.; Switzerland; China; Roche Diagnostics; Rotkreuz; Guangzhou Wondfo Biotech Co. SARS-CoV-2 Wondfo; Elecys Anti-SARS-CoV-2 IgG, IgM	No data	-
Melo (Federal University of Sergipe) ⁴⁶⁹	2020-06-01 to 2020-06-30	Sergipe	Regional	High	471	NR	NR	Non-probability	Health care workers and caregivers	13.6%	Boditech Med Inc. Ichroma COVID-19 Ab Test IgG	95.8%, 97.0% (Author-reported independent evaluation)	10.7% (5.8-15.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Costa (Faculdade De Medicina da Universidade) ⁴⁷⁵	2020-05-14 to 2020-05-28	São Paulo State São Paulo	Sublocal	Moderate	4987	<30 (n=1512), 31-40 (n=1539), 51-60 (n=636), 61+ (n=150)	72.9	Non-probability	Health care workers and caregivers	14.1% (13.1-15.0%)	Wondfo-China Rapid Chromatographic Immunoassay IgG, IgM	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Silva (Centro de Terapia Oncológica) ⁴⁸²	2020-04-09 to 2020-04-29	Rio de Janeiro Petrópolis	Sublocal	High	61	NR	NR	Non-probability	Health care workers and caregivers	4.9%	NR NR IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	3.4% (0.0-11.5%)
Columbia													
Ariza (Pontificia Universidad Javeriana) ⁴⁸⁶	2020-06-25 to 2020-08-10	Capital District Cundinamarca Bogotá	Sublocal	High	351	Median 31.5 (Seronegative); 29.4 (Seropositive) (IQR 27.5-38.6 (Seronegative); 26.9-37 (Seropositive))	58.7	Non-probability	Health care workers and caregivers	8.3% (5.8-11.6%)	Columbia SD Biosensor; Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Idrovo (Universidad Industrial de Santander) ⁴⁸⁷	2020-04-17 to 2020-07-14		National	High	4234	NR	NR	Non-probability	Non-essential workers and unemployed persons	4.0%	NR NR IgG, IgM	66.0%, 96.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	1.0% (0.0-2.1%)
Cuba													
Giraldoni (University of Medical Sciences of Cienfuegos) ⁴⁸⁸	2020-03-23 to 2020-04-06	Cienfuegos Aguada de Pasajeros	Local	Unclear	200	NR	NR	Non-probability	Contacts of COVID patients	0.0%	NR NR IgG, IgM	No data	215
Mexico													
Cruz-Arenas (Instituto Nacional de	2020-08-10 to 2020-09-09	Mexico City	Sublocal	Moderate	300	< 30 (n=41); 30-44 (n=124); 45-59	65.0	Probability	Health care workers and caregivers	11.0%	; Hangzhou Biotest Biotech Co. Ltd.	1.0%, 1.0% (FINDDx / MUHC	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Rehabilitacion) ⁴⁹⁴						(n = 114) ; 60+ (n = 7)					COVID-19 IgG/IgM Rapid Test Cassette IgG, IgM	independent evaluation)	
Díaz-Salazar (Universidad Autónoma de Nuevo Leon) ⁴⁹⁷	2020-07-09 to 2020-07-23	Nuevo Leon Guadalupe	Local	Moderate	3268	Median 40 (IQR 3-49)	38.6	Non-probability	Multiple populations	5.7% (4.9-6.6%)	Roche elecsys Elecsys Anti-SARS-CoV-2 Roche COBAS e801 IgG, IgM	99.5%, 99.8% (Used author-adjusted estimate)	5.7% (4.9-6.5%)
Panama													
Villarreal (Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT -AIP)) ⁴⁹⁸	2020-04-30 to 2020-07-07	Colon, Panama	National	High	351	Mean 39.5 (SD 11.5)	67.8	Non-probability	Health care workers and caregivers	12.8% (8.6-15.4%)	N/A - Author Designed Chinese Academy of Science Test (CAST) IgG, IgM	87.0%, 98.9% (Test developer / manufacturer evaluation)	12.8% (5.8-18.6%)
Peru													
Álvarez-Antonio (Universidad de Ingeniería y Tecnología) ⁵⁰⁰	2020-07-15 to 2020-08-15	Iquitos	Local	Low	1337	Mean 29.2 (Range 3 months - 89)	NR	Probability	Multiple populations	68.1% (65.6-70.6%)	China); Zhejiang Orient Gene (Biotech Co LTD COVID-19 IgG/IgM Rapid Test Cassette IgG, IgM	95.8%, 100.0% (Used author-adjusted estimate)	68.1% (65.6-70.6%)
North Africa and Middle East													
Egypt													
Kassem (Cairo University) ⁵⁰³	2020-06-01 to 2020-06-14	Cairo	Local	High	74	Median 32 (Range 23-48)	59.5	Non-probability	Health care workers and caregivers	12.2%	Artron Laboratories COVID-19 IgM/IgG antibody rapid diagnostic test IgG, IgM	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Mostafa (Ain Shams University) ⁵⁰⁴	2020-04-22 to 2020-05-14	Cairo Governorate Cairo	Local	High	4040	18-24 (n=603); 25-29 (n=1279); 30-39	61.5	Non-probability	Health care workers and caregivers	1.3%	Artron Laboratories Artron One Step COVID-19	0.4%, 1.0% (FINDDx / MUHC	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
						(n=1057); 40-49 (n=700); >=50 (n=401)					IgM/IgG Antibody Test IgG, IgM	independent evaluation)	
Iran													
Poustchi (Teheran University of Medical Sciences) ⁵⁰⁵	2020-04-17 to 2020-06-02	Kerman, Shiraz, Esfahan , Urmia, Tehran, Sari, Ahvaz, Zahedan, Qom, Ardabil, Hamedan, Sanandaj, Kermanshah, Mashhad, Gorgan, Tabriz, Babol , Rasht	National	Moderate	5372	≤19 (n = 11); 20–29 (n = 770); 30–39 (n = 2003); 40–49 (n = 1675); 50–59 (n =749); ≥60 (n = 164)	NR	Probability	Multiple populations	14.9% (13.8- 16.0%)	Pishtaz Teb PT-SARS- COV-2.IgM-96 and PT-SARS- COV-2.IgG-96 IgG, IgM	66.9%, 98.2% (Author- reported independent evaluation)	19.4% (14.1- 23.7%)
Saberian (Teheran University of Medical Sciences) ⁵⁰⁶	2020-03-20 to 2020-05-20	Tehran Tehran	Sublocal	High	243	Mean 36.14 (SD 8.70)	12.3	Non- probability	Essential non- healthcare workers	41.6%	KarmaAzmaAn dish Co. COVID-19 IgM/IgG rapid test IgG, IgM	71.1%, 58.7% (Test developer / manufacturer evaluation)	13.4% (0.0- 46.8%)
Armin (High Institute for Research and Education in Transfusion Medicine) ⁵⁰⁷	2020-04-20 to 2020-05-05	Tehran Tehran	Sublocal	High	475	<40 (n=238), 40-62 (n=97)	81.5	Non- probability	Health care workers and caregivers	29.4%	Hangzhou AllTest Biotech Co. Rapid Test Dipstick IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Vazirinejad (University of Pecs) ⁵⁰⁸	2020-03-01 to 2020-04-30	Kerman	Local	High	238	Mean 30.77 (SD 19.3)	54.2	Non- probability	Contacts of COVID patients	15.6%	NR NR IgG, IgM	No data	-
Ossareh (Iran University of Medical Sciences) ⁵¹⁰	2020-02-20 to 2020-03-20	Tehran Tehran	Sublocal	High	178	Mean 58.9 (SD 16.5)	31.5	Non- probability	Multiple populations	18.0%	Pishtaz Diagnostics Iran ELISA Pishtaz Teb Diagnostics Iran IgG, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	20.7% (13.5- 28.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Kuwait													
Alali (University of Kuwait) ⁵¹¹	2020-05-23 to 2020-06-26		National	High	525	Median 43 (NR)	0.0	Probability	Essential non-healthcare workers	38.1% (34.0-42.3%)	Biozek Medical; Netherlands COVID-19 Rapid Test Cassette IgG, IgM	66.0%, 97.0% (Test developer / manufacturer evaluation)	58.9% (42.4-83.2%)
Libya													
Kammon (Al-Zintan University) ⁵¹²	2020-04-02 to 2020-05-18	Libya Alzintan City	Local	High	142	<=40 (n = 78); >40 (n = 64)	65.5	Probability	Multiple populations	4.2%	Guangzhou Wondfo Biotech One Step Novel COVID-19 IgM/IgG Antibody Test IgG, IgM	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Kammon (Al-Zintan University) ⁵¹²	2020-04-02 to 2020-05-18	Libya Alzintan City	Local	High	77	<=40 (n = 59); >40 (n = 18)	29.9	Probability	Health care workers and caregivers	0.0%	Guangzhou Wondfo Biotech One Step Novel COVID-19 IgM/IgG Antibody Test IgG, IgM	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Qatar													
Jeremijenko (Cornell University) ⁵¹⁴	2020-06-21 to 2020-09-09		National	High	4970	<29 (n=1579), 30-39 (n=1973), 40-49 (n=1040), 50+ (n=339)	5.0	Non-probability	Non-essential workers and unemployed persons	64.4% (63.0-65.7%)	Roche Diagnostics Roche Elecsys® Anti-SARS-CoV-2 NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
MohamedH.A l-Thani (Ministry of Public Health) ⁵¹⁵	2020-07-26 to 2020-09-09		National	Moderate	2641	Median 35 (Range 18-80)	NR	Probability	Non-essential workers and unemployed persons	55.3% (53.3-57.3%)	Switzerland; Roche Roche Elecsys Anti-SARS-CoV-2 NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	45.3% (42.0-49.7%)
Nasrallah (Cornell University - Qatar) ⁵¹⁶	2020-07-26 to 2020-09-09		National	High	394	NR	NR	Non-probability	Essential non-healthcare workers	40.6% (35.9-45.5%)	France; BioMérieux; Marcy-l'Etoile	88.6%, 99.9% (Test developer /	46.3% (37.0-56.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
											BioMérieux VidasIII IgG	manufacturer evaluation)	
Saudi Arabia													
Alharbi (King Fahad General Hospital) ⁵¹⁸	2020-04-18 to 2020-06-17	Hejaz Madinah	Local	High	330	NR	NR	Non-probability	Health care workers and caregivers	24.2%	Vircell Microbiologists IgM/IgA Kit #MA1032, IgG Kit #G1032 IgG, IgA, IgM	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	29.4% (23.2-36.2%)
Alserehi (Saudi Center for Disease Prevention and Control) ⁵¹⁹	2020-05-20 to 2020-05-30	Qassim, Emirate of the Eastern Province, Baha, Najran, Norther Border, Jazan, Madinah, Riyadh, Makkah, Hail, Aseer	National	Moderate	12621	NR	NR	Non-probability	Health care workers and caregivers	2.4%	Abbott Laboratories Abbott Architect SARS-CoV-2 IgG IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Turkey													
Alkurt (University of Health Sciences) ⁵²¹	2020-05-30 to 2020-06-06	Istanbul, Darica	Local	Moderate	813	Mean 34.8 (SD 9.54)	64.0	Non-probability	Health care workers and caregivers	2.7%	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
South Asia													
India													
Goenka (Apollo Gleneagles Hospitals) ⁵²⁸	2020-08-01 to 2020-08-31	West Bengal Kolkata	Sublocal	High	117	<30 (n=57); 31-40 (n=35); 41-50 (n=19); >50 (n=6)	47.0	Non-probability	Health care workers and caregivers	32.5%	Ortho Clinical Diagnostics Vitros ECi IgG assay IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Goenka (Apollo Gleneagles Hospitals) ⁵³²	2020-07-12 to 2020-08-23	West Bengal Kolkata	Sublocal	Moderate	1122	<30 (n=364); 30-50 (n=665); >50 (n=93)	34.6	Probability	Health care workers and caregivers	11.9%	Ortho Clinical Diagnostics Vitros anti-SARS-COV-2 IgG IgG	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Siddiqui (Max Super Specialty Hospital) ⁵³⁴	2020-04-15 to 2020-08-15	NCT Delhi New Delhi	Local	High	780	18-20 (n=19); 21-30 (n=239); 31-40 (n=204); 41-50 (n=139); 51-60 (n=74); >60 (n=33)	29.4	Non-probability	Multiple populations	19.5%	Roche Diagnostics Elecsys Anti-SARS-CoV-2 kit NR	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Kumar (Amrita Institute of Medical Sciences & Research Centre) ⁵⁴⁰	2020-07-11 to 2020-07-24	Kerala	Sublocal	High	635	Mean 34.8 (Range 19-70)	NR	Non-probability	Health care workers and caregivers	0.2%	Roche Diagnostics ElecsysR Anti-SARS-CoV-2 total antibodies assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Malani (Tata Institute for Fundamental Research) ⁵⁴¹	2020-06-29 to 2020-07-19	Mumbai	Local	Low	4202	12-24 (n=702), 25-39 (n=1480), 40-60 (n=1695), 61+ (n=325)	54.3	Probability	Persons living in slums	54.1% (52.7-55.5%)	Abbott Laboratories Abbott Diagnostics Architect IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	45.1% (42.7-47.3%)
Unclear (Ahmedabad Municipal Corporation) ⁵⁴⁶	2020-06-16 to 2020-07-11	Gujarat Ahmedabad	Local	Unclear	30054	NR	NR	Non-probability	Multiple populations	17.6%	NR NR NR	No data	-
Kumar (Postgraduate Institute of Medical Education and Research) ⁵⁴⁹	2020-06-01 to 2020-06-30	Maharashtra Mumbai	Local	High	801	20-40 (n=413); 40-60 (n=380); >=60 (n=8)	48.2	Non-probability	Health care workers and caregivers	11.1% (9.1-13.5%)	Roche Diagnostics Elecsys Anti-SARS-CoV-2 Assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Singhal (Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute) ⁵⁵⁰	2020-06-01 to 2020-06-30	Maharashtra Mumbai	Sublocal	High	208	NR	NR	Non-probability	Health care workers and caregivers	12.5%	1) Abbott 2) Roche Architect, Abbott, USA, and later in the study by Elecsys®, Roche, Switzerland. NR	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	11.1% (6.4-16.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Khan (Government Medical College) ⁵⁵¹	2020-06-15 to 2020-06-29	Kashmir	Local	Moderate	2905	Mean 38.6 (NR)	35.8	Non-probability	Health care workers and caregivers	2.5% (2.0-3.1%)	Abbott Laboratories NR IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Rao (Sri Jayadeva Institute of Cardiovascular Sciences and Research) ⁵⁵³	2020-05-23 to 2020-06-06	Karnataka Bengaluru	Sublocal	Unclear	1000	30-40 (n=1000)	45.0	Non-probability	Health care workers and caregivers	1.0%	New Life Healthcare NR IgG	No data	-
Pakistan													
Zaidi (National Institute of Blood Diseases and Bone Marrow Transplant) ⁵⁵⁷	2020-05-15 to 2020-07-15	Karachi	Local	High	1675	18-60	NR	Non-probability	Multiple populations	36.0%	Roche Diagnostics electrochemiluminescence immunoassay analyzer method on Cobas e-411 IgG, IgA, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Noor (Hayatabad Medical Complex) ⁵⁵⁹	2020-07-13 to 2020-07-15	Khyber Pakhtunkhwa Peshawar	Sublocal	Moderate	1011	Mean 33.25 (COVID-19 receiving hospital); 33.94 (Non-COVID-19 receiving hospital) (SD 8.71 (COVID-19 receiving hospital); 11.77 (Non-COVID-19 receiving hospital))	31.9	Probability	Health care workers and caregivers	30.8%	Roche Elecsys® Anti-SARS-CoV-2 immunoassay IgG, IgM	0.8%, 1.0% (FINDDx / MUHC independent evaluation)	-
Haq (Riphah International University) ⁵⁶⁰	2020-06-15 to 2020-06-29	Khyber Pakhtunkhwa Peshawar City	Local	Moderate	1011	Mean 33.6 (SD 10.5)	31.9	Non-probability	Health care workers and caregivers	30.7% (27.8-33.6%)	Roche Diagnostics Elecsys® Anti-SARS-CoV-2 antibody test NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Chughtai (Chughtai)	2020-05-20 to 2020-05-30	Lahore	Local	High	154	Mean 27.1 (SD 3.8)	0.0	Non-probability	Essential non-	15.6%	Abbott Abbott Architect	0.4%, 1.0% (FINDDx /	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Institute of Pathology) ⁵⁶¹									healthcare workers		SARS-CoV-2 IgG assay IgG	MUHC independent evaluation)	
Southeast Asia, East Asia, And Oceania													
China													
Li (Fudan University) ⁵⁶²	2020-05-15 to 2020-10-15	Shanghai Municipality Shanghai	Sublocal	High	6414	NR	NR	Non-probability	Patients seeking care for non-COVID-19 reasons	0.3%	Bioscience NR IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
He (Wuhan University) ⁵⁶⁴	2020-05-13 to 2020-06-10	Hubei Wuhan	Sublocal	High	1059	Median 32.69 (NR)	75.3	Non-probability	Health care workers and caregivers	9.3%	Livzon Diagnostics Diagnostic Kit for IgM/IgG Antibody to Coronavirus IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
He (Renmin Hospital of Wuhan University) ⁵⁶⁵	2020-05-15 to 2020-05-29	Hubei Wuhan	Sublocal	Unclear	4614	Median 36.86 (SD 10.644)	70.3	Non-probability	Health care workers and caregivers	3.3%	Livzon Diagnostics Inc. Diagnostic Kit for IgM/IgG Antibody IgG	0.5%, 0.6% (FINDDx / MUHC independent evaluation)	-
Tong (Nanjing University Medical School) ⁵⁶⁸	2020-05-12 to 2020-05-15	Hubei Wuhan	Local	High	191	Mean 32 (Range 24-58)	70.2	Non-probability	Health care workers and caregivers	0.0%	Shenzhen YHLO Biotech Co NR IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Liang (The First Affiliated Hospital of Guangzhou Medical University) ⁵⁶⁹	2020-01-20 to 2020-04-30	Guangdong Guangzhou	Local	High	8782	Median 54 (IQR 44-62)	51.6	Non-probability	Multiple populations	0.6%	Shenzhen YHLO Biotech Co SARS-CoV-2 IgM/IgG CLIA kits IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)
Liang (The First Affiliated Hospital of Guangzhou Medical University) ⁵⁶⁹	2020-01-19 to 2020-04-30	Hubei Wuhan	Local	High	8272	Median 55 (IQR 38-67)	50.0	Non-probability	Multiple populations	2.1%	Innovita 2019-nCoV Ab Test (Colloidal Gold) IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Liu (Zhongnan Hospital of Wuhan University) ⁵⁷¹	2020-02-29 to 2020-04-29	Hubei Wuhan	Local	Moderate	3832	Mean 37.1 (95% CI 36.7-37.4)	32.3	Non-probability	Health care workers and caregivers	4.0% (3.4-4.7%)	YHLO SARS-CoV-2 IgM/IgG CLIA kits IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Lei (Tongji Medical College) ⁵⁷²	2020-02-17 to 2020-04-28	Hubei Wuhan	Local	High	11766	NR	NR	Non-probability	Multiple populations	0.5%	YHLO YHLO Biotech SARS-CoV-2 IgM/IgG Test IgG, IgM	66.7%, 99.5% (Test developer / manufacturer evaluation)	0.3% (0.0-0.7%)
Want (Huazhong University of Science and Technology) ⁵⁷⁴	2020-01-23 to 2020-04-24	Hubei Xiangyang, Wuhan	Local	Unclear	299	Median 5.2 (Range 2 months - 16 years)	58.9	Non-probability	Patients seeking care for non-COVID-19 reasons	0.0%	NR NR IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.2% (0.0-1.0%)
Liu (Sun Yat-sen University) ⁵⁷⁵	2020-02-07 to 2020-04-21	Hubei Wuhan	Local	High	420	Mean 35.8 (NR)	68.1	Non-probability	Health care workers and caregivers	0.0%	YHLO SARS-CoV-2 IgM/IgG CLIA kits IgG	1.0%, 1.0% (FINDDx / MUHC independent evaluation)	-
Wu (Wuhan University) ⁵⁷⁷	2020-04-03 to 2020-04-15	Hubei Wuhan	Sublocal	High	1021	NR	NR	Non-probability	Essential non-healthcare workers	9.6%	Innovita Biological Technology Co. Ltd 2019-nCoV Ab Test IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	-
Xu (National Clinical Research Centre for Kidney Disease) ⁵⁷⁸	2020-03-09 to 2020-04-10	Hubei, Sichuan, Guangdong Chengdu, Wuhan, Guangzhou	National	High	10449	Median 50 (IQR 35-49)	52.3	Non-probability	Multiple populations	0.8%	Bioscience Magnetic Chemiluminescence Enzyme Immunoassay Kit IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)
Xu (National Clinical Research Centre for Kidney Disease) ⁵⁷⁸	2020-03-09 to 2020-04-10	Hubei, Sichuan, Guangdong Jinzhou, Chongqing, Foshan, Chengdu, Honghu, Wuhan, Guangzhou	National	High	6919	Median 41 (IQR 31-56)	63.1	Non-probability	Multiple populations	2.5%	Bioscience Magnetic Chemiluminescence Enzyme Immunoassay Kit IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.3% (0.0-0.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Zhang (Huazhong University of Science and Technology) ⁵⁸⁰	2020-01-23 to 2020-03-27	Hubei Wuhan	Sublocal	High	44	Median 6 (Range 1-15)	38.6	Non-probability	Patients seeking care for non-COVID-19 reasons	0.0%	NR NR IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	1.6% (0.0-6.6%)
Zhou (Zhongnan Hospital of Wuhan University) ⁵⁸¹	2020-03-16 to 2020-03-25	Hubei Wuhan	Sublocal	Moderate	3674	18-30 (n=1378); 31-50 (n=1656); >50 (n=640)	67.7	Non-probability	Health care workers and caregivers	1.7%	Shenzhen Yahuilong Biotechnology Co. COVID-19 IgM/IgG chemiluminescence test kit IgG	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Li (National Center for Medical Service Administration) ⁵⁸²	2020-02-10 to 2020-03-22	Hubei Wuhan	Sublocal	High	300	Mean 46.3 (SD 10.3)	NR	Non-probability	Contacts of COVID patients	47.7%	Innovita Biological Technology Co. Ltd NR IgG, IgM	0.6%, 1.0% (FINDDx / MUHC independent evaluation)	52.2% (46.7-57.6%)
Tang (Tongji Medical College) ⁵⁸³	2020-03-08 to 2020-03-21	Hubei Wuhan	Local	Moderate	1027	Mean 60.3 (SD 13.4)	39.7	Non-probability	Patients seeking care for non-COVID-19 reasons	4.6%	Ltd."; "Tangshan Yingnuote Biotechnology Enterprise Co. Tangshan Colloidal Gold Immunochromatography Assay IgG, IgM	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Tu (Wuhan Institute of Virology) ⁵⁸⁴	2020-03-19 to 2020-03-20	Hubei Wuhan	Sublocal	High	325	NR	NR	Probability	Health care workers and caregivers	24.3%	Zhu Hai Livzon Diagnostics Ins Zhu Hai Livzon ELISA IgG	0.7%, 1.0% (FINDDx / MUHC independent evaluation)	-
Zhang (Shenzhen Second People's Hospital) ⁵⁸⁵	2020-02-29 to 2020-03-18	Guangdong Shenzhen	Local	High	1589	Mean 36.4 (Range 11-89)	NR	Non-probability	Non-essential workers and unemployed persons	0.4%	Shenzhen Sciarray Biotech Ltd shenzhen ELISA IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Xiong (Huazhong University of Science and Technology) ⁵⁸⁶	2020-02-12 to 2020-03-17	Hubei Wuhan	Local	Unclear	797	Median 31 (Range 23-53)	88.5	Non-probability	Health care workers and caregivers	4.4%	NR NR IgG	75.6%, 97.6% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	2.5% (0.6-4.8%)
Zhao (Renmin Hospital of Wuhan University) ⁵⁸⁸	2020-01-14 to 2020-02-21	Hubei Wuhan	Sublocal	High	1060	NR	NR	Non-probability	Health care workers and caregivers	8.3%	Shenzhen YHLO Biotech Co NR IgG, IgM	97.8%, 97.8% (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	6.3% (4.6-8.2%)
Chen (Nanjing University Medical School) ⁵⁸⁹	2020-02-19 to 2020-02-19	Jiangsu Nanjing	Local	High	105	Median 30 (IQR 26-62)	79.0	Non-probability	Health care workers and caregivers	17.1%	Author-designed N/A - Author-designed IgG, IgM	93.3%, 100.0% (Test developer / manufacturer evaluation)	17.5% (10.1-26.2%)
Zhang (Shengjing Hospital of China Medical University) ⁵⁹⁰	2020-01-21 to 2020-02-16	Liaoning Shenyang	Regional	High	63	Median 40 (Range 25-61)	88.9	Non-probability	Health care workers and caregivers	0.0%	Shenzhen Yahuilong Biotechnology Co. Chemiluminescence Detection Kit IgG	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Thailand													
Nopsopon (Chulalongkorn University) ⁵⁹³	2020-04-08 to 2020-06-26		National	Moderate	857	Median 37 (IQR 27-45)	74.7	Non-probability	Multiple populations	5.5% (4.1-7.2%)	Baiya Phytopharm Baiya Rapid COVID-19 IgG/IgM Test Kit IgM	94.1%, 98.0% (Author-reported independent evaluation)	3.5% (0.4-6.1%)
Nopsopon (Chulalongkorn University) ⁵⁹⁴	2020-04-17 to 2020-05-17	Ranong	Sublocal	Moderate	844	Median 42 (IQR 32-50)	71.7	Non-probability	Health care workers and caregivers	0.8% (0.4-1.7%)	Baya Phytopharm; Thailand Baya Rapid IgG/IgM test kit IgG, IgM	94.1%, 98.0% (Test developer / manufacturer evaluation)	0.3% (0.0-0.9%)
Vietnam													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (95% Credible Interval)
Chau (Oxford University Clinical Research Unit) ⁵⁹⁵	2020-08-23 to 2020-08-30	Đông Nam Bộ Ho Chi Minh City	Sublocal	High	408	Median 32 (Range 20-60)	64.7	Non-probability	Health care workers and caregivers	0.0%	Roche Diagnostics Elecsys Anti-SARS-CoV-2 assay NR	0.9%, 1.0% (FINDDx / MUHC independent evaluation)	-
Sub-Saharan Africa													
Malawi													
Chibwana (Malawi-Liverpool-Wellcome Trust Clinical Research Programme) ⁶⁰⁰	2020-05-22 to 2020-06-19	Southern Region Malawi Blantyre	National	High	500	Median 31 (Range 20-64)	52.8	Non-probability	Health care workers and caregivers	16.8%	Omega diagnostics COVID-19 IgG ELISA IgG	88.1%, 93.2% (Test developer / manufacturer evaluation)	11.3% (1.9-19.1%)
Nigeria													
Asuquo (Joseph Ukpo Hospitals and Research Institutes) ⁶⁰²	2020-06-17 to 2020-06-24	Cross River State Calabar	Sublocal	High	66	NR	42.4	Non-probability	Multiple populations	26.0%	Healgen Scientific COVID-19 IgG / IgM Rapid Test Cassette IgG	1.0%, 1.0% (FINDDx / MUHC independent evaluation)	-
South Africa													
Shaw (Stellenbosch University) ⁶⁰³	2020-08-17 to 2020-09-04	Cape Town	Sublocal	High	405	Median 38 (Range 18-69)	53.6	Non-probability	Essential non-healthcare workers	23.7%	Abbott Laboratories Abbott SARS-CoV-2 IgG assay IgG	0.4%, 1.0% (FINDDx / MUHC independent evaluation)	-
Togo													
Halatoko (Universite de Lome) ⁶⁰⁵	2020-04-23 to 2020-05-08	Lome	Local	High	955	Median 36 (IQR 32-43)	28.4	Non-probability	Non-essential workers and unemployed persons	0.9% (0.4-1.8%)	"Hangzhou Clongene Biotech Co; Ltd." Lungene Rapid Test IgG, IgM	0.7%, 0.9% (FINDDx / MUHC independent evaluation)	-

S3 Table. Risk of bias results for each included study

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Central Europe, Eastern Europe, and Central Asia											
Armenia											
Grigoryan	2020-06-29	Yes	Unclear	No	No	Unclear	Yes	Yes	No	Unclear	High
Bulgaria											
Tsaneva-Damyanova	2020-04-20	Yes	No	No	No	Unclear	No	Yes	No	Unclear	High
Croatia											
Vince	2020-07-31	Yes	No	No	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Lapic	2020-05-31	No	Unclear	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Vilibic-Cavlek	2020-05-24	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Jerkovic	2020-04-28	Yes	No	Yes	Yes	No	Yes	Yes	No	Unclear	High
Czechia											
Bloomfield	2020-08-19	Yes	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Malickova	2020-04-15	Yes	Unclear	No	Yes	Yes	Unclear	Yes	No	Unclear	Unclear
Estonia											
Jogi	2020-07-31	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Jogi	2020-07-31	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Veerus	2020-06-10	No	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Georgia											
Tsertsvadze	2020-05-27	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Hungary											
Merkely	2020-05-16	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	No	Moderate
Poland											
Ciechanowicz	2020-10-31	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Kasztelewicz	2020-08-09	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Gujski	2020-07-08	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
Romania											
MedLife (MedLife)	2020-04-21	Yes	Unclear	No	No	Unclear	Unclear	No	No	Unclear	Unclear
Russian Federation											
Popova	2020-07-19	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Moderate
Popova	2020-07-11	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	Unclear	Unclear	Unclear
Popova	2020-06-26	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Yes	High
Barchuk	2020-06-26	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Low
Popova	2020-06-20	Yes	Yes	Yes	No	Unclear	Unclear	Yes	No	Yes	High
Popova	2020-06-20	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	No	No	High
Tickle	2020-06-18	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Krechetova	2020-06-15	No	Unclear	Yes	Unclear	Unclear	Unclear	Yes	No	Unclear	Unclear
Kiselyov	2020-06-10	Yes	Unclear	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
High-income											
Andorra											
Royo-Cebrecos	2020-05-28	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Argentina											
Munoz	2020-07-16	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Moderate
Silva	2020-07-06	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Moderate
Figar	2020-07-01	Yes	No	No	No	Unclear	No	Yes	No	Unclear	High
Insua	2020-06-09	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Australia											
Hicks	2020-06-15	No	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Unclear
Macartney	2020-04-10	Yes	No	Yes	No	Yes	Yes	Yes	No	Unclear	Moderate
Austria											
Ladage	2020-06-15	Yes	Yes	Yes	Yes	No	Unclear	Yes	No	No	High
Fuereder	2020-06-04	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Fuereder	2020-06-04	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Hackner	2020-04-30	No	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Knabl	2020-04-27	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Wagner	2020-04-17	No	Unclear	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Reiter	2020-03-29	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Yes	High
Orth-Holler	2020-03-27	Yes	No	No	Yes	No	No	Yes	No	Unclear	High
Belgium											
Duysburgh	2020-09-30	Yes	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	Unclear
Herzog	2020-07-04	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Blairon	2020-06-19	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	No	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Herzog	2020-06-13	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Herzog	2020-05-25	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Berardis	2020-05-19	Yes	No	No	Yes	Yes	No	Yes	No	Unclear	High
Martin	2020-05-18	Yes	No	No	Yes	Unclear	Unclear	Yes	No	No	High
Steensels	2020-04-30	No	No	Yes	No	Yes	Yes	Yes	Yes	Yes	High
Herzog	2020-04-26	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Buntinx	2020-04-16	Yes	No	No	No	No	No	Yes	No	Yes	High
Herzog	2020-04-05	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Canada											
Canadian Blood Services	2020-11-25	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Canadian Blood Services	2020-10-31	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Manny	2020-10-23	Yes	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Brousseau	2020-09-24	No	No	Yes	Yes	Yes	No	Yes	No	No	High
Bolotin	2020-08-21	No	No	Yes	No	Unclear	No	Yes	No	Unclear	High
Bolotin	2020-07-31	No	No	Yes	No	Unclear	No	Yes	No	Unclear	High
Bardai	2020-07-27	Yes	No	No	Yes	No	Unclear	Yes	No	Unclear	High
Hema-Quebec	2020-07-09	No	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Bolotin	2020-06-30	No	No	Yes	No	Unclear	No	Yes	No	Unclear	High
Majdoubi	2020-06-19	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Canadian Blood Services	2020-06-18	No	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Bolotin	2020-05-30	No	No	Yes	No	Unclear	No	Yes	No	Unclear	High
Skowronski	2020-05-27	No	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Vijh	2020-05-14	Yes	No	No	Yes	Yes	Yes	Yes	No	No	High
Bolotin	2020-04-30	No	No	Yes	No	Unclear	No	Yes	No	Unclear	High
Skowronski	2020-03-13	No	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Chile											
Torres	2020-05-19	No	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	High
Torres	2020-05-19	No	Yes	No	Yes	Yes	Unclear	Yes	No	Yes	High
Denmark											
Laursen	2020-08-10	No	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Egerup	2020-07-03	No	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Egerup	2020-07-03	No	No	Yes	No	Unclear	No	Yes	No	Yes	Moderate
Egerup	2020-07-03	No	No	Yes	Yes	Unclear	No	Yes	No	Yes	Moderate
Jespersen	2020-06-30	No	Unclear	No	No	Unclear	Yes	Yes	No	Unclear	High
Jespersen	2020-06-30	No	Unclear	No	No	Unclear	Yes	Yes	No	Unclear	High
Pedersen	2020-06-26	No	No	Yes	No	Unclear	Yes	Yes	Yes	Unclear	Moderate
Jespersen	2020-06-19	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Pedersen	2020-06-19	No	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	No	Moderate
Storgaard	2020-06-04	Yes	No	No	Yes	No	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Freiesleben	2020-05-21	No	No	No	Yes	No	Unclear	Yes	No	Yes	High
Erikstrup	2020-05-03	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Iversen	2020-04-22	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Iversen	2020-04-22	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Freiesleben	2020-04-17	No	No	Yes	Yes	No	Unclear	Yes	No	Yes	High
Faroe Islands											
Petersen	2020-05-01	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low
Finland											
Kantele	2020-05-15	Yes	No	Yes	Yes	Unclear	No	Yes	No	Yes	High
France											
Anna	2020-07-31	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Dimeglio	2020-07-10	No	No	Yes	Yes	Unclear	Unclear	Yes	No	No	High
Roederer	2020-07-02	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Pere	2020-06-26	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Tsatsarisa	2020-06-26	Yes	No	No	Yes	Yes	Yes	Yes	No	Unclear	High
Gallais	2020-06-26	No	No	No	Yes	Yes	Yes	Yes	No	Unclear	High
Carrat	2020-06-23	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
Mesnil	2020-06-22	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Yes	High
Delmas	2020-06-17	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Yes	High
Capai	2020-06-15	No	No	Yes	Yes	Unclear	No	Yes	No	Yes	Moderate
Mattern	2020-05-31	Yes	No	No	No	No	Unclear	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Bal	2020-05-28	No	Unclear	No	Unclear	Unclear	Unclear	Yes	No	Unclear	High
Vu	2020-05-17	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Moderate
Cohen	2020-05-12	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Fumery	2020-05-11	No	No	No	Yes	Unclear	Yes	Yes	No	Yes	High
Fontanet	2020-04-30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Solodky	2020-04-16	Yes	No	No	No	No	Unclear	Yes	No	Unclear	High
Solodky	2020-04-16	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Vu	2020-04-12	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Moderate
Gallian	2020-04-07	No	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Grzelak	2020-03-24	No	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Germain	2020-03-16	No	No	No	Yes	Yes	Yes	Yes	No	Unclear	High
Vu	2020-03-15	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Moderate
Germany											
Fuest	2020-11-18	Yes	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	Unclear
Robert Koch Institute	2020-11-05	No	Yes	Yes	No	Yes	Unclear	Yes	No	Unclear	Moderate
Armann	2020-10-13	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Thielecke	2020-10-02	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Moderate
Schwarz	2020-09-01	Yes	No	Yes	No	Unclear	Unclear	No	No	Unclear	High
Rauber	2020-08-06	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Hoffmann	2020-07-31	Yes	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Finkenzeller	2020-07-29	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Finkenzeller	2020-07-29	Unclear	Unclear	Yes	Yes	Unclear	Yes	Yes	No	No	High
Laub	2020-07-22	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Brehm	2020-07-17	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Mack	2020-06-30	No	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Epstude	2020-06-30	No	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Epstude	2020-06-30	No	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Aziz	2020-06-30	No	No	Yes	Yes	No	Yes	Yes	No	Yes	High
Aziz	2020-06-30	No	No	No	Yes	No	Yes	Yes	No	Unclear	High
Bahrs	2020-06-19	No	No	Yes	Yes	Unclear	Yes	Yes	No	No	High
Herzberg	2020-06-16	No	No	Yes	Yes	Unclear	Yes	No	No	Yes	High
Runkel	2020-06-15	No	Unclear	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Santos-Hovener	2020-06-09	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Malferteiner	2020-06-07	Yes	No	No	Unclear	Unclear	Unclear	Unclear	No	Unclear	High
Herrmann	2020-06-04	Unclear	Unclear	No	No	Unclear	Yes	Yes	No	Unclear	High
Fischer	2020-06-03	No	No	Yes	No	No	Yes	Yes	No	Unclear	High
Thieme	2020-05-31	Yes	No	No	Yes	Yes	Unclear	Yes	No	Yes	High
Erber	2020-05-29	No	No	Yes	Yes	Yes	Unclear	Yes	No	No	High
Weis	2020-05-22	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Choi	2020-05-19	Yes	Unclear	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Weis	2020-05-16	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Neumann	2020-05-16	Yes	Unclear	No	No	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Tonshoff	2020-05-15	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Moderate
Zollkau	2020-05-13	No	Unclear	No	Yes	Unclear	No	Yes	No	Unclear	High
Schmidt	2020-04-30	Yes	No	No	Yes	Unclear	Yes	Yes	No	Yes	High
Reisinger	2020-04-22	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Korth	2020-04-21	No	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Harsch	2020-04-21	Yes	No	No	No	Unclear	Yes	Yes	No	No	High
Behrens	2020-04-17	No	Unclear	No	No	Unclear	No	Yes	No	Unclear	High
Kern	2020-04-16	Yes	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Krachling	2020-04-14	No	No	Yes	Yes	No	Yes	Yes	No	Unclear	High
Lackermair	2020-04-06	No	No	No	Yes	No	Unclear	Yes	No	Unclear	High
Streeck	2020-04-06	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Yes	Low
Greece											
Tsitsilonis	2020-07-15	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Moderate
Psichogiou	2020-05-15	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Moderate
Vlachoyiannopoulou	2020-05-10	Yes	Unclear	No	Yes	Unclear	No	Yes	No	Unclear	High
Bogogiannidou	2020-04-30	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Iceland											
Gudbjartsson	2020-06-12	No	Yes	Yes	Unclear	Yes	Yes	Yes	No	Unclear	Moderate
Ireland											
Igoe	2020-07-16	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	No	Moderate
Israel											

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Rabinowitz	2020-08-15	Yes	Yes	Yes	No	Yes	Unclear	Unclear	No	Unclear	Moderate
Efrati	2020-06-02	Yes	Yes	Yes	No	Yes	Unclear	Unclear	No	Unclear	Moderate
Italy											
Caponigro	2020-10-19	Unclear	Unclear	No	No	Unclear	Yes	Yes	No	Unclear	Unclear
Russo	2020-08-30	No	No	No	Yes	No	Yes	Yes	No	Unclear	High
Ralli	2020-07-31	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Italian Ministry of Health	2020-07-15	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Norsa	2020-07-10	No	No	No	Yes	Yes	Unclear	Yes	No	Yes	High
Cento	2020-07-05	No	No	Yes	Yes	No	Yes	Yes	No	Yes	Moderate
Medas	2020-06-30	No	No	No	Yes	Unclear	Unclear	Yes	No	Yes	High
Berte	2020-06-15	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Berte	2020-06-15	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Capasso	2020-06-15	Yes	No	No	Yes	Yes	No	Yes	No	Yes	High
Capasso	2020-06-15	No	No	Yes	Yes	Yes	No	Yes	No	Yes	Moderate
Capasso	2020-06-15	Yes	No	No	Yes	Yes	No	Yes	No	Yes	Moderate
Pagani	2020-06-07	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	Moderate
Cosma	2020-06-04	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Amante	2020-06-03	Yes	Unclear	Yes	No	Yes	Unclear	Unclear	No	Unclear	Moderate
Lorenzo	2020-05-31	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Lastrucci	2020-05-31	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Papalini	2020-05-31	Unclear	Unclear	Yes	No	Unclear	No	Yes	No	Unclear	Unclear
Papalini	2020-05-31	No	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Fiore	2020-05-31	No	No	Yes	Yes	Unclear	No	Yes	No	Yes	High
Sperotto	2020-05-30	Yes	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Stellato	2020-05-29	No	No	No	No	No	Unclear	No	No	Unclear	High
Stellato	2020-05-29	No	No	Yes	No	No	Unclear	No	No	Unclear	High
Plebani	2020-05-29	Yes	Unclear	Yes	Yes	Yes	No	Yes	No	Unclear	High
Poletti	2020-05-25	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Alessi	2020-05-24	Yes	No	Yes	Yes	No	No	Yes	No	No	High
Calcagno	2020-05-20	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Carlo	2020-05-18	Yes	No	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Martella	2020-05-17	No	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Cavaliere	2020-05-16	Yes	No	No	No	Unclear	Unclear	Yes	No	Yes	High
Sandri	2020-05-16	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Bianchi	2020-05-15	No	Unclear	No	No	Unclear	Unclear	No	No	Unclear	Unclear
Bianchi	2020-05-15	No	Unclear	No	No	Unclear	Unclear	No	No	Unclear	Unclear
Stefanelli	2020-05-15	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Low
Marra	2020-05-11	No	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Guerriero	2020-05-08	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Yes	Moderate
Baracco	2020-05-05	No	No	Yes	Yes	Yes	Unclear	Yes	No	Yes	High
Baracco	2020-05-05	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Denina	2020-04-30	Yes	No	No	Yes	Unclear	Unclear	No	No	Unclear	High
Zambelli	2020-04-30	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Vena	2020-04-30	No	No	Yes	Yes	Yes	Yes	No	No	Unclear	High
Carozzi	2020-04-30	Yes	No	Yes	No	Unclear	No	No	No	Unclear	High
Bontadi	2020-04-29	No	No	Yes	Yes	Unclear	Unclear	No	No	No	High
Landro	2020-04-28	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Volta	2020-04-27	No	No	No	Yes	Yes	Unclear	Yes	No	Yes	High
Lahner	2020-04-27	No	Yes	Yes	No	Yes	No	Yes	No	Unclear	High
Landro	2020-04-24	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Loconsole	2020-04-21	Yes	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Cito	2020-04-19	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Paradiso	2020-04-17	No	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	High
Sotgiu	2020-04-16	Yes	No	No	Yes	Yes	No	Yes	No	Unclear	High
Amendola	2020-04-15	No	No	Yes	No	Unclear	Unclear	Yes	No	Yes	High
Canetti	2020-04-15	No	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Valenti	2020-04-08	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Percivalle	2020-04-06	No	Unclear	No	No	Yes	Yes	Yes	No	Unclear	High
Fusco	2020-04-02	No	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Milani	2020-03-31	Yes	No	No	No	No	Unclear	Yes	No	Yes	High
Pancrazzi	2020-03-21	Yes	No	No	No	No	No	Yes	No	Unclear	High
Apolone	2020-03-10	No	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Japan											
Oka	2020-10-30	No	No	No	No	No	Yes	Yes	No	Unclear	High
Matthews	2020-08-31	No	No	Yes	No	Unclear	Yes	Yes	No	No	High
Hibino	2020-08-25	Yes	No	No	Yes	Yes	Unclear	Yes	No	No	High
Fukuda	2020-08-21	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Hibino	2020-07-30	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Unclear
Nawa	2020-07-05	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Okuda	2020-06-28	No	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Nishida	2020-06-19	Yes	No	Yes	Yes	No	Yes	Yes	No	Yes	Moderate
Chong	2020-06-15	Yes	No	No	No	Yes	Unclear	Yes	No	No	High
Suda	2020-05-31	No	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Nakamura	2020-05-29	Yes	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Kobashi	2020-05-28	No	Unclear	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Takita	2020-05-20	No	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Denyer	2020-05-18	Yes	No	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Fujita	2020-04-20	No	No	No	Yes	Yes	Unclear	Unclear	No	Unclear	High
Doi	2020-04-07	No	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Suzuki	2020-04-03	No	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Suda	2020-03-31	No	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Liechtenstein											
Schaffner	2020-10-06	Unclear	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Unclear

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Luxembourg											
Snoeck	2020-05-05	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Monaco											
Binacchi	2020-06-16	Unclear	No	Yes	No	Unclear	Unclear	Unclear	No	No	Unclear
Netherlands											
Vos	2020-05-11	Yes	Yes	No	Yes	Unclear	No	Yes	Yes	Unclear	Low
Vos	2020-05-11	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	Unclear	Low
Slot	2020-04-15	No	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Moderate
Westerhuis	2020-04-07	No	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Westerhuis	2020-03-06	No	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
New Zealand											
Craigie	2020-08-04	Yes	No	Yes	Yes	Yes	No	No	No	Unclear	High
Norway											
Tunheim	2020-05-17	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Trieu	2020-04-09	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Kuwelker	2020-04-04	No	No	No	Yes	Unclear	Unclear	Yes	No	No	High
Cox	2020-04-04	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Portugal											
Figueiredo-Campos	2020-07-10	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Figueiredo-Campos	2020-07-10	Yes	No	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Kislaya	2020-07-08	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Gonclaves	2020-06-30	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Republic of Korea											
KBS World	2020-10-15	Unclear	Unclear	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
KBS World	2020-10-15	Unclear	Unclear	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Ji-Ho	2020-07-09	No	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Song	2020-06-05	No	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Noh	2020-05-29	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Ko	2020-05-09	Yes	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Ko	2020-05-09	Yes	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Singapore											
Kurohi	2020-04-15	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Kurohi	2020-04-15	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Ng	2020-04-03	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
Spain											
SavirÃ³n-Cornudella	2020-08-31	Yes	No	No	No	Unclear	No	Yes	No	Unclear	High
Garde-Noguera	2020-06-30	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Prados	2020-06-26	Yes	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	Unclear
Cabezon-Gutierrez	2020-06-19	No	No	No	Yes	No	Yes	Yes	No	Unclear	High
Camba	2020-06-15	Yes	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Brotos	2020-06-03	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Moderate
Flores	2020-06-03	Yes	Yes	Yes	No	Yes	Unclear	Unclear	No	Yes	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Perez-Garcia	2020-05-30	No	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Fabre	2020-05-29	No	Unclear	No	No	No	Unclear	Yes	No	Unclear	High
Barallat	2020-05-22	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Yes	High
Vinuela	2020-05-21	Yes	No	No	Yes	Yes	Unclear	Yes	No	Yes	High
Soriano	2020-05-16	No	Yes	Yes	Yes	No	Unclear	Yes	No	Yes	High
Pollan	2020-05-11	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low
Villalain	2020-05-10	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	Moderate
Gras-Valenti	2020-05-08	No	No	Yes	No	No	Unclear	Unclear	No	Yes	Unclear
Crovetto	2020-05-05	No	No	Yes	No	No	Unclear	No	No	Unclear	High
Valdivia	2020-04-30	No	Unclear	Yes	No	Unclear	No	Yes	No	Unclear	High
Galan	2020-04-27	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Yes	High
Olalla	2020-04-25	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Montenegro	2020-04-24	Yes	Yes	No	Yes	Yes	Unclear	Unclear	No	No	High
Borraz	2020-04-21	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Borraz	2020-04-21	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Dacosta-Urbieta	2020-04-16	Yes	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Martin	2020-04-15	Yes	No	Yes	Yes	Unclear	No	Yes	No	Yes	High
Fernandez	2020-04-14	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Yes	High
Sweden											
Dopico	2020-12-11	No	Yes	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Rashid-Abdi	2020-08-19	Yes	No	No	Yes	Yes	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Laursen	2020-08-10	No	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
The Local	2020-07-22	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Region	2020-07-15	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Lidstrom	2020-06-25	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Lundkvist	2020-06-18	Yes	Yes	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Lundkvist	2020-06-18	Yes	Yes	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Hassan	2020-06-17	No	No	No	Yes	No	Yes	Yes	No	Yes	High
Swedish Public Health Agency	2020-06-14	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Swedish Public Health Agency	2020-06-07	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Swedish Public Health Agency	2020-05-31	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Swedish Public Health Agency	2020-05-24	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Roxhed	2020-05-21	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
Swedish Public Health Agency	2020-05-17	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Swedish Public Health Agency	2020-05-10	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Rudberg	2020-05-08	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Swedish Public Health Agency	2020-05-03	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Swedish Public Health Agency	2020-04-26	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Lindahl	2020-04-20	Yes	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Switzerland											
Ulyte	2020-11-19	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Low
Anker	2020-10-14	Yes	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Moderate
Kahlert	2020-08-15	No	No	Yes	Yes	Yes	Unclear	Yes	No	No	Moderate
Universita della Svizzera Italiana	2020-07-31	Unclear	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Emmenegger	2020-07-15	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Emmenegger	2020-07-15	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Ulyte	2020-07-09	Yes	Yes	No	No	Unclear	Yes	Yes	Yes	Unclear	Moderate
Bi	2020-06-30	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Moderate
Richard	2020-06-30	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Low
Fenwick	2020-06-27	Yes	Unclear	No	No	Unclear	Yes	Yes	No	Unclear	High
Fenwick	2020-06-27	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Dupraz	2020-06-27	Yes	Yes	No	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Dupraz	2020-06-27	Yes	Yes	No	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Posfay-Barbe	2020-04-30	No	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Emmenegger	2020-04-30	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Emmenegger	2020-04-30	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Kohler	2020-04-03	Yes	No	Yes	Yes	Yes	Unclear	No	No	Unclear	High
Emmenegger	2020-03-31	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
The United Kingdom											
Office for National Statistics	2021-01-14	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Office for National Statistics	2021-01-14	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Office for National Statistics	2021-01-14	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Office for National Statistics	2021-01-14	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Office for National Statistics	2020-12-17	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Office for National Statistics	2020-12-17	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Office for National Statistics	2020-12-17	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Office for National Statistics	2020-12-17	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Taubel	2020-12-02	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Lumley	2020-11-30	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Office for National Statistics	2020-11-19	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Office for National Statistics	2020-11-19	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Office for National Statistics	2020-11-19	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Office for National Statistics	2020-11-19	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Office for National Statistics	2020-10-22	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Office for National Statistics	2020-10-22	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Office for National Statistics	2020-10-22	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Office for National Statistics	2020-10-22	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Ward	2020-09-28	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	No	Moderate
Office for National Statistics	2020-09-24	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Office for National Statistics	2020-09-24	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Public Health England	2020-09-18	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Abo-Leyah	2020-09-02	No	Yes	No	No	Yes	Unclear	Yes	No	Unclear	High
Abo-Leyah	2020-09-02	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Public Health England	2020-08-30	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Office for National Statistics	2020-08-27	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Harris	2020-08-20	Yes	No	Yes	Yes	Unclear	Unclear	No	No	Unclear	Moderate
Public Health England	2020-08-16	No	Yes	Yes	No	Yes	Yes	Yes	No	Unclear	Moderate
Public Health England	2020-08-16	No	Yes	Yes	No	Yes	Yes	Yes	Yes	Unclear	Low
Roarty	2020-08-15	Yes	No	Yes	No	Unclear	No	Yes	No	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Ward	2020-08-13	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	No	Moderate
Public Health Scotland	2020-08-09	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Public Health Scotland	2020-08-09	No	No	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Cooper	2020-08-07	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Public Health England	2020-08-05	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Moderate
Black	2020-08-03	No	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Office for National Statistics	2020-07-30	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Public Health England	2020-07-28	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Claudiani	2020-07-27	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Ward	2020-07-13	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Low
Martin	2020-07-13	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Hanrath	2020-07-06	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Yes	High
Predecki	2020-07-03	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Waterfield	2020-07-03	Yes	No	Yes	Yes	Yes	No	Yes	No	Unclear	High
Office for National Statistics	2020-07-02	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Rowland	2020-06-30	No	No	No	Yes	No	Yes	Yes	No	Unclear	High
Public Health England	2020-06-30	No	Yes	Yes	No	Unclear	Yes	Yes	Yes	Unclear	Moderate
Graham	2020-06-30	No	No	No	No	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Davis	2020-06-30	No	No	Yes	Yes	No	Yes	Yes	No	No	High
Public Health England	2020-06-28	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Gulraj	2020-06-17	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Lumley	2020-06-15	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Unclear	Yes	Moderate
Jones	2020-06-15	Yes	No	Yes	Yes	Unclear	Unclear	No	No	No	High
Favara	2020-06-15	Yes	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Pallett	2020-06-12	Yes	No	No	Yes	No	No	Yes	No	No	High
Baxendale	2020-06-10	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Arif	2020-06-08	No	No	No	Yes	Yes	Unclear	Unclear	No	Unclear	High
Razvi	2020-06-08	Yes	No	Yes	Yes	No	Unclear	Yes	No	No	High
Favara	2020-06-07	Yes	Yes	No	No	Unclear	No	Yes	No	Yes	High
Bampoe	2020-06-05	Yes	Unclear	No	Yes	No	Yes	Yes	No	Unclear	High
Grant	2020-06-05	Yes	No	Yes	No	Yes	Yes	Yes	No	No	High
McCafferty	2020-06-04	Yes	No	Yes	No	No	Yes	Yes	No	Unclear	High
Office for National Statistics	2020-06-04	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Wells	2020-06-02	No	Unclear	No	Yes	Unclear	Yes	Yes	No	No	High
Ladhani	2020-05-31	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Public Health England	2020-05-31	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Public Health England	2020-05-31	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Khalil	2020-05-28	No	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Hughes	2020-05-24	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Thompson	2020-05-18	No	Yes	Yes	Yes	No	Yes	Yes	No	Unclear	Moderate
Poulikakos	2020-05-06	Yes	No	No	No	No	Unclear	Yes	No	Unclear	High
Public Health England	2020-04-30	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Public Health England	2020-04-30	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Public Health England	2020-04-26	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Shields	2020-04-25	Yes	No	No	Yes	Yes	Yes	Yes	No	Unclear	High
Public Health England	2020-04-24	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Sikora	2020-04-24	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Public Health England	2020-04-20	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Public Health England	2020-04-16	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Public Health England	2020-04-13	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Ladhani	2020-04-13	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Yes	High
Houlihan	2020-04-08	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Public Health England	2020-04-03	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Public Health England	2020-03-31	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Public Health England	2020-03-31	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Public Health England	2020-03-27	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
United States of America											
Maleck	2020-12-14	Yes	Yes	Yes	No	Unclear	Unclear	Yes	No	No	Moderate
Craver	2020-12-09	Yes	Yes	Yes	No	No	Unclear	Unclear	Unclear	Unclear	Unclear
Stout	2020-12-06	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Jolley	2020-11-30	Yes	No	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Coffman	2020-11-16	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	No	Unclear
Coffman	2020-11-16	Yes	No	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Godbout	2020-10-02	No	No	Yes	Yes	Yes	Unclear	Yes	No	Yes	High
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-24	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-23	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-23	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-23	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-23	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-22	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-22	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-22	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-22	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-22	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-22	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-22	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-22	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Fountain Hills Times	2020-09-21	Yes	Yes	No	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Bajema	2020-09-19	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Bajema	2020-09-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-10	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Jimenez-Kurlander	2020-09-10	Yes	No	No	Yes	Unclear	Unclear	Unclear	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Bajema	2020-09-05	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-04	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-04	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-03	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-03	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-03	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-03	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-03	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-02	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-09-01	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Maleck	2020-08-31	Yes	Unclear	No	No	Unclear	Yes	Yes	Yes	No	Moderate
Halbrook	2020-08-31	Yes	Unclear	Yes	Yes	Yes	Unclear	Yes	No	Unclear	Moderate
Halbrook	2020-08-31	Yes	Unclear	Yes	Yes	Yes	Unclear	Yes	No	Unclear	Moderate
Bajema	2020-08-29	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-27	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-26	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Bajema	2020-08-17	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bruckner	2020-08-16	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Low
Brant-Zawadzki	2020-08-15	Yes	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Brant-Zawadzki	2020-08-15	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	High
Sabourin	2020-08-15	Yes	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Heim	2020-08-15	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Bajema	2020-08-14	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-13	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-13	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Bajema	2020-08-12	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-11	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Bajema	2020-08-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-10	No	No	No	No	Unclear	Yes	No	Yes	Unclear	High
Bajema	2020-08-10	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-08	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-07	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-07	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-05	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-05	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-04	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-03	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-03	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Bajema	2020-08-02	No	No	Yes	No	Unclear	Yes	No	Yes	Unclear	Moderate
Coffman	2020-07-31	Unclear	Unclear	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Feehan	2020-07-31	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Vassallo	2020-07-31	No	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Moderate
Azzi	2020-07-29	Yes	No	Yes	No	No	Yes	Yes	No	Unclear	Moderate
Nicholson	2020-07-28	Yes	No	Yes	No	Unclear	Yes	No	No	Unclear	High
Spencer	2020-07-27	No	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Yamaki	2020-07-27	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Haizler-Cohen	2020-07-24	Yes	Unclear	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Klawiter	2020-07-23	No	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Klawiter	2020-07-23	Yes	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Mahajan	2020-07-22	Yes	Yes	No	Yes	No	Yes	Yes	No	No	High
Mahajan	2020-07-22	Yes	Yes	No	Yes	No	Yes	Yes	No	No	High
McMillan	2020-07-20	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Lopez	2020-07-20	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Zauzmer	2020-07-15	Yes	No	Yes	No	Unclear	Unclear	No	No	Unclear	High
Jin	2020-07-15	No	No	Yes	Yes	No	Unclear	Yes	No	Unclear	High
Reuben	2020-07-15	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Yes	High
Kaufman	2020-07-10	Yes	No	Yes	No	Unclear	Unclear	No	No	Unclear	High
Shah	2020-07-09	Yes	Unclear	No	Yes	No	Unclear	No	No	Unclear	High
Shah	2020-07-09	Yes	Unclear	No	Yes	No	Unclear	No	No	Unclear	High
Mohr	2020-07-08	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Dimcheff	2020-07-08	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Kamath	2020-07-07	No	No	Yes	Yes	No	Yes	Yes	No	Unclear	High
Childs	2020-07-06	Yes	No	Yes	No	No	No	Yes	No	Unclear	High
Stadlbauer	2020-07-05	No	Yes	Yes	Yes	No	Yes	Yes	No	Unclear	High
Stadlbauer	2020-07-05	No	No	Yes	Yes	No	Yes	Yes	No	Unclear	High
Freeman	2020-07-04	Yes	No	Yes	Yes	No	Unclear	Yes	No	Unclear	High
Walker	2020-07-01	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Barrett	2020-06-30	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Wilkins	2020-06-30	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Moderate
Nailescu	2020-06-30	Yes	No	No	Yes	Yes	Yes	Yes	No	Unclear	High
Viglienzoni	2020-06-30	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Samore	2020-06-30	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Moderate
Rivas	2020-06-28	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Patel	2020-06-27	Yes	No	No	Yes	Unclear	Yes	Yes	No	No	High
Baker	2020-06-26	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Moderate
McBride	2020-06-25	Yes	No	Yes	Unclear	Unclear	Unclear	Yes	No	Unclear	High
Mahajan	2020-06-23	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Moderate
Moscola	2020-06-23	Yes	No	Yes	Yes	Yes	No	No	No	Unclear	High
Barzin	2020-06-19	No	No	Yes	Yes	No	Yes	Yes	Yes	Unclear	Moderate
Spectrum News Staff	2020-06-19	Yes	No	Yes	No	Yes	Unclear	Unclear	No	No	High
Self	2020-06-19	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Dodd	2020-06-15	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Reifer	2020-06-15	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Sutton	2020-06-15	No	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Rebeiro	2020-06-15	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Anand	2020-06-15	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Akinbami	2020-06-13	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Dora	2020-06-12	Yes	No	No	No	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Hynes	2020-06-10	Yes	Yes	No	No	Unclear	Unclear	Yes	No	No	High
Harden	2020-06-10	No	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Yogo	2020-06-08	No	No	Yes	Yes	Yes	Yes	Yes	No	No	High
Hogan	2020-06-08	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Yes	High
Rudavsky	2020-06-08	Yes	Yes	Yes	No	Yes	Unclear	Unclear	No	Unclear	Moderate
Barzin	2020-06-04	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Flannery	2020-06-03	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Coffman	2020-05-31	Unclear	Unclear	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Addetia	2020-05-31	No	No	No	No	No	Unclear	Yes	No	Yes	High
Gray	2020-05-31	Yes	Unclear	No	No	Unclear	Unclear	Yes	No	Unclear	High
Brunner	2020-05-29	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	High
Brunner	2020-05-29	Unclear	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Ohnesorge	2020-05-29	Yes	No	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Sims	2020-05-28	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
Hayden	2020-05-28	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	Unclear
Liu	2020-05-26	No	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Osher	2020-05-26	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Mukherjee	2020-05-26	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Stavert	2020-05-24	No	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Ahmad	2020-05-22	No	Unclear	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Jackson	2020-05-22	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Jackson	2020-05-22	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Jackson	2020-05-22	Yes	Yes	No	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Jackson	2020-05-22	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Staletovich	2020-05-22	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Leidner	2020-05-22	Yes	No	Yes	Yes	Yes	No	Yes	No	Unclear	High
Pritchett	2020-05-21	No	Unclear	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Shukla	2020-05-21	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Rosser	2020-05-20	Yes	No	Yes	Yes	Yes	No	Yes	No	Unclear	High
Alfini	2020-05-20	Yes	No	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Alfini	2020-05-20	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Montgomery	2020-05-20	No	No	Yes	No	Unclear	Unclear	No	No	Unclear	High
Geraci	2020-05-20	No	Unclear	No	No	Unclear	Unclear	Yes	No	Unclear	High
Tarabichi	2020-05-19	Yes	No	No	Yes	Yes	Unclear	Yes	No	Yes	High
Mughal	2020-05-19	No	No	No	Yes	Unclear	Yes	Yes	No	Yes	High
McLaughlin	2020-05-19	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Morris	2020-05-18	Yes	Unclear	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Feehan	2020-05-15	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Moderate
Meyer	2020-05-15	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Dietrich	2020-05-15	No	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
City of Boston	2020-05-15	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Unclear	No	Moderate
Parker-Magyar	2020-05-14	Yes	No	No	No	Unclear	Unclear	Unclear	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Iwuji	2020-05-13	Yes	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
CBS Los Angeles	2020-05-12	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Nesbitt	2020-05-11	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Tilley	2020-05-08	Yes	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Hunter	2020-05-08	Yes	No	Yes	Yes	No	Yes	Yes	No	Unclear	High
Ripperger	2020-05-07	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Racine-Brzostek	2020-05-07	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	Moderate
Regan	2020-05-06	Yes	Unclear	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Regan	2020-05-06	No	Unclear	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Sydney	2020-05-04	Yes	No	Yes	Yes	Unclear	Unclear	Unclear	No	No	High
Bajema	2020-05-03	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Low
Biggs	2020-05-03	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Menachemi	2020-05-03	Yes	No	No	Yes	Yes	Yes	Yes	No	Unclear	High
Reagan	2020-05-02	No	Unclear	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Venugopal	2020-05-01	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Moderate
Bajema	2020-05-01	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Jeremias	2020-04-30	No	No	Yes	Yes	Yes	Unclear	No	No	No	High
Cohen	2020-04-30	Yes	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Jeong	2020-04-30	No	No	No	Yes	Unclear	Unclear	Yes	No	Yes	High
Menachemi	2020-04-29	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Moderate
Chamie	2020-04-28	Yes	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Rosenberg	2020-04-28	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Zou	2020-04-27	No	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Bryan	2020-04-26	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Lewis	2020-04-25	Yes	No	No	Yes	Yes	Unclear	Yes	No	Yes	High
Appa	2020-04-24	Yes	No	Yes	Yes	No	Yes	Yes	No	Yes	Moderate
Payne	2020-04-24	No	No	No	No	Unclear	Unclear	Yes	No	No	High
Sassoon	2020-04-24	Yes	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Dingens	2020-04-24	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Kiefer	2020-04-23	No	No	No	Yes	No	Unclear	Yes	No	No	High
Morrison	2020-04-22	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Morcuende	2020-04-21	No	No	No	Yes	No	Yes	Yes	No	No	High
McCormack	2020-04-21	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Paterson	2020-04-21	No	Unclear	No	No	Unclear	Unclear	Yes	Unclear	Unclear	Unclear
Stock	2020-04-20	No	No	No	Yes	No	Unclear	Yes	No	Unclear	High
Madsen	2020-04-19	No	No	No	No	Unclear	Yes	Yes	No	Yes	High
Caban-Martinez	2020-04-17	No	No	No	Yes	Yes	No	Yes	No	Unclear	High
Naranbhai	2020-04-15	Yes	No	No	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Sood	2020-04-14	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Moderate
Ng	2020-04-13	No	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	High
Goldberg	2020-04-06	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Bendavid	2020-04-04	No	No	Yes	Yes	No	No	Yes	Yes	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Mansour	2020-04-04	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Ng	2020-03-31	No	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Schuchat	2020-03-31	No	No	No	No	Unclear	Unclear	Unclear	No	Unclear	High
McPherson	2020-03-06	Yes	No	No	Yes	Yes	Yes	Yes	No	No	High
Chu	2020-02-03	Yes	No	No	No	Unclear	Yes	Yes	No	Yes	High
Basavaraju	2020-01-17	No	No	Yes	Yes	No	Yes	Yes	No	Unclear	Moderate
Latin America and Caribbean											
Brazil											
Buss	2020-10-24	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Buss	2020-10-17	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Buss	2020-09-29	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Buss	2020-09-14	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Buss	2020-08-29	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Buss	2020-08-19	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Santana	2020-08-15	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
daSilva	2020-08-08	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Oliveira	2020-08-04	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Buss	2020-07-31	No	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	Unclear
Silva	2020-07-31	No	No	No	Yes	Unclear	Unclear	Unclear	No	Unclear	High
Paula	2020-07-31	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Yes	High
Buss	2020-07-25	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Buss	2020-07-15	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Melo	2020-06-30	Yes	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Horta	2020-06-24	Yes	Yes	Yes	Yes	No	No	Yes	No	Yes	Moderate
Buss	2020-06-20	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Picon	2020-06-17	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Moderate
Buss	2020-06-15	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Picon	2020-06-04	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Moderate
Vieira	2020-05-31	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Sales	2020-05-31	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	Moderate
Jr	2020-05-30	Unclear	Unclear	No	Yes	Yes	Unclear	Unclear	Unclear	Unclear	Unclear
Costa	2020-05-28	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Yes	Moderate
Vieira	2020-05-24	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Buss	2020-05-21	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Vieira	2020-05-17	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Chioro	2020-05-15	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Gomes	2020-05-15	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Gomes	2020-05-15	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Buss	2020-05-14	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Tess	2020-05-12	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Moderate
Watanabe	2020-05-12	Yes	Yes	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Silveira	2020-05-11	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Vieira	2020-05-10	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Borges	2020-05-09	No	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	High
Vieira	2020-05-03	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Buss	2020-04-30	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Silva	2020-04-29	Yes	Unclear	No	No	Unclear	Unclear	Yes	No	Unclear	High
Silveira	2020-04-27	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Filho	2020-04-27	No	No	Yes	Yes	Unclear	No	Yes	Yes	Yes	Moderate
Vieira	2020-04-26	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Vieira	2020-04-19	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Buss	2020-04-17	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Gurgel	2020-04-15	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Silveira	2020-04-13	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Buss	2020-03-21	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Buss	2020-03-12	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Buss	2020-02-29	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Buss	2020-02-13	No	No	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Columbia											
Mattar	2020-09-01	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Ariza	2020-08-10	Yes	No	No	Yes	Unclear	Yes	Yes	No	No	High
Idrovo	2020-07-14	No	No	Yes	No	No	Unclear	Unclear	No	No	High
Cuba											

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Giraldoni	2020-04-06	No	No	No	Yes	Unclear	Unclear	Unclear	No	Unclear	Unclear
Dominican Republic											
Paulino-Ramirez	2020-06-15	No	Yes	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Ecuador											
Brutto	2020-06-30	No	Yes	No	Yes	Yes	Yes	Yes	No	Yes	High
Brutto	2020-05-25	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
French Guiana											
Flamand	2020-07-23	No	No	No	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Honduras											
Nunez	2020-06-23	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Mexico											
Cruz-Arenas	2020-09-09	Yes	Yes	No	Yes	Yes	Unclear	Yes	No	Unclear	Moderate
Martinez-Acuna	2020-08-30	No	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Remes-Troche	2020-07-31	No	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Diaz-Salazar	2020-07-23	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Panama											
Villarreal	2020-07-07	No	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Villarreal	2020-07-07	No	No	No	Yes	No	No	Yes	No	Unclear	High
Paraguay											
Ultimahora	2020-12-15	Yes	Unclear	Yes	No	No	Unclear	Unclear	Unclear	Yes	Unclear
Peru											

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Alvarex-Antonio	2020-08-15	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low
Peruvian Government	2020-07-09	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	High
Angulo-Bazan	2020-05-02	Yes	No	No	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
North Africa and Middle East											
Egypt											
Kassem	2020-06-14	No	No	No	Yes	Unclear	Yes	Yes	No	No	High
Mostafa	2020-05-14	Yes	No	Yes	Yes	Yes	No	Yes	No	Unclear	High
Iran											
Poustchi	2020-06-02	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Poustchi	2020-06-02	Yes	Yes	Yes	No	Unclear	No	Yes	Yes	Yes	Moderate
Saberian	2020-05-20	Yes	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Armin	2020-05-05	Yes	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Vazirinejad	2020-04-30	Yes	No	No	No	Unclear	Unclear	Yes	No	No	High
Shakiba	2020-04-19	Yes	Yes	No	Yes	Unclear	No	Yes	Yes	No	Moderate
Ossareh	2020-03-20	No	Unclear	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Kuwait											
Alali	2020-06-26	No	Yes	No	Yes	Unclear	No	Yes	No	Unclear	High
Libya											
Kammon	2020-05-18	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	High
Kammon	2020-05-18	No	Unclear	No	Yes	Yes	No	Yes	No	Yes	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Elfakhri	2020-05-07	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Qatar											
Jeremijenko	2020-09-09	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
MohamedH.AI-Thani	2020-09-09	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Nasrallah	2020-09-09	No	Unclear	No	No	Unclear	No	Yes	No	Unclear	High
Saudi Arabia											
Mahallawi	2020-07-15	No	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Alharbi	2020-06-17	Yes	No	No	No	Unclear	No	Yes	No	Unclear	High
Alserehi	2020-05-30	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	Moderate
Turkey											
Sozcu	2020-06-25	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Alkurt	2020-06-06	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
South Asia											
India											
Khan	2020-11-04	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Low
Kumar	2020-10-24	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Sharma	2020-10-21	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Low
Ramanath	2020-10-18	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Banerjee	2020-10-17	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Moderate
Babu	2020-09-16	Yes	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Sharma	2020-09-07	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Low

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Goenka	2020-08-31	No	No	No	Yes	Unclear	Unclear	Yes	No	Yes	High
Kshatri	2020-08-31	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	High
Singh	2020-08-30	Unclear	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Mohanan	2020-08-29	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Moderate
Goenka	2020-08-23	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
Dixit	2020-08-19	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Siddiqui	2020-08-15	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Ray	2020-08-08	No	No	No	Yes	Yes	No	Yes	No	Unclear	High
Satpati	2020-08-08	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Bedi	2020-08-07	Yes	Unclear	Yes	No	Yes	Unclear	Unclear	Unclear	Unclear	Unclear
Sharma	2020-08-07	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Low
Dey	2020-08-07	Unclear	Unclear	Yes	No	Unclear	Yes	Yes	Yes	Unclear	Unclear
Ghose	2020-08-05	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Moderate
Kumar	2020-07-24	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Malani	2020-07-19	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Low
Malani	2020-07-19	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Low
Husain	2020-07-19	No	Yes	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
India.com News Desk	2020-07-19	Yes	Yes	Yes	No	No	Unclear	Unclear	No	Unclear	High
Khan	2020-07-15	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Mishra	2020-07-15	No	Yes	Yes	No	Unclear	Unclear	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Unclear	2020-07-11	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Saxena	2020-07-10	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Dey	2020-07-10	Unclear	Unclear	Yes	No	Unclear	Yes	Yes	Yes	Unclear	Unclear
Prakash	2020-07-07	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Kumar	2020-06-30	No	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Singhal	2020-06-30	No	No	No	No	No	Yes	No	No	No	High
Khan	2020-06-29	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
Kumar	2020-06-12	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Rao	2020-06-06	Yes	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	Unclear
Murhekar	2020-06-04	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low
Kher	2020-05-25	Yes	Yes	Yes	No	Yes	Unclear	Yes	No	Unclear	Moderate
Pakistan											
Nisar	2020-08-22	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Moderate
Nisar	2020-08-22	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Moderate
Zaidi	2020-07-15	No	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Younas	2020-07-15	No	No	No	Yes	No	Unclear	No	No	Unclear	High
Noor	2020-07-15	Yes	Yes	Yes	Yes	Unclear	No	Yes	No	Yes	Moderate
Nisar	2020-07-11	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Moderate
Nisar	2020-07-11	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Moderate
Haq	2020-06-29	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Chughtai	2020-05-30	Yes	No	No	Yes	No	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Nisar	2020-04-25	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Moderate
Nisar	2020-04-25	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Moderate
Southeast Asia, East Asia, an Oceania											
China											
Li	2020-10-15	Yes	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Wang	2020-08-31	No	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	Moderate
He	2020-06-10	No	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
He	2020-05-29	Yes	Unclear	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Unclear
He	2020-05-29	Yes	Unclear	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Unclear
Liu	2020-05-26	Yes	Unclear	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Pan	2020-05-26	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Tong	2020-05-15	Yes	Unclear	No	No	No	Unclear	Yes	No	Unclear	High
Liang	2020-04-30	Yes	No	Yes	Yes	Unclear	No	Yes	No	Yes	High
Liang	2020-04-30	Yes	Unclear	Yes	Yes	Unclear	No	Yes	No	Yes	High
Chang	2020-04-30	No	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Liu	2020-04-29	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Liu	2020-04-29	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Liu	2020-04-29	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Lei	2020-04-28	No	No	Yes	No	Unclear	No	Yes	No	Unclear	High
Ling	2020-04-28	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Want	2020-04-24	Yes	Unclear	No	Yes	Yes	Unclear	Unclear	Unclear	Unclear	Unclear

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Liu	2020-04-21	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Wang	2020-04-18	Yes	Yes	Yes	Yes	Yes	No	Unclear	No	Unclear	Moderate
Wu	2020-04-15	Yes	Unclear	No	No	Unclear	Unclear	Yes	No	Unclear	High
Wu	2020-04-15	No	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Xu	2020-04-10	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Xu	2020-04-10	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Xu	2020-04-02	No	Yes	Yes	Yes	No	Unclear	Yes	No	Unclear	High
Zhang	2020-03-27	No	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Zhou	2020-03-25	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Li	2020-03-22	Unclear	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Tang	2020-03-21	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Moderate
Tu	2020-03-20	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Zhang	2020-03-18	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Xiong	2020-03-17	Unclear	Unclear	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Unclear
To	2020-03-17	Yes	Yes	Yes	No	Yes	No	Yes	No	Unclear	Moderate
Chang	2020-03-15	No	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Chang	2020-03-15	No	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Zhao	2020-02-21	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Yes	High
Chen	2020-02-19	No	Yes	No	Yes	Yes	Yes	Yes	No	Yes	High
Zhang	2020-02-16	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Zhang	2020-02-16	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Zhang	2020-02-16	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
To	2020-02-13	No	No	No	No	Unclear	No	Yes	No	Unclear	High
To	2020-01-31	No	No	Yes	No	Unclear	No	Yes	No	Unclear	High
Hallowell	2020-01-28	No	Yes	No	Yes	Yes	Unclear	Yes	No	Yes	High
Malaysia											
Sam	2020-06-06	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Thailand											
Nopsopon	2020-06-26	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Nopsopon	2020-05-17	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Vietnam											
Chau	2020-08-30	Yes	No	No	Yes	Unclear	Yes	Yes	No	No	High
Sub-Saharan Africa											
Congo											
Batchi-Bouyou	2020-07-31	Unclear	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Ethiopia											
Kempen	2020-05-21	No	No	No	Yes	Yes	Yes	Yes	No	Unclear	High
Alemu	2020-04-28	Yes	Yes	No	Yes	Unclear	No	Yes	No	Unclear	Moderate
Kenya											
Adetifa	2020-09-30	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Low
Malawi											
Chibwana	2020-06-19	Yes	No	No	Yes	Yes	No	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Nigeria											
Majiya	2020-06-30	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Asuquo	2020-06-24	Unclear	Yes	No	No	No	Unclear	Yes	No	Unclear	High
South Africa											
Shaw	2020-09-04	No	No	No	Yes	Unclear	Yes	Yes	No	No	High
Hsiao	2020-08-07	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Togo											
Halatoko	2020-05-08	Yes	Yes	Yes	Yes	Unclear	No	Yes	No	Unclear	High

S4 Table. Summary of unadjusted meta-analysis results

Factor	Reference Group	Comparison Group	Number of Studies	Risk Ratio (95% CI) ^a	Heterogeneity (I ²)
Age	Adults (18-64)	Youth (0-17)	82	0.91 (0.83-1.00)	86.5%
	Adults (18-64)	Seniors (65+)	127	0.84 (0.77-0.92)	92.7%
Sex/Gender	Female	Male	129	1.02 (0.98-1.06)	87.1%
Race	Caucasian	Black	19	2.46 (2.14-2.83)	87.7%
	Caucasian	Asian	17	1.77 (1.44-2.17)	90.8%
	Caucasian	Indigenous	8	2.00 (1.14-3.50)	81.1%
	Caucasian	Multiple/other	18	1.55 (1.37-1.76)	63.5%
Close contact with COVID-19 patients	Individuals with no close contact	Individuals with close contact	35	1.97 (1.32-2.92)	98.4%
	Health care workers with no close contact	Health care workers with close contact	44	1.57 (1.33-1.85)	94.8%
Health care worker status	Non-health care workers and caregivers	Health care workers and caregivers	19	1.24 (0.99-1.54)	95.2%

^aUsing adjusted seroprevalence estimates. Abbreviations: CI= confidence interval.

S5 Table. Summary of serological tests used in included seroprevalence studies

Manufacturer	Test Name	Isotype	No. of studies
Abbott Laboratories	Abbott Architect SARS-CoV-2 IgG	IgG	124
	Abbott Alinity SARS-COV-2 IgG	IgG	1
ACRO Biotech Inc.	Acro Biotech COVID-19 Rapid POC test	IgM	2
		IgG	1
	Not available	IgG; IgM	2
Artron Laboratories Inc.	One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test	IgG; IgM	4
		IgG	1
		IgM	1
Aurora Biomed Inc	COVID-19 IgG/IgM Rapid Test	IgG; IgM	1
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd	Wantai SARS-CoV-2 Ab ELISA	Total Ig	9
	Wantai SARS-CoV-2 IgM ELISA	IgM	2
	Wantai SARS-CoV-2 Ab ELISA	IgG	1
BioMedomics, Inc.	COVID-19 IgM-IgG Dual Antibody Rapid Test	IgG	4
		IgM	4
		IgG; IgM	3
Cellex Inc.	COVID-19 IgG/IgM Rapid Test Cassette	IgG; IgM	1
CTK Biotech, Inc.	OnSite COVID-19 IgG/IgM Rapid Test	IgG; IgM	1
DiaSorin SpA	Liaison SARS-CoV-2 S1/S2 IgG	IgG	19
DRG International, Inc.	Novel Coronavirus COVID-19 IgG	IgG	1
Euroimmun AG	Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)	IgG	35
	EI SARS-Cov-2 IgG assay	IgG	34
	Anti-SARS-CoV-2 ELISA (IgA) (manual, automated)	IgA	6
	Anti-SARS-CoV-2 ELISA (IgA) (manual, automated); Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)	IgA; IgG	7
	Euroimmun EIA	IgA	4
	Euroimmun	IgG	1
Epitope Diagnostics, Inc.	EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit	IgG	7
	EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit	IgM	3
	EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit; EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit	IgG; IgM	2
ET Healthcare	Pylon COVID-19 IgG/IgM assay	IgG	1
		IgG; IgM	1
		IgM	1
Guangzhou Wondfo Biotech Co., Ltd	Wondfo SARS-CoV-2 Antibody Test (lateral flow method)	IgG; IgM	12
	Finecare SARS-CoV-2 Antibody test	Total Ig	4
Hangzhou AllTest Biotech Co., Ltd	2019-nCoV IgG/IgM Rapid Test Cassette	IgG	2
		IgG; IgM	2
		IgM	1
Hangzhou Biotest Biotech Co., Ltd	COVID-19 IgG/IgM Rapid Test Cassette	IgG; IgM	2
Hangzhou Clongene Biotech Co., Ltd	2019-nCoV IgG/IgM Rapid Test	IgG	1
		IgG; IgM	1
		IgM	1
Healgen	COVID-19 IgG/IgM Rapid Test Cassette	IgG	1
		IgG; IgM	1
		IgM	1
ImmunoDiagnostics limited	SARS-CoV-2 NP IgG ELISA Kit	IgG	1
	SARS-CoV-2 NP IgM ELISA Kit	IgM	1
Innovita Biological Technology Co. Ltd	2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)	IgG; IgM	6
	SARS-CoV-2 IgG Ab Rapid Test	IgM	2
Mikrogen GmbH	recomWell SARS-CoV-2 IgG ELISA	IgG	1
Mologic Ltd	SARS-CoV-2 ELISA Serology	IgG	1
Multi-G B.V.	COVID-19 IgG/IgM Ab Test Cassette (Whole Blood/Serum/Plasma)	IgG	1
nal von minden GmbH	NADAL® COVID-19 IgG/IgM Test	IgG	1
		IgM	1
Ortho Clinical Diagnostics	VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total	Total Ig	5
	VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 IgG	IgG	12


Manufacturer	Test Name	Isotype	No. of studies
PCL Inc.	PCL COVID19 IgG/IgM Rapid Gold	IgG; IgM	1
Phamatech	COVID19 RAPID TEST	IgG; IgM	1
Premier Biotech	COVID-19 IgG/IgM Rapid Test Cassette	IgG; IgM	2
PRIMA Lab S.A.	PRIMA COVID-19 IgG/IgM Rapid Test	IgG; IgM	3
		IgG	2
RayBiotech	Novel Coronavirus IgG antibody test kit (colloidal gold method)	IgG	1
Roche Diagnostics, Basel, Switzerland	Elecsys Anti-SARS-CoV-2	Total Ig	17
		IgG; IgM	20
	Anti-SARS-CoV-2 ELISA (IgA) (manual, automated)	IgA; IgG; IgM	4
Shanghai Kehua Bio-engineering Co., Ltd	Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold)	IgG; IgM	3
Shenzhen Yahuilong Biotechnology Co Ltd	2019-nCoV IgG/IgM Antibody Detection Kit	IgG	4
		IgM	4
Shenzhen Yhlo Biotech Co. Ltd	SARS-CoV-2 IgM and IgG chemiluminescence immunoassay	IgG	7
		IgM	4
	iFlash-SARS-CoV-2 IgG	IgG	2
	SARS-CoV-2 IgM/IgG CLIA kits	IgG	1
		IgM	1
iFlash-SARS-CoV-2 IgM	IgM	1	
Siemens	Atellica® IM SARS-CoV-2 Total (COV2T)	Total Ig	4
Snibe Co., Ltd (Shenzhen New Industries Biomedical Engineering Co., Ltd)	MAGLUMI 2019-nCoV IgG (CLIA)	IgG	10
	MAGLUMI 2019-nCoV IgM (CLIA)	IgM	7
Sugentech, Inc.	SGTi-flex COVID-19 IgM/IgG (manual)	IgG; IgM	1
SureScreen Diagnostics	COVID-19 IgG/IgM Rapid Test Cassette	IgG	1
Tangshan Yingnuote Biotechnology Enterprise Co., Ltd.	Colloidal Gold Immunochromatography Assay (CGIA) kit	IgG; IgM	1
TestsealabsE	SARS-COV-2-IgG/IgM Test Cassette	IgG; IgM	2
		IgG	1
		IgM	1
UCP Biosciences	Coronavirus IgG/IgM Antibody (COVID-19) Test Cassette	IgG; IgM	2
		IgG	1
		IgM	1
Vircell S.L.	COVID-19 ELISA IgG	IgG	3
	COVID-19 ELISA IgM+IgA	IgA; IgM	3
VivaChek Biotech (Hangzhou) Co., Ltd	VivaDiag COVID-19 IgM/IgG Rapid Test	IgG; IgM	3
Wadsworth Center, New York State Department of Health	New York SARS-CoV Microsphere Immunoassay for Antibody Detection	Total Ig	1
Xiamen Wantai Kairui Biotechnology	Not available	Total Ig	7
Zhejiang Orient Gene Biotech	COVID-19 IgG/IgM Rapid Test	IgG	9
		IgG; IgM	8
		IgM	7
Zhuhai Livzon Diagnostics Inc	2019-nCoV IgG/IgM Antibody Detection Kit	IgG	4
		IgM	4
		IgG; IgM	2
	Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow)	IgG	2
		IgG; IgM	2
No independent evaluation available	Multiple tests used	-	275
	Author designed or validated test, not in Finddx database	-	139
	Not enough test information reported to match	-	89
	Commercially available but not in the Finddx database	-	66
	Evaluations for separate isotypes, review authors report combined positivity rate (and/or isotype)	-	12
	Evaluation for combined isotype, study examined individual isotypes	-	9

S6 Table. Summary of meta-regression results

Study Characteristics	Analysis using uncorrected seroprevalence estimates			Analysis using corrected seroprevalence estimates		
	Change in Seroprevalence (coefficient β) ^{a,b} (95% CI)	Risk ratio (95%CI)	p-value	Change in Seroprevalence (coefficient β) ^{a,c} (95% CI)	Risk ratio (95%CI)	p-value
Risk of Bias						
Low	Reference	-	-	Reference	-	-
Moderate	-0.02 (-0.33, 0.30)	0.98 (0.72, 1.35)	0.92	-0.51 (-0.83, -0.20)	0.60 (0.44, 0.82)	0.001
High	0.02 (-0.30, 0.35)	1.02 (0.74, 1.42)	0.89	-0.43 (-0.76, -0.10)	0.65 (0.47, 0.90)	0.01
Unclear	-0.30 (-0.69, 0.08)	0.74 (0.50, 1.09)	0.12	-0.96 (-1.49, -0.43)	0.38 (0.22, 0.65)	<0.001
Population Group						
Household and community sample	Reference	-	-	Reference	-	-
Blood donors	-0.15 (-0.35, 0.06)	0.86 (0.70, 1.06)	0.16	0.04 (-0.20, 0.27)	1.04 (0.82, 1.31)	0.77
Residual sera	-0.33 (-0.49, -0.16)	0.72 (0.61, 0.85)	<0.001	-0.12 (-0.30, 0.06)	0.89 (0.74, 1.06)	0.19
Estimate Grade						
National	Reference	-	-	Reference	-	-
Regional	-0.02 (-0.23, 0.19)	0.98 (0.79, 1.20)	0.84	0.50 (0.26, 0.74)	1.65 (1.30, 2.09)	<0.001
Local	0.43 (0.22, 0.64)	1.54 (1.25, 1.90)	<0.001	0.76 (0.52, 1.00)	2.14 (1.68, 2.72)	<0.001
Sublocal	0.50 (0.16, 0.85)	1.66 (1.17, 2.34)	0.004	0.66 (0.21, 1.11)	1.93 (1.23, 3.03)	0.004
Cases per 100,000 population						
Cases per 100,000	0.43 (0.31, 0.55)	1.54 (1.37, 1.73)	<0.001	0.30 (0.18, 0.43)	1.35 (1.19, 1.53)	<0.001
GBD Region						
High-Income	Reference	-	-	Reference	-	-
North Africa and Middle East	0.65 (-0.03, 1.32)	1.91 (0.97, 3.75)	0.06	-0.22 (-0.91, 0.47)	0.80 (0.40, 1.60)	0.53
Southeast Asia, East Asia, and Oceania	-1.28 (-1.67, -0.88)	0.28 (0.19, 0.41)	<0.001	-1.74 (-2.41, -1.07)	0.18 (0.09, 0.34)	<0.001
Central Europe, Eastern Europe, and Central Asia	0.45 (0.04, 0.87)	1.57 (1.04, 2.38)	0.03	1.04 (0.56, 1.52)	2.83 (1.75, 4.55)	<0.001
Latin America and Caribbean	0.39 (0.16, 0.63)	1.48 (1.17, 1.87)	<0.001	1.00 (0.73, 1.26)	2.71 (2.07, 3.54)	<0.001
South Asia	1.20 (0.93, 1.47)	3.30 (2.52, 4.33)	<0.001	1.04 (0.74, 1.35)	2.84 (2.09, 3.85)	<0.001
Sub-Saharan Africa	1.34 (0.75, 1.93)	3.81 (2.11, 6.89)	<0.001	1.61 (1.06, 2.16)	5.01 (2.89, 8.69)	<0.001
<p>^aThe regression coefficient β refers to the change in the log seroprevalence of antibodies to SARS-CoV-2 given changes in the covariate. ^bDetails of uncorrected model: Intercept coefficient β -3.45 (95%CI -3.76, -3.13); Mixed-Effects Model (k = 570); tau² 0.4759 (SE = 0.1331); I²=99.64%; R²=21.26%. Test of Moderators (coefficients 2:16): QM(df = 15) = 263.86, p-val < 0.0001. ^cDetails of corrected model: Intercept coefficient β -3.45 (95%CI -3.78, -3.12); Mixed-Effects Model (k = 417); tau² =0.3574(SE =0.0791); I²=98.94%; R²=63.97%. Test of Moderators (coefficients 2:16): QM(df = 15) = 322.6942, p-val < 0.0001. Abbreviations: B = beta; CI = confidence interval; exp = exponentiated; GBD = global burden of disease.</p>						


Supplementary figures

S1 Figure. Map of serosurvey distribution by global burden of disease region



The number of countries reporting any serosurvey in each GBD region were: Central Europe, Eastern Europe, and Central Asia (n=26); in High Income regions (n=747); in Latin America and Caribbean (n=69); in North Africa and Middle East (n=21); in South Asia (n=49); in Southeast Asia, East Asia, and Oceania (n=46); and in Sub-Saharan Africa (n=10).

S2 Figure. Seroprevalence to cumulative case incidence ratios using cumulative incidence nine days prior to the serosurvey end date



References for all included studies

1. Grigoryan A. Antibodies found in Armenia's 61 medical workers from 380 examinations: Testing continues. Armen Press. 30 Jun 2020. Available: <https://armenpress.am/eng/news/1020040/>. Accessed 13 Mar 2021.
2. Tsaneva-Damyanova D. SARS-CoV-2: Seroepidemiological pattern in northeastern Bulgaria. *Biotechnology & Biotechnological Equipment*. 2020;34: 441–446. doi:10.1080/13102818.2020.1772105
3. Vince A, Zadro R, Šostar Z, Sternak SL, Vraneš J, Škaro V, et al. SARS-CoV-2 Seroprevalence in a Cohort of Asymptomatic, RT-PCR Negative Croatian First League Football Players. *medRxiv*. 2020; 2020.10.30.20223230. doi:10.1101/2020.10.30.20223230
4. Lapić I, Rogić D, Šegulja D, Kralik Oguić S, Knežević J. The reliability of SARS-CoV-2 IgG antibody testing - a pilot study in asymptomatic health care workers in a Croatian university hospital. *Croat Med J*. 2020;61: 485–490.
5. Vilibic-Cavlek T, Stevanovic V, Tabain I, Betica-Radic L, Sabadi D, Peric L, et al. Severe acute respiratory syndrome coronavirus 2 seroprevalence among personnel in the healthcare facilities of Croatia, 2020. *Revista da Sociedade Brasileira de Medicina Tropical*. 2020;53. doi:10.1590/0037-8682-0458-2020
6. Jerkovic I, Ljubic T, Basic Z, Kruzic I, Kunac N, Bezic J, et al. SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia. *medRxiv*. 2020; 2020.05.11.20095158. doi:10.1101/2020.05.11.20095158
7. Bloomfield M, Pospisilova I, Cabelova T, Sediva A, Ibrahimova M, Borecka K, et al. Searching for COVID-19 Antibodies in Czech Children—A Needle in the Haystack. *Front Pediatr*. 2020;8. doi:10.3389/fped.2020.597736
8. Malickova K, Kratka Z, Luxova S, Bortlik M, Lukas M. Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: Are we currently able to provide COVID-free IBD clinics? *medRxiv*. 2020;55: 917–919. doi:10.1080/00365521.2020.1791244
9. Jõgi P, Soeorg H, Ingerainen D, Soots M, Lättekivi F, Naaber P, et al. Seroprevalence of SARS-CoV-2 IgG antibodies in two regions of Estonia (KoroSero-EST-1). 2020 [cited 15 May 2021]. doi:10.1101/2020.10.21.20216820
10. Veerus P, Salumets A, Naaber P, Krjutškov K, Tilk K, Laanpere M, et al. Seroprevalence of SARS-CoV-2 antibodies among pregnant women in Estonia: A call for epidemiological studies. *Acta Obstet Gynecol Scand*. 2020;99: 1736–1737. doi:10.1111/aogs.13995
11. Tsertsvadze T, Gatsrelia L, Mirziashvili M, Dvali N, Abutidze A, Metchurchlishvili R, et al. SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia. *medRxiv*. 2020; 2020.09.18.20195024. doi:10.1101/2020.09.18.20195024
12. Merkely B, Szabó AJ, Kosztin A, Berényi E, Sebestyén A, Lengyel C, et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. *GeroScience*. 2020;42: 1063–1074. doi:10.1007/s11357-020-00226-9
13. Ciechanowicz P, Dopytalska K, Mikucka-Wituszyńska A, Dźwigala M, Wiszniewski K, Herniczek W, et al. The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy. *Journal of Dermatological Treatment*. 2020;0: 1–4. doi:10.1080/09546634.2020.1861177
14. Kasztelewicz B, Janiszewska K, Burzyńska J, Szydłowska E, Migdał M, Dzierżanowska-Fangrat K. Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland. *medRxiv*. 2020; 2020.11.28.20239848. doi:10.1101/2020.11.28.20239848

15. Gujski M, Jankowski M, Pinkas J, Wierzba W, Samel-Kowalik P, Zaczyński A, et al. Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland, June–July 2020. *Journal of Clinical Medicine*. 2020;9: 3245. doi:10.3390/jcm9103245
16. MedLife. Concluzii preliminare, studiu MedLife: “Cel mai probabil populatia nu are imunitate dobandita natural pentru COVID 19. Respectarea masurilor de protectie si extinderea testarii reprezinta sansa noastra de a functiona in siguranta si de a reporni economia”. MedLife; 24 Apr 2020. Available: <https://www.medlife.ro/comunicat-de-presa/concluzii-preliminare-studiu-medlife-cel-mai-probabil-populatia-nu-are-imunitate-dobandita-natural-pentru-covid-19-respectarea-masurilor-de-protectie-si-extinderea-testarii-reprezinta-sansa-noastra-de-a-functiona-in-siguranta-si-de-a>
17. Popova AYU, Ezhlova EB, Mel’nikova AA, Balakhonov SV, Chesnokova MV, Dubrovina VI, et al. Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak. *Problemy Osobo Opasnykh Infektsii*. 2020; 106–113. doi:10.21055/0370-1069-2020-3-106-113
18. Popova AYU, Ezhlova EB, The Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation, Melnikova AA, The Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, Moscow, Russian Federation, Mikailova OM, et al. The structure of seroprevalence to the SARS-CoV-2 virus among residents of the Moscow Region during the period of epidemic incidence of COVID-19. *Infekc bolezni*. 2020;18: 17–26. doi:10.20953/1729-9225-2020-4-17-26
19. Popova AYU, Ezhlova EB, Mel’nikova AA, Historik OA, Mosevich OS, Lyalina LV, et al. Assessment of the Herd Immunity to SARS-CoV-2 among the Population of the Leningrad Region during the COVID-19 Epidemic. *Problemy Osobo Opasnykh Infektsii*. 2020; 114–123. doi:10.21055/0370-1069-2020-3-114-123
20. Barchuk A, Skougarevskiy D, Titaev K, Shirokov D, Raskina Y, Novkunskaya A, et al. Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: A population-based study. medRxiv. 2020; 2020.11.02.20221309. doi:10.1101/2020.11.02.20221309
21. Popova AYU, Ezhlova EB, Mel’nikova AA, Bashketova NS, Fridman RK, Lyalina LV, et al. Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic. *Problemy Osobo Opasnykh Infektsii*. 2020; 124–130. doi:10.21055/0370-1069-2020-3-124-130
22. Попова АЮ, Ежлова ЕБ, Мельникова АА, Степанова ТФ, Шаруха ГВ, Летушев АН, et al. Distribution of SARS-CoV-2 seroprevalence among residents of the Tyumen Region during the COVID-19 epidemic period. *Журнал микробиологии, эпидемиологии и иммунобиологии*. 2020 [cited 21 Mar 2021]. Available: <https://microbiol.elpub.ru/jour/article/view/890>
23. Tickle J. Large-scale antibody testing reveals that over 2 million Muscovites may already have contracted Covid-19. *Russian Times*. 26 Jun 2020. Available: <https://www.rt.com/russia/493055-moscow-mass-antibody-testing/>. Accessed 13 Mar 2021.
24. Krechetova L, Vtorushina V, Inviyaeva EV, Ivanets TYu, Donnikov AYU, Dolgushina NV, et al. Detection of antibodies to SARS-CoV-2 in healthcare professionals of the National Center during the COVID-19 pandemic (April–June 2020). *Obstetrics and Gynecology (Moscow)*. 2020;7: 122–128. doi:10.18565/aig.2020.7.122-128
25. Kiselyov S. 1 in 7 Russians Have ‘Coronavirus Immunity’ – Official. *The Moscow Times*. 10 Jun 2020. Available: <https://www.themoscowtimes.com/2020/06/10/1-in-7-russians-have-coronavirus-immunity-official-a70540>
26. Mass SARS-CoV-2 serological screening for the Principality of Andorra. 2020 [cited 16 Feb 2021]. doi:10.21203/rs.3.rs-119323/v1
27. Muñoz L, Pifano M, Bolzán A, Varela T, Comes Y, Specogna M, et al. Surveillance and Seroprevalence: Evaluation of IgG antibodies for SARS-Cov2 by ELISA in the popular neighborhood Villa Azul, Quilmes, province of Buenos Aires, Argentina. 2020 Aug. doi:10.1590/SciELOPreprints.1147

28. Silva AP, Fernanda Aguirre M, Ballejo C, Jimena Marro M, Gamarnik AV, Vargas G, et al. Seroprevalence of the SARS-CoV-2 infection in health workers of the Sanitary Region VIII, at province of Buenos Aires. medRxiv. 2020; 2020.09.07.20189050. doi:10.1101/2020.09.07.20189050
29. Figar S, Pagotto V, Luna L, Salto J, Wagner Manslau M, Mistchenko A, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: A participatory research. medRxiv. 2020 [cited 13 Nov 2020]. doi:10.1101/2020.07.14.20153858
30. Insúa C, Stedile G, Figueroa V, Hernández C, Svartz A, Ferrero F, et al. Seroprevalence of SARS-CoV-2 antibodies among physicians from a children's hospital. Arch Argent Pediatr. 2020;118: 381–385. doi:10.5546/aap.2020.eng.381
31. Hicks SM, Pohl K, Neeman T, McNamara HA, Parsons KM, He J, et al. A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. The Journal of Infectious Diseases. 2021;223: 10–14. doi:10.1093/infdis/jiaa623
32. Macartney K, Quinn HE, Pillsbury AJ, Koirala A, Deng L, Winkler N, et al. Transmission of SARS-CoV-2 in Australian educational settings: A prospective cohort study. The Lancet Child & Adolescent Health. 2020;4: 807–816. doi:10.1016/S2352-4642(20)30251-0
33. Ladage D, Höglinger Y, Ladage D, Adler C, Yalcin I, Braun RJ. SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population. medRxiv. 2020 [cited 23 Feb 2021]. doi:doi.org/10.1101/2020.11.03.20219121
34. Fuereder T, Berghoff AS, Heller G, Haslacher H, Perkmann T, Strassl R, et al. SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. ESMO Open. 2020;5. doi:10.1136/esmoopen-2020-000889
35. Hackner K, Errhalt P, Willheim M, Grasl M-A, Lagumdžija J, Riegler W, et al. Diagnostic accuracy of two commercially available rapid assays for detection of IgG and IgM antibodies to SARS-CoV-2 compared to ELISA in a low-prevalence population. Research Square. 2020 [cited 13 Nov 2020]. doi:10.21203/rs.3.rs-50887/v1
36. Knabl L, Mitra T, Kimpel J, Roessler A, Volland A, Walser A, et al. High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl. medRxiv. 2020; 2020.08.20.20178533. doi:10.1101/2020.08.20.20178533
37. Wagner A, Guzek A, Ruff J, Jasinska J, Scheikl U, Zwazl I, et al. A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms. medRxiv. 2020; 2020.12.22.20248604. doi:10.1101/2020.12.22.20248604
38. Reiter T, Pajenda S, Wagner L, Gaggl M, Atamaniuk J, Holzer B, et al. Covid-19 serology in nephrology health care workers. medRxiv. 2020; 2020.07.21.20136218. doi:10.1101/2020.07.21.20136218
39. Orth-Höller D, Eigentler A, Weseslindtner L, Möst J. Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection. Emerging Microbes & Infections. 2020;9: 1692–1694. doi:10.1080/22221751.2020.1793690
40. Duysburgh E, Mortgat L, Barbezange C, Dierick K, Fischer N, Heyndrickx L, et al. Persistence of IgG response to SARS-CoV-2. The Lancet Infectious Diseases. 2020;0. doi:10.1016/S1473-3099(20)30943-9
41. Herzog S, Bie JD, Abrams S, Wouters I, Ekinici E, Patteet L, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: A serial prospective cross-sectional nationwide study of residual samples. medRxiv. 2020; 2020.06.08.20125179. doi:10.1101/2020.06.08.20125179
42. Blairon L, Mokrane S, Wilmet A, Dessilly G, Kabamba-Mukadi B, Beukinga I, et al. Large-scale, molecular and serological SARS-CoV-2 screening of healthcare workers in a 4-site public hospital in Belgium after COVID-19 outbreak. Journal of Infection. 2020; S0163445320305144. doi:10.1016/j.jinf.2020.07.033

43. Berardis S, Verroken A, Vetillart A, Struyf C, Gilbert M, Gruson D, et al. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. *Journal of Cystic Fibrosis*. 2020; S1569199320308213. doi:10.1016/j.jcf.2020.08.005
44. Martin C, Montesinos I, Dauby N, Gilles C, Dahma H, Van Den Wijngaert S, et al. Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff. *Journal of Hospital Infection*. 2020;106: 102–106. doi:10.1016/j.jhin.2020.06.028
45. Steensels D, Oris E, Coninx L, Nuyens D, Delforge M-L, Vermeersch P, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. *JAMA*. 2020. doi:10.1001/jama.2020.11160
46. Buntinx F, Claes P, Gulikers M, Verbakel J, Jan DL, Elst MV der, et al. Added value of anti-SARS-CoV-2 antibody testing in a Flemish nursing home during an acute COVID-19 outbreak in April 2020. *Acta Clinica Belgica*. 2020;0: 1–6. doi:10.1080/17843286.2020.1834285
47. Canadian Blood Services CBS. COVID-19 Seroprevalence Report 4 – January 12, 2021. 2021 Jan. Available: N/A
48. Canadian Blood Services CBS. COVID-19 Seroprevalence Report 3– December 18, 2020. 2020 Dec. Available: <https://www.covid19immunitytaskforce.ca/wp-content/uploads/2021/01/COVID-19-October-Report-for-CITF.pdf>
49. Manny E, Carroll A, Charlton C, Robinson J, Subbarao P, Azad MB, et al. Increased Mask Use and Fewer Gatherings Associated with Lower SARS-CoV-2 Seropositivity Among Young School-Age Children. *SSRN Journal*. 2020 [cited 15 May 2021]. doi:10.2139/ssrn.3728570
50. Brousseau N, Morin L, Ouakki M, Savard P, Quach C, Cheng M, et al. COVID-19 : Étude de séroprévalence chez des travailleurs de la santé de centres hospitaliers au Québec. *Institut National de Sante Publique du Quebec*; 2020 Nov p. 20.
51. Bolotin S, Tran V, Osman S, Brown KA, Buchan SA, Joh E, et al. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline. *The Journal of Infectious Diseases*. 2021 [cited 22 Apr 2021]. doi:10.1093/infdis/jiaa796
52. Bardai G, Ouellet J, Engelhardt T, Bertolizio G, Wu Z, Rauch F. Prevalence of SARS-CoV-2 infections in a pediatric orthopedic hospital. von Ungern-Sternberg B, editor. *Pediatr Anaesth*. 2021;31: 247–248. doi:10.1111/pan.14047
53. Héma-Québec. Blood Donors Seroprevalence Study: 2.23% of Quebec Adults Contracted COVID-19. Héma-Québec; 5 Aug 2020. Available: <https://www.hema-quebec.qc.ca/publications/communiqués/archives/2020/communiqués-2020/etude-seroprevalence-resultats.en.html>
54. Majdoubi A, Michalski C, O’Connell SE, Dada S, Narpala S, Gelinias J, et al. Antibody reactivity to SARS-CoV-2 is common in unexposed adults and infants under 6 months. *medRxiv*. 2020; 2020.10.05.20206664. doi:10.1101/2020.10.05.20206664
55. Canadian Blood Services CBS. COVID-19 Seroprevalence Report 1– August 19, 2020. 2020 Aug. Available: https://www.covid19immunitytaskforce.ca/wp-content/uploads/2020/09/COVID-19-Public-Report_2.pdf
56. Skowronski DM, Sekirov I, Sabaiduc S, Zou M, Morshed M, Lawrence D, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020. *medRxiv*. 2020; 2020.07.13.20153148. doi:10.1101/2020.07.13.20153148
57. Vijh R, Ghafari C, Hayden A, Schwandt M, Sekirov I, Morshed M, et al. Serological survey following SARS-COV-2 outbreaks at long-term care facilities in metro Vancouver, British Columbia: Implications for outbreak management and infection control policies. *Am J Infect Control*. 2020. doi:10.1016/j.ajic.2020.10.009
58. Torres JP, Piñera C, De La Maza V, Lagomarcino AJ, Simian D, Torres B, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence in Blood in a Large School Community Subject to a Coronavirus Disease 2019 Outbreak: A Cross-sectional Study. *Clinical Infectious Diseases*. 2020; ciaa955. doi:10.1093/cid/ciaa955

59. Laursen J, Petersen J, Didriksen M, Iversen K, Ullum H. Prevalence of SARS-CoV-2 IgG/IgM Antibodies among Danish and Swedish Falek Emergency and Non-Emergency Healthcare Workers. *International Journal of Environmental Research and Public Health*. 2021;18: 923. doi:10.3390/ijerph18030923
60. Egerup P, Fich Olsen L, Christiansen A-MH, Westergaard D, Severinsen ER, Hviid KVR, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns. *Obstetrics & Gynecology*. 2021;137: 49–55. doi:10.1097/AOG.0000000000004199
61. Jespersen S, Mikkelsen S, Greve T, Kaspersen KA, Tolstrup M, Boldsen JK, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region. *Clinical Infectious Diseases*. 2020; ciaa1471. doi:10.1093/cid/ciaa1471
62. Pedersen OB, Nissen J, Dinh KM, Schwinn M, Kaspersen KA, Boldsen JK, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Fatality Rate Among Elderly Danes: A Cross-sectional Study on Retired Blood Donors. *Clinical Infectious Diseases*. 2020 [cited 12 Jan 2021]. doi:10.1093/cid/ciaa1627
63. Storgaard SF, Eiset AH, Abdullahi F, Wejse C. First wave of COVID-19 did not reach the homeless population in Aarhus. *Dan Med J*. 2020;67.
64. la Cour Freiesleben N, Egerup P, Hviid KVR, Severinsen ER, Kolte AM, Westergaard D, et al. SARS-CoV-2 in first trimester pregnancy: A cohort study. *Human Reproduction*. 2020; deaa311. doi:10.1093/humrep/deaa311
65. Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. *medRxiv*. 2020; 2020.04.24.20075291. doi:10.1101/2020.04.24.20075291
66. Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et al. Risk of COVID-19 in health-care workers in Denmark: An observational cohort study. *Lancet Infect Dis*. 2020. doi:10.1016/S1473-3099(20)30589-2
67. Petersen MS, Strøm M, Christiansen DH, Fjallsbak JP, Eliassen EH, Johansen M, et al. Seroprevalence of SARS-CoV-2–Specific Antibodies, Faroe Islands. *Emerg Infect Dis*. 2020;26: 2760–2762. doi:10.3201/eid2611.202736
68. Kantele A, Lääveri T, Kareinen L, Pakkanen SH, Blomgren K, Mero S, et al. SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: Serosurvey, symptoms and risk factors. *Travel Medicine and Infectious Disease*. 2021;39: 101949. doi:10.1016/j.tmaid.2020.101949
69. Anna F, Goyard S, Lalanne AI, Nevo F, Gransagne M, Souque P, et al. High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris. *European Journal of Immunology*. 2020;51: 180–190. doi:10.1002/eji.202049058
70. Dimeglio C, Herin F, Miedougé M, Cambus J-P, Abravanel F, Mansuy J-M, et al. Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. *Journal of Infection*. 2020;0. doi:10.1016/j.jinf.2020.09.035
71. Roederer T, Mollo B, Vincent C, Nikolay B, Llosa AE, Nesbitt R, et al. Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: A cross-sectional study. *Lancet Public Health*. 2021. doi:10.1016/S2468-2667(21)00001-3
72. Péré H, Wack M, Védie B, Demory Guinet N, Kassis Chikani N, Janot L, et al. Sequential SARS-CoV-2 IgG assays as confirmatory strategy to confirm equivocal results: Hospital-wide antibody screening in 3,569 staff health care workers in Paris. *Journal of Clinical Virology*. 2020;132: 104617. doi:10.1016/j.jcv.2020.104617
73. Tsatsaris V, Mariaggi A-A, Launay O, Couffignal C, Rousseau J, Ancel PY, et al. SARS-COV-2 IgG antibody response in pregnant women at delivery. *Journal of Gynecology Obstetrics and Human Reproduction*. 2020;50: 102041. doi:10.1016/j.jogoh.2020.102041

74. Gallais F, Velay A, Nazon C, Wendling M-J, Partisani M, Sibilia J, et al. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France - Volume 27, Number 1—January 2021 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases. 2020 [cited 23 Jan 2021]. doi:10.3201/eid2701.203611
75. Carrat F, Lamballerie X de, Rahib D, Blanche H, Lapidus N, Artaud F, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: A multicohort study. medRxiv. 2020; 2020.09.16.20195693. doi:10.1101/2020.09.16.20195693
76. Mesnil M, Joubel K, Yavchitz A, Miklaszewski N, Devys J-M. Seroprevalence of SARS-Cov-2 in 646 professionals at the Rothschild Foundation Hospital (ProSeCoV study). Anaesthesia Critical Care & Pain Medicine. 2020;39: 595–596. doi:10.1016/j.accpm.2020.08.003
77. Delmas C, Plu-Bureau G, Canoui E, Mouthon L, Meritet J-F. Clinical characteristics and persistence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in 4,607 French healthcare workers: Comparison with European countries. Infect Control Hosp Epidemiol. 2020; 1–2. doi:10.1017/ice.2020.1309
78. Capai L, Ayhan N, Masse S, Canarelli J, Priet S, Simeoni M-H, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020. Journal of Clinical Medicine. 2020;9: 3569. doi:10.3390/jcm9113569
79. Mattern J, Vauloup-Fellous C, Zakaria H, Benachi A, Carrara J, Letourneau A, et al. Post lockdown COVID-19 seroprevalence and circulation at the time of delivery, France. PLOS ONE. 2020;15: e0240782. doi:10.1371/journal.pone.0240782
80. Bal A, Brengel-Pesce K, Gaymard A, Quéromès G, Guibert N, Frobert E, et al. Clinical and microbiological assessments of COVID-19 in healthcare workers: A prospective longitudinal study. medRxiv. 2020; 2020.11.04.20225862. doi:10.1101/2020.11.04.20225862
81. Vu SL, Jones G, Anna F, Rose T, Richard J-B, Bernard-Stoecklin S, et al. Prevalence of SARS-CoV-2 antibodies in France: Results from nationwide serological surveillance. medRxiv. 2020 [cited 8 Mar 2021]. doi:doi.org/10.1101/2020.10.20.20213116
82. Cohen R, Jung C, Ouldali N, Sellam A, Batard C, Cahn-Sellem F, et al. Assessment of SARS-CoV-2 infection by Reverse transcription-PCR and serology in the Paris area: A cross-sectional study. BMJ Paediatrics Open. 2020;4: e000887. doi:10.1136/bmjpo-2020-000887
83. Fumery M, Matias C, Brochot E. Seroconversion of Immunoglobulins to SARS-CoV2 in Patients With Inflammatory Bowel Disease Patients Treated by Biologics. Journal of Crohn's and Colitis. 2020; jjaa154. doi:10.1093/ecco-jcc/jjaa154
84. Fontanet A, Grant R, Tondeur L, Madec Y, Grzelak L, Cailleau I, et al. SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission. medRxiv. 2020; 2020.06.25.20140178. doi:10.1101/2020.06.25.20140178
85. Solodky ML, Galvez C, Russias B, Detourbet P, N'Guyen-Bonin V, Herr A-L, et al. Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. Annals of Oncology. 2020;31: 1087–1088. doi:10.1016/j.annonc.2020.04.475
86. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Research. 2020;181: 104880. doi:10.1016/j.antiviral.2020.104880
87. Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Science Translational Medicine. 2020;12: eabc3103. doi:10.1126/scitranslmed.abc3103

88. Germain N, Herwegh S, Hatzfeld A-S, Bocket L, Prévost B, Danzé P-M, et al. Retrospective study of COVID-19 seroprevalence among tissue donors at the onset of the outbreak before implementation of strict lockdown measures in France. *Cell Tissue Bank*. 2021 [cited 19 Mar 2021]. doi:10.1007/s10561-021-09901-3
89. Fuest C, Neumeier F, Peichl A, Universitätsmedizin Berlin C -, Sozialforschung und statistische Analysen mbH FG für, GmbH PHS. Die Deutschen und Corona. ifo Institut; 2020 Nov. Available: <https://www.ifo.de/en/publikationen/2020/monograph-authorship/die-deutschen-und-corona>
90. Institute RK. Serological tests of blood donations for antibodies against SARS-CoV-2 (SeBluCo study). 2020 Nov. Available: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/SeBluCo_Zwischenbericht.html;jsessionid=0C30892A66A0F7CDD897F3809AA3F10F.internet102
91. Armann JP, Unrath M, Kirsten C, Lück C, Dalpke AH, Berner R. SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): Persistent low seroprevalence and transmission rates between May and October 2020. *medRxiv*. 2020; 2020.07.16.20155143. doi:10.1101/2020.07.16.20155143
92. Thielecke M, Theuring S, Loon W van, Hommes F, Mall MA, Rosen A, et al. SARS-CoV-2 infections in kindergartens and associated households at the start of the second wave in Berlin, Germany – a cross sectional study. *medRxiv*. 2020; 2020.12.08.20245910. doi:10.1101/2020.12.08.20245910
93. Schwarz S, Jenetzky E, Krafft H, Maurer T, Steuber C, Reckert T, et al. Corona bei Kindern: Die Co-Ki Studie: Relevanz von SARS-CoV-2 in der ambulanten pädiatrischen Versorgung in Deutschland. *Monatsschr Kinderheilkd*. 2020;169: 39–45. doi:10.1007/s00112-020-01050-3
94. Rauber C, Tiwari-Heckler S, Pfeiffenberger J, Mehrabi A, Lund F, Gath P, et al. SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study. *Transplant Proc*. 2020. doi:10.1016/j.transproceed.2020.11.009
95. Hoffmann S, Spallek J, Heinz-Detlef G, Schiebel J, Hufert F. Testing the backbone of the healthcare system: A prospective serological-epidemiological cohort study of healthcare workers in rural Germany. *Research Square*. 2020 [cited 15 Jan 2021]. doi:10.21203/rs.3.rs-84703/v1
96. Finkenzeller T, Faltlhauser A, Dietl K-H, Paetzel C, Szczypien N, Klawonn F, et al. SARS-CoV-2-Antikörper bei Intensiv- und Klinikpersonal. *Med Klin Intensivmed Notfmed*. 2020;115: 139–145. doi:10.1007/s00063-020-00761-5
97. Laub O, Leipold G, Toncheva A, Peterhoff D, Einhauser S, Borchers N, et al. Coronavirus antibody screening identifies children with mild to moderate courses of PMIS. *Preprints*; 2020 Dec. doi:10.22541/au.160776187.78854537/v1
98. Brehm T, Schwinge D, Lampalzer S, Schlicker V, Küchen J, Thompson M, et al. Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study. *International Journal of Hygiene and Environmental Health*. 2021;232: 113671. doi:10.1016/j.ijheh.2020.113671
99. Mack D, Gärtner BC, Rössler A, Kimpel J, Donde K, Harzer O, et al. Prevalence of SARS-CoV-2 IgG antibodies in a large prospective cohort study of elite football players in Germany (May–June 2020): Implications for a testing protocol in asymptomatic individuals and estimation of the rate of undetected cases. *Clinical Microbiology and Infection*. 2020;27: 473.e1–473.e4. doi:10.1016/j.cmi.2020.11.033
100. Epstude J, Harsch IA. Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic. *GMS Hygiene and Infection Control*; 15:Doc18. 2020 [cited 15 Oct 2020]. doi:10.3205/DGKH000353
101. Aziz NA, Corman VM, Echterhoff AKC, Richter A, Schmandke A, Schmidt ML, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany. *medRxiv*. 2020; 2020.08.24.20181206. doi:10.1101/2020.08.24.20181206

102. Bahrs C, Kimmig A, Weis S, Ankert J, Hagel S, Maschmann J, et al. Seroprevalence of SARS CoV-2 antibodies in healthcare workers and administration employees: A prospective surveillance study at a 1,400-bed university hospital in Germany. medRxiv. 2020 [cited 18 Feb 2021]. doi:10.1101/2020.09.29.20203737
103. Herzberg J, Vollmer T, Fischer B, Becher H, Becker A-K, Sahly H, et al. Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital. *International Journal of Infectious Diseases*. 2021;102: 136–143. doi:10.1016/j.ijid.2020.10.026
104. Runkel S, Kowalzik F, Gehring S, Winter J, Grandt CL, Marron M, et al. Prevalence of Severe Acute Respiratory Syndrome Coronavirus-2-specific Antibodies in German Blood Donors during the COVID-19 Pandemic. *Clin Lab*. 2020;66. doi:10.7754/Clin.Lab.2020.200915
105. Santos-Hövenner C, Neuhauser HK, Rosario AS, Busch M, Schlaud M, Hoffmann R, et al. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. *Eurosurveillance*. 2020;25: 2001752. doi:10.2807/1560-7917.ES.2020.25.47.2001752
106. Fill Malfertheiner S, Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva AA, et al. Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study. *Journal of Clinical Virology*. 2020;130: 104575. doi:10.1016/j.jcv.2020.104575
107. Herrmann BL. Die Prävalenz von SARS-CoV-2-IgG-AK liegt bei 1,2%: Screening bei asymptomatischen ambulanten Patienten. *MMW - Fortschritte der Medizin*. 2020;162: 44–46. doi:10.1007/s15006-020-0750-y
108. Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. *Eurosurveillance*. 2020;25. doi:10.2807/1560-7917.ES.2020.25.28.2001285
109. Thieme CJ, Zgoura P, Todorova I, Babel D, Witzke O, Viebahn R, et al. Coronavirus Disease 2019 Associated Risk Score, Behavior, and Symptom Prevalence in German Transplant Recipients. *Transplant Proc*. 2020 [cited 6 Feb 2021]. doi:10.1016/j.transproceed.2020.12.001
110. Erber J, Kappler V, Haller B, Mijočević H, Galhoz A, da Costa CP, et al. Strategies for infection control and prevalence of anti-SARS-CoV-2 IgG in 4,554 employees of a university hospital in Munich, Germany. 2020 [cited 15 May 2021]. doi:10.1101/2020.10.04.20206136
111. Weis S, Scherag A, Baier M, Kiehntopf M, Kamradt T, Kolanos S, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR- sampled and quarantined community after a COVID-19 outbreak - the CoNAN study. medRxiv. 2020; 21. Available: <https://doi.org/10.1101/2020.07.15.20154112>
112. Choi M, Bachmann F, Naik MG, Duettmann W, Duerr M, Zukunft B, et al. Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center. *JCM*. 2020;9: 3401. doi:10.3390/jcm9113401
113. Weis S, Scherag A, Baier M, Kiehntopf M, Kamradt T, Kolanos S, et al. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak—the CoNAN study. *Clinical Microbiology and Infection*. 2020;27: 470.e1–470.e9. doi:10.1016/j.cmi.2020.11.009
114. Neumann J, Zeeb H, Dotzauer A, Janssen-Weets O. Low anti-SARS-CoV-2 seroprevalence among public sector employees in Bremen. *Zeitschrift für medizinische Prävention*. 2020;55: 515–516. Available: <https://www.asu-arbeitsmedizin.com/node/153868/print>
115. Tönshoff B, Müller B, Elling R, Renk H, Meissner P, Hengel H, et al. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. *JAMA Pediatrics*. 2021 [cited 15 May 2021]. doi:10.1001/jamapediatrics.2021.0001
116. Zöllkau J, Baier M, Scherag A, Schleußner E, Groten T. Periodenprävalenz von SARS-CoV-2 in einer unselektierten Stichprobe schwangerer Frauen in Jena, Thüringen. *Z Geburtshilfe Neonatol*. 2020;224: 194–198. doi:10.1055/a-1206-1033

117. Schmidt SB, Grüter L, Boltzmann M, Rollnik JD. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. Adrish M, editor. PLoS ONE. 2020;15: e0235417. doi:10.1371/journal.pone.0235417
118. Reisinger EC, von Possel R, Warnke P, Geerdes-Fenge HF, Hemmer CJ, Pfefferle S, et al. [Screening of Mothers in a COVID-19 Low-Prevalence Region: Determination of SARS-CoV-2 Antibodies in 401 Mothers from Rostock by ELISA and Confirmation by Immunofluorescence]. Dtsch Med Wochenschr. 2020. doi:10.1055/a-1197-4293
119. Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. Journal of Clinical Virology. 2020;128: 104437. doi:10.1016/j.jcv.2020.104437
120. Harsch IA, Skiba M, Konturek PC, Epstude J. Prevalence of antibodies against COVID-19 in the staff of a COVID-19 regular ward. GMS Hyg Infect Control. 2020;15. doi:10.3205/dgkh000344
121. Behrens GMN, Cossmann A, Stankov MV, Schulte B, Streeck H, Förster R, et al. Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. Infect Dis Ther. 2020 [cited 13 Nov 2020]. doi:10.1007/s40121-020-00334-1
122. Kern PM, Müller H-H, Menzel T, Weisser H. Studie zur Immunität gegen SARS-CoV-2: Keine signifikante humorale Immunität gegen SARS-CoV-2 im medizinischen Personal eines Klinikums der Maximalversorgung und in der Stadtregion Fulda. Der Klinikarzt. 2020;49: 268–273. doi:10.1055/a-1198-1243
123. Kraehling V, Kern M, Halwe S, Mueller H, Rohde C, Savini M, et al. Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area. medRxiv. 2020; 2020.05.20.20107730. doi:10.1101/2020.05.20.20107730
124. Lackermair K, William F, Grzanna N, Lehmann E, Fichtner S, Kucher HB, et al. Infection with SARS-CoV-2 in primary care health care workers assessed by antibody testing. Family Practice. 2020; cmaa078. doi:10.1093/fampra/maa078
125. Streeck H, Schulte B, Kümmerer BM, Richter E, Höller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nat Commun. 2020;11: 5829. doi:10.1038/s41467-020-19509-y
126. Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastitis E, et al. Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life. 2020;10: 214. doi:10.3390/life10090214
127. Psychogiou M, Karabinis A, Pavlopoulou ID, Basoulis D, Petsios K, Roussos S, et al. Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. PLOS ONE. 2020;15: e0243025. doi:10.1371/journal.pone.0243025
128. Vlachoyiannopoulos P, Alexopoulos H, Apostolidi I, Bitzogli K, Barba C, Athanasopoulou E, et al. Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece. Clinical Immunology. 2020;221: 108619. doi:10.1016/j.clim.2020.108619
129. Bogogiannidou Z, Vontas A, Dadouli K, Kyritsi MA, Soteriades S, Nikoulis DJ, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. Eurosurveillance. 2020;25: 2001369. doi:10.2807/1560-7917.ES.2020.25.31.2001369
130. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383: 1724–1734. doi:10.1056/NEJMoa2026116
131. Derval Igoe, Janice Bailie, Fiona O’Callaghan, Aoife Colgan, Jeff Connell, Paul Crowley, et al. Preliminary report of the results of the Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence study, June-July 2020. Health Protection Surveillance Centre; 2020 Aug p. 9. Available: <https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/scopi/SCOPI>

132. Antibody tests show a third in Israeli ultra-Orthodox hot spot had coronavirus. Haaretz.com; [cited 23 Apr 2021]. Available: <https://www.haaretz.com/israel-news/.premium-antibody-tests-30-percent-of-bnei-brak-residents-have-been-infected-with-covid-1.9217689>
133. Efrati I. Up to 270000 Israelis Had Coronavirus, New Study Concludes. Haaretz. 2 Jun 2020. Available: <https://www.haaretz.com/israel-news/.premium-up-to-270-000-israelis-had-coronavirus-new-study-concludes-1.8888435>. Accessed 13 Mar 2021.
134. Caponigro G, Fusco O, Pastorini A, Deligiannis P, Maiolani M, Cubeddu A, et al. RAPID SEROLOGICAL TEST IN THE COVID-19 ERA: OUR EXPERIENCE. *Tumori Journal*. 2020;106: 1–215. doi:10.1177/0300891620953388
135. Russo A, Calò F, Fraia AD, Starace M, Minichini C, Gentile V, et al. Assessment and Comparison of Two Serological Approaches for the Surveillance of Health Workers Exposed to SARS-CoV-2. *Infection and Drug Resistance*; 17 Dec 2020 [cited 1 Feb 2021]. doi:10.2147/IDR.S282652
136. Ralli M, Cedola C, Urbano S, Latini O, Shkodina N, Morrone A, et al. Assessment of SARS-CoV-2 infection through rapid serology testing in the homeless population in the City of Rome, Italy. Preliminary results. *Journal of Public Health Research*. 2020;9. doi:10.4081/jpshr.2020.1986
137. Ministero della Salute. Covid-19, illustrati i risultati dell'indagine di sieroprevalenza. 2020 Aug. Available: <https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=4998>
138. Norsa L, Cosimo P, Indriolo A, Sansotta N, D'Antiga L, Callegaro A. Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment. *Gastroenterology*. 2020; S0016508520351179. doi:10.1053/j.gastro.2020.08.046
139. Cento V, Alteri C, Merli M, Di Ruscio F, Tartaglione L, Rossotti R, et al. Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy. Jin D-Y, editor. *PLoS ONE*. 2020;15: e0242765. doi:10.1371/journal.pone.0242765
140. Medas F, Cappellacci F, Anedda G, Canu GL, Del Giacco S, Calò PG, et al. Seroprevalence of SARS-Cov-2 in the setting of a non-dedicated COVID-19 hospital in a low CoV-2 incidence area: Implications for surgery. *Annals of Medicine and Surgery*. 2020;60: 261–262. doi:10.1016/j.amsu.2020.11.006
141. Berte' R, Mazza S, Stefanucci MR, Noviello D, Costa S, Ciafardini C, et al. Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy. *Journal of Crohn's and Colitis*. 2020; jjaa237. doi:10.1093/ecco-jcc/jjaa237
142. Capasso N, Palladino R, Montella E, Pennino F, Lanzillo R, Carotenuto A, et al. Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. *JCM*. 2020;9: 4066. doi:10.3390/jcm9124066
143. Gabriele Pagani, Federico Conti, Andrea Giacomelli, Dario Bernacchia, Rossana Rondanin, Andrea Prina, et al. Seroprevalence of SARS-CoV-2 IgG significantly varies with age: Results from a mass 7 population screening (SARS-2-SCREEN-CdA). 2020 Jun. Available: <https://www.medrxiv.org/content/10.1101/2020.06.24.20138875v1.full.pdf>
144. Cosma S, Borella F, Carosso A, Sciarrone A, Cusato J, Corcione S, et al. The “scar” of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy. *J Med Virol*. 2020; jmv.26267. doi:10.1002/jmv.26267
145. Angelo Amante. Over half of people tested in Italy's Bergamo have COVID-19 antibodies. *The Jakarta Post*. 9 Jun 2020. Available: <https://www.thejakartapost.com/news/2020/06/09/over-half-of-people-tested-in-italys-bergamo-have-covid-19-antibodies.html>
146. Lorenzo D, Carrisi C. COVID-19 exposure risk for family members of healthcare workers: An observational study. *International Journal of Infectious Diseases*. 2020;98: 287–289. doi:10.1016/j.ijid.2020.06.106

147. Lastrucci V, Lorini C, Del Riccio M, Gori E, Chiesi F, Sartor G, et al. SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato (Tuscany, Italy). *Vaccines*. 2020;8: 778. doi:10.3390/vaccines8040778
148. Papalini C, Paciosi F, Schiaroli E, Pierucci S, Busti C, Bozza S, et al. Seroprevalence of anti SARS-CoV2 antibodies in Umbrian persons living with HIV: SARS-CoV-2 and HIV. *Mediterr J Hematol Infect Dis*. 2020;12: e2020080. doi:10.4084/mjihid.2020.080
149. Fiore JR, Centra M, De Carlo A, Granato T, Rosa A, Sarno M, et al. Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. *J Med Virol*. 2020; jmv.26425. doi:10.1002/jmv.26425
150. Sperotto A, Candoni A, Petruzzellis G, Mullai R, Patriarca F, Tascini C, et al. Screening procedure for SARS-CoV-2 infection combining triage, nasopharyngeal swab and serological test in allogeneic stem cell transplantation recipients undergoing outpatient posttransplant follow-up. *J Med Virol*. 2020;93: 1244–1246. doi:10.1002/jmv.26586
151. Stellato P, Granata A, De Matteo A, Capelli C, Paparo M, Parasole R, et al. Successful management plan of COVID-19 in a pediatric hemato-oncology department: A single-centre experience. *bmjpo*. 2020;4: e000818. doi:10.1136/bmjpo-2020-000818
152. Plebani M, Padoan A, Fedeli U, Schievano E, Vecchiato E, Lippi G, et al. SARS-CoV-2 serosurvey in health care workers of the Veneto Region. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2020;58: 2107–2111. doi:10.1515/cclm-2020-1236
153. Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Marziano V, et al. Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020. *Eurosurveillance*. 2020;25: 2001383. doi:10.2807/1560-7917.ES.2020.25.31.2001383
154. Allesi D, Borré S, Barale A, Isabella A, Milano F, Rossi MA, et al. Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period? *Epidemiol Prev*. 2020;44. doi:doi: 10.19191/EP20.5-6.S2.119
155. Calcagno A, Ghisetti V, Emanuele T, Trunfio M, Faraoni S, Boglione L, et al. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. *Emerg Infect Dis*. 2021;27: 303–305. doi:10.3201/eid2701.203027
156. De Carlo A, Lo Caputo S, Paolillo C, Rosa AM, D’Orsi U, De Palma M, et al. SARS-COV-2 Serological Profile in Healthcare Professionals of a Southern Italy Hospital. *International Journal of Environmental Research and Public Health*. 2020;17: 9324. doi:10.3390/ijerph17249324
157. Martella F, Pozzessere D, Rossi F, Di Lieto M, Milandri C, Santini S, et al. SARS-COV-2 SCREENING AND MONITORING IN CANCER PATIENTS: AZIENDA USL TOSCANA CENTRO ONCOLOGY DEPARTMENT EXPERIENCE. *Tumori Journal*. 2020;106: 1–215. doi:10.1177/0300891620953388
158. Cavaliere AF, Carabeanu AI, Perelli F, Matarrese D, Brunelli T, Casprini P, et al. Universal screening for SARS-CoV-2 in pregnant women admitted for delivery: How to manage antibody testing? *The Journal of Maternal-Fetal & Neonatal Medicine*. 2020; 1–2. doi:10.1080/14767058.2020.1793317
159. Sandri MT, Azzolini E, Torri V, Carloni S, Pozzi C, Salvatici M, et al. SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy. *medRxiv*. 2020; 2020.05.24.20111245. doi:10.1101/2020.05.24.20111245
160. Sartore-Bianchi A, Patelli G, Tosi F, Campisi D, Di Ruscio F, Bencardino K, et al. INCIDENCE OF SARS-COV-2 INFECTION IN PATIENTS WITH ACTIVE CANCER: MONO-INSTITUTIONAL SERIES OF A COMPREHENSIVE CANCER INSTITUTION IN LOMBARDY DURING THE COVID-19 PANDEMIC (NIGUARDA CANCER CENTER, MILANO, ITALY). *Tumori Journal*. 2020. pp. 1–215. doi:10.1177/0300891620953388

161. Stefanelli P, Bella A, Fedele G, Pancheri S, Leone P, Vacca P, et al. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: A population-based study. *Clinical Microbiology and Infection*. 2020;0. doi:10.1016/j.cmi.2020.11.013
162. Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, et al. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. *Annals of Oncology*. 2020;32: 113–119. doi:10.1016/j.annonc.2020.10.473
163. Guerriero M, Bisoffi Z, Poli A, Micheletto C, Conti A, Pomari C. Prevalence of SARS-CoV-2, Verona, Italy, April–May 2020 - Volume 27, Number 1—January 2021 - *Emerging Infectious Diseases journal - CDC*. *Emerging Infectious Diseases*. 2020 [cited 11 Mar 2021]. doi:10.3201/eid2701.202740
164. Baracco A, Perotti G, Filippin A, Anesi A, Beccarini V, Raimondi L, et al. SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre. Rochester, NY: Social Science Research Network; 2020 Jul. Report No.: ID 3650227. Available: <https://papers.ssrn.com/abstract=3650227>
165. Denina M, Pellegrino F, Morotti F, Coppo P, Bonsignori IM, Garazzino S, et al. All that glitters is not COVID: Low prevalence of seroconversion against SARS-CoV-2 in a pediatric cohort of patients with Chilblain-like lesions. *Journal of the American Academy of Dermatology*. 2020 [cited 25 Sep 2020]. doi:10.1016/j.jaad.2020.08.021
166. Zambelli A, Fotia V, Bosetti T, Negrini G, di Croce A, Moro C, et al. 1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARS-CoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy. *Annals of Oncology*. 2020;31: S994. doi:10.1016/j.annonc.2020.08.1741
167. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. *Journal of Clinical Medicine*. 2020;9: 2780. doi:10.3390/jcm9092780
168. Carozzi FM, Cusi MG, Pistello M, Galli L, Bartoloni A, Anichini G, et al. Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: Results from a large-scale screening program based on rapid serological testing. medRxiv. 2020 [cited 13 Nov 2020]. doi:10.1101/2020.07.30.20149567
169. Bontadi D, Bergamo L, Torri P, Patanè PA, Bertoldi A, Lonardi U. Efficacia delle misure volte a contenere la diffusione del virus Sars-Cov-2 negli ambienti di lavoro: Un'indagine in nove aziende con sede nella regione Veneto. *Med Lav*. 2020;111: 404–410. doi:10.23749/mdl.v111i5.10037
170. Di Landro A. Bergamo serological tests, the results of Nembro and Alzano arrive: 61% positive. Bergamo Chronicle. 30 Apr 2020. Available: https://bergamo.corriere.it/notizie/cronaca/20_aprile_30/coronavirus-bergamo-primi-risultati-test-61percento-positivi-85e8e36c-8a6b-11ea-94d3-9879860c12b6.shtml. Accessed 13 Mar 2021.
171. Dalla Volta A, Valcamonico F, Pedersini R, Fornaro C, Tovazzi V, Monteverdi S, et al. The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures. *Front Oncol*. 2020;10: 1574. doi:10.3389/fonc.2020.01574
172. Lahner E, Dilaghi E, Prestigiacomo C, Alessio G, Marcellini L, Simmaco M, et al. Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy. *Int J Environ Res Public Health*. 2020;17. doi:10.3390/ijerph17124417
173. Loconsole D, Centrone F, Morcavallo C, Campanella S, Sallustio A, Quarto M, et al. The Light and Shadow of Rapid Serological Tests for SARS-CoV-2 Infection: Results from a Study in a Large Emergency Department. *IJERPH*. 2020;17: 6493. doi:10.3390/ijerph17186493
174. Cito F, Amato L, Di Giuseppe A, Danzetta ML, Iannetti S, Petrini A, et al. A COVID-19 Hotspot Area: Activities and Epidemiological Findings. *Microorganisms*. 2020;8: 1711. doi:10.3390/microorganisms8111711
175. Paradiso AV, Summa simona D, Silvestris N, Tommasi S, Tufaro A, Palma GD, et al. COVID-19 SCREENING AND MONITORING OF ASYMPTOMATIC HEALTH WORKERS WITH A RAPID SEROLOGICAL TEST. medRxiv. 2020; 2020.05.05.20086017. doi:10.1101/2020.05.05.20086017

176. Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, et al. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. *BMC Pulm Med.* 2020;20: 203. doi:10.1186/s12890-020-01237-0
177. Amendola A, Tanzi E, Folgori L, Barcellini L, Bianchi S, Gori M, et al. Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave. *Infect Control Hosp Epidemiol.* 2020; 1–2. doi:10.1017/ice.2020.401
178. Canetti D, Dell'Acqua R, Riccardi N, Della Torre L, Bigoloni A, Muccini C, et al. SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic. *New Microbiol.* 2020;43: 161–165.
179. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. *Blood Transfusion.* 2021 [cited 22 Apr 2021]. doi:10.2450/2021.0324-20
180. Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. *Eurosurveillance.* 2020;25. doi:10.2807/1560-7917.ES.2020.25.24.2001031
181. Fusco FM, Pisaturo M, Iodice V, Bellopede R, Tambaro O, Parrella G, et al. COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: Results of a cross-sectional surveillance study. *Journal of Hospital Infection.* 2020;105: 596–600. doi:10.1016/j.jhin.2020.06.021
182. Milani GP, Montomoli E, Bollati V, Albetti B, Bandi C, Bellini T, et al. SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy. *European Journal of Internal Medicine.* 2020;78: 161–163. doi:10.1016/j.ejim.2020.06.010
183. Pancrazzi A, Magliocca P, Lorubbio M, Vaggelli G, Galano A, Mafucci M, et al. Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity. *Clinical Biochemistry.* 2020;84: 87–92. doi:10.1016/j.clinbiochem.2020.07.002
184. Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I, et al. Unexpected detection of SARS-CoV-2 antibodies in the pre-pandemic period in Italy. *Tumori.* 2020; 030089162097475. doi:10.1177/0300891620974755
185. Oka S, Higuchi T, Furukawa H, Shimada K, Hashimoto A, Matsui T, et al. Detection of anti-SARS-CoV-2 antibodies in patients with rheumatoid arthritis. 2020 [cited 7 Feb 2021]. doi:10.21203/rs.3.rs-112294/v1
186. Matthews MM, Kim TG, Shibata S, Shibata N, Butcher C, Hyun J, et al. COVID-19 serological survey using micro blood sampling. *medRxiv.* 2021; 2020.10.09.20209858. doi:10.1101/2020.10.09.20209858
187. Hibino S, Hayashida K, Ahn AC, Hayashida Y. COVID-19 seropositivity changes in asymptomatic individuals during the second and third waves of COVID-19 in Tokyo. *medRxiv.* 2021; 2020.09.21.20198796. doi:10.1101/2020.09.21.20198796
188. Fukuda H, Seyama K, Ito K, Hori S, Wakita M, Saito K, et al. SARS-CoV-2 seroprevalence in healthcare workers at a frontline hospital in Tokyo. In Review; 2020 Oct. doi:10.21203/rs.3.rs-96870/v1
189. Hibino M, Iwabuchi S, Munakata H. SARS-CoV-2 IgG seroprevalence among medical staff in a general hospital that treated patients with COVID-19 in Japan: Retrospective evaluation of nosocomial infection control. *Journal of Hospital Infection.* 2020;107: 103–104. doi:10.1016/j.jhin.2020.10.001
190. Nawa N, Kuramochi J, Sonoda S, Yamaoka Y, Nukui Y, Miyazaki Y, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): A household- and population-based study. *medRxiv.* 2020; 2020.07.20.20155945. doi:10.1101/2020.07.20.20155945
191. わかやま県政ニュース. [cited 22 Apr 2021]. Available: <http://wave.pref.wakayama.lg.jp/news/kensei/shiryō.php?sid=31587>

192. Nishida T, Iwahashi H, Yamauchi K, Kinoshita N, Okauchi Y, Suzuki N, et al. Seroprevalence of SARS-CoV-2 Antibodies Among 925 Staff Members in an Urban Hospital Accepting COVID-19 Patients in Osaka Prefecture, Japan. *medRxiv*. 2020; 2020.09.10.20191866. doi:10.1101/2020.09.10.20191866
193. Yong Chong, Naoki Tani, Hideyuki Ikematsu, Nobuto Terazawa, Hitoshi Nakashima, Nobuyuki Shimono, et al. Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan. *Research Square*. 2020. doi:10.21203/rs.3.rs-64266/v1
194. Suda G, Ogawa K, Kimura M, Maehara O, Kitagataya T, Ohara M, et al. Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19. *Hepatology*. 2020. doi:10.1111/hepr.13551
195. Nakamura A, Sato R, Ando S, Oana N, Nozaki E, Endo H, et al. Orthogonal antibody testing for COVID-19 among healthcare workers in a non-epidemic place and time: Japan's Iwate Prefecture, May 18-31, 2020. *Fukushima Journal of Medical Science*. 2021;67: 27–32. doi:10.5387/fms.2020-21
196. The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers. *International Immunopharmacology*. 2021;92: 107360. doi:10.1016/j.intimp.2020.107360
197. Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, et al. Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing. *J Prim Care Community Health*. 2020;11: 215013272094269. doi:10.1177/2150132720942695
198. Denyer S. Japanese firm's blanket testing of employees could serve as model. *LMT Online*. 21 Jun 2020. Available: <https://www.google.com/url?rct=j&sa=t&url=https://www.lmtonline.com/ne>. Accessed 13 Mar 2021.
199. Fujita K, Kada S, Kanai O, Hata H, Odagaki T, Satoh-Asahara N, et al. Quantitative SARS-CoV-2 Antibody Screening of Healthcare Workers in the Southern Part of Kyoto City During the COVID-19 Pre-pandemic Period. *Front Public Health*. 2020;8. doi:10.3389/fpubh.2020.595348
200. Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study. *medRxiv*. 2020; 2020.04.26.20079822. doi:10.1101/2020.04.26.20079822
201. Suzuki T, Hayakawa K, Ainai A, Iwata-Yoshikawa N, Sano K, Nagata N, et al. Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers. *Journal of Infection and Chemotherapy*. 2021;27: 120–122. doi:10.1016/j.jiac.2020.09.006
202. Schaffner A, Risch L, Aeschbacher S, Risch C, Weber MC, Thiel SL, et al. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. *Journal of Clinical Medicine*. 2020;9: 3989. doi:10.3390/jcm9123989
203. Snoeck C. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: The CON-VINCE study. Preprint.
204. Fabien Binacchi. Monaco has tested its population and the seroprevalence rate is very low. *Teller Report*; 16 Jun 2020 [cited 28 Apr 2021]. Available: <https://www.tellerreport.com/news/2020-06-16-monaco-has-tested-its-population-and-the-seroprevalence-rate-is-very-low.SJ66VJ4UT8.html>
205. Vos ERA, Hartog G den, Schepp RM, Kaaijk P, Vliet J van, Helm K, et al. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave. *J Epidemiol Community Health*. 2020 [cited 23 Jan 2021]. doi:10.1136/jech-2020-215678
206. Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. *Nature Communications*. 2020;11: 5744. doi:10.1038/s41467-020-19481-7

207. Westerhuis BM, de Bruin E, Chandler FD, Ramakers CRB, Okba NMA, Li W, et al. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands. medRxiv. 2020; 2020.08.21.20177857. doi:10.1101/2020.08.21.20177857
208. Craigie A, McGregor R, Whitcombe A, Carlton L, Harte D, Sutherland M, et al. SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020. medRxiv. 2020; 2020.10.20.20215616. doi:10.1101/2020.10.20.20215616
209. Gro Tunheim, Anne-Marte Bakken Kran, Gunnar Rø, Anneke Steens, Olav Hungnes, Fridtjof Lund-Johansen, et al. Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in April/May 2020 and August 2019. Norwegian Institute of Public Health; 2020 Jun p. 13. Available: https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/covid-19/seroprevalence-of-sars-cov-2-in-the-norwegian-population_report-26-06-2020.pdf
210. Trieu M-C, Bansal A, Madsen A, Zhou F, Sævik M, Vahokoski J, et al. SARS-CoV-2–Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. *The Journal of Infectious Diseases*. 2020 [cited 29 Jan 2021]. doi:10.1093/infdis/jiaa737
211. Kuwelker K, Zhou F, Blomberg B, Lartey S, Brokstad KA, Trieu MC, et al. High attack rates of SARS-CoV-2 infection through household-transmission: A prospective study. 2020 [cited 2 Mar 2021]. doi:10.1101/2020.11.02.20224485
212. Cox RJ, Brokstad KA, Krammer F, Langeland N. Seroconversion in household members of COVID-19 outpatients. *Lancet Infect Dis*. 2021;21: 168. doi:10.1016/S1473-3099(20)30466-7
213. Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. *European Journal of Immunology*. 2020;50: 2025–2040. doi:10.1002/eji.202048970
214. Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. *European Journal of Immunology*. 2020;50: 2025–2040. doi:10.1002/eji.202048970
215. Kislaya I, Gonçalves P, Barreto M, Sousa R de, Garcia AC, Matos R, et al. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). *Acta Médica Portuguesa*. 2021;34: 87–94. doi:10.20344/amp.15122
216. Gonçalves J, Sousa RL, Jacinto MJ, Silva DA, Paula F, Sousa R, et al. Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures. *Front Med*. 2020;7. doi:10.3389/fmed.2020.603996
217. COVID-19 Serology Tests Still Show Low Antibody Rate of 0.07%. KBS World Radio; [cited 7 Mar 2021]. Available: http://world.kbs.co.kr/service/news_view.htm?lang=e&Seq_Code=157801
218. Yang Ji-ho. Few Koreans Test Positive for Coronavirus Antibodies. Chosunlibo. 10 Jul 2020. Available: http://english.chosun.com/site/data/html_dir/2020/07/10/2020071001864.html
219. Song S-K, Lee D-H, Nam J-H, Kim K-T, Do J-S, Kang D-W, et al. IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea. *J Korean Med Sci*. 2020;35. Available: <https://doi.org/10.3346/jkms.2020.35.e269>
220. Noh JY, Seo YB, Yoon JG, Seong H, Hyun H, Lee J, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea. *Journal of Korean Medical Science*. 2020;35. doi:10.3346/jkms.2020.35.e311
221. Ko J-H, Lee JY, Kim HA, Kang S-J, Baek JY, Park S-J, et al. Serologic Evaluation of Healthcare Workers Caring for COVID-19 Patients in the Republic of Korea. *Front Microbiol*. 2020;11. doi:10.3389/fmicb.2020.587613

222. Rei Kurohi, Linette Lai. Coronavirus: Community transmission in S'pore very low, but so is herd immunity, NCID says. *The Straits Times*; 29 Apr 2020. Available: <https://www.straitstimes.com/singapore/health/coronavirus-community-transmission-in-spore-very-low-but-so-is-herd-immunity-says>
223. Ng OT, Marimuthu K, Koh V, Pang J, Linn KZ, Sun J, et al. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: A retrospective cohort study. *The Lancet Infectious Diseases*. 2021;21: 333–343. doi:10.1016/S1473-3099(20)30833-1
224. Savirón-Cornudella R, Villalba A, Zapardiel J, Andeyro-Garcia M, Esteban LM, Pérez-López FR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2020;256: 400–404. doi:10.1016/j.ejogrb.2020.11.069
225. Garde-Noguera J, Fernández-Murga ML, Giner-Bosch V, Dominguez-Márquez V, Sánchez JG, Soler-Cataluña JJ, et al. Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population. *Cancers*. 2020;12: 3513. doi:10.3390/cancers12123513
226. Prados N, González-Ravina C, Vergara V, Herrero J, Cruz M, Requena A. RISK FACTOR ANALYSIS FOR SARS-COV-2 SEROPOSITIVITY WITHIN ASSISTED REPRODUCTIVE. *Fertility and Sterility*. 2020;114: e547. doi:10.1016/j.fertnstert.2020.09.077
227. Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Oliveros-Acebes E, García-Navarro MJ, Khosravi-Shahi P. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data. *Cancer Treatment Reviews*. 2020;90: 102102. doi:10.1016/j.ctrv.2020.102102
228. Hernández Camba A, Marcelino Reyes R, Hernández-Guerra M, Blasco Amato OA, Bennemann P, Diaz Machin S, et al. Pre-Procedural Antibody Testing for SARS-CoV-2 in routine endoscopic practice. *Rev Esp Enferm Dig*. 2020 [cited 31 Jan 2021]. doi:10.17235/reed.2020.7434/2020
229. Brotons P, Launes C, Buetas E, Fumado V, Henares D, de Sevilla MF, et al. Susceptibility to Sars-COV-2 Infection Among Children And Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain. *Clinical Infectious Diseases*. 2020 [cited 23 Jan 2021]. doi:10.1093/cid/ciaa1721
230. FLORES D. Coronavirus | Los test serológicos de Torrejón de Ardoz arrojan un 20,18 % de personas con anticuerpos de coronavirus. RTVEes: NOTICIAS. 17 Jun 2020. Available: <https://www.rtve.es/noticias/20200617/test-serologicos-torrejón-ardož-arrojan-2018-habitantes-tiene-anticuerpos-coronavirus/2018787.shtml>. Accessed 7 Oct 2020.
231. Pérez-García F, Pérez-Zapata A, Arcos N, De la Mata M, Ortiz M, Simón E, et al. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among hospital workers in a severely affected institution in Madrid, Spain: A surveillance cross-sectional study. *Infect Control Hosp Epidemiol*. 2020; 1–7. doi:10.1017/ice.2020.1303
232. Fabre M, Ruiz-Martinez S, Monserrat Cantera M, Cortizo Garrido A, Beunza Fabra Z, Peran M, et al. SARS-CoV-2 immunochromatographic IgM/IgG rapid test in pregnancy: A false friend? *Ann Clin Biochem*. 2020;58: 149–152. doi:10.1177/0004563220980495
233. Barallat J, Fernández-Rivas G, Quirant-Sánchez B, González V, Doladé M, Martínez-Caceres E, et al. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. *PLOS ONE*. 2020;15: e0244348. doi:10.1371/journal.pone.0244348
234. Viñuela MC, De León-Luis JA, Alonso R, Catalán P, Lizarraga S, Muñoz P, et al. SARS-CoV-2 screening of asymptomatic women admitted for delivery must be performed with a combination of microbiological techniques: An observational study. *Rev Esp Quimioter*. 2020;33: 415–421. doi:10.37201/req/088.2020
235. Soriano V, Meiriño R, Corral O, Guallar MP. Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. *Clinical Infectious Diseases*. 2020 [cited 14 Nov 2020]. doi:10.1093/cid/ciaa769

236. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. *The Lancet*. 2020; S0140673620314835. doi:10.1016/S0140-6736(20)31483-5
237. Villalaín C, Herraiz I, Luczkowiak J, Pérez-Rivilla A, Folgueira MD, Mejía I, et al. Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome. Cruz-Martinez R, editor. *PLoS ONE*. 2020;15: e0243029. doi:10.1371/journal.pone.0243029
238. Gras-Valentí P, Chico-Sánchez P, Algado-Sellés N, Gimeno-Gascón MA, Mora-Muriel JG, Jiménez-Sepúlveda NJ, et al. Estudio de sero-epidemiología de la infección por SARS-CoV-2 en profesionales sanitarios de un departamento sanitario. *Enfermedades Infecciosas y Microbiología Clínica*. 2020; S0213005X20303098. doi:10.1016/j.eimc.2020.09.015
239. Crovetto F, Crispi F, Llurba E, Figueras F, Gómez-Roig MD, Gratacós E. Seroprevalence and presentation of SARS-CoV-2 in pregnancy. *The Lancet*. 2020;396: 530–531. doi:10.1016/S0140-6736(20)31714-1
240. Valdivia A, Torres I, Huntley D, Alcaraz MJ, Albert E, Solano de la Asunción C, et al. Caveats in interpreting SARS-CoV-2 IgM+/IgG– antibody profile in asymptomatic health care workers. *Journal of Medical Virology*. 2020;n/a. doi:10.1002/jmv.26400
241. Galán MI, Velasco M, Casas ML, Goyanes MJ, Rodríguez-Caravaca G, Losa-García JE, et al. Hospital-Wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital. *Enfermedades Infecciosas y Microbiología Clínica*. 2020; S0213005X20304183. doi:10.1016/j.eimc.2020.11.015
242. Olalla J, Correa AM, Martín-Escalante MD, Hortas ML, Martín-Sendarrubias MJ, Fuentes V, et al. Search for asymptomatic carriers of SARS-CoV-2 in healthcare workers during the pandemic: A Spanish experience. *QJM: An International Journal of Medicine*. 2020 [cited 14 Nov 2020]. doi:10.1093/qjmed/hcaa238
243. Montenegro P, Brotons C, Serrano J, Fernández D, García-Ramos C, Ichazo B, et al. Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain. *Family Practice*. 2020 [cited 8 Jan 2021]. doi:10.1093/fampra/cmaa096
244. Moreno Borraz LA, Giménez López M, Carrera Lasfuentes P, González Pérez E, Ortiz Domingo C, Bonafonte Marteles JL, et al. Prevalencia de infección por coronavirus SARS-CoV-2 en pacientes y profesionales de un hospital de media y larga estancia en España. *Revista Española de Geriatria y Gerontología*. 2020;56: 75–80. doi:10.1016/j.regg.2020.10.005
245. Dacosta-Urbieta A, Rivero-Calle I, Pardo-Seco J, Redondo-Collazo L, Salas A, Gómez-Rial J, et al. Seroprevalence of SARS-CoV-2 Among Pediatric Healthcare Workers in Spain. *Front Pediatr*. 2020;8. doi:10.3389/fped.2020.00547
246. Martín V, Fernández-Villa T, Lamuedra Gil de Gomez M, Mencía-Ares O, Rivero Rodríguez A, Reguero Celada S, et al. Prevalence of SARS-CoV-2 infection in general practitioners and nurses in primary care and nursing homes in the Healthcare Area of León and associated factors. *Medicina de Familia SEMERGEN*. 2020;46: 35–39. doi:10.1016/j.semerg.2020.05.014
247. Garralda Fernandez J, Molero Vilches I, Bermejo Rodríguez A, Cano Torres I, Colino Romay EI, García Arata I, et al. Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain. Page K, editor. *PLoS ONE*. 2021;16: e0245001. doi:10.1371/journal.pone.0245001
248. Dopico XC, Muschiol S, Christian M, Hanke L, Sheward DJ, Grinberg NF, et al. Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden. *medRxiv*. 2020; 2020.12.24.20248821. doi:10.1101/2020.12.24.20248821
249. Rashid-Abdi M, Krifors A, Sälléber A, Eriksson J, Månsson E. Low rate of COVID-19 seroconversion in health-care workers at a Department of Infectious Diseases in Sweden during the later phase of the first wave; a prospective longitudinal seroepidemiological study. *Infectious Diseases*. 2020;53: 169–175. doi:10.1080/23744235.2020.1849787

250. The Local SE. 14% of coronavirus antibody tests positive in Sweden in July. The Local SE. 23 Jul 2020. Available: <https://www.thelocal.se/20200723/14-of-antibody-tests-positive-in-sweden>
251. Stockholm Region. 16 juli: Lägesrapport om arbetet med det nya coronaviruset. Stockholm Region. 16 Jul 2020. Available: <https://www.sll.se/verksamhet/halsa-och-varld/nyheter-halsa-och-varld/2020/07/16-juli-lagesrapport-om-arbetet-med-det-nya-coronaviruset/>
252. Lidström A-K, Sund F, Albinsson B, Lindbäck J, Westman G. Work at inpatient care units is associated with an increased risk of SARS-CoV-2 infection; a cross-sectional study of 8679 healthcare workers in Sweden. *null*. 2020;125: 305–310. doi:10.1080/03009734.2020.1793039
253. Lundkvist Å, Hanson S, Olsen B. Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden. *Infection Ecology & Epidemiology*. 2020;10: 1806505. doi:10.1080/20008686.2020.1806505
254. Hassan SS, Seigerud Å, Mühr LSA, Kleppe SN, Pin E, Månberg A, et al. SARS-CoV-2 infections among personnel providing home care services for the elderly in Stockholm, Sweden. *medRxiv*. 2020 [cited 15 May 2021]. doi:10.1101/2020.12.18.20248511
255. Agency SPH. Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 1). Swedish Public Health Agency; 2020 Jun. Available: <https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf>
256. Niclas Roxhed, Hong M-G, Bendes A, Matilda Dale, Mattsson C, Dodig-Crnkovic T, et al. A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood | *medRxiv*. *medRxiv*. 2020 [cited 6 Jul 2020]. Available: <https://www.medrxiv.org/content/10.1101/2020.07.01.20143966v1>
257. Rudberg A-S, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. *Nature Communications*. 2020;11: 5064. doi:10.1038/s41467-020-18848-0
258. Lindahl JF, Hoffman T, Esmailzadeh M, Olsen B, Winter R, Amer S, et al. High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden. *null*. 2020;10: 1789036. doi:10.1080/20008686.2020.1789036
259. Ulyte A, Radtke T, Abela IA, Haile SR, Berger C, Huber M, et al. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school-children: Prospective cohort study of 55 schools in Switzerland. *medRxiv*. 2020; 2020.12.19.20248513. doi:10.1101/2020.12.19.20248513
260. Anker D, Chiorelo A, Epure A, Schmid A, Carmeli C, Rodondi P-Y, et al. Corona Immunitas Fribourg Immunité de la population Episode 1/2020. *Corona Immunitas*; 2020 Nov. Available: <https://www.corona-immunitas.ch/en/news/corona-immunitas-ticino-insieme-per-reagire-al-via-la-seconda-fase-del-progetto-1-1-1/>
261. Kahlert CR, Persi R, Güsewell S, Egger T, Leal-Neto OB, Sumer J, et al. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among Hospital Workers – a multicentre cross-sectional study. *medRxiv*. 2020; 2020.11.10.20229005. doi:10.1101/2020.11.10.20229005
262. Corona Immunitas Ticino, the first results are in. [cited 23 Apr 2021]. Available: <https://www.biomed.usi.ch/en/feeds/8913>
263. Emmenegger M, De Cecco E, Lamparter D, Jacquat RPB, Ebner D, Schneider MM, et al. Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region. *medRxiv*. 2020 [cited 14 May 2021]. doi:10.1101/2020.05.31.20118554
264. Ulyte A, Radtke T, Abela IA, Haile SH, Blankenberger J, Jung R, et al. Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes. *medRxiv*. 2020; 2020.09.18.20191254. doi:10.1101/2020.09.18.20191254

265. Bi Q, Lessler J, Eckerle I, Lauer SA, Kaiser L, Vuilleumier N, et al. Household Transmission of SARS-CoV-2: Insights from a Population-based Serological Survey. *Epidemiology*; 2020 Nov. doi:10.1101/2020.11.04.20225573
266. Richard A, Wisniak A, Perez-Saez J, Garrison-Desany H, Petrovic D, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: A population-based study. *medRxiv*. 2020 [cited 15 May 2021]. doi:10.1101/2020.12.16.20248180
267. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. Subbarao K, editor. *J Virol*. 2020;95: e01828–20, /jvi/95/3/JVI.01828–20.atom. doi:10.1128/JVI.01828-20
268. Dupraz J, Butty A, Duperrex O, Estoppey S, Faivre V, Thabard J, et al. Prevalence of SARS-CoV-2 in household members and other close contacts of COVID-19 cases: A serologic study in canton of Vaud, Switzerland. *medRxiv*. 2020; 2020.11.27.20239244. doi:10.1101/2020.11.27.20239244
269. Posfay-Barbe KM, Andrey DO, Virzi J, Cohen P, Pigny F, Goncalves AR, et al. Prevalence of Immunoglobulin G (IgG) Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Evaluation of a Rapid MEDsan IgG Test in Children Seeking Medical Care. *Clinical Infectious Diseases*. 2020; ciaa1702. doi:10.1093/cid/ciaa1702
270. Kohler PP, Kahlert CR, Sumer J, Flury D, Güsewell S, Leal-Neto OB, et al. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study. *Infect Control Hosp Epidemiol*. 2020; 1–5. doi:10.1017/ice.2020.1244
271. Steel K, Donnarumma. H. Coronavirus (COVID-19) Infection Survey: Antibody data for the UK, January 2021. Office for National Statistics; 2021 Jan. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/antibodydatafortheukjanuary2021#likelihood-of-testing-positive-for-covid-19-antibodies-in-england-wales-northern-ireland-and-scotland>
272. Steel K, Davies B. Coronavirus (COVID-19) Infection Survey: Characteristics of people testing positive for COVID-19 in England and antibody data for the UK - Office for National Statistics. Office for National Statistics; 2020 Dec p. 12. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020>
273. Taubel J, Cole ST, Spencer CS, Freier A, Camilleri D, Lorch U. Why the SARS-CoV-2 antibody test results may be misleading: Insights from a longitudinal analysis of COVID-19. *medRxiv*. 2020; 2020.12.08.20245894. doi:10.1101/2020.12.08.20245894
274. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med*. 2020; NEJMoa2034545. doi:10.1056/NEJMoa2034545
275. Steel K, Davies B. Coronavirus (COVID-19) Infection Survey: Characteristics of people testing positive for COVID-19 in England and antibody data for the UK - Office for National Statistics. Office for National Statistics; 2020 Nov p. 12. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/december2020>
276. Steel K, Davies B. Coronavirus (COVID-19) Infection Survey: Characteristics of people testing positive for COVID-19 in England and antibody data for the UK - Office for National Statistics. Office for National Statistics; 2020 Oct p. 12. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/november2020>

277. Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining prevalence of antibody positivity to SARS-CoV-2: A community study of 365,000 adults. medRxiv. 2020; 2020.10.26.20219725. doi:10.1101/2020.10.26.20219725
278. Steel K, Davies B. Coronavirus (COVID-19) Infection Survey: Characteristics of people testing positive for COVID-19 in England and antibody data for the UK - Office for National Statistics. Office for National Statistics; 2020 Sep p. 12. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/november2020>
279. England PH. National COVID-19 surveillance report: 2 October 2020 (week 40). Public Health England; 2020 Oct. Available: <https://www.gov.uk/government/publications/national-covid-19-surveillance-reports>
280. Abo-Leyah H, Gallant S, Cassidy D, Giam YH, Killick J, Marshall B, et al. Seroprevalence of SARS-COV-2 Antibodies in Scottish Healthcare Workers. medRxiv. 2020; 2020.10.02.20205641. doi:10.1101/2020.10.02.20205641
281. England PH. National COVID-19 surveillance report: 11 September 2020 (week 37). Public Health England; 2020 Sep. Available: <https://www.gov.uk/government/publications/national-covid-19-surveillance-reports>
282. Steel K, Davies B. Coronavirus (COVID-19) Infection Survey: Characteristics of people testing positive for COVID-19 in England and antibody data for the UK - Office for National Statistics. Office for National Statistics; 2020 Aug p. 12. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/november2020>
283. Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et al. Serological surveillance of SARS-CoV-2: Trends and humoral response in a cohort of public health workers. medRxiv. 2020; 2020.10.21.20216689. doi:10.1101/2020.10.21.20216689
284. Roarty C, Tonry C, McFetridge L, Mitchell H, Watson C, Waterfield T, et al. Kinetics and seroprevalence of SARS-CoV-2 antibodies in children. *The Lancet Infectious Diseases*. 2020;0. doi:10.1016/S1473-3099(20)30884-7
285. Andrew McAuley, Elizabeth Dickson, Norah Palmateer, Josie Murray, Craig Waugh, Lesley Wallace, et al. Enhanced Surveillance of COVID-19 in Scotland Population-based seroprevalence surveillance. Public Health Scotland; 2020 Sep. Available: <https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/>
286. Cooper DJ, Lear S, Watson L, Shaw A, Ferris M, Doffinger R, et al. A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital. medRxiv. 2020; 2020.11.03.20220699. doi:10.1101/2020.11.03.20220699
287. Black JT, Haroon U, Barnes SC, Mayaleh S, Bagul A. Seroprevalence of SARS-CoV-2 IgG antibodies in the current COVID-19 pandemic amongst co-workers at a UK renal transplant centre. *Transplant International*. n/a. doi:10.1111/tri.13791
288. England PH. National COVID-19 surveillance report: 7 August 2020 (week 32). Public Health England; 2020 Aug. Available: <https://www.gov.uk/government/publications/national-covid-19-surveillance-reports>
289. Claudiani S, Rosadas C, McClure M, Khan M, Tedder R, Innes A, et al. Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia. *Blood*. 2020;136. Available: <https://ashpublications.org/crawlpreservation/governor?content=>
290. Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. *Nature Communications*. 2021;12: 905. doi:10.1038/s41467-021-21237-w

291. Martin CA, Patel P, Goss C, Jenkins DR, Price A, Barton L, et al. Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. *Journal of Public Health*. 2020 [cited 14 Mar 2021]. doi:10.1093/pubmed/fdaa199
292. Hanrath AT, Loeff IS van der, Lendrem DW, Baker KF, Price DA, McDowall P, et al. SARS-CoV-2 testing of 11,884 healthcare workers at an acute NHS hospital trust in England: A retrospective analysis. medRxiv. 2020; 2020.12.22.20242362. doi:10.1101/2020.12.22.20242362
293. Prendecki M, Clarke C, Gleeson S, Greathead L, Santos E, McLean A, et al. Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients. *JASN*. 2020;31: 2753–2756. doi:10.1681/ASN.2020081152
294. Waterfield T, Watson C, Moore R, Ferris K, Tonry C, Watt A, et al. Seroprevalence of SARS-CoV-2 antibodies in children: A prospective multicentre cohort study. *Archives of Disease in Childhood*. 2020 [cited 14 Mar 2021]. doi:10.1136/archdischild-2020-320558
295. Steel K, Davies B. Coronavirus (COVID-19) Infection Survey: Characteristics of people testing positive for COVID-19 in England and antibody data for the UK - Office for National Statistics. Office for National Statistics; 2020 Jul p. 12. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/november2020>
296. Rowland TAJ, Whitaker H, Jeffery-Smith A, Lang N, Sendall K, McLaren R, et al. Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemic. *Journal of Infection*. 2020; S0163445320306952. doi:10.1016/j.jinf.2020.10.035
297. Nsn G, C J, R M, P R, N L, Sn L, et al. High rates of SARS-CoV-2 seropositivity in nursing home residents. *Journal of Infection*. 2020; S0163445320305740. doi:10.1016/j.jinf.2020.08.040
298. Davis KAS, Carr E, Leightley D, Vitiello V, Bergin-Cartwright G, Lavelle G, et al. Indicators of past COVID-19 infection status: Findings from a large occupational cohort of staff and postgraduate research students from a UK university. medRxiv. 2021; 2020.12.07.20245183. doi:10.1101/2020.12.07.20245183
299. England PH. National COVID-19 surveillance report: 9 July 2020 (week 28). Public Health England; 2020 Jul. Available: <https://www.gov.uk/government/publications/national-covid-19-surveillance-reports>
300. Gulraj P. After in-house GHA screening programme, Govt rethinks its plans for anti-body tests. *Gibraltar Chronicle*. 17 Jun 2020. Available: <https://www.chronicle.gi/after-in-house-gha-screening-programme-govt-rethinks-its-plans-for-anti-body-tests/>. Accessed 13 Mar 2021.
301. Lumley SF, Eyre DW, McNaughton AL, Howarth A, Hoosdally S, Hatch SB, et al. SARS-CoV-2 antibody prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14 April to 15 June 2020. *Eurosurveillance*. 2020;25: 2001721. doi:10.2807/1560-7917.ES.2020.25.41.2001721
302. Jones CR, Hamilton FW, Thompson A, Morris TT, Moran E. SARS-CoV-2 IgG seroprevalence in healthcare workers and other staff at North Bristol NHS Trust: A sociodemographic analysis. *Journal of Infection*. 2020;0. doi:10.1016/j.jinf.2020.11.036
303. Favara DM, McAdam K, Cooke A, Bordessa-Kelly A, Budriunaite I, Bossingham S, et al. SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic. medRxiv. 2020; 2020.09.18.20197590. doi:10.1101/2020.09.18.20197590
304. Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E, et al. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: A prospective multicentre cohort study. *The Lancet Respiratory Medicine*. 2020;8: 885–894. doi:10.1016/S2213-2600(20)30315-5
305. Baxendale HE, Wells D, Gronlund J, Nadesalingam A, Paloniemi M, Carnell G, et al. Critical care workers have lower seroprevalence of SARS-CoV-2 IgG compared with non-patient facing staff in first wave of COVID19. medRxiv. 2020; 2020.11.12.20145318. doi:10.1101/2020.11.12.20145318

306. Arif M, Maaref Doost M. Prevalence of COVID-19 Among Typical Ambulatory Care Patients in a District General Hospital in the United Kingdom. *Cureus*. 2020 [cited 15 May 2021]. doi:10.7759/cureus.11398
307. Razvi S, Oliver R, Moore J, Beeby A. Exposure of hospital healthcare workers to the novel coronavirus (SARS-CoV-2). *Clin Med*. 2020;20: e238–e240. doi:10.7861/clinmed.2020-0566
308. Favara DM, Cooke A, Doffinger R, McAdam K, Corrie P, Ainsworth NL. COVID-19 Serology in Oncology Staff Study: Understanding SARS-CoV-2 in the Oncology Workforce. *Clin Oncol (R Coll Radiol)*. 2021;33: e61–e63. doi:10.1016/j.clon.2020.07.015
309. Bampoe S, Lucas DN, Neall G, Sceales P, Aggarwal R, Caulfield K, et al. A cross-sectional study of immune seroconversion to SARS-CoV-2 in frontline maternity health professionals. *Anaesthesia*. 2020;75: 1614–1619. doi:10.1111/anae.15229
310. Grant JJ, Wilmore SMS, McCann NS, Donnelly O, Lai RWL, Kinsella MJ, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. *Infection Control & Hospital Epidemiology*. 2020/08/04 ed. 2020; 1–3. doi:10.1017/ice.2020.402
311. McCafferty K, Davari M, Price K, Rajakariar R, Cove-Smith A, Forbes SH. COVID-19 prevalence and seroconversion in an urban hemodialysis unit in the United Kingdom. *Hemodialysis International*. 2020;25: 137–139. doi:10.1111/hdi.12883
312. Steel K, Davies B. Coronavirus (COVID-19) Infection Survey: Characteristics of people testing positive for COVID-19 in England and antibody data for the UK - Office for National Statistics. Office for National Statistics; 2020 Jun p. 12. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsinthecommunityinengland/november2020>
313. Wells PM, Doores KM, Couvreur S, Martin Martinez R, Seow J, Graham C, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. *medRxiv*. 2020; 2020.07.29.20162701. doi:10.1101/2020.07.29.20162701
314. Ladhani SN, Andrews N, Aiano F, Baawuah F, Amin-Chowdhury Z, Brown KE, et al. Secondary attack rate and family clustering of SARS-CoV-2 infection in children of healthcare workers with confirmed COVID-19. *Clinical Infectious Diseases*. 2020 [cited 14 Mar 2021]. doi:10.1093/cid/ciaa1737
315. Khalil A, Hill R, Wright A, Ladhani S, O'Brien P. SARS-CoV-2-Specific Antibody Detection in Healthcare Workers in a UK Maternity Hospital: Correlation With SARS-CoV-2 RT-PCR Results. *Clinical Infectious Diseases*. 2020 [cited 14 Nov 2020]. doi:10.1093/cid/ciaa893
316. Hughes EC, Amat JAR, Haney J, Parr YA, Logan N, Palmateer N, et al. SARS-CoV-2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting. *The Journal of Infectious Diseases*. 2020 [cited 31 Jan 2021]. doi:10.1093/infdis/jiaa788
317. Thompson CP, Grayson NE, Paton RS, Bolton JS, Lourenço J, Penman BS, et al. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. *Eurosurveillance*. 2020;25: 2000685. doi:10.2807/1560-7917.ES.2020.25.42.2000685
318. Poulidakos D, Sinha S, Kalra PA. SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England. *J Clin Virol*. 2020/07/07 ed. 2020;129: 104545–104545. doi:10.1016/j.jcv.2020.104545
319. England PH. National COVID-19 surveillance report: 21 August 2020 (week 34). Public Health England; 2020 Aug pp. 31–34. Available: <https://www.gov.uk/government/publications/national-covid-19-surveillance-reports>
320. England PH. National COVID-19 surveillance report: 28 August 2020 (week 35). Public Health England; 2020 Aug. Available: <https://www.gov.uk/government/publications/national-covid-19-surveillance-reports>

321. Shields AM, Faustini SE, Perez-Toledo M, Jossi S, Aldera EL, Allen JD, et al. SARS-CoV-2 seroconversion in health care workers. medRxiv. 2020; 2020.05.18.20105197. doi:10.1101/2020.05.18.20105197
322. Sikora K, Barwick I, Hamilton C. Serological prevalence of antibodies to SARS CoV-2 amongst cancer centre staff. medRxiv. 2020; 2020.05.16.20099408. doi:10.1101/2020.05.16.20099408
323. Ladhani SN, Jeffery-Smith A, Patel M, Janarthanan R, Fok J, Crawley-Boevey E, et al. High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study, England. EClinicalMedicine. 2020;28. doi:10.1016/j.eclinm.2020.100597
324. Houlihan CF, Vora N, Byrne T, Lewer D, Kelly G, Heaney J, et al. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. The Lancet. 2020;396: e6–e7. doi:10.1016/S0140-6736(20)31484-7
325. Malecki K, Nikodemova M, Schultz A, Walsh M, Bersch A, Sethi A, et al. Population Changes in Seroprevalence among a Statewide Sample in the United States. medRxiv. 2020; 2020.12.18.20248479. doi:10.1101/2020.12.18.20248479
326. Craver R. Wake Forest Baptist’s COVID-19 antibodies study expands to Triangle, eastern N.C. Winston-Salem Journal; 20 Dec 2020 [cited 6 Mar 2021]. Available: https://journalnow.com/news/local/wake-forest-baptists-covid-19-antibodies-study-expands-to-triangle-eastern-n-c/article_b8e94704-3e1e-11eb-8742-470dc9941f17.html
327. Stout RL, Rigatti SJ. The Silent Pandemic COVID-19 in the Asymptomatic Population. medRxiv. 2021 [cited 18 Jan 2021]. doi:doi.org/10.1101/2020.11.10.20215145
328. Jolley F. Lake, Sumter residents testing positive for COVID antibody remain below state average. dailycommercial; 3 Dec 2020 [cited 7 Mar 2021]. Available: <https://www.dailycommercial.com/story/news/2020/12/03/area-residents-covid-antibody-below-state-average/6475413002/>
329. Coffman B. Co-Immunity Project shows COVID-19 infection rate in Jefferson County increased tenfold since September | UofL News. UofLNews; 24 Nov 2020 [cited 8 Mar 2021]. Available: <https://www.uoflnews.com/post/uofltoday/co-immunity-project-shows-covid-19-infection-rate-in-jefferson-county-increased-tenfold-since-september/>
330. Godbout EJ, Pryor R, Harmon M, Montpetit A, Greer J, Bachmann LM, et al. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence among healthcare workers in a low prevalence region. Infection Control & Hospital Epidemiology. 2020; 1–3. doi:10.1017/ice.2020.1374
331. Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern Med. 2020 [cited 20 Jan 2021]. doi:10.1001/jamainternmed.2020.7976
332. Maricopa County COVID-19 serosurvey results reported. Fountain Hills Times; [cited 6 Mar 2021]. Available: https://www.fhtimes.com/news/local_news/maricopa-county-covid-19-serosurvey-results-reported/article_6be4ab0a-3983-11eb-ab22-a3b73c8957c7.html
333. Jimenez-Kurlander L, Antal Z, DeRosa A, Diotallevi D, Pottenger E, Wilson N, et al. COVID-19 in pediatric survivors of childhood cancer and hematopoietic cell transplantation from a single center in New York City. Pediatr Blood Cancer. 2020;68. doi:10.1002/pbc.28857
334. Demonbreun AR, McDade TW, Pesce L, Vaught LA, Reiser NL, Bogdanovic E, et al. Patterns and persistence of SARS-CoV-2 IgG antibodies in a US metropolitan site. medRxiv. 2020; 2020.11.17.20233452. doi:10.1101/2020.11.17.20233452
335. Halbrook M, Gadoth A, Martin-Blais R, Grey A, Contreras D, Kashani S, et al. Incidence of SARS-CoV-2 infection among asymptomatic frontline health workers in Los Angeles County, California. medRxiv. 2020; 2020.11.18.20234211. doi:10.1101/2020.11.18.20234211

336. Bruckner TA, Parker DM, Bartell SM, Vieira VM, Khan S, Noymer A, et al. Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California. *Scientific Reports*. 2021;11: 3081. doi:10.1038/s41598-021-82662-x
337. Brant-Zawadzki M, Fridman D, Robinson PA, Zahn M, Chau C, German R, et al. Prevalence and Longevity of SARS-CoV-2 Antibodies Among Health Care Workers. *Open Forum Infectious Diseases*. 2021;8. doi:10.1093/ofid/ofab015
338. Sabourin KR, Schultz J, Romero J, Lamb MM, Larremore D, Morrison TE, et al. Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders - the COVID-19 Arapahoe SErosurveillance Study (CASES) Project. *J Occup Environ Med*. 2020. doi:10.1097/JOM.0000000000002099
339. Heim M. Wisconsin COVID-19: Less than 2% of state population have antibodies. *Post Crescent*. 5 Oct 2020. Available: <https://www.postcrescent.com/story/news/2020/10/05/wisconsin-covid-19-less-than-2-of-state-population-have-antibodies/3457334001/>
340. Coffman B. New Co-Immunity Project data show COVID-19 infection among health care workers may be lower than the general population | UofL News. *UofLNews*; 24 Aug 2020 [cited 8 Mar 2021]. Available: <http://www.uoflnews.com/post/uofltoday/new-co-immunity-project-data-show-covid-19-infection-among-health-care-workers-may-be-lower-than-the-general-population/>
341. Feehan AK, Velasco C, Fort D, Burton JH, Price-Haywood EG, Katzmarzyk PT, et al. Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA. *Emerg Infect Dis*. 2021;27: 314–317. doi:10.3201/eid2701.203808
342. Vassallo RR, Bravo MD, Dumont LJ, Hazegh K, Kamel H. Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors. *medRxiv*. 2020; 2020.09.17.20195131. doi:10.1101/2020.09.17.20195131
343. Azzi Y, Parides M, Alani O, Loarte-Campos P, Bartash R, Forest S, et al. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. *Kidney International*. 2020;98: 1559–1567. doi:10.1016/j.kint.2020.10.004
344. Nicholson L, McLawhon RW, Kurian S, Fitzgerald RL, Case J, Marsh C, et al. Healthcare worker seroconversion for SARS-CoV-2 at two large health systems in San Diego. *American Journal of Infection Control*. 2020;0. doi:10.1016/j.ajic.2020.12.017
345. Spencer BR, Foster GA, Xu M, Dodd RY, Haynes JM, Groves J, et al. COVID-19 Antibody Testing in Blood Donors: Prevalence, Symptoms, and Suitability for Convalescent Plasma Donation. *AABB*; 2020. Available: <https://aabb.confex.com/aabb/2020/meetingapp.cgi/Paper/8581>
346. Yamaki J, Peled H, Mathews S, Park D, Firoozi M, Smith K, et al. Seroprevalence of Novel Coronavirus SARS-CoV-2 at a Community Hospital Emergency Department and Outpatient Laboratory in Northern Orange County, California. *J Racial and Ethnic Health Disparities*. 2020 [cited 20 Jan 2021]. doi:10.1007/s40615-020-00918-0
347. Haizler-Cohen L, Davidov A, Blitz MJ, Fruhman G. Severe acute respiratory syndrome coronavirus 2 antibodies in pregnant women admitted to labor and delivery units. *American Journal of Obstetrics & Gynecology*. 2020;0. doi:10.1016/j.ajog.2020.09.022
348. Klawiter E, Smith J, Brewer K, Stockel K, Fischinger S, Luedemann C, et al. Low prevalence of SARS-COV-2 antibodies in people with multiple sclerosis residing in massachusetts. *Mult Scler*. 2020;26: 43–117. doi:10.1177/1352458520974938
349. Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, et al. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. *Am J Med*. 2020. doi:10.1016/j.amjmed.2020.09.024
350. Rob McMillan. 6 percent of Riverside County residents had COVID-19, according to antibody study. *ABC News*. 29 Jul 2020. Available: <https://abc7.com/riverside-county-covid-update-coronavirus-ie-covid-19/6340600/>

351. Lopez L, Nguyen T, Weber G, Kleimola K, Bereda M, Liu Y, et al. Seroprevalence of anti-SARS-CoV-2 IgG Antibodies in the Staff of a Public School System in the Midwestern United States. medRxiv. 2020; 2020.10.23.20218651. doi:10.1101/2020.10.23.20218651
352. Julie Zauzmer. D.C. Has tested 13,706 blood samples. Only 809 carried coronavirus antibodies. The Washington Post. 15 Jul 2020. Available: <https://www.washingtonpost.com/dc-md-va/2020/07/15/dc-health-lab-has-tested-13706-blood-samples-only-809-people-carried-coronavirus-antibodies/>
353. Jin DK, Nesbitt DJ, Yang J, Chen H, Horowitz J, Jones M, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and “Reopening.” medRxiv. 2020; 2020.11.06.20220087. doi:10.1101/2020.11.06.20220087
354. Reuben J, Sherman A, Ellison JA, Gunn JKL, Tran A, McCarroll M, et al. SARS-CoV-2 Seroprevalence among First Responders in the District of Columbia, May – July 2020. medRxiv. 2020; 2020.11.25.20225490. doi:10.1101/2020.11.25.20225490
355. Kaufman HW, Chen Z, Meyer WA, Wohlgemuth JG. Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March–July 2020. Population Health Management. 2020; pop.2020.0256. doi:10.1089/pop.2020.0256
356. Shah VP, Hainy CM, Swift MD, Breeher LE, Theel ES, Sampathkumar P. Unrecognized severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence among healthcare personnel in a low-prevalence area. Infect Control Hosp Epidemiol. 2020; 1–3. doi:10.1017/ice.2020.1341
357. Mohr N, Harland K, Krishnadasan A, Santibanez S, Talan D. Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis. Annals of Emergency Medicine. 2020. doi:10.1016/j.annemergmed.2020.12.007
358. Dimcheff DE, Schildhouse RJ, Hausman MS, Vincent BM, Markovitz E, Chensue SW, et al. Seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection among Veterans Affairs healthcare system employees suggests higher risk of infection when exposed to SARS-CoV-2 outside the work environment. Infection Control & Hospital Epidemiology. undefined/ed; 1–7. doi:10.1017/ice.2020.1220
359. Kamath K, Baum-Jones E, Jordan G, Haynes W, Waitz R, Shon J, et al. Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York. medRxiv. 2020; 2020.10.19.20215368. doi:10.1101/2020.10.19.20215368
360. Childs J. Study reveals data on COVID-19 antibody prevalence in Ventura County. Ventura County Star. 30 Aug 2020. Available: <https://www.vcstar.com/story/news/2020/08/30/covid-19-data-coronavirus-antibodies-ventura-county/3436858001/>
361. Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, et al. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature. 2020. doi:10.1038/s41586-020-2912-6
362. Freeman MC, Rapsinski GJ, Zilla ML, Wheeler SE. Immunocompromised Seroprevalence and Course of Illness of SARS-CoV-2 in One Pediatric Quaternary Care Center. Journal of the Pediatric Infectious Diseases Society. 2020;10: 426–431. doi:10.1093/jpids/piaa123
363. Walker AG, Sibbel S, Wade C, Moulton N, Marlowe G, Young A, et al. SARS-CoV-2 Antibody Seroprevalence Among Maintenance Dialysis Patients in the United States. Kidney Medicine. 2021;0. doi:10.1016/j.xkme.2021.01.002
364. Barrett ES, Horton DB, Roy J, Xia W, Greenberg P, Andrews T, et al. Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospital Workers: Results From a Screening Study in New Jersey, United States in Spring 2020. Open Forum Infectious Diseases. 2020;7. doi:10.1093/ofid/ofaa534

365. Wilkins JT, Gray EL, Wallia A, Hirschhorn LR, Zembower TR, Ho J, et al. Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago. *Open Forum Infectious Diseases*. 2021;8. doi:10.1093/ofid/ofaa582
366. Nailescu C, Khalid M, Wilson AC, Amanat F, Arregui S, Canas J, et al. Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients. *Front Pediatr*. 2020;8. doi:10.3389/fped.2020.601327
367. Viglienzoni C. Early results of UVM research tracking COVID's spread in Vermont. WCAX3. 17 Jul 2020. Available: <https://www.wcax.com/2020/07/17/early-results-of-uvm-research-tracking-covids-spread-in-vermont/>. Accessed 13 Mar 2021.
368. Samore MH, Looney A, Orleans B, Greene T, Seegert N, Delgado JC, et al. SARS-CoV-2 seroprevalence and detection fraction in Utah urban populations from a probability-based sample. *medRxiv*. 2020; 2020.10.26.20219907. doi:10.1101/2020.10.26.20219907
369. Noval Rivas M, Ebinger JE, Wu M, Sun N, Braun J, Sobhani K, et al. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers. *Journal of Clinical Investigation*. 2020 [cited 5 Jan 2021]. doi:10.1172/JCI145157
370. Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, Coughlin MM, Feldstein LR, et al. Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. *JAMA*. 2020;324: 1781. doi:10.1001/jama.2020.18796
371. Baker JM, Nelson KN, Overton E, Lopman BA, Lash TL, Photakis M, et al. Quantification of Occupational and Community Risk Factors for SARS-CoV-2 Seropositivity Among Health Care Workers in a Large U.S. Health Care System. *Ann Intern Med*. 2021 [cited 19 Mar 2021]. doi:10.7326/M20-7145
372. McBride SM, Bundick K, Hubbeling H, Freret M, Modlin LA, Kamboj M, et al. Results and Impact of Intensive SARS-CoV-2 Testing in a High Volume, Outpatient Radiation Oncology Clinic in a Pandemic Hotspot. *medRxiv*. 2020; 2020.08.11.20172551. doi:10.1101/2020.08.11.20172551
373. Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al. Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. *JAMA*. 2020;324: 893–895. doi:10.1001/jama.2020.14765
374. Barzin A, Schmitz JL, Rosin S, Sirpal R, Almond M, Robinette C, et al. SARS-CoV-2 Seroprevalence among a Southern U.S. Population Indicates Limited Asymptomatic Spread under Physical Distancing Measures. Schultz-Cherry S, editor. *mBio*. 2020;11: e02426–20, /mbio/11/5/mBio.02426–20.atom. doi:10.1128/mBio.02426-20
375. Staff SN. Study Finds Rate of Exposure to COVID-19 in Louisville Higher Than Expected. *Spectrum News 1*. 23 Jul 2020. Available: <https://spectrumnews1.com/ky/louisville/news/2020/07/23/uofl-coimmunity-project-phase-2-results>
376. Self WH, Tenforde MW, Stubblefield WB, Feldstein LR, Steingrub JS, Shapiro NI, et al. Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network — 13 Academic Medical Centers, April–June 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69: 1221–1226. doi:10.15585/mmwr.mm6935e2
377. Dodd RY, Xu M, Stramer SL. Change in Donor Characteristics and Antibodies to SARS-CoV-2 in Donated Blood in the US, June–August 2020. *JAMA*. 2020;324: 1677–1679. doi:10.1001/jama.2020.18598
378. Reifer J, Hayum N, Heszel B, Klagsbald I, Strevva VA. SARS-CoV-2 IgG antibody responses in New York City. *Diagnostic Microbiology and Infectious Disease*. 2020;98: 115128. doi:10.1016/j.diagmicrobio.2020.115128
379. Sutton M. Notes from the Field: Seroprevalence Estimates of SARS-CoV-2 Infection in Convenience Sample — Oregon, May 11–June 15, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69. doi:10.15585/mmwr.mm6932a4
380. Rebeiro PF, Levinson KJ, Jolly L, Kassens E, Dizikes GJ, Steece RS, et al. Prevalence of IgG antibodies against the severe acute respiratory syndrome coronavirus-2 among healthcare workers in Tennessee during May and June, 2020. *Infectious Diseases (except HIV/AIDS)*; 2020 Nov. doi:10.1101/2020.11.12.20230912

381. Anand S, Montez-Rath M, Han J, Bozeman J, Kerschmann R, Beyer P, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: A cross-sectional study. *The Lancet*. 2020;396: 1335–1344. doi:10.1016/S0140-6736(20)32009-2
382. Akinbami LJ, Vuong N, Petersen LR, Sami S, Patel A, Lukacs SL, et al. SARS-CoV-2 Seroprevalence among Healthcare, First Response, and Public Safety Personnel, Detroit Metropolitan Area, Michigan, USA, May–June 2020 - Volume 26, Number 12—December 2020 - *Emerging Infectious Diseases journal - CDC*. 2020 [cited 15 May 2021]. doi:10.3201/eid2612.203764
383. Dora AV, Winnett A, Fulcher JA, Sohn L, Calub F, Lee-Chang I, et al. Using Serologic Testing to Assess the Effectiveness of Outbreak Control Efforts, Serial Polymerase Chain Reaction Testing, and Cohorting of Positive Severe Acute Respiratory Syndrome Coronavirus 2 Patients in a Skilled Nursing Facility. *Clinical Infectious Diseases*. 2020 [cited 14 Mar 2021]. doi:10.1093/cid/ciaa1286
384. Hynes M. Nevada COVID-19 infection rate 5 times higher, antibody tests show. *Las Vegas Review Journal*. 8 Jul 2020. Available: <https://www.google.com/url?rct=j&sa=t&url=https://www.reviewjournal.com/local/local-nevada/nevada-covid-19-infection-rate-5-times-higher-antibody-tests-show-2070094/&ct=ga&cd=CAAYBzIaOTBkZWE5ODk5NGU5MTg1OTpj206ZW46VVM&usg=AFQjCNGG4t16ng9mGv7ghgkKQP4Qm3hotw>. Accessed 13 Mar 2021.
385. Kari Harden. One new positive COVID-19 case in Routt County, antibody testing ramping up. *Steamboat Pilot & Today*. 14 Jun 2020. Available: <https://www.steamboatpilot.com/news/one-new-positive-covid-19-case-in-routt-county-antibody-testing-ramping-up/>
386. Yogo N, Greenwood KL, Thompson L, Wells PJ, Munday S, Smith TC, et al. Point prevalence survey to evaluate the seropositivity for coronavirus disease 2019 (COVID-19) among high-risk healthcare workers. *Infect Control Hosp Epidemiol*. 2020; 1–6. doi:10.1017/ice.2020.1370
387. Hogan CA, Gombar S, Wang H, Röltgen K, Shi R-Z, Holubar M, et al. Large-Scale Testing of Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 27, Number 1—January 2021 - *Emerging Infectious Diseases journal - CDC*. *Emerging Infectious Diseases*. 2020 [cited 22 Jan 2021]. doi:10.3201/eid2701.203892
388. Rudavsky S. Fairbanks study indicates that 'virus has slowed its spread' in Indiana. *Indy Star*. 17 Jun 2020. Available: <https://www.indystar.com/story/news/health/2020/06/17/indiana-coronavirus-fairbanks-study-indicates-spread-has-slowed/3208509001/>. Accessed 13 Mar 2021.
389. Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al. SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Sci Immunol*. 2020;5: eabd5709. doi:10.1126/sciimmunol.abd5709
390. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. McAdam AJ, editor. *J Clin Microbiol*. 2020;58: e02107–20, /jcm/58/11/JCM.02107–20.atom. doi:10.1128/JCM.02107-20
391. Gray A. Prevalence Of COVID-19 Antibodies In Washoe Co. Expected To Be Low. 22 Jun 2020. Available: <https://www.kunr.org/post/prevalence-covid-19-antibodies-washoe-co-expected-be-low#stream/0>
392. Brunner WM, Hirabayashi L, Krupa NL, Scribani MB, Jenkins P, Clark SD, et al. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG results among healthcare workers in a rural upstate New York hospital system. *Infection Control & Hospital Epidemiology*. 2020; 1–4. doi:10.1017/ice.2020.1296
393. Steve Ohnesorge. Antibody testing continues in Burke County. *WBTV*. 29 May 2020. Available: <https://www.wbvtv.com/2020/05/29/antibody-testing-continues-burke-county/>

394. Sims MD, Maine GN, Childers KL, Podolsky RH, Voss DR, Berkiw-Scenna N, et al. COVID-19 seropositivity and asymptomatic rates in healthcare workers are associated with job function and masking. *Clin Infect Dis*. 2020. doi:10.1093/cid/ciaa1684
395. Nicole Hayden. Coachella Valley far from COVID-19 herd immunity, preliminary antibody test results show. *Desert Sun*. 29 May 2020. Available: https://www.google.com/url?rct=j&sa=t&url=https://www.desertsun.com/story/news/health/2020/05/29/coachella-valley-far-covid-19-herd-immunity-preliminary-antibody-tests-show/5280021002/&ct=ga&cd=CAAYKzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNFQxOqwjTX2Kz2_mnj1RV7Upa8rEg
396. Liu F, Nguyen M, Vijayakumar P, Kaplan A, Meir A, Dai Y, et al. Newborn Dried Blood Spots for Serologic Surveys of COVID-19. *Pediatric Infectious Disease Journal*. 2020;39: e454–e456. doi:10.1097/INF.0000000000002918
397. Osher G, Lamb CC, Ibarra Y, Erickson-Samson D. Observational study of SARS-CoV-2 antibody immune response in a cohort of patients at a North Suburban Chicago, Illinois, in a physician’s practice. *LymphoSign Journal*. 2020;7: 104–108. doi:10.14785/lymphosign-2020-0007
398. Shomik Mukherjee. 1% of early Humboldt County coronavirus tests show antibodies. *Times Standard*. 2 Jun 2020. Available: <https://www.times-standard.com/2020/06/02/1-of-early-humboldt-county-coronavirus-tests-show-antibodies/>
399. Stavert R, Meydani-Korb A, Leon D de, Osgood R, Blau J, Luu T. Evaluation of SARS-CoV-2 antibodies in 24 patients presenting with chilblains-like lesions during the COVID-19 pandemic. *Journal of the American Academy of Dermatology*. 2020;83: 1753–1755. doi:10.1016/j.jaad.2020.08.049
400. Ahmad K, Rezvanizadeh V, Dahal S, Kinninger A, Ghanem AK, Lakshmanan S, et al. COVID-19 IgG/IgM antibody testing in Los Angeles County, California. *Eur J Clin Microbiol Infect Dis*. 2020 [cited 19 Jan 2021]. doi:10.1007/s10096-020-04111-3
401. Jackson A. Almost everyone at one Michigan prison tests positive for COVID-19 antibodies. *Detroit Free Press*. 28 May 2020. Available: https://www.petoskeynews.com/news/state-region/almost-everyone-at-one-michigan-prison-tests-positive-for-covid-19-antibodies/article_423c1ef0-a018-5b50-b746-c93fcb82f71f.html. Accessed 13 Mar 2021.
402. Staletovich J. South Florida Cities Begin Testing Employees For COVID-19 Antibodies. *WLRN*. 22 May 2020. Available: <https://www.wlrn.org/health-care/2020-05-22/south-florida-cities-begin-testing-employees-for-covid-19-antibodies>. Accessed 13 Mar 2021.
403. Leidner R, Frary A, Cramer J, Ball D, Weerasinghe R, Schmidt M, et al. Longitudinal SARS-CoV-2 serosurveillance of over ten thousand health care workers in the Providence Oregon cohort. *medRxiv*. 2020; 2020.08.16.20176107. doi:10.1101/2020.08.16.20176107
404. Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations. *ACR Meeting Abstracts*; [cited 4 Feb 2021]. Available: <https://acrabstracts.org/abstract/assessing-cytokine-profiles-and-covid-serology-in-patients-on-immunosuppression-to-guide-care-recommendations/>
405. Shukla V, Lau CSM, Towns M, Mayer J, Kalkbrenner K, Beuerlein S, et al. COVID-19 Exposure Among First Responders in Arizona. *Journal of Occupational and Environmental Medicine*. 2020;62. Available: https://journals.lww.com/joem/Fulltext/2020/12000/COVID_19_Exposure_Among_First_Responders_in.1.aspx
406. Rosser JJ, Röltgen K, Dymock M, Shepard J, Martin A, Hogan CA, et al. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence in healthcare personnel in northern California early in the coronavirus disease 2019 (COVID-19) pandemic. *Infection Control & Hospital Epidemiology*. 2020; 1–7. doi:10.1017/ice.2020.1358
407. Alfini M. Antibody tests for coronavirus so far trend overwhelmingly negative. *WKOW*. 20 May 2020. Available: <https://wkow.com/2020/05/20/antibody-tests-for-coronavirus-so-far-trend-overwhelmingly-negative/>. Accessed 13 Mar 2021.

408. Montgomery J. Iowa begins to release serology test results, showing greater local spread of COVID-19. *Telegraph Herald*. 20 May 2020. Available: https://www.telegraphherald.com/coronavirus/article_b5f56348-317d-5f49-abe-0e7cff653cbb.html. Accessed 13 Mar 2021.
409. Geraci L. Antibody tests show just 2% exposure rate to COVID-19. *The Lancaster News*. 23 May 2020. Available: <https://www.thelancasternews.com/content/antibody-tests-show-just-2-exposure-rate-covid-19>
410. Tarabichi Y, Watts B, Collins T, Margolius D, Avery A, Gunzler D, et al. SARS-CoV-2 Infection among Serially Tested Emergency Medical Services Workers. *Prehospital Emergency Care*. 2020;0: 1–7. doi:10.1080/10903127.2020.1831668
411. Mughal MS, Kaur IP, Patton CD, Mikhail NH, Vareechon C, Granet KM. The prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in intensive care unit (ICU) healthcare personnel (HCP) and its implications—a single-center, prospective, pilot study. *Infection Control & Hospital Epidemiology*. 2020/06/12 ed. 2020; 1–2. doi:10.1017/ice.2020.298
412. McLaughlin CC, Doll MK, Morrison KT, McLaughlin WL, O'Connor T, Sholukh AM, et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. *medRxiv*. 2020; 2020.07.19.20157198. doi:10.1101/2020.07.19.20157198
413. Morris CR, Camacho-Gonzalez A, Chen C, Heilman S, Iyer S, Mantus G, et al. 321 Prevalence of SARS-CoV-2 Antibodies in Pediatric Health Care Workers in Atlanta, Georgia. *Annals of Emergency Medicine*. 2020;76: S124–S125. doi:10.1016/j.annemergmed.2020.09.336
414. Feehan AK, Fort D, Garcia-Diaz J, Price-Haywood EG, Velasco C, Sapp E, et al. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. *Emerg Infect Dis*. 2020;26: 2765–2768. doi:10.3201/eid2611.203029
415. Meyer M. New COVID-19 antibody testing in Winona gives health officials a better picture of the spread. *News 8000*. 15 May 2020. Available: <https://www.news8000.com/new-covid-19-antibody-testing-in-winona-gives-health-officials-a-better-picture-of-the-spread/>. Accessed 13 Mar 2021.
416. Dietrich ML, Norton EB, Elliott D, Smira AR, Rouelle JA, Bond NG, et al. SARS-CoV-2 Seroprevalence Rates of Children in Louisiana During the State Stay at Home Order. *medRxiv*. 2020; 2020.07.07.20147884. doi:10.1101/2020.07.07.20147884
417. Boston C of. RESULTS RELEASED FOR ANTIBODY AND COVID-19 TESTING OF BOSTON RESIDENTS. City of Boston. 18 May 2020. Available: <https://www.boston.gov/news/results-released-antibody-and-covid-19-testing-boston-residents>
418. Parker-Magyar A. Few among Long Hill first responders test positive for COVID-19 antibodies. *Echoes Sentinel News*. 1 Jun 2020. Available: https://www.google.com/url?rct=j&sa=t&url=https://www.newjerseyhills.com/echoes-sentinel/news/few-among-long-hill-first-responders-test-positive-for-covid-19-antibodies/article_007ac367-b3b2-5375-b471-f0a817998f62.html&ct=ga&cd=CAAYFDIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHWg839bXiyzOxO1Y7-QOECGMRCMw
419. Iwuji K, Islam E, Berdine G, Nugent K, Test V, Tijerina A. Prevalence of Coronavirus Antibody Among First Responders in Lubbock, Texas. *J Prim Care Community Health*. 2020 Jan-Dec;11: 2150132720971390. doi:10.1177/2150132720971390
420. Angeles CL. LA County 'Still Far Away From Herd Immunity' New Antibody Numbers Show. *CBS Los Angeles*. 20 May 2020. Available: <https://losangeles.cbslocal.com/2020/05/20/la-county-still-far-away-from-herd-immunity-new-antibody-numbers-show/>. Accessed 13 Mar 2021.
421. Nesbitt DJ, Jin D, Hogan JW, Chan PA, Simon MJ, Vargas M, et al. Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats. *medRxiv*. 2020; 2020.07.20.20157743. doi:10.1101/2020.07.20.20157743

422. Tilley K, Ayvazyan V, Martinez L, Nanda N, Kawaguchi ES, O’Gorman M, et al. A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population. *Journal of Adolescent Health*. 2020;67: 763–768. doi:10.1016/j.jadohealth.2020.09.001
423. Hunter BR, Dbeibo L, Weaver CS, Beeler C, Saysana M, Zimmerman MK, et al. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure. *Infection Control & Hospital Epidemiology*. 2020/08/03 ed. 2020; 1–2. doi:10.1017/ice.2020.390
424. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. *Immunity*. 2020;53: 925–933.e4. doi:10.1016/j.immuni.2020.10.004
425. Racine-Brzostek SE, Yang HS, Chadburn A, Orlander D, An A, Campion TR, et al. COVID-19 Viral and Serology Testing in New York City Health Care Workers. *American Journal of Clinical Pathology*. 2020;154: 592–595. doi:10.1093/ajcp/aqaa142
426. Regan T. Fellowship Village Benefits from Covid-19 Antibody Tests. *Senior Housing News*. 24 Jun 2020. Available: <https://seniorhousingnews.com/2020/06/24/fellowship-village-benefits-from-covid-19-antibody-tests-juniper-plans-pilot/>. Accessed 13 Mar 2021.
427. Sydney ER, Kishore P, Laniado I, Rucker LM, Bajaj K, Zinaman MJ. Antibody evidence of SARS-CoV-2 infection in healthcare workers in the Bronx. *Infection Control & Hospital Epidemiology*. 2020/08/26 ed. 2020;41: 1348–1349. doi:10.1017/ice.2020.437
428. Bajema KL, Dahlgren FS, Lim TW, Bestul N, Biggs HM, Tate JE, et al. Comparison of Estimated SARS-CoV-2 Seroprevalence through Commercial Laboratory Residual Sera Testing and a Community Survey. *Clinical Infectious Diseases*. 2020 [cited 22 Jan 2021]. doi:10.1093/cid/ciaa1804
429. Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies — Two Georgia Counties, April 28–May 3, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69: 965–970. doi:10.15585/mmwr.mm6929e2
430. Menachemi N, Yiannoutsos CT, Dixon BE, Duszynski TJ, Fadel WF, Wools-Kaloustian KK, et al. Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69: 960–964. doi:10.15585/mmwr.mm6929e1
431. Reagan N. Results show 2% of tested MUSC staff have COVID-19 antibodies. *WCSC*. 4 May 2020. Available: <https://www.live5news.com/2020/05/04/results-show-tested-musc-staff-have-covid-antibodies/>. Accessed 13 Mar 2021.
432. Venugopal U, Jilani N, Rabah S, Shariff MA, Jawed M, Batres AM, et al. SARS-CoV-2 seroprevalence among health care workers in a New York City hospital: A cross-sectional analysis during the COVID-19 pandemic. *International Journal of Infectious Diseases*. 2020;102: 63–69. doi:10.1016/j.ijid.2020.10.036
433. Jeremias A, Nguyen J, Levine J, Pollack S, Engellenner W, Thakore A, et al. Prevalence of SARS-CoV-2 Infection Among Health Care Workers in a Tertiary Community Hospital. *JAMA Internal Medicine*. 2020 [cited 15 Nov 2020]. doi:10.1001/jamainternmed.2020.4214
434. Cohen DE, Marlowe G, Contreras G, Sosa MA, Mendoza JM, Lenz O, et al. Assessment of a Laboratory-Based SARS-CoV-2 Antibody Test Among Hemodialysis Patients: A Quality Improvement Initiative. *medRxiv*. 2020; 2020.08.03.20163642. doi:10.1101/2020.08.03.20163642
435. Jeong JM, Radeos MS, Shee B, Kindschuh M, Hernandez C, Sasson C, et al. COVID-19 Seroconversion in Emergency Professionals at an Urban Academic Emergency Department in New York City. *Annals of Emergency Medicine*. 2020;76: 815–816. doi:10.1016/j.annemergmed.2020.06.038

436. Chamie G, Marquez C, Crawford E, Peng J, Petersen M, Schwab D, et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco. *Clinical Infectious Diseases*. 2020; ciaa1234. doi:10.1093/cid/ciaa1234
437. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. *Annals of Epidemiology*. 2020;48: 23–29.e4. doi:10.1016/j.annepidem.2020.06.004
438. Zou J, Bretin A, Gewirtz A. Antibodies to SARS/CoV-2 in arbitrarily-selected Atlanta residents. medRxiv. 2020; 2020.05.01.20087478. doi:10.1101/2020.05.01.20087478
439. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho. medRxiv. 2020; 2020.04.27.20082362. doi:10.1101/2020.04.27.20082362
440. Lewis NM, Chu VT, Ye D, Conners EE, Gharpure R, Laws RL, et al. Household Transmission of SARS-CoV-2 in the United States. *Clinical Infectious Diseases*. 2020 [cited 16 Dec 2020]. doi:10.1093/cid/ciaa1166
441. Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Duarte E, et al. Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. *Open Forum Infectious Diseases*. 2021;8. doi:10.1093/ofid/ofaa531
442. Payne DC, Smith-Jeffcoat SE, Nowak G, Chukwuma U, Geibe JR, Hawkins RJ, et al. SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members - USS Theodore Roosevelt, April 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69: 714–721. doi:10.15585/mmwr.mm6923e4
443. Alessandro Sassoon. OMNI Healthcare’s COVID-19 antibody testing data for Brevard shows low rates of immunity. *Florida Today*. 24 Apr 2020. Available: <https://www.floridatoday.com/story/news/2020/04/24/omni-covid-19-immunity-testing-data-brevard-county-florida-antibody/3022571001/>
444. Dingens AS, Crawford KHD, Adler A, Steele SL, Lacombe K, Eguia R, et al. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. *Nature Communications*. 2020;11: 4378. doi:10.1038/s41467-020-18178-1
445. Kiefer MK, McKiever ME, Russo JR, Ma’ayeh M, Gee SE, Smith DD, et al. Exposure and seroconversion to severe acute respiratory syndrome coronavirus 2 among obstetrical healthcare providers following a contained outbreak. *American Journal of Obstetrics & Gynecology*. 2020;223: 601–603.e2. doi:10.1016/j.ajog.2020.06.029
446. Morrison R. CrushTheCurveIdaho finds small population with antibodies: ‘We are far from herd immunity’. 22 Apr 2020. Available: <https://idahonews.com/news/coronavirus/crushthecurveidaho-finds-small-population-with-antibodies-we-are-far-from-herd-immunity>. Accessed 13 Mar 2021.
447. Morcuende M, Guglielminotti J, Landau R. Anesthesiologists’ and Intensive Care Providers’ Exposure to COVID-19 Infection in a New York City Academic Center: A Prospective Cohort Study Assessing Symptoms and COVID-19 Antibody Testing. *Anesth Analg*. 2020;131: 669–676. doi:10.1213/ANE.0000000000005056
448. McCormack J. What the Coronavirus-Antibody Study of Major League Baseball Tells Us. *National Review*. 11 May 2020. Available: <https://www.nationalreview.com/2020/05/coronavirus-antibody-study-major-league-baseball-herd-immunity/>
449. Blake Paterson. Takeaways from coronavirus antibody tests: Infections might be more widespread than cases suggest. *The Advocate*. 28 Apr 2020. Available: https://www.theadvocate.com/baton_rouge/news/coronavirus/article_b499efa0-8983-11ea-a3f1-af936ecb1d2c.html
450. Stock AD, Bader ER, Cezayirli P, Inocencio J, Chalmers SA, Yassari R, et al. COVID-19 Infection Among Healthcare Workers: Serological Findings Supporting Routine Testing. *Front Med*. 2020;7. doi:10.3389/fmed.2020.00471

451. Madsen T, Levin N, Niehus K, Law K, Mayer J, Chapman M, et al. Prevalence of IgG antibodies to SARS-CoV-2 among emergency department employees. *Am J Emerg Med.* 2020. doi:10.1016/j.ajem.2020.04.076
452. Caban-Martinez AJ, Schaefer-Solle N, Santiago K, Louzado-Feliciano P, Brotons A, Gonzalez M, et al. Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: A cross-sectional study. *Occup Environ Med.* 2020;77: 857–861. doi:10.1136/oemed-2020-106676
453. Naranbhai V, Chang CC, Beltran WFG, Miller TE, Astudillo MG, Villalba JA, et al. High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. *The Journal of Infectious Diseases.* 2020;222: 1955–1959. doi:10.1093/infdis/jiaa579
454. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10–11, 2020. *JAMA.* 2020;Published Online. doi:doi:10.1001/jama.2020.8279
455. Ng DL, Goldgof GM, Shy BR, Levine AG, Balcerak J, Bapat SP, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. *medRxiv.* 2020 [cited 15 May 2021]. doi:10.1101/2020.05.19.20107482
456. Goldberg SA, Lennerz J, Klompas M, Mark E, Pierce VM, Thompson RW, et al. Presymptomatic Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Among Residents and Staff at a Skilled Nursing Facility: Results of Real-time Polymerase Chain Reaction and Serologic Testing. *Clinical Infectious Diseases.* 2020 [cited 15 Nov 2020]. doi:10.1093/cid/ciaa991
457. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. *International Journal of Epidemiology.* 2021; dyab010. doi:10.1093/ije/dyab010
458. Mansour M, Leven E, Muellers K, Stone K, Mendu DR, Wajnberg A. Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City. *Journal of General Internal Medicine.* 2020;35: 2485–2486. doi:10.1007/s11606-020-05926-8
459. Anne Schuchat. Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24–April 21, 2020. US Department of Health and Human Services/Centers for Disease Control and Prevention; 2020 May. Available: <https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e2-H.pdf>
460. McPherson TD, Ghinai I, Binder AM, Freeman BD, Hoskin Snelling C, Hunter JC, et al. Lack of Serologic Evidence of Infection Among Health Care Personnel and Other Contacts of First 2 Confirmed Patients With COVID-19 in Illinois, 2020. *Public Health Rep.* 2020;136: 88–96. doi:10.1177/0033354920966064
461. Chu V, Freeman-Ponder B, Lindquist S, Spitters C, Kawakami V, Dyal J, et al. Investigation and Serologic Follow-Up of Contacts of an Early Confirmed Case-Patient with COVID-19, Washington, USA. *Emerging Infectious Disease journal.* 2020;26: 1671. doi:10.3201/eid2608.201423
462. Basavaraju SV, Patton ME, Grimm K, Rasheed MAU, Lester S, Mills L, et al. Serologic testing of U.S. Blood donations to identify SARS-CoV-2-reactive antibodies: December 2019–January 2020. *Clinical Infectious Diseases.* 2020 [cited 20 Jan 2021]. doi:10.1093/cid/ciaa1785
463. Buss LF, Prete CA, Abraham CMM, Mendrone A, Salomon T, Almeida-Neto C de, et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science.* 2021;371: 288–292. doi:10.1126/science.abe9728
464. Santena F, Lopes J, Perez M, Campana G, Levi J, Lopes F, et al. Seroconversion for SARS-CoV-2 in rheumatic patients on synthetic and biologics Disease Modifying Anti-Rheumatic Drugs in São Paulo, Brazil. 2020 [cited 23 Feb 2021]. doi:10.21203/rs.3.rs-97191/v1
465. Silva AAM da, Lima-Neto LG, Azevedo C de MPeS, Costa LMM da, Bragança MLBM, Filho AKDB, et al. Population-based seroprevalence of SARS-CoV-2 is more than halfway through the herd immunity threshold in the State of Maranhão, Brazil. *Public and Global Health;* 2020 Sep. doi:10.1101/2020.08.28.20180463

466. Oliveira LM da S, Tiyo BT, Silva LT da, Fonseca LAM, Rocha RC, Santos VA dos, et al. Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large public university hospital in Sao Paulo, Brazil. *Revista do Instituto de Medicina Tropical de São Paulo*. 2020;62. doi:10.1590/s1678-9946202062091
467. Silva VO, de Oliveira EL, Castejon MJ, Yamashiro R, Ahagon CM, López-Lopes GI, et al. Prevalence of antibodies against sars-cov-2 in professionals of a public health laboratory at são paulo, sp, brazil. *medRxiv*. 2020 [cited 15 May 2021]. doi:10.1101/2020.10.19.20213421
468. de Paula CC, Passos JPC, Shimoya-Bittencour W, de Lamare CAV, de Oliveira RG. PREVALENCE OF MOLECULAR AND SEROLOGICAL TESTS OF THE NEW CORONAVIRUS (SARS-CoV-2) IN CARLOS CHAGAS-SABIN LABORATORIES IN CUIABÁ. *medRxiv*. 2020 [cited 15 May 2021]. doi:10.1101/2020.10.26.20219683
469. de Melo MS, Borges LP, de Souza DRV, Martins AF, de Rezende Neto JM, Ribeiro AA, et al. Anti-SARS-CoV-2 IgM and IgG antibodies in health workers in Sergipe, Brazil. *Infectious Diseases (except HIV/AIDS)*; 2020 Sep. doi:10.1101/2020.09.24.20200873
470. Horta BL, Silveira MF, Barros AJD, Barros FC, Hartwig FP, Dias MS, et al. Prevalence of antibodies against SARS-CoV-2 according to socioeconomic and ethnic status in a nationwide Brazilian survey. *Rev Panam Salud Publica*. 2020;44: e135. doi:10.26633/RPSP.2020.135
471. Picon RV, Carreno I, da Silva AA, Mossmann M, Laste G, Domingues G de C, et al. Coronavirus disease 2019 population-based prevalence, risk factors, hospitalization, and fatality rates in southern Brazil. *International Journal of Infectious Diseases*. 2020;100: 402–410. doi:10.1016/j.ijid.2020.09.028
472. Vieira MA da CeS, Vieira CP de B, Borba A de S, Melo MC de C, Oliveira M de S, Melo RM, et al. Sequential serological surveys in the early stages of the coronavirus disease epidemic: Limitations and perspectives. *Rev Soc Bras Med Trop*. 2020;53: e20200351. doi:10.1590/0037-8682-0351-2020
473. Sales MJT, Kerr LRFS, Brizolara RV, Barreto IC de HC, Almeida RLF de, Goes PSA de, et al. Fernando de Noronha: How an island controlled the community transmission of COVID-19 in Brazil. *medRxiv*. 2020; 2020.10.22.20216010. doi:10.1101/2020.10.22.20216010
474. Confirma um estudo sobre a pandemia de Covid-19 em Biguaçu em gráficos. *Jornais em foco*; 2 Jun 2020 [cited 23 Apr 2021]. Available: <http://jbfoco.com.br/2020/06/confirma-um-estudo-sobre-a-pandemia-de-covid-19-em-biguaçu-em-gráficos/>
475. Costa SF, Giavina-Bianchi P, Buss L, Mesquita Peres CH, Rafael MM, dos Santos LGN, et al. SARS-CoV-2 seroprevalence and risk factors among oligo/asymptomatic healthcare workers(HCW): Estimating the impact of community transmission. *Clinical Infectious Diseases*. 2020 [cited 23 Jan 2021]. doi:10.1093/cid/ciaa1845
476. Chioro A, Calife K, Santos Barros CR dos, Martins LC, Calvo M, Estanislau E, et al. Covid-19 - COVID-19 em uma Região Metropolitana: Vulnerabilidade social e políticas públicas em contextos de desigualdades. 2020 [cited 26 Apr 2021]. doi:10.1590/SciELOPreprints.1270
477. Costa Gomes C, Cerutti Jr. C, Zandonade E, Noia Maciel EL, Carvalho de Alencar FE, Almada GL, et al. A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: Methodology and results of the first stage. *medRxiv*. 2020 [cited 16 Jun 2020]. doi:10.1101/2020.06.13.20130559
478. Tess BH, Granato CFH, Alves MCGP, Pintao MC, Rizzatti E, Nunes MC, et al. SARS-CoV-2 seroprevalence in the municipality of Sao Paulo, Brazil, ten weeks after the first reported case. *medRxiv*. 2020 [cited 12 Nov 2020]. doi:10.1101/2020.06.29.20142331
479. Phillippe Watanabe. Nos bairros de SP mais afetados pela Covid-19, só 5% tiveram contato com o vírus. *Folha De S Paulo*. 17 May 2020. Available: <https://www1.folha.uol.com.br/equilibrioesaude/2020/05/nos-bairros-de-sp-mais-afetados-pela-covid-19-so-5-tiveram-contato-com-o-virus.shtml>

480. Silveira MF, Barros AJD, Horta BL, Pellanda LC, Victora GD, Dellagostin OA, et al. Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. *Nat Med.* 2020;26: 1196–1199. doi:10.1038/s41591-020-0992-3
481. Borges LP, Martins AF, Melo MS de, Oliveira MGB de, Neto JM de R, Dósea MB, et al. Seroprevalence of SARS-CoV-2 IgM and IgG antibodies in an asymptomatic population in Sergipe, Brazil. *Revista Panamericana de Salud Pública.* 2020;44: 1. doi:10.26633/RPSP.2020.108
482. Ismael Amaral Silva PA, Ismael C, Marchon da Silva C, Domenge C. 1761P Universal screening of SARS-CoV-2 of oncology healthcare workers — a Brazilian experience. *Annals of Oncology.* 2020;31: S1024. doi:10.1016/j.annonc.2020.08.1825
483. Filho LA, Szwarcwald CL. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil. : 10.
484. Gurgel RQ, Sá LC de, Souza DRV, Martins AF, Matos ILS, Lima AGA, et al. SARS-CoV-2 has been circulating in northeastern Brazil since February 2020: Evidence for antibody detection in asymptomatic patients. *Journal of Infection.* 2020;0. doi:10.1016/j.jinf.2020.11.037
485. Mattar S, Alvis-Guzman N, Garay E, Rivero R, García A, Botero Y, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries? *Open Forum Infectious Diseases.* 2020;7. doi:10.1093/ofid/ofaa550
486. Ariza B, Torres X, Salgado D, Cepeda M, Restrepo CG, Castellanos JC, et al. Seroprevalence and seroconversion rates to SARS-CoV-2 in interns, residents, and medical doctors in a University Hospital in Bogotá, Colombia. *Infectio.* 2021;25: 145–152. doi:10.22354/in.v25i3.938
487. Idrovo AJ, Moreno-Montoya J, Pinzón-Flórez CE. Desempeño de las pruebas combinadas de IgM e IgG rápidas en la vigilancia ocupacional de COVID-19 en empresas colombianas. *biomedica.* 2020;40: 139–147. doi:10.7705/biomedica.5829
488. Morejón Giraldoni A, Rivera Rosa ER, Díaz Mesa MÁ, Pérez Cruz Y, Morales Bolaño G, Sardiñas Méndez Y, et al. Acciones de vigilancia y control ante la notificación de casos confirmados a la COVID-19. Aguada de Pasajeros, Cienfuegos. Cuba. *MediSur.* 2020;18: 721–725. Available: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1727-897X2020000400721&lng=es&nrm=iso&tlng=es
489. Paulino-Ramirez R, Báez AA, Degaudenzi AV, Tapia L. Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic. *The American Journal of Tropical Medicine and Hygiene.* 2020;103: 2343–2346. doi:10.4269/ajtmh.20-0907
490. Brutto OHD, Costa AF, Mera RM, Recalde BY, Bustos JA, García HH. Late incidence of SARS-CoV-2 infection in a highly-endemic remote rural village. A prospective population-based cohort study. *Pathogens and Global Health.* 2020;114: 457–462. doi:10.1080/20477724.2020.1826152
491. Del Brutto OH, Costa AF, Mera RM, Recalde BY, Bustos JA, García HH. SARS-CoV-2 in Rural Latin America. A Population-based Study in Coastal Ecuador. *Clin Infect Dis.* 2020 [cited 15 Oct 2020]. doi:10.1093/cid/ciaa1055
492. Flamand C, Enfissi A, Bailly S, Sarmiento CA, Beillard E, Gaillet M, et al. Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. *medRxiv.* 2020; 2020.09.27.20202465. doi:10.1101/2020.09.27.20202465
493. Rene Mejía Núñez M, Ángel Lara J, Araujo Pleitez S, Ariel Ramírez G. Vista de Vigilancia seroepidemiológica de la circulación del SARS-CoV-2 en 41 municipios de Honduras sin reporte de casos activos, COVID-19, del 16- 23 junio 2020. | Población y Salud en Mesoamérica. *Revista Población y Salud en Mesoamérica.* 2020;18. doi:10.15517/psm.v18i2.43261
494. Cruz-Arenas E, Cabrera-Ruiz E, Laguna-Barcenas S, Colin-Castro CA, Chavez T, Franco-Cendejas R, et al. Serological prevalence of SARS-CoV-2 infection and associated factors in health care workers in a “non-COVID” hospital in Mexico City. *medRxiv.* 2020; 2020.11.30.20241331. doi:10.1101/2020.11.30.20241331

495. Martínez-Acuña N, Avalos-Nolazco D, Rodríguez-Rodríguez D, Martínez-Liu C, Taméz RC, Flores-Arechiga A, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in blood donors from Nuevo Leon state, Mexico, during the beginning of the COVID-19 pandemic. medRxiv. 2020; 2020.11.28.20240325. doi:10.1101/2020.11.28.20240325
496. Remes-Troche JM, Ramos-De-la-Medina A, Manríquez-Reyes M, Martínez-Pérez Maldonado L, Solís-Gonzalez MA, Hernández Flores KG, et al. Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico). medRxiv. 2020 [cited 15 May 2021]. doi:10.1101/2020.10.19.20215558
497. Cristina Díaz-Salazar, Adriana Sánchez-García, René Rodríguez-Gutiérrez, Adrián Camacho-Ortiz, Donato Saldívar-Rodríguez, José Gerardo González-González. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival. Research Square. 2020 [cited 15 May 2021]. doi:10.21203/rs.3.rs-84890/v1
498. Villarreal A, Rangel G, Zhang X, Wong D, Britton G, Fernandez PL, et al. Performance of a point of care test for detecting IgM and IgG antibodies against SARS-CoV-2 and seroprevalence in blood donors and health care workers in Panama. medRxiv. 2020; 2020.09.25.20201459. doi:10.1101/2020.09.25.20201459
499. El 30% de testeados en el Este tuvieron Covid. ultimahora.com; [cited 22 Apr 2021]. Available: <https://www.ultimahora.com/el-30-testeados-el-este-tuvieron-covid-n2918654.html>
500. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Loreto, Peru. medRxiv. 2021; 2021.01.17.21249913. doi:10.1101/2021.01.17.21249913
501. Government P. Minsa divulga ficha técnica del estudio que revela que el 25.3% de Lima y Callao adquirió el COVID-19. Gestion; 27 Jul 2020. Available: <https://gestion.pe/peru/coronavirus-peru-minsa-divulga-ficha-tecnica-del-estudio-que-revela-que-el-253-de-lima-y-callao-adquirio-el-covid-19-cuarentena-estado-de-emergencia-nndc-noticia/>
502. Angulo-Bazan Y, Solís G, Cardenas F, Jorge A, Acosta J, Cabezas C. Household transmission in people infected with SARS-CoV-2 (COVID-19) in Lima-Perú. medRxiv. 2020; 2020.09.06.20189456. doi:10.1101/2020.09.06.20189456
503. Kassem AM, Talaat H, Shawky S, Fouad R, Amer K, Elnagdy T, et al. SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility. Arab Journal of Gastroenterology. 2020;21: 151–155. doi:10.1016/j.ajg.2020.07.005
504. Mostafa A, Kandil S, El-Sayed MH, Girgis S, Hafez H, Yosef M, et al. Universal COVID-19 screening of 4040 health care workers in a resource-limited setting: An Egyptian pilot model in a university with 12 public hospitals and medical centers. International Journal of Epidemiology. 2020 [cited 23 Jan 2021]. doi:10.1093/ije/dyaa173
505. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: A population-based cross-sectional study. The Lancet Infectious Diseases. 2020;0. doi:10.1016/S1473-3099(20)30858-6
506. Saberian P, Mireskandari SM, Baratloo A, Hasani-Sharamin P, Babaniamansour S, Aliniagerdroudbari E, et al. Antibody Rapid Test Results in Emergency Medical Services Personnel during COVID-19 Pandemic; a Cross Sectional study. Arch Acad Emerg Med. 2020;9. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720855/>
507. Armin S, Karbasian F, Hoseinifatemí SM, Mansour Ghanaie R, Rafiei Tabatabaei S, Fahimzad SA, et al. Prevalence of SARS-CoV-2 Specific Antibodies in the Staff of a Children's Hospital, in Tehran, Iran. Jundishapur Journal of Microbiology; 30 Sep 2020 [cited 27 Jan 2021]. doi:10.5812/jjm.108592
508. Europe PMC. [cited 2 Feb 2021]. Available: <https://europepmc.org/article/ppr/ppr257302#fulltext-permissions->
509. Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SS, Rezvani SM, et al. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerging Infectious Disease journal. 2021;27. doi:10.3201/eid2702.201960

510. Shahrzad Ossareh, Seyed Morteza Bagheri, Mohsen Abbasi, Sara Abolfathi, Azam Bohlooli. Role of Screening for COVID-19 in Hemodialysis Wards, Results of a Single Center Study. *IJKD*. 2020;14: 389–98. Available: <http://www.ijkd.org/index.php/ijkd/article/view/5832/1205>
511. Alali WQ, Bastaki H, Longenecker JC, Aljunid SM, AlSeidan M, Chehadeh W, et al. Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait. *Journal of Travel Medicine*. 2020 [cited 16 Feb 2021]. doi:10.1093/jtm/taaa223
512. Kammon AM, El-Arabi AA, Erhouma EA, Mehemed TM, Mohamed OA. Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya. *medRxiv*. 2020; 2020.05.25.20109470. doi:10.1101/2020.05.25.20109470
513. Elfakhri AA, Abdelghffar AF, Elhassi AF, Elmehdawi RR, Belkasem FS, Elhaddad AB, et al. Population-Based Random Survey for detection of COVID-19 Infection and Seroprevalence in Benghazi- Libya May/2020. *Journal of Preventive Medicine*. 2020;5. Available: <https://preventive-medicine.imedpub.com/abstract/populationbased-random-survey-for-detection-of-covid19-infection-and-seroprevalence-in-benghazi-libya-may2020-32698.html>
514. Jeremijenko A, Chemaitelly H, Ayoub HH, Abdulla MAH, Abou-Samra AB, Ajmi JAAAA, et al. Evidence for and level of herd immunity against SARS-CoV-2 infection: The ten-community study. *medRxiv*. 2020; 2020.09.24.20200543. doi:10.1101/2020.09.24.20200543
515. Al-Thani MH, Farag E, Bertollini R, Romaihi HEA, Abdeen S, Abdelkarim A, et al. Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar. *medRxiv*. 2020; 2020.11.24.20237719. doi:10.1101/2020.11.24.20237719
516. Nasrallah GK, Dargham SR, Shurrab F, Al-Sadeq DW, Al-Jighefee H, Chemaitelly H, et al. Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting. *medRxiv*. 2020; 2020.12.14.20248163. doi:10.1101/2020.12.14.20248163
517. Mahallawi WH, Al-Zalabani AH. The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia. *Saudi Journal of Biological Sciences*. 2020 [cited 17 Feb 2021]. doi:10.1016/j.sjbs.2020.12.009
518. Alharbi SA, Almutairi AZ, Jan AA, Alkhalify AM. Enzyme-Linked Immunosorbent Assay for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgM/IgA and IgG Antibodies Among Healthcare Workers. *Cureus*. 2020 [cited 7 Feb 2021]. doi:10.7759/cureus.10285
519. Alserehi HA, Alqunaibet AM, Al-Tawfiq JA, Alharbi NK, Alshukairi AN, Alanazi KH, et al. Seroprevalence of SARS-CoV-2 (COVID-19) among healthcare workers in Saudi Arabia: Comparing case and control hospitals. *Diagnostic Microbiology and Infectious Disease*. 2020;99: 115273. doi:10.1016/j.diagmicrobio.2020.115273
520. Sozcu. Health Minister Fahrettin Koca announced the antibody test results of Turkey. *Sozcu*; 2 Jul 2020. Available: https://www.sozcu.com.tr/2020/saglik/saglik-bakani-fahrettin-koca-turkiyenin-antikor-testi-sonuclarini-acikladi-5906832/?utm_source=dahafazla_haber&utm_medium=free&utm_campaign=dahafazlahaber
521. Alkurt G, Murt A, Aydin Z, Tatli O, Agaoglu NB, Irvem A, et al. Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey. *medRxiv*. 2020; 2020.08.19.20178095. doi:10.1101/2020.08.19.20178095
522. Khan SMS, Qurieshi MA, Haq I, Majid S, Ahmad J, Ayub T, et al. Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case. Rochester, NY: Social Science Research Network; 2021 Apr. Report No.: ID 3820632. doi:10.2139/ssrn.3820632
523. Ashok Kumar. 6% rise in seropositivity among Delhi's neighbours". 3 Nov 2020. Available: <https://www.thehindu.com/news/cities/Delhi/6-rise-in-seropositivity-among-delhis-neighbours/article33006634.ece>

524. Sharma N, Sharma P, Basu S, Saxena S, Chawla R, Dushyant K, et al. The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population-based seroepidemiological study. medRxiv. 2020 [cited 15 May 2021]. doi:10.1101/2020.12.13.20248123
525. Ramanath R. Survey: 50% of Bhubaneswar residents have antibodies | Bhubaneswar News - Times of India. Times of India. Available: <https://timesofindia.indiatimes.com/city/bhubaneswar/survey-50-of-bhubaneswar-residents-have-antibodies/articleshow/78966615.cms>. Accessed 7 Mar 2021.
526. Banerjee A, Gaikwad B, Desale A, Jadhav SL, Bhawalkar J, Salve P, et al. SARS-CoV-2 Seroprevalence Study in Pimpri-Chinchwad, Maharashtra, India Coinciding with Falling Trend – Do the Results Suggest Imminent Herd Immunity? 2020 [cited 14 Mar 2021]. Available: <https://papers.ssrn.com/abstract=3729394>
527. Babu GR, Sundaresan R, Athreya S, Akhtar J, Pandey PK, Maroor PS, et al. The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide survey in Karnataka, India. medRxiv. 2020; 2020.12.04.20243949. doi:10.1101/2020.12.04.20243949
528. Goenka MK, Shah BB, Goenka U, Das SS, Afzalpurkar S, Mukherjee M, et al. COVID-19 prevalence among health-care workers of Gastroenterology department: An audit from a tertiary-care hospital in India. JGH Open. 2021;5: 56–63. doi:10.1002/jgh3.12447
529. Kshatri JS, Bhattacharya D, Kanungo S, Giri S, Palo SK, Parai D, et al. Findings from serological surveys (in August 2020) to assess the exposure of adult population to SARS Cov-2 infection in three cities of Odisha, India. 2020 [cited 15 May 2021]. doi:10.1101/2020.10.11.20210807
530. Sep 17 AS/T/, 2020, Ist 09:01. 11.9% seroprevalence in Ujjain, finds survey | Bhopal News - Times of India. The Times of India; [cited 22 Apr 2021]. Available: <https://timesofindia.indiatimes.com/city/bhopal/11-9-seroprevalence-in-ujjain-finds-survey/articleshow/78159395.cms>
531. Mohanan M, Malani A, Krishnan K, Acharya A. Prevalence of SARS-CoV-2 in Karnataka, India. JAMA. 2021 [cited 19 Feb 2021]. doi:10.1001/jama.2021.0332
532. Goenka M, Afzalpurkar S, Goenka U, Das SS, Mukherjee M, Jajodia S, et al. Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India. J Assoc Physicians India. 2020;68: 14–19.
533. Dixit JV, Iravane J, Andurkar SP, Gandal U, Padalkar N, Sayyed M, et al. SEROPREVALENCE OF COVID-19 IN AURANGABAD DISTRICT. IJCRT. 2020;8: 3675–3683. Available: <https://ijcrt.org/papers/IJCRT2009467.pdf>
534. Siddiqui S, Naushin S, Pradhan S, Misra A, Tyagi A, Loomba M, et al. SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting. medRxiv. 2020 [cited 14 May 2021]. doi:10.1101/2020.09.02.20186486
535. Ray A, Singh K, Chattopadhyay S, Mehdi F, Batra G, Gupta A, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North India. medRxiv. 2020; 2020.08.22.20179937. doi:10.1101/2020.08.22.20179937
536. Satpati P, Sarangi S, Gantait K, Endow S, Mandal N, Panchanan K, et al. Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur, West Bengal, India. Infectious Diseases (except HIV/AIDS); 2020 Sep. doi:10.1101/2020.09.12.20193219
537. Aneesha Bedi. 28.3% of Delhi's population now exposed to Covid, shows second sero survey, up from 23.4%. The Print. 19 Aug 2020. Available: <https://theprint.in/health/28-3-of-delhis-population-now-exposed-to-covid-shows-second-sero-survey-up-from-23-4/484455/>
538. Smarajit Dey. Serial SARS-CoV-2 Seropravelence Studies in Delhi July-August 2020: Indications of Pre-existing Cross-reactive Antibodies and Implications for Disease Progression. Research Square. 2021. doi:10.21203/rs.3.rs-80259/v1

539. Ghose A, Bhattacharya S, Karthikeyan AS, Kudale A, Monteiro JM, Joshi A, et al. Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in an Indian metropolitan city. medRxiv. 2020; 2020.11.17.20228155. doi:10.1101/2020.11.17.20228155
540. Kumar A, Sathyapalan D, Ramachandran A, Subhash K, Biswas L, Beena KV. SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India. *Clinical Microbiology and Infection*. 2021;27: 481–483. doi:10.1016/j.cmi.2020.09.013
541. Malani A, Shah D, Kang G, Lobo GN, Shastri J, Mohanan M, et al. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. *The Lancet Global Health*. 2021;9: e110–e111. doi:10.1016/S2214-109X(20)30467-8
542. Yusra Husain. 4% 'healthy' blood donors in Lucknow found with Covid antibodies. *The Times of India*. 19 Jul 2020. Available: <https://timesofindia.indiatimes.com/city/lucknow/4-healthy-blood-donors-in-city-found-with-covid-antibodies/articleshow/77044828.cms>
543. Desk India com N. COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report. *Indiacom*. 23 Jul 2020. Available: <https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/>
544. Khan SMS, Qurieshi MA, Haq I, Majid S, Bhat AA, Nabi S, et al. Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India – A cross-sectional study. *PLOS ONE*. 2020;15: e0239303. doi:10.1371/journal.pone.0239303
545. Archana Mishra. Sero survey: 1,544 tested, 180 found with Covid-19 antibodies in Haryana. *Hindustan Times*. 21 Jul 2020. Available: <https://www.hindustantimes.com/gurugram/sero-survey-1-544-tested-180-found-with-covid-19-antibodies-in-haryana/story-k7DUZ8WH4jYqAzCsUmXkEJ.html>
546. Ahmedabad has no herd immunity, only 17.6% have antibodies. *The Times of India*. 24 Jul 2020. Available: <https://timesofindia.indiatimes.com/city/ahmedabad/ahmedabad-has-no-herd-immunity-only-17-6-have-antibodies/articleshow/77137851.cms>. Accessed 13 Mar 2021.
547. Astha Saxena. New plan to check Covid spread in Delhi: Sero survey every month. *The Indian Express*. 23 Jul 2020. Available: <https://indianexpress.com/article/cities/delhi/delhi-coronavirus-latest-updates-sero-surveys-6518032/>
548. Prakash O, Solanki B, Sheth JK, Joshi B, Kadam M, Vyas S, et al. Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: A cross-sectional study. *BMJ Open*. 2021;11: e044101. doi:10.1136/bmjopen-2020-044101
549. Kumar N, Bhartiya S, Singh T. Duration of anti-SARS-CoV-2 antibodies much shorter in India. *Vaccine*. 2021;39: 886–888. doi:10.1016/j.vaccine.2020.10.094
550. Singhal T, Shah S, Naik R, Kazi A, Thakkar P. Prevalence of COVID-19 Antibodies in Healthcare Workers at the Peak of the Pandemic in Mumbai, India: A Preliminary Study. *Indian Journal of Medical Microbiology*. 2020;38: 461–463. doi:10.4103/ijmm.IJMM_20_308
551. Khan MS, Haq I, Qurieshi MA, Majid S, Bhat AA, Obaid M, et al. SARS-CoV-2 seroprevalence in healthcare workers of dedicated-COVID hospitals and non-COVID hospitals of District Srinagar, Kashmir. medRxiv. 2020; 2020.10.23.20218164. doi:10.1101/2020.10.23.20218164
552. Aswin Kumar. Initial trend: Positivity rate low in antibody testing. *The Times of India*. 14 Jun 2020. Available: <https://timesofindia.indiatimes.com/city/thiruvananthapuram/initial-trend-positivity-rate-low-in-antibody-testing/articleshow/76363847.cms>
553. Rao S. Covid-19: Jayadeva says its survey hints at herd immunity. *The Times of India*. 6 Jun 2020. Available: <https://timesofindia.indiatimes.com/city/bengaluru/covid-19-jayadeva-says-its-survey-hints-at-herd-immunity/articleshow/76228490.cms>. Accessed 13 Mar 2021.

554. Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Thangaraj JWV, et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. *Indian Journal of Medical Research*. 2020;152: 48. doi:10.4103/ijmr.IJMR_3290_20
555. Swatee Kher. Six Maharashtra districts have higher Covid-19 prevalence than nation's finding. *The Times of India*. 22 Jun 2020. Available: <https://timesofindia.indiatimes.com/city/pune/6-maha-districts-have-higher-ncov-prevalence-than-nations-finding/articleshow/76500273.cms>
556. Nisar MI, Ansari N, Amin M, Hotwani A, Khalid F, Rehman N, et al. Serial population-based sero-surveys for COVID-19 in low and high transmission neighborhoods of urban Pakistan. 2020 [cited 15 May 2021]. doi:10.1101/2020.07.28.20163451
557. Zaidi S, Rizwan F, Riaz Q, Siddiqui A, Khawaja S, Imam M, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi—challenges in acquiring herd immunity for COVID 19. *Journal of Public Health*. 2020 [cited 2 Jun 2021]. doi:10.1093/pubmed/fdaa170
558. Younas A, Waheed S, Khawaja S, Imam M, Borhany M, Shamsi T. Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. *Transfusion and Apheresis Science*. 2020; 102923. doi:10.1016/j.transci.2020.102923
559. Noor M, Haq M, Ul Haq N, Amin S, Rahim F, Bahadur S, et al. Does Working in a COVID-19 Receiving Health Facility Influence Seroprevalence to SARS-CoV-2? *Cureus*. 2020 [cited 4 Mar 2021]. doi:10.7759/cureus.11389
560. Haq M, Rehman A, Noor M, Ahmed J, Ahmad J, Irfan M, et al. Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan. *medRxiv*. 2020; 2020.09.29.20203125. doi:10.1101/2020.09.29.20203125
561. Chughtai O, Batool H, Khan M, Chughtai A. Frequency of COVID-19 IgG Antibodies among Special Police Squad Lahore, Pakistan. *J Coll Physicians Surg Pak*. 2020;30: 735–739. doi:10.29271/jcpsp.2020.07.735
562. Li S, Qiu Y, Tang L, Wang Z, Cao W, Sun X. Seroprevalence of antibodies to SARS-CoV-2 is particularly high in patient population with ocular surface diseases. *medRxiv*. 2020; 2020.09.22.20198465. doi:10.1101/2020.09.22.20198465
563. Wang R, Jin F, Cao S, Yuan H, Qu J, Zhang J, et al. Seroprevalence of SARS-CoV-2 infections among children visiting a hospital. *Pediatric Investigation*. 2020;4: 236–241. doi:10.1002/ped4.12231
564. He L, Zeng Y, Zeng C, Zhou Y, Li Y, Xie X, et al. Positive Rate of Serology and RT-PCR for COVID-19 among healthcare workers during different periods in Wuhan, China. *Journal of Infection*. 2020 [cited 15 Nov 2020]. doi:10.1016/j.jinf.2020.08.027
565. He L, Zeng Y, Zeng C, Zhou Y, Li Y, Xie X, et al. Positive Rate of Serology and RT-PCR for COVID-19 between Community Residents and Healthcare Workers in Wuhan, China. *Japanese Journal of Infectious Diseases*. 2020;advpub. doi:10.7883/yoken.JJID.2020.691
566. Liu A, Li Y, Wan Z, Wang W, Lei X, Lv Y. Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China. *JAMA Netw Open*. 2020;3: e2025717. doi:10.1001/jamanetworkopen.2020.25717
567. Pan Y, Li X, Yang G, Fan J, Tang Y, Hong X, et al. Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: Part of the city-wide massive testing campaign. *Clinical Microbiology and Infection*. 2020;27: 253–257. doi:10.1016/j.cmi.2020.09.044
568. Tong X, Ning M, Huang R, Jia B, Yan X, Xiong Y, et al. Surveillance of SARS-CoV-2 infection among frontline health care workers in Wuhan during COVID-19 outbreak. *Immun Inflamm Dis*. 2020;8: 840–843. doi:10.1002/iid3.340
569. Liang W, Lin Y, Bi J, Li J, Liang Y, Wong S-S, et al. Serosurvey of SARS-CoV-2 among hospital visitors in China. *Cell Research*. 2020;30: 817–818. doi:10.1038/s41422-020-0371-0

570. Le Chang, Wangheng Hou, Lei Zhao, Yali Zhang, Yanbin Wang, Linfeng Wu, et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. *medRxiv*. 2020; 32. doi:10.1101/2020.07.13.20153106
571. Liu T, Wu S, Tao H, Zeng G, Zhou F, Wang X. Prevalence of IgG Antibodies to SARS-CoV-2 in Wuhan – Implications for the Longevity of Antibodies Against SARS-CoV-2. *Research Square*. 2020 [cited 15 May 2021]. doi:10.21203/rs.3.rs-99748/v1
572. Lei Q, Li Y, Hou H, Wang F, Ouyang Z, Zhang Y, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. *Allergy*. 2020;76: 551–561. doi:10.1111/all.14622
573. Ling R, Yu Y, He J, Zhang J, Xu S, Sun R, et al. Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China. *medRxiv*. 2020; 28. doi:10.1101/2020.06.16.20132423
574. Wang S, Tao F, Hou Y, Zhang A, Xiong H, Sun J, et al. Screening of SARS-CoV-2 in 299 Hospitalized Children with Hemato-oncological Diseases: A Multicenter Survey in Hubei, China. *Current Medical Science*. 2020;40: 642–645. doi:10.1007/s11596-020-2228-7
575. Liu M, Cheng S-Z, Xu K-W, Yang Y, Zhu Q-T, Zhang H, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: Cross sectional study. *BMJ*. 2020;369. doi:10.1136/bmj.m2195
576. Wang X, Gao W, Cui S, Zhang Y, Zheng K, Ke J, et al. A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China. *medRxiv*. 2020 [cited 14 May 2021]. doi:10.1101/2020.09.23.20197756
577. Wu X, Fu B, Chen L, Feng Y. Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China. *Journal of Medical Virology*. 2020;92: 1795–1796. doi:10.1002/jmv.25904
578. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. *Nature Medicine*. 2020;26: 1193–1195. doi:10.1038/s41591-020-0949-6
579. Xu R, Huang J, Duan C, Liao Q, Shan Z, Wang M, et al. Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China. *Journal of Medical Virology*. n/a. doi:10.1002/jmv.26445
580. Zhang A, Hu Q, Liu A, Wang S, Jin S, Wang Y, et al. Prevention of COVID-19 infection in a pediatric oncology ward in Wuhan. *Pediatric Blood & Cancer*. 2020;67: e28424. doi:10.1002/pbc.28424
581. Zhou F, Li J, Lu M, Ma L, Pan Y, Liu X, et al. Tracing asymptomatic SARS-CoV-2 carriers among 3674 hospital staff: a cross-sectional survey. *EClinicalMedicine*. 2020;26. doi:10.1016/j.eclinm.2020.100510
582. Li Y, He Q, Yu R, Jiang H, Wang W, Feng D, et al. Highlighted Prospects of an IgM/IgG Antibodies Test in Identifying Individuals With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *Archives of Pathology & Laboratory Medicine*. 2021;145: 39–45. doi:10.5858/arpa.2020-0310-SA
583. Tang H, Tian J-B, Dong J-W, Tang X-T, Yan Z-Y, Zhao Y-Y, et al. Serologic Detection of SARS-CoV-2 Infections in Hemodialysis Centers: A Multicenter Retrospective Study in Wuhan, China. *American Journal of Kidney Diseases*. 2020;76: 490–499.e1. doi:10.1053/j.ajkd.2020.06.008
584. Tu D, Shu J, Wu X, Li H, Xia Z, Zhang Y, et al. Immunological detection of serum antibodies in pediatric medical workers exposed to varying levels of SARS-CoV-2. *J Infect*. 2021;82: 159–198. doi:10.1016/j.jinf.2020.07.023
585. Zhang C, Lin L, Tang D, Liu F, Li M, Li Q, et al. Antibody responses to SARS-CoV-2 in healthy individuals returning to Shenzhen. *Journal of Medical Virology*. 2020;n/a. doi:10.1002/jmv.26355
586. Xiong S, Guo C, Dittmer U, Zheng X, Wang B. The prevalence of antibodies to SARS-CoV-2 in asymptomatic healthcare workers with intensive exposure to COVID-19. *medRxiv*. 2020; 2020.05.28.20110767. doi:10.1101/2020.05.28.20110767

587. To KK-W, Cheng VC-C, Cai J-P, Chan K-H, Chen L-L, Wong L-H, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: A multicohort study. *The Lancet Microbe*. 2020;1: e111–e118. doi:10.1016/S2666-5247(20)30053-7
588. Zhao D, Wang M, Wang M, Zhao Y, Zheng Z, Li X, et al. Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China. *International Journal of Infectious Diseases*. 2020;99: 219–225. doi:10.1016/j.ijid.2020.07.082
589. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. *J Infect*. 2020;81: 420–426. doi:10.1016/j.jinf.2020.05.067
590. Zhang J, Zhang X, Liu J, Ban Y, Li N, Wu Y, et al. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. *International Immunopharmacology*. 2020;88: 106861. doi:10.1016/j.intimp.2020.106861
591. Hallowell BD, Carlson CM, Jacobs JR, Pomeroy M, Steinberg J, Tenforde MW, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020 - Volume 26, Number 9—September 2020 - *Emerging Infectious Diseases journal - CDC*. EID. 2020;29. doi:10.3201/eid2609.201590
592. Sam I-C, Chong YM, Tan CW, Chan YF. Low postpandemic wave SARS-CoV-2 seroprevalence in Kuala Lumpur and Selangor, Malaysia. *Journal of Medical Virology*. n/a. doi:10.1002/jmv.26426
593. Nopsopon T, Pongpirul K, Chotirosniramit K, Hiransuthikul N. COVID-19 Antibody in Thai Community Hospitals. *medRxiv*. 2020; 2020.06.24.20139188. doi:10.1101/2020.06.24.20139188
594. Nopsopon T, Pongpirul K, Chotirosniramit K, Jakaew W, Kaewwijit C, Kanchana S, et al. Seroprevalence of Hospital Staff in Province with Zero COVID-19 Cases. *medRxiv*. 2020; 2020.07.13.20151944. doi:10.1101/2020.07.13.20151944
595. Chau NVV, Toan LM, Man DNH, Thao HP, Lan NPH, Ty DTB, et al. Absence of SARS-CoV-2 antibodies in health care workers of a tertiary referral hospital for COVID-19 in southern Vietnam. *Journal of Infection*. 2020;82: e36–e37. doi:10.1016/j.jinf.2020.11.018
596. Batchi-Bouyou AL, Lobaloba Ingoba L, Ndounga M, Vouvougui JC, Mfoutou Mapanguy CC, Boumpoutou KR, et al. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo. *International Journal of Infectious Diseases*. 2020;106: 3–7. doi:10.1016/j.ijid.2020.12.065
597. Kempen JH, Abashawl A, Suga HK, Nigussie Difabachew M, Kempen CJ, Tesfaye Debele M, et al. SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia. *The American Journal of Tropical Medicine and Hygiene*. 2020;103: 2022–2023. doi:10.4269/ajtmh.20-0816
598. Alemu BN, Addissie A, Mamo G, Deyessa N, Abebe T, Abagero A, et al. Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia. *Microbiology*; 2020 Oct. doi:10.1101/2020.10.13.337287
599. Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al. Temporal trends of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19 epidemic in Kenya. *medRxiv*. 2021; 2021.02.09.21251404. doi:10.1101/2021.02.09.21251404
600. Chibwana MG, Jere KC, kamng'ona R, Mandolo J, Katunga-Phiri V, Tembo D, et al. High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. *medRxiv*. 2020; 2020.07.30.20164970. doi:10.1101/2020.07.30.20164970
601. Majiya H, Aliyu-Paiko M, Balogu VT, Musa DA, Salihu IM, Kawu AA, et al. Seroprevalence of COVID-19 in Niger State. *medRxiv*. 2020 [cited 12 Nov 2020]. doi:10.1101/2020.08.04.20168112
602. Asuquo MI, Effa E, Otu A, Ita O, Udoh U, Umoh V, et al. Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients. *medRxiv*. 2020; 2020.07.02.20145441. doi:10.1101/2020.07.02.20145441

603. Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, et al. Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. Musuka G, editor. PLoS ONE. 2021;16: e0247852. doi:10.1371/journal.pone.0247852
604. Hsiao M, Davies M-A, Kalk E, Hardie D, Naidoo M, Center C, et al. SARS-CoV-2 seroprevalence in the Cape Town Metropolitan sub-districts after the peak of infections. NICD COVID-19 Special Public Health Surveillance Bulletin. 2020;18: 9. Available: https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf
605. Halatoko WA, KONU YR, Gbeasor-Komlanvi FA, Sadio AJ, Tchankoni MK, Komlanvi KS, et al. Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020. medRxiv. 2020; 2020.08.07.20163840. doi:10.1101/2020.08.07.20163840